Document

0001012477-19-000012.txt : 20191112 0001012477-19-000012.hdr.sgml : 20191112 20191112155946 ACCESSION NUMBER: 0001012477-19-000012 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 93 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191112 DATE AS OF CHANGE: 20191112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 191209151 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 10-Q 1 avdl2019q3.htm 10-Q Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-Q

———————

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2019

———————

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

———————



Ireland	000-28508	98-1341933
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Block 10-1, Blanchardstown Corporate Park

Ballycoolin

Dublin 15, Ireland

(Address of Principal Executive Office and Zip Code)

+353-1-485-1200

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

———————

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	¨	Accelerated filer	þ
Non-accelerated	¨	Smaller reporting company	¨
(Do not check if a smaller reporting company)		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

At November 8, 2019, 37,450,300 ordinary shares, nominal value $0.01 each, of the Company were outstanding.

TABLE OF CONTENTS



		Page #
Cautionary Note Regarding Forward Looking Statements		3

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	30
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	46
Item 4.	Controls and Procedures	46

PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	47
Item 1A.	Risk Factors	47
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	47
Item 3.	Defaults Upon Senior Securities	48
Item 4.	Mine Safety Disclosures	48
Item 5.	Other Information	48
Item 6.	Exhibits	48

- 2 -

Cautionary Note Regarding Forward-Looking Statements

This quarterly report on Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These include statements as to our future expectations, beliefs, plans, strategies, objectives, events, conditions, financial performance, prospects, or other events. In some cases, forward-looking statements can be identified by the use of words such as “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, and the negatives thereof.

Our forward-looking statements are based on estimates and assumptions that are made within the bounds of our knowledge of our business and operations and that we consider reasonable. However, our business and operations are subject to significant risks and as a result there can be no assurance that actual results of our research, development and commercialization activities and the results of our business and operations will not differ materially from the results contemplated in such forward-looking statements. Factors that could cause actual results to differ from expectations in our forward-looking statements include:

(a) risks relating to our recent net losses and restructuring plan, including risks relating to the following:


•	due to a decrease in our available liquid assets, our business strategy has been refocused and is now substantially dependent upon a single product, FT218;


•	our recent restructuring plan may not be as effective as we anticipate and may have unintended negative impacts;


•	further restructuring actions, if needed, may require third-party consents (including consents under the indenture governing our convertible debt) and such consents may not be granted; and


•	the Chapter 11 bankruptcy filing by our subsidiary Avadel Specialty Pharmaceuticals LLC may have unexpected adverse results.

(b) risks relating to the following:


•	our three products Bloxiverz®, Vazculep® and Akovaz®, which are not patent protected, and have a small number of customers, currently produce substantially all of our revenues, and could face further competition resulting in a further loss of market share and/or forcing us to further reduce our prices for those products;


•	our current “unapproved marketed drug” (UMD) product candidate, AV001, could fail to achieve FDA approval; or we could fail to develop future potential UMD product candidates, or competitors could develop such products and market such products with FDA approval before us;


•	we could experience failure or further delay in completing the Phase III clinical trial for FT218, and if the FDA ultimately approves such product, the approval may not include any period of market exclusivity;


•	we may not have sufficient cash or the ability to raise sufficient cash to service our $143.75 million Exchangeable Senior Notes due 2023, including cash necessary to repay such Notes at maturity, to settle exchanges of such Notes in cash or to repurchase such Notes as required following a “fundamental change” event described in the indenture governing such Notes;


•	we depend on one or a limited number of third parties to manufacture certain of our products and to provide certain raw materials used in our products;


•	our competitors may develop and market technologies or products that are more effective or safer than ours, or obtain regulatory approval and market such technologies or products before we do;


•	we face challenges in protecting intellectual property underlying our products and drug delivery technologies; and


•	we depend on key personnel to execute our business plan.

(c) the other risks and uncertainties described in the “Risk Factors” section of Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2018 which we filed with the Securities and Exchange Commission on March 15, 2019.

Forward-looking statements speak only as of the date they are made and are not guarantees of future performance. Accordingly, you should not place undue reliance on forward-looking statements. We do not undertake any obligation to publicly update or revise the forward-looking statements contained in this Quarterly Report.

- 3 -

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS

(In thousands, except per share data)

(Unaudited)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018

Revenues:
Product sales	$	14,229		$	19,826		$	48,220		$	82,103
License revenue	—			—			—			246
Total revenues	14,229			19,826			48,220			82,349
Operating expenses:
Cost of products	2,823			3,120			9,711			13,224
Research and development expenses	7,539			11,402			25,160			33,243
Selling, general and administrative expenses	5,316			24,829			22,520			77,159
Intangible asset amortization	205			1,620			610			4,996
Changes in fair value of related party contingent consideration	627			(7,115		)	2,384			(17,036		)
Restructuring costs	1,866			65			4,600			268
Total operating expenses	18,376			33,921			64,985			111,854
Operating loss	(4,147		)	(14,095		)	(16,765		)	(29,505		)
Investment and other income, net	781			208			2,548			845
Interest expense	(3,125		)	(3,000		)	(9,293		)	(7,577		)
Loss on deconsolidation of subsidiary	—			—			(2,840		)	—
Other (expense) income - changes in fair value of related party payable	(139		)	425			(496		)	1,432
Loss before income taxes	(6,630		)	(16,462		)	(26,846		)	(34,805		)
Income tax provision (benefit)	2,234			(691		)	3,641			(3,360		)
Net loss	$	(8,864	)	$	(15,771	)	$	(30,487	)	$	(31,445	)

Net loss per share - basic	$	(0.24	)	$	(0.43	)	$	(0.82	)	$	(0.84	)
Net loss per share - diluted	(0.24		)	(0.43		)	(0.82		)	(0.84		)

Weighted average number of shares outstanding - basic	37,436			36,904			37,382			37,410
Weighted average number of shares outstanding - diluted	37,436			36,904			37,382			37,410

See accompanying notes to unaudited condensed consolidated financial statements.

- 4 -

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(In thousands)

(Unaudited)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2019			2018			2019			2018

Net loss	$	(8,864	)	$	(15,771	)	$	(30,487	)	$	(31,445	)
Other comprehensive (loss) income, net of tax:
Foreign currency translation gain (loss)	(210		)	(60		)	(309		)	(293		)
Net other comprehensive income (loss), net of ($5), ($18), ($46) and ($88) tax, respectively	86			68			753			(92		)
Total other comprehensive income (loss), net of tax	(124		)	8			444			(385		)
Total comprehensive loss	$	(8,988	)	$	(15,763	)	$	(30,043	)	$	(31,830	)

See accompanying notes to unaudited condensed consolidated financial statements.

- 5 -

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)



	September 30, 2019			December 31, 2018
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	12,867		$	9,325
Marketable securities	59,587			90,590
Accounts receivable	8,725			11,330
Inventories	2,260			4,770
Prepaid expenses and other current assets	5,163			8,836
Total current assets	88,602			124,851
Property and equipment, net	770			1,911
Operating lease right-of-use assets	4,385			—
Goodwill	18,491			18,491
Intangible assets, net	1,019			1,629
Research and development tax credit receivable	7,694			7,272
Other non-current assets	34,927			36,146
Total assets	$	155,888		$	190,300

LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY
Current liabilities:
Current portion of long-term debt	$	35		$	106
Current portion of long-term related party payable	7,588			9,439
Current portion of operating lease liability	1,596			—
Accounts payable	3,538			3,503
Accrued expenses	17,017			21,695
Other current liabilities	1,989			3,640
Total current liabilities	31,763			38,383
Long-term debt, less current portion	120,132			115,734
Long-term related party payable, less current portion	14,118			19,401
Long-term operating lease liability	2,866			—
Other non-current liabilities	13,972			14,002
Total liabilities	182,851			187,520

Shareholders’ (deficit) equity:
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; none issued or outstanding at September 30, 2019 and December 31, 2018, respectively	—			—
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 42,857 issued and 37,450 outstanding at September 30, 2019 and 42,720 issued and 37,313 outstanding at December 31, 2018	428			427
Treasury shares, at cost, 5,407 shares held at September 30, 2019 and December 31, 2018, respectively	(49,998		)	(49,998		)
Additional paid-in capital	434,055			433,756
Accumulated deficit	(388,476		)	(357,989		)
Accumulated other comprehensive loss	(22,972		)	(23,416		)
Total shareholders’ (deficit) equity	(26,963		)	2,780
Total liabilities and shareholders’ (deficit) equity	$	155,888		$	190,300

See accompanying notes to unaudited condensed consolidated financial statements.

- 6 -

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY

(In thousands)

(Unaudited)

Nine Months Ended September 30, 2019



	Ordinary shares			Additional			Accumulated			Accumulated other comprehensive			Treasury shares				Total shareholders’
	Shares	Amount		paid-in capital			deficit			(loss) income			Shares	Amount			(deficit) equity
Balance, December 31, 2018	42,720	$	427	$	433,756		$	(357,989	)	$	(23,416	)	5,407	$	(49,998	)	$	2,780
Net loss	—	—		—			(13,018		)	—			—	—			(13,018		)
Other comprehensive income	—	—		—			—			213			—	—			213
Vesting of restricted shares	1	—		—			—			—			—	—			—
Employee share purchase plan share issuance	42	—		92			—			—			—	—			92
Stock-based compensation expense	—	—		351			—			—			—	—			351
Balance, March 31, 2019	42,763	$	427	$	434,199		$	(371,007	)	$	(23,203	)	5,407	$	(49,998	)	$	(9,582	)
Net loss	—	—		—			(8,605		)	—			—	—			(8,605		)
Other comprehensive income	—	—		—			—			355			—	—			355
Stock-based compensation expense	—	—		55			—			—			—	—			55
Balance, June 30, 2019	42,763	$	427	$	434,254		$	(379,612	)	$	(22,848	)	5,407	$	(49,998	)	$	(17,777	)
Net loss	—	—		—			(8,864		)	—			—	—			(8,864		)
Other comprehensive income	—	—		—			—			(124		)	—	—			(124		)
Stock-based compensation expense	—	—		(229		)	—			—			—	—			(229		)
Vesting of restricted shares	82	1		(1		)	—			—			—	—			—
Employee share purchase plan share issuance	12	—		31			—			—			—	—			31
Balance, September 30, 2019	42,857	$	428	$	434,055		$	(388,476	)	$	(22,972	)	5,407	$	(49,998	)	$	(26,963	)

- 7 -

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY

(In thousands)

(Unaudited)

Nine Months Ended September 30, 2018



	Ordinary shares			Additional			Accumulated			Accumulated other comprehensive			Treasury shares				Total shareholders’
	Shares	Amount		paid-in capital			deficit			(loss) income			Shares	Amount			equity
Balance, December 31, 2017	41,463	$	414	$	393,478		$	(262,685	)	$	(23,266	)	2,117	$	(22,361	)	$	85,580
Net loss	—	—		—			(12,236		)	—			—	—			(12,236		)
Other comprehensive loss	—	—		—			—			(404		)	—	—			(404		)
Exercise of warrants	603	6		2,905			—			—			—	—			2,911
Expiration of warrants	—	—		2,167			—			—			—	—			2,167
Stock-based compensation expense	—	—		2,134			—			—			—	—			2,134
Equity component of 2023 Notes	—	—		26,699			—			—			—	—			26,699
Share repurchases	—	—		—			—			—			2,307	(20,212		)	(20,212		)
Balance, March 31, 2018	42,066	$	420	$	427,383		$	(274,921	)	$	(23,670	)	4,424	$	(42,573	)	$	86,639
Net loss	—	—		—			(3,438		)	—			—	—			(3,438		)
Other comprehensive income	—	—		—			—			11			—	—			11
Exercise of stock options	82	1		534			—			—			—	—			535
Stock-based compensation expense	—	—		2,224			—			—			—	—			2,224
Share repurchases	—	—		—			—			—			983	(7,425		)	(7,425		)
Balance, June 30, 2018	42,148	$	421	$	430,141		$	(278,359	)	$	(23,659	)	5,407	$	(49,998	)	$	78,546
Net loss	—	—		—			(15,771		)	—			—	—			(15,771		)
Other comprehensive income	—	—		—			—			8			—	—			8
Stock-based compensation expense	—	—		2,832			—			—			—	—			2,832
Vesting of restricted shares	247	3		(3		)	—			—			—	—			—
Employee share purchase plan share issuance	24	—		127			—			—			—	—			127
Balance, September 30, 2018	42,419	$	424	$	433,097		$	(294,130	)	$	(23,651	)	5,407	$	(49,998	)	$	65,742

- 8 -

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)



	Nine Months Ended September 30,
	2019			2018

Cash flows from operating activities:
Net loss	$	(30,487	)	$	(31,445	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,690			5,625
Loss on disposal of property and equipment	478			—
Amortization of premiums on marketable securities	(275		)	2,889
Remeasurement of related party acquisition-related contingent consideration	2,384			(17,036		)
Remeasurement of related party financing-related contingent consideration	496			(1,432		)
Amortization of debt discount and debt issuance costs	4,424			3,402
Change in deferred tax and income tax deferred charge	1,333			(4,675		)
Stock-based compensation expense	177			7,190
Loss on deconsolidation of subsidiary	1,750			—
Other adjustments	(392		)	117
Net changes in assets and liabilities
Accounts receivable	2,026			5,059
Inventories	2,465			(548		)
Prepaid expenses and other current assets	(1,859		)	2,194
Research and development tax credit receivable	(749		)	(1,350		)
Accounts payable & other current liabilities	259			4,312
Accrued expenses	(2,379		)	(11,660		)
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value	(8,640		)	(16,254		)
Royalty payments for related party payable in excess of original fair value	(1,374		)	(2,362		)
Other assets and liabilities	(1,399		)	(2,216		)
Net cash used in operating activities	(30,072		)	(58,190		)

Cash flows from investing activities:
Purchases of property and equipment	(29		)	(167		)
Proceeds from the disposal of property and equipment	154			—
Purchase of intangible asset	—			(20,000		)
Proceeds from sales of marketable securities	57,242			308,015
Purchases of marketable securities	(23,814		)	(341,036		)
Net cash provided by (used in) investing activities	33,553			(53,188		)

Cash flows from financing activities:
Earn-out payments for related party contingent consideration	—			(645		)
Proceeds from debt issuance	—			143,750
Payments for debt issuance costs	—			(6,190		)
Share repurchases	—			(27,637		)
Proceeds from issuance of ordinary shares and warrants	123			3,488
Other financing activities, net	(109		)	(31		)
Net cash provided by financing activities	14			112,735

Effect of foreign currency exchange rate changes on cash and cash equivalents	47			(84		)

Net change in cash and cash equivalents	3,542			1,273
Cash and cash equivalents at January 1,	9,325			16,564
Cash and cash equivalents at September 30,	$	12,867		$	17,837

Supplemental disclosures of cash flow information:
Interest paid	$	6,469		$	3,359
Income taxes paid	$	140		$	413

See accompanying notes to unaudited condensed consolidated financial statements.

- 9 -

AVADEL PHARMACEUTICALS PLC

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except per share data)

NOTE 1: Summary of Significant Accounting Policies

Nature of Operations. Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company. Our primary focus is on the development and potential U.S. Food and Drug Administration (“FDA”) approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted a new drug application (“NDA”) in March 2019 on a fourth sterile injectable drug which we refer to as AV001, for use in the hospital setting. AV001, if approved, could contribute revenues to Avadel starting in 2020. In May 2019, the FDA accepted the NDA for AV001, with a Prescription Drug User Fee Act (PDUFA) target action date of December 15, 2019.

Our current marketed products include:


•	Akovaz® (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.


•	Bloxiverz® (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.


•	Vazculep® (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Each of our Akovaz, Bloxiverz and Vazculep products is used primarily in the hospital setting and was developed under our UMD program.

The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the U.S. Securities and Exchange Commission (“SEC”). These filings are also available to the public at www.sec.gov.

The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “The Reincorporation Merger” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

- 10 -

Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French société par actions simplifiée, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities.

Basis of Presentation. The unaudited condensed consolidated balance sheet as of September 30, 2019, which is derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.

The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.

On February 6, 2019, the Company’s indirect wholly-owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”), filed a voluntary petition for reorganization under Chapter 11 of the United States (“U.S.”) Code (the “Bankruptcy Code”). in the U.S. District Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case No. 19-10248. Specialty Pharma is operating and managing its business as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma’s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See Note 3: Subsidiary Bankruptcy and Deconsolidation. Our results of operations for the period January 1, 2019 through February 6, 2019 include the results of Specialty Pharma prior to its February 6, 2019 voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code.

Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC Therapeutics and FSC Laboratories, Inc., (collectively “FSC”), prior to its February 16, 2018 disposition date. See Note 14: Divestiture of the Pediatric Assets, for additional information. All intercompany accounts and transactions have been eliminated.

Revenue. Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (“R&D”) achievements.

Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer’s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Sales and Services

The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns,

- 11 -

chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis.

License Revenue

The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.

For a complete discussion of the accounting for net product revenue and license revenues, see Note 4: Revenue Recognition.

NOTE 2: Newly Issued Accounting Standards

Recent Accounting Guidance Not Yet Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.

In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments(“ASU 2016-13”).” This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will be effective for the Company for fiscal years beginning on or after January 1, 2020, including interim periods within those annual reporting periods and early adoption is permitted. We are currently evaluating the impact of our adoption of ASU 2016-13 on our condensed consolidated financial statements.

NOTE 3: Subsidiary Bankruptcy and Deconsolidation

Bankruptcy Filing and Deconsolidation

As a result of Specialty Pharma’s bankruptcy filing on February 6, 2019, Avadel has ceded authority for managing the business to the Bankruptcy Court, and Avadel management cannot carry on Specialty Pharma’s activities in the ordinary course of business without Bankruptcy Court approval. Avadel manages the day-to-day operations of Specialty Pharma, but does not have discretion to make significant capital or operating budgetary changes or decisions and purchase or sell significant assets, as Specialty Pharma’s material decisions are subject to review by the Bankruptcy Court. For these reasons, we have concluded that Avadel has lost control of Specialty Pharma, and no longer has significant influence over Specialty Pharma during the pendency of the bankruptcy. Therefore, we deconsolidated Specialty Pharma effective with the filing of the Chapter 11 bankruptcy in February 2019.

In order to deconsolidate Specialty Pharma, the carrying values of the assets and certain liabilities of Specialty Pharma were removed from our unaudited condensed consolidated balance sheet as of February 5, 2019, and we recorded our investment in Specialty Pharma at its estimated fair value of $0. As the estimated fair value of our investment in Specialty Pharma was lower than its net book value immediately prior to the deconsolidation, we recorded a non-cash charge of approximately $2,840 for the nine months ended September 30, 2019 associated with the deconsolidation of Specialty Pharma. Subsequent to the deconsolidation of Specialty Pharma, we are accounting for our investment in Specialty Pharma using the cost method of accounting because Avadel does not exercise significant influence over the operations of Specialty Pharma due to the Chapter 11 filing.

On April 26, 2019, Specialty Pharma sold its intangible assets and remaining inventory to an unaffiliated third party in exchange for aggregate cash proceeds of approximately $250, pursuant to an order approving such sale which was issued by the Bankruptcy

- 12 -

Court on April 15, 2019. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business.

On July 2, 2019, Specialty Pharma was made aware of a $50,695 claim made by the Internal Revenue Service (IRS) as part of the bankruptcy claims process against Specialty Pharma. On October 2, 2019 the IRS amended the original claim filed in July, reducing the claim to $9,302. Specialty Pharma files its U.S. federal tax return as a member of the Company’s consolidated U.S. tax group. As such, the IRS claim was filed against Specialty Pharma in the bankruptcy proceedings due to IRS tax law requirements for joint and several liability of all members in a consolidated U.S. tax group. Both Specialty Pharma and the Company disagree with the merits of the amended IRS claim and intend to defend their positions vigorously.

DIP Financing – Related Party Relationship

In connection with the bankruptcy filing, Specialty Pharma entered into a Debtor in Possession Credit and Security Agreement with Avadel US Holdings (“DIP Credit Agreement”) dated as of February 8, 2019, in an aggregate amount of up to $2,700, of which the funds are to be used by Specialty Pharma solely to fund operations through February 6, 2020. As of September 30, 2019, the Company had funded $407 under the DIP Credit Agreement. As the Company has assessed that it is unlikely that Specialty Pharma will pay back the loan to Avadel, the $407 has been recorded as part of the loss on deconsolidation of subsidiary within the unaudited condensed consolidated statements of loss. At September 30, 2019 the fair value of the remaining commitment under the DIP Credit Agreement is not material.

NOTE 4: Revenue Recognition

The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.

Product Sales and Services

Effective January 1, 2018, the Company implemented ASC 606, “Revenue From Contracts With Customers”. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product and the Company’s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

Reserves to Reduce Gross Revenues to Net Revenues

Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

Product Returns

Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products and other judgments and analysis.

- 13 -

Chargebacks, Discounts and Rebates

Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.

Revenue from licensing arrangements

The terms of the Company’s licensing agreements may contain multiple performance obligations, including certain R&D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments. Each of these payments results in license revenues.

License of Intellectual Property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Disaggregation of revenue

The Company’s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company’s revenues by product, see Note 18: Company Operations by Product.

Contract Balances

The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.

A receivable is recognized in the period the Company sells its products and when the Company’s right to consideration is unconditional.

There were no material deferred contract costs at September 30, 2019.

Transaction Price Allocated to the Remaining Performance Obligation

For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.

For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product.

The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.

NOTE 5: Fair Value Measurement

The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business

- 14 -

combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.

ASC 820, “Fair Value Measurements and Disclosures,” defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques:


•	Income approach, which is based on the present value of a future stream of net cash flows.


•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:


•	Level 1 - Quoted prices for identical assets or liabilities in active markets.


•	Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means.


•	Level 3 - Unobservable inputs that reflect estimates and assumptions.

The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:



	As of September 30, 2019						As of December 31, 2018
Fair Value Measurements:	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3

Marketable securities (see Note 6)
Equity securities	$	4,176	$	—	$	—	$	9,145	$	—	$	—
Money market and mutual funds	44,091		—		—		52,996		—		—
Corporate bonds	—		4,258		—		—		6,339		—
Government securities - U.S.	—		5,344		—		—		12,701		—
Other fixed-income securities	—		1,718		—		—		9,409		—
Total assets	$	48,267	$	11,320	$	—	$	62,141	$	28,449	$	—

Related party payable (see Note 10)	$	—	$	—	$	21,706	$	—	$	—	$	28,840
Total liabilities	$	—	$	—	$	21,706	$	—	$	—	$	28,840

A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the periods ended September 30, 2019 and December 31, 2018, respectively, there were no transfers in and out of Level 1, 2, or 3. During the three month periods ended September 30, 2019 and 2018, respectively, we did not recognize any other-than-temporary impairment loss.

Some of the Company’s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.

Debt

We estimate the fair value of our $143,750 aggregate principal amount of 4.50% exchangeable senior notes due 2023 (the “2023 Notes”), a Level 2 input, based on interest rates that would be currently available to the Company for issuance of similar types of debt instruments with similar terms and remaining maturities or recent trading prices obtained from brokers. The estimated fair value of the 2023 Notes at September 30, 2019 is $76,425 compared to a book value of $120,132.

Additionally, the Company’s other debt is reflected in the balance sheet at carrying value. The fair value of these loans is impracticable to estimate as these represent non-interest bearing grants from the French government and are repayable only if the

- 15 -

research project is technically or commercially successful.

See Note 11: Long-Term Debt for additional information regarding our debt obligations.

NOTE 6: Marketable Securities

The Company has investments in equity and available-for-sale debt securities which are recorded at fair market value. The change in the fair value of equity investments is recognized in our unaudited condensed consolidated statements of loss and the change in the fair value of available-for-sale debt investments is recorded as other comprehensive income (loss) in shareholders’ (deficit) equity, net of income tax effects.

The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of September 30, 2019 and December 31, 2018, respectively:



	September 30, 2019
Marketable Securities:	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value

Equity securities	$	4,200	$	—	$	(24	)	$	4,176
Money market and mutual funds	43,306		785		—			44,091
Corporate bonds	4,190		69		(1		)	4,258
Government securities - U.S.	5,217		129		(2		)	5,344
Other fixed-income securities	1,693		26		(1		)	1,718
Total	$	58,606	$	1,009	$	(28	)	$	59,587



	December 31, 2018
Marketable Securities:	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value

Equity securities	$	10,101	$	—	$	(956	)	$	9,145
Money market and mutual funds	52,733		316		(53		)	52,996
Corporate bonds	6,411		7		(79		)	6,339
Government securities - U.S.	12,714		66		(79		)	12,701
Other fixed-income securities	9,400		22		(13		)	9,409
Total	$	91,359	$	411	$	(1,180	)	$	90,590

We determine realized gains or losses on the sale of marketable securities on a specific identification method. We reflect these gains and losses as a component of investment and other income in the accompanying unaudited condensed consolidated statements of loss.

We recognized gross realized gains of $71 and $143 for the three months ended September 30, 2019, and 2018, respectively. These realized gains were offset by realized losses of $64 and $22 for the three months ended September 30, 2019, and 2018, respectively.

We recognized gross realized gains of $339 and $378 for the nine months ended September 30, 2019, and 2018, respectively. These realized gains were offset by realized losses of $211 and $350 for the nine months ended September 30, 2019 and 2018, respectively. We reflect these gains and losses as a component of investment and other income in the accompanying condensed consolidated statements of income (loss).

- 16 -

The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of September 30, 2019:



	Maturities
Marketable Debt Securities:	Less than 1 Year		1-5 Years		5-10 Years		Greater than 10 Years		Total

Corporate bonds	$	556	$	3,360	$	342	$	—	$	4,258
Government securities - U.S.	—		4,600		—		744		5,344
Other fixed-income securities	49		1,669		—		—		1,718
Total	$	605	$	9,629	$	342	$	744	$	11,320

The Company has classified our investment in available-for-sale marketable debt securities as current assets in the unaudited condensed consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in our investment portfolio.

NOTE 7: Inventories

The principal categories of inventories, net reserves of $1,212 and $4,757 at September 30, 2019 and December 31, 2018, respectively, are comprised of the following:



Inventory:	September 30, 2019		December 31, 2018

Finished goods	$	1,883	$	4,270
Raw materials	377		500
Total	$	2,260	$	4,770

Total net reserves decreased by $3,545 during the nine months ended September 30, 2019 largely driven by the deconsolidation of Specialty Pharma.

NOTE 8: Goodwill and Intangible Assets

The Company’s amortizable and unamortizable intangible assets at September 30, 2019 and December 31, 2018 are as follows:



	September 30, 2019							December 31, 2018
Goodwill and Intangible Assets:	Gross Value		Accumulated Amortization			Net Carrying Amount		Gross Value		Accumulated Amortization			Impairment			Net Carrying Amount

Amortizable intangible assets:
Acquired developed technology - Noctiva	$	—	$	—		$	—	$	73,111	$	(7,024	)	$	(66,087	)	$	—
Acquired developed technology - Vazculep	12,061		(11,042		)	1,019		12,061		(10,432		)	—			1,629
Total amortizable intangible assets	$	12,061	$	(11,042	)	$	1,019	$	85,172	$	(17,456	)	$	(66,087	)	$	1,629

Unamortizable intangible assets:
Goodwill	$	18,491	$	—		$	18,491	$	18,491	$	—		$	—		$	18,491
Total unamortizable intangible assets	$	18,491	$	—		$	18,491	$	18,491	$	—		$	—		$	18,491

The Company recorded amortization expense related to amortizable intangible assets of $205 and $1,620 for the three months ended September 30, 2019 and 2018, respectively and $610 and $4,996 for the nine months ended September 30, 2019 and 2018, respectively.

- 17 -

During the fourth quarter 2018, certain conditions came to light, largely the lack of a meaningful increase in Noctiva prescriptions despite the substantial investment of resources, which indicated that the carrying value of the asset, may not be fully recoverable. As such, the Company performed an impairment test based on a comparison of the pretax discounted cash flows expected to be generated by the asset, which is a Level 3 fair value estimate, to the recorded value of the asset and concluded that the associated cash flows did not support any of the carrying value of the intangible asset and the Company recorded a full impairment charge of $66,087 at December 31, 2018 related to the acquired developed technology associated with Noctiva. The February 6, 2019 Chapter 11 bankruptcy filing of Specialty Pharma, the subsidiary which markets, sells and distributes Noctiva, confirmed management’s conclusion on the impairment.

Amortizable intangible assets are amortized over their estimated useful lives, which generally range from three to fifteen years. Estimated amortization of intangible assets for the next five years is as follows:



Estimated Annual Amortization Expense:	Amount

2019	$	815
2020	814
2021	—
2022	—
2023	—

NOTE 9: Leases

In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. On January 1, 2019, the Company adopted the ASU using the modified retrospective transition approach and elected the transition option to recognize the adjustment in the period of adoption rather than in the earliest period presented. As of January 1, 2019, adoption of the new guidance resulted in the initial recognition of operating lease right-of-use assets of $5,046 and operating lease liabilities of $5,131. At September 30, 2019, the balances of the operating lease right-of-use asset and total operating lease liability were $4,385 and $4,462, respectively, of which $1,596 of the operating lease liability is current.

The Company leases certain facilities for office and manufacturing purposes, comprising approximately 99% of the total lease population. All leased facilities are classified as operating leases with remaining lease terms between one and seven years. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. For all of the Company’s leases, lease and non-lease components are accounted for as a single lease component, as all non-lease components are immaterial to break out separately.

The components of lease costs, which are included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the three and nine months ended September 30 were as follows:



Lease cost:	Three months ended September 30, 2019		Nine months ended September 30, 2019

Operating lease costs ⁽¹⁾	$	411	$	1,150
Sublease income ⁽²⁾	82		187
Total lease cost	$	329	$	963

⁽¹⁾Variable lease costs were immaterial for the three and nine months ended September 30, 2019.

⁽²⁾ Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020. The Company also vacated portions of its office facility in St. Louis, Missouri during May 2019 and August 2019 and started receiving sublease income starting in May 2019 and August 2019 from two different tenants. The lease agreement ends in April 2025 and the sublease agreement that started in May 2019 ends in May 2020, with a one year renewal and the sublease agreement that started in August 2019 ends in July 2020, and can continue thereafter on a month-to-month basis.

During the three and nine months ended September 30, 2019, the Company reduced its operating lease liabilities by $411 and $1,115 for cash paid. In addition, during the nine months ended September 30, 2019, new operating leases commenced resulting

- 18 -

in the recognition of operating lease right-of-use assets and liabilities of $1,000 and $0, respectively, as the entire lease payment was paid on March 31, 2019. There were no new leases during the three months ended September 30, 2019. As of September 30, 2019, the Company is aware of one additional embedded lease that has not yet commenced and will not commence until the time of FDA approval of the product (if approved). Once FDA approval is given and the start date is determined, annual production suite fees of approximately $3,000 to $4,000 would commence and at that time an operating lease right-of-use asset and corresponding operating lease liability will be recorded.

In connection with the 2019 French Restructuring plan discussed in Note 15: Restructuring Costs, during the three months ended September 30, 2019, the Company came to an agreement with the landlord of the leased office space in France, to exit the lease by December 31, 2019 with an early termination payment of approximately $820. The Company accounted for this change in the lease term as a modification of the original lease. As a result of this modification, the right-of-use asset and liability related to the French office lease that was remeasured, and the asset was subsequently tested for impairment as the fair value was less than the book value. Since the fair value was determined to be less than the book value, the Company recorded an impairment to the right of use asset of $826, which was recorded as a restructuring cost in the unaudited condensed consolidated statements of loss.

As of September 30, 2019, our operating leases have a weighted-average remaining lease term of 4.3 years and a weighted-average discount rate of 5.3%. Nearly all of Avadel’s lease contracts do not provide a readily determinable implicit rate. For these contracts, Avadel’s estimated incremental borrowing rate is based on information available at the inception of the lease.

Maturities of the Company’s operating lease liabilities were as follows:



Maturities:	Operating Leases

Remaining three months of 2019	$	1,117
2020	879
2021	670
2022	678
2023	690
Thereafter	941
Total lease payments	4,975
Less: interest	513
Present value of lease liabilities	$	4,462

Under the prior lease guidance, minimum rental commitments for non-cancelable leases as of December 31, 2018 were:



Lease Commitment:	Operating Leases

2019	$	1,191
2020	1,208
2021	1,008
2022	767
2023	695
Thereafter	967
Total minimum lease payments	$	5,836

- 19 -

NOTE 10: Long-Term Related Party Payable

Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2019 and December 31, 2018:



				Activity during the Nine Months Ended September 30, 2019
							Changes in Fair Value of Related Party Payable
Long-Term Related Party Payable:	Balance, December 31, 2018			Payments to Related Parties			Operating Expense		Other Expense		Balance, September 30, 2019

Acquisition-related contingent consideration:
Earn-out payments - Éclat Pharmaceuticals (a)	$	25,615		$	(8,640	)	$	2,384	$	—	$	19,359
Financing-related:
Royalty agreement - Deerfield (b)	2,184			(930		)	—		330		1,584
Royalty agreement - Broadfin (c)	1,041			(444		)	—		166		763
Total related party payable	28,840			$	(10,014	)	$	2,384	$	496	21,706
Less: current portion	(9,439		)								(7,588		)
Total long-term related party payable	$	19,401									$	14,118

Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2019 and June 30, 2019:



				Activity during the Three Months Ended September 30, 2019
							Changes in Fair Value of Related Party Payable
Long-Term Related Party Payable:	Balance, June 30, 2019			Payments to Related Parties			Operating Expense		Other Expense		Balance, September 30, 2019

Acquisition-related contingent consideration:
Earn-out payments - Éclat Pharmaceuticals (a)	$	21,582		$	(2,850	)	$	627	$	—	$	19,359
Financing-related:
Royalty agreement - Deerfield (b)	1,799			(309		)	—		94		1,584
Royalty agreement - Broadfin (c)	866			(148		)	—		45		763
Total related party payable	24,247			$	(3,307	)	$	627	$	139	21,706
Less: current portion	(8,264		)								(7,588		)
Total long-term related party payable	$	15,983									$	14,118

(a) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s former CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.

(b)

As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products.


(c)	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.

- 20 -

At September 30, 2019, the fair value of each related party payable listed in (a), (b) and (c) above was estimated using a discounted cash flow model based on estimated and projected annual net revenues or gross profit, as appropriate, of each of the specified Éclat products using an appropriate risk-adjusted discount rate of 15%. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management’s revision of key assumptions, will be recorded in the unaudited condensed consolidated statements of loss in the line items entitled “Changes in fair value of related party contingent consideration” for items noted in (b) above and in “Other expense - changes in fair value of related party payable” for items (b) and (c) above. See Note 1: Summary of Significant Accounting Policies under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K for more information on key assumptions used to determine the fair value of these liabilities.

The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for its royalty agreements detailed in items (b) and (c) above. These financing-related liabilities are recorded at fair market value on the unaudited condensed consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – change in fair value of related party payable” on the unaudited condensed consolidated statements of loss.

The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the nine-month periods ended September 30, 2019 and 2018, respectively:



Related Party Payable Rollforward:	Balance

Balance, December 31, 2017	$	98,925
Payments of related party payable	(19,261		)
Fair value adjustments ⁽¹⁾	(18,468		)
Expiration of warrants	(2,167		)
Disposition of the pediatric assets	(20,337		)
Balance, September 30, 2018	$	38,692

Balance, December 31, 2018	$	28,840
Payments of related party payable	(10,014		)
Fair value adjustments ⁽¹⁾	2,880
Balance, September 30, 2019	$	21,706

⁽¹⁾Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.

NOTE 11: Long-Term Debt

Long-term debt is summarized as follows:



	September 30, 2019			December 31, 2018
Principal amount of 4.50% exchangeable senior notes due 2023	$	143,750		$	143,750
Less: debt discount and issuance costs, net	(23,618		)	(28,059		)
Net carrying amount of liability component	120,132			115,691
Other debt	35			149
Subtotal	120,167			115,840
Less: current maturities	(35		)	(106		)
Long-term debt	$	120,132		$	115,734

Equity component:
Equity component of exchangeable notes, net of issuance costs	$	(26,699	)	$	(26,699	)

- 21 -

NOTE 12: Income Taxes

The components of loss before income taxes are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Loss Before Income Taxes:	2019			2018			2019			2018

Ireland	$	(14,302	)	$	(18,314	)	$	(36,625	)	$	(34,203	)
United States	5,952			1,773			12,309			(1,043		)
France	1,720			79			(2,530		)	441
Total loss before income taxes	$	(6,630	)	$	(16,462	)	$	(26,846	)	$	(34,805	)

The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Income Tax Rate Reconciliation:	2019			2018			2019			2018

Statutory tax rate	12.5		%	12.5		%	12.5		%	12.5		%
International tax rates differential	(4.3		)%	7.0		%	4.1		%	6.9		%
Change in valuation allowance	(31.1		)%	(18.3		)%	(27.0		)%	(14.9		)%
Change in fair value of nondeductible contingent consideration	4.1		%	8.7		%	(0.1		)%	9.9		%
Nondeductible stock-based compensation	—		%	(3.5		)%	(0.2		)%	(2.6		)%
Unrecognized tax benefits	(8.8		)%	(3.5		)%	(3.3		)%	(3.1		)%
State and local income taxes, net of federal	(0.2		)%	0.1		%	(0.2		)%	0.2		%
Nondeductible interest expense	(4.5		)%	—		%	(2.6		)%	—		%
Other	(1.3		)%	1.2		%	3.1		%	0.8		%
Effective income tax rate	(33.6		)%	4.2		%	(13.7		)%	9.7		%

Income tax benefit - at statutory tax rate	$	(829	)	$	(2,058	)	$	(3,355	)	$	(4,351	)
International tax rates differential	283			(1,153		)	(1,108		)	(2,394		)
Change in valuation allowance	2,059			3,007			7,242			5,188
Change in fair value of nondeductible contingent consideration	(270		)	(1,431		)	33			(3,436		)
Nondeductible stock-based compensation	1			578			50			914
Unrecognized tax benefits	581			578			873			1,086
State and local income taxes, net of federal	14			(13		)	41			(70		)
Nondeductible interest expense	299			—			709			—
Other	96			(199		)	(844		)	(297		)
Income tax provision (benefit) - at effective income tax rate	$	2,234		$	(691	)	$	3,641		$	(3,360	)

The income tax provision was $2,234 for the three months ended September 30, 2019 and a benefit of $691 for the three months ended September 30, 2018. The increase in the income tax provision for the three months ended September 30, 2019 is primarily the result of a decrease in the amount of nontaxable gain from the revaluation of contingent consideration and an increase in the amount of valuation allowances recorded on foreign income tax losses.

The income tax provision was $3,641 for the nine months ended September 30, 2019 and a benefit of $3,360 for the nine months ended September 30, 2018. The increase in the income tax provision for the nine months ended September 30, 2019 is primarily the result of a decrease the amount of nontaxable gain from the revaluation of contingent consideration and an increase in the amount of valuation allowances recorded on foreign income tax losses.

The IRS commenced an examination of the Company's U.S. income tax returns for 2016 and 2017 during the second quarter 2019.

- 22 -

NOTE 13: Other Assets and Liabilities

Various other assets and liabilities are summarized as follows:



Prepaid Expenses and Other Current Assets:	September 30, 2019		December 31, 2018

Valued-added tax recoverable	$	807	$	1,378
Prepaid and other expenses	2,757		2,145
Guarantee from Armistice (see Note 14)	560		534
Income tax receivable	594		921
Research and development tax credit receivable	270		283
Short-term deposit	—		3,350
Other	175		225
Total	$	5,163	$	8,836



Other Non-Current Assets:	September 30, 2019		December 31, 2018

Deferred tax assets, net	$	21,636	$	23,029
Long-term deposits	1,477		1,477
Guarantee from Armistice (see Note 14)	5,271		5,697
Right of use assets at contract manufacturing organizations	6,494		5,894
Other	49		49
Total	$	34,927	$	36,146



Accrued Expenses	September 30, 2019		December 31, 2018

Accrued compensation	$	2,322	$	3,971
Accrued social charges	482		1,009
Accrued restructuring (see Note 15)	1,737		879
Customer allowances	6,244		6,541
Accrued contract research organization charges	3,389		1,000
Accrued contract manufacturing organization costs	1,284		2,028
Accrued contract sales organization and marketing costs	—		3,469
Other	1,559		2,798
Total	$	17,017	$	21,695



Other Non-Current Liabilities:	September 30, 2019		December 31, 2018

Provision for retirement indemnity	$	—	$	1,024
Customer allowances	923		1,352
Unrecognized tax benefits	7,717		5,315
Guarantee to Deerfield (see Note 14)	5,289		5,717
Other	43		594
Total	$	13,972	$	14,002

14: Divestiture of the Pediatric Assets

On February 12, 2018, the Company, together with its subsidiaries Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics, LLC (“FSC Therapeutics”), and Avadel US Holdings, Inc. (“Holdings”), as the “Sellers,” entered into an asset purchase agreement (the “Purchase Agreement”) with Cerecor, Inc. (“Cerecor”). The transaction closed on February 16, 2018 wherein Cerecor purchased from the Sellers four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™, together with certain associated business assets – which were held by FSC. The Company acquired FSC in February 2016 from Deerfield and certain of its affiliates. Pursuant to the Purchase Agreement, Cerecor assumed the Company’s remaining payment obligations to Deerfield under the Membership Interest Purchase Agreement, dated as of February

- 23 -

5, 2016, between Holdings, Flamel Technologies SA (the predecessor of the Company) and Deerfield and certain of its affiliates, which payment obligations consist of the following (collectively, the “Assumed Obligations”): (i) a quarterly payment of $263 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625; (ii) a payment in January 2021 of $15,263; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 5, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300. Cerecor also assumed certain contracts and other obligations related to the acquired assets, and in that connection Holdings agreed to pay Cerecor certain make-whole payments associated with obligations Cerecor is assuming related to a certain supply contract related to Karbinal™ ER.

In conjunction with the divestiture, the Company also entered into the following arrangements:

License and Development Agreement

Also, in connection with the closing under the Purchase Agreement, Flamel Ireland Limited, an Irish limited company operating under the trade name of Avadel Ireland (“Avadel Ireland”) and a wholly-owned subsidiary of the Company, and Cerecor entered into a license and development agreement (the “License and Development Agreement”) pursuant to which, among other things:


•	Avadel Ireland will provide Cerecor with four product formulations utilizing Avadel Ireland’s LiquiTime™ technology, and will complete pilot bioequivalence studies for such product formulations within 18 months;


•	Cerecor will reimburse Avadel Ireland for development costs of the four LiquiTime™ products in excess of $1,000 in the aggregate;


•	Upon transfer of the four product formulations, Cerecor will assume all remaining development costs and responsibilities for the product development, clinical studies, NDA applications and associated filing fees; and


•	Upon regulatory approval and commercial launch of any LiquiTime™ products, Cerecor will pay Avadel Ireland quarterly royalties based on a percentage of net sales of any such products in the mid-single digit range.

Effective October 25, 2019, Cerecor and Avadel Ireland agreed to terminate the License and Development Agreement.

Deerfield Guarantee

In connection with the closing under the Purchase Agreement, the Company and Holdings provided their guarantee (the “Deerfield Guarantee”) in favor of Deerfield. Under the Deerfield Guarantee, the Company and Holdings guaranteed to Deerfield the payment by Cerecor of the Assumed Obligations under the Membership Interest Purchase Agreement between the Company and Deerfield dated February 5, 2016. The Assumed Obligations include (i) a quarterly payment of $263 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625; (ii) a payment in January 2021 of $15,263; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 6, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300. In addition, under the Deerfield Guarantee, the Company and Holdings guaranteed that Deerfield would receive certain minimum annual FSC Product Royalties through February 6, 2026 (the “Minimum Royalties”). Given the Company’s explicit guarantee to Deerfield, the Company recorded the guarantee in accordance with ASC 460. A valuation was performed, which was based largely on an analysis of the potential timing of each possible cash outflow described above and the likelihood of Cerecor’s default on such payments assuming an S&P credit rating of CCC+. The result of this valuation identified a guarantee liability of $6,643. This liability is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield. At September 30, 2019, the carrying value of this liability was $5,851.

Armistice Guarantee

In connection with the closing under the Purchase Agreement, Armistice Capital Master Fund, Ltd., the then majority shareholder of Cerecor, guaranteed to Holdings the payment by Cerecor of the Assumed Obligations, including the Minimum Royalties. A valuation of the guarantee asset was performed in accordance with ASC 460 and a guarantee asset of $6,620 was recorded. This asset is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield noted above. At September 30, 2019, the carrying value of this asset was $5,831.

The fair values of the Avadel guarantee to Deerfield and the guarantee received by Avadel from Armistice largely offset and when combined are not material.

- 24 -

Based on management’s review of ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, the disposition of our pediatric assets and related liabilities did not qualify for discontinued operations reporting. Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC, prior to its February 16, 2018 disposition date.

Recent Updates to Guarantees

On October 10, 2019 Cerecor entered into a purchase and sale agreement with a Aytu BioScience, Inc (“Buyer”) pursuant to which the Buyer will purchase certain assets from Cerecor and assume certain of Cerecor’s liabilities, including all of Cerecor’s liabilities assumed as part of the Purchase Agreement noted above. As part of this transaction, on November 1, 2019, Armistice has agreed to deposit $15,000 in an escrow account governed by an escrow agreement between Armistice and Deerfield having the purpose of securing the $15,000 balloon payment due January 2021 as part of the Membership Interest Purchase Agreement. As part of the Cerecor transaction with the buyer, Deerfield contractually acknowledges and agrees that they will seek payment from the escrow funds before requesting payment from the Company pursuant to the Deerfield Guarantee discussed above. As a result, the Company is in process of assessing the impact this escrow deposit has on the fair values of the guarantees and will adjust such carrying values in the quarter ending December 31, 2019.

The net impact of this transaction was not material to the unaudited condensed consolidated statements of loss.

NOTE 15: Restructuring Costs

2019 French Restructuring

During the second quarter of 2019, the Company initiated a plan to substantially reduce all of its workforce at its Vénissieux, France site (“2019 French Restructuring”). This reduction is an effort to align the Group’s cost structure with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of calendar year 2019, and to result in employee severance, benefits and other costs of up to approximately $3,500, which are likely to be recognized through December 31, 2019. Restructuring charges associated with this plan of $1,259 and $3,198 were recognized during the three and nine months ended September 30, 2019. Included in the 2019 French Restructuring charges of $3,198 were charges for employee severance, benefits and other costs of $2,774, a charge of $598 related to fixed asset impairment, a charge of $826 related to the early termination penalty related to the office lease termination (see Note 9: Leases) as well as a benefit of $1,000 related to the reversal of the French retirement indemnity obligation.

The following table sets forth activities for the Company’s cost reduction plan obligations for the three and nine months ended September 30, 2019:



2019 French Restructuring Obligation:	2019

Balance of restructuring accrual at January 1,	$	—
Charges for employee severance, benefits and other costs	2,774
Payments	(1,837		)
Foreign currency impact	(42		)
Balance of restructuring accrual at September 30,	$	895

The 2019 French Restructuring liabilities of $884 and $11 are included in the unaudited condensed consolidated balance sheet in accrued expenses and accounts payable at September 30, 2019, respectively.

2019 Corporate Restructuring

During the first quarter of 2019, the Company announced a plan to reduce its Corporate workforce by more than 50% (“2019 Corporate Restructuring”). The reduction in workforce is primarily a result of the exit of Noctiva during the first quarter of 2019 (see Note 3: Subsidiary Bankruptcy and Deconsolidation), as well as an effort to better align the Company’s remaining cost structure at our U.S. and Ireland locations with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of calendar year 2019, and to result in employee severance, benefits and other costs of up to approximately $3,000, which are likely to be recognized through December 31, 2019. The restructuring charges associated with this plan of $607 and $1,570 were recognized during the three and nine months ended September 30, 2019, respectively. Included in the 2019 Corporate Restructuring expense of $607 for the three months ended September 30, 2019 were charges for employee severance, benefit and other costs. Included in the 2019 Corporate Restructuring charges of $1,570 for the nine months

- 25 -

ended September 30, 2019, were charges for employee severance, benefit and other costs of $2,966, as well as a benefit of $1,396 related to share based compensation forfeitures related to the employees affected by the global reduction in workforce.

The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2019:



2019 Corporate Restructuring Obligation:	2019

Balance of restructuring accrual at January 1,	$	—
Charges for employee severance, benefits and other costs	2,966
Payments	(2,113		)
Balance of restructuring accrual at September 30,	$	853

2019 Corporate Restructuring liabilities of $853 are included in the unaudited condensed consolidated balance sheet in accrued expenses at September 30, 2019.

2017 French Restructuring

During the first quarter of 2017, the Company announced a plan to reduce its workforce at the Venissieux, France site by approximately 50% (“2017 French Restructuring”). This reduction was an effort to align the Company’s cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council for our French operations and received approval from the French Labor Commission (DIRECCTE) to implement the plan. The reduction was substantially complete at September 30, 2019. The 2017 French restructuring costs for the three months ended September 30, 2019 and 2018 were immaterial. The 2017 French Restructuring income of $168 and restructuring charges of $268 were recognized during the nine months ended September 30, 2019 and 2018, respectively. The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2019 and 2018:



2017 French Restructuring Obligation:	2019			2018

Balance of restructuring accrual at January 1,	$	879		$	1,000
Charges for employee severance, benefits and other	(168		)	268
Payments	(663		)	(668		)
Foreign currency impact	(10		)	(19		)
Balance of restructuring accrual at September 30,	$	38		$	581

The 2017 French Restructuring accrual is included in the unaudited condensed consolidated balance sheet in other non-current liabilities at September 30, 2019 and 2018.

NOTE 16: Net Loss Per Share

Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during each period. Diluted net (loss) income per share is calculated by dividing net (loss) income by the diluted number of shares outstanding during each period. Except where the result would be anti-dilutive to net loss, diluted net loss per share would be calculated assuming the impact of the conversion of the 2023 Notes, the exercise of outstanding equity compensation awards, ordinary shares expected to be issued under our employee stock purchase plan (“ESPP”) and the exercise of contingent consideration warrants, all which have been exercised or have expired during the first quarter of 2018.

We have a choice to settle the conversion obligation under the 2023 Notes in cash, shares or any combination of the two. We utilize the if-converted method to reflect the impact of the conversion of the 2023 Notes, unless the result is anti-dilutive. This method assumes the conversion of the 2023 Notes into shares of our ordinary shares and reflects the elimination of the interest expense related to the 2023 Notes.

The dilutive effect of the warrants, stock options, RSU’s and ordinary shares expected to be issued under or ESPP has been calculated using the treasury stock method.

- 26 -

A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Net Loss Per Share:	2019			2018			2019			2018

Net loss	$	(8,864	)	$	(15,771	)	$	(30,487	)	$	(31,445	)

Weighted average shares:
Basic shares	37,436			36,904			37,382			37,410
Effect of dilutive securities—employee and director equity awards outstanding and 2023 Notes	—			—			—			—
Diluted shares	37,436			36,904			37,382			37,410

Net loss per share - basic	$	(0.24	)	$	(0.43	)	$	(0.82	)	$	(0.84	)
Net loss per share - diluted	$	(0.24	)	$	(0.43	)	$	(0.82	)	$	(0.84	)

Potential common shares of 19,544 and 18,742 were excluded from the calculation of weighted average shares for the three months ended September 30, 2019 and 2018, respectively, because their effect was considered to be anti-dilutive. Potential common shares of 20,512 and 16,647 were excluded from the calculation of weighted average shares for the nine months ended September 30, 2019 and 2018, respectively. For the three and nine months ended September 30, 2019 and 2018, the effects of dilutive securities were entirely excluded from the calculation of net loss per share as a net loss was reported in this period.

NOTE 17: Comprehensive Loss

The following table shows the components of accumulated other comprehensive loss for the three and nine months ended September 30, 2019 and 2018, respectively, net of tax effects:



	Three Months Ended September 30,						Nine Months Ended September 30,
Accumulated Other Comprehensive Loss:	2019			2018			2019			2018

Foreign currency translation adjustment:
Beginning balance	$	(23,720	)	$	(23,435	)	$	(23,621	)	$	(23,202	)
Net other comprehensive loss	(210		)	(60		)	(309		)	(293		)
Balance at September 30,	$	(23,930	)	$	(23,495	)	$	(23,930	)	$	(23,495	)

Unrealized gain (loss) on marketable debt securities, net
Beginning balance	$	872		$	(224	)	$	205		$	(64	)
Net other comprehensive income (loss), net of ($5), ($18), ($46) and ($88) tax, respectively	86			68			753			(92		)
Balance at September 30,	$	958		$	(156	)	$	958		$	(156	)
Accumulated other comprehensive loss at September 30,	$	(22,972	)	$	(23,651	)	$	(22,972	)	$	(23,651	)

The effect on the Company’s unaudited condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.

NOTE 18: Revenue by Product

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

- 27 -

The following table presents a summary of total revenues by these products:



	Three Months Ended September 30,					Nine Months Ended September 30,
Revenues by Product:	2019			2018		2019		2018

Bloxiverz	$	1,466		$	3,656	$	6,392	$	16,691
Vazculep	8,786			8,759		27,669		33,097
Akovaz	4,208			5,991		13,946		28,083
Other	(231		)	1,420		213		4,232
Total product sales	14,229			19,826		48,220		82,103
License revenue	—			—		—		246
Total revenues	$	14,229		$	19,826	$	48,220	$	82,349

NOTE 19: Commitments and Contingencies

Litigation

The Company is subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At September 30, 2019 and December 31, 2018, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s unaudited condensed consolidated financial position, results of operations, cash flows or liquidity.

Litigation Related to Noctiva

Note 3: Subsidiary Bankruptcy and Deconsolidation briefly describes the Chapter 11 bankruptcy case which our subsidiary Specialty Pharma commenced on February 6, 2019, and which on April 26, 2019 resulted in the bankruptcy court-approved sale of all of Specialty Pharma’s intangible assets and inventory to an unaffiliated third party. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business. During the pendency of the bankruptcy case, all pending litigation against Specialty Pharma is automatically stayed and any new litigation against Specialty Pharma is precluded unless the bankruptcy court orders otherwise. Below are descriptions of a litigation to which Specialty Pharma is a party and a contract dispute involving Specialty Pharma, both of which matters are subject to the automatic stay during the bankruptcy case.

Ferring Litigation. Some of the patents covering the Noctiva^TM product (the “Noctiva Patents”) are the subject of litigation initiated by Ferring Pharmaceuticals Inc. and two of its foreign affiliates, who manufacture a competing product known as Nocdurna. Nocdurna was approved by the FDA in June 2018 and commercially launched in the U.S. in November 2018. In this litigation, Ferring seeks to invalidate and disputes the inventorship of the Noctiva Patents, seeks damages for various alleged breaches of contractual and common law duties, and seeks damages for alleged infringement by Noctiva^TM of Ferring’s “Nocdurna” trademark. Specialty Pharma and certain other parties including Serenity Pharmaceuticals, LLC (“Serenity”) (the licensor of the Noctiva Patents) have defended this litigation, and have made counterclaims against Ferring, including for infringement of the Noctiva Patents and a declaratory judgment of noninfringement with respect to Ferring’s “Nocdurna” trademark. The court dismissed Ferring’s inventorship claim and its claims for alleged breaches of contractual and common law duties, although these dismissals may be appealed by Ferring. On February 15, 2019, Specialty Pharma and its co-defendants moved to stay the litigation pending completion of the bankruptcy proceeding of Specialty Pharma. On May 15, 2019, that motion was denied due to an impending settlement of the litigation with respect to just Ferring and Specialty Pharma.

Contract Dispute. On January 21, 2019, Serenity gave notice to Specialty Pharma of an alleged breach of the parties’ Noctiva license agreement. Serenity alleges that Specialty Pharma breached its contractual obligation to devote commercially reasonable efforts to the commercialization of Noctiva and seeks unspecified damages. On January 27, 2019, Specialty Pharma notified Serenity of a claim for $1.7 million in damages as a result of Serenity’s breach of its contractual obligation to pay the costs of the Ferring Litigation. Serenity’s notice to Specialty Pharma invoked the dispute resolution provisions of the Noctiva license agreement, which culminate in arbitration, but neither party has yet initiated an arbitration proceeding or filed suit.

- 28 -

Material Commitments

Due to the Chapter 11 bankruptcy case of Specialty Pharma, the Company’s various commitments to purchase finished product from suppliers has changed from what was included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K. As of September 30, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:



Purchase Commitments:	Balance

2019	$	7,194
2020	1,320
2021	1,320
2022	1,320
2023	220
Thereafter	—
Total	$	11,374

Other than commitments disclosed in Note 15: Contingent Liabilities and Commitments to the Company’s audited consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt obligations which are disclosed in Note 10: Long-Term Debt, respectively, to the Company’s consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K and long-term contingent consideration payable as disclosed in Note 10: Long-Term Related Party Payable, to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this report.

- 29 -

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management’s Discussion and Analysis

(In thousands, except per share data)

(Unaudited)

You should read the discussion and analysis of our financial condition and results of operations set forth in this Item 2 together with our unaudited condensed consolidated financial statements and the related notes appearing elsewhere in this quarterly report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties, and reference is made to the “Cautionary Note Regarding Forward-Looking Statements” set forth immediately following the Table of Contents of this Quarterly Report on Form 10-Q for further information on the forward looking statements herein. In addition, you should read the “Risk Factors” section in Part I, Item 1A of our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 15, 2019 and Part II, Item 1A in this quarterly report on Form 10-Q for a discussion of additional important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this quarterly report.

Overview

General Overview

Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company. Our primary focus is on the development and potential U.S. Food and Drug Administration (“FDA”) approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Our current marketed products include:


•	Akovaz® (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.


•	Bloxiverz® (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.


•	Vazculep® (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Each of our Akovaz, Bloxiverz and Vazculep products is used primarily in the hospital setting and was developed under our UMD program.

Business Strategies

Our primary business strategy is to focus on the development and potential FDA approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from EDS and cataplexy. In addition, we will continue market and distribute our current approved hospital products portfolio, including seeking FDA approval for and the commercialization of our fourth UMD product. Additionally, we will continue to evaluate opportunities to expand our product portfolio. These strategies are described below in greater detail.

FT218 (Micropump® sodium oxybate): FT218 (Micropump® sodium oxybate): Avadel is developing a product that uses our Micropump® drug-delivery technology for the treatment of EDS and cataplexy in patients suffering from narcolepsy. Avadel

- 30 -

currently refers to this product as FT218. FT218 is a Micropump®-based formulation of sodium oxybate. Sodium oxybate is the sodium salt of gamma hydroxybutyrate, an endogenous compound and metabolite of the neurotransmitter gamma-aminobutyric acid. Sodium oxybate has been described as a therapeutic agent with high medical value. Sodium oxybate is approved in Europe and the United States as a twice nightly formulation indicated for the treatment of EDS and cataplexy in patients with narcolepsy.

In preparation for a clinical trial of FT218, Avadel reached an agreement with the FDA for the design and planned analysis of our pivotal Phase 3 study, Rest-On through a Special Protocol Assessment (“SPA”). A SPA is an acknowledgment by the FDA that the design and planned analysis of a pivotal clinical trial adequately addresses the objectives necessary to support a regulatory submission. Pursuant to the SPA, in December 2016, Avadel initiated patient enrollment and dosing for the Rest-On clinical trial to assess the safety and efficacy of a once-nightly formulation of FT218 for the treatment of EDS and cataplexy in patients suffering from narcolepsy. The study is a randomized, double-blind, placebo-controlled study of 264 patients being conducted in 45 to 55 clinical sites in the U.S., Canada, Western Europe and Australia. Avadel believes that, if successful, this study could demonstrate improved efficacy, safety and patient satisfaction over the current primary product serving this market, which is a twice nightly sodium oxybate formulation, for which the marketer has forecasted revenues of approximately $1.6 billion for the year ended December 31, 2019.

In September 2019, the Company announced that the FDA agreed to the Company’s proposed amendments to the statistical analysis plan and protocol under its SPA for FT218, resulting in a lower sample size needed to demonstrate significance for both excessive daytime sleepiness and cataplexy in narcolepsy patients. No modifications were made to the fundamental design of the study, including the primary or secondary endpoints, dosing scheme or duration of the study, and the SPA remains intact. The study will now target enrolling 205 patients. Based on this updated target size and current enrollment, the Company expects to complete enrollment by the end of 2019 and have topline data in the second quarter of 2020.

In January 2018, the FDA granted FT218 Orphan Drug Designation, which makes the drug eligible for certain development and commercial incentives, including a potential U.S. market exclusivity for up to seven years as the only once-nightly formulation. However, please see the information set forth under the caption “- Risks Related to Regulatory and Legal Matters - If FT218 is approved by the FDA, we may not obtain orphan drug marketing exclusivity” in the “Risk Factors” included in Part I, Item 1A of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

Development of Micropump®-Based Products

Avadel’s Micropump® drug delivery technology presents product development opportunities, representing either “life cycle” opportunities, whereby additional intellectual property can be added to a pharmaceutical product to extend the commercial viability of a currently marketed product, or innovative formulation opportunities for new chemical entities (“NCEs”). FT218 is formulated using this technology. If approved by the FDA, this product may be commercialized either by Avadel and/or by partners via licensing/distribution agreements.

Unapproved Marketed Drug (“UMD”) Products

In 2006, the FDA issued its Marketed Unapproved Drugs - Compliance Policy Guide with the intention to incentivize pharmaceutical companies to pursue approvals for pharmaceutical products, many of which pre-date the establishment of the FDA. Although in most cases these products are not protected by patents or similar intellectual property, the FDA’s Compliance Policy Guide dictates that should the FDA approve a new drug application for any such products via a 505(b)(2) process, the FDA will remove competing unapproved manufacturers until a generic application is approved. Avadel believes that over a thousand unapproved drugs are marketed in the United States today and, while many of these products are outdated therapies, we strategically evaluate those UMD products that are more commonly used as candidates for possible future FDA approval and marketing under our UMD program.

To date, Avadel has received FDA approvals for three UMD products which we currently market under the brand names Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulfate injection).

Additional UMD Products. Avadel is developing and intends to seek FDA approval of an NDA for AV001, a sterile injectable product for use in the hospital setting. If the NDA is approved, AV001 could contribute revenues to Avadel starting in 2020. The Company submitted the NDA in March 2019, and it was originally granted Priority Review status by the FDA resulting in a six-month review period with an initial assigned PDUFA target date of September 15, 2019. However, on July 31, 2019, the Company received notification that the FDA extended the PDUFA date to December 15, 2019. This extension relates to recent submissions the Company made in response to FDA requests for additional analytical information. The FDA determined that these submissions constitute a major amendment and will require additional time to review. The Company believes that this three-month extension

- 31 -

should not impact the launch timeline, which is still anticipated for early 2020. In addition, Avadel continues to monitor and evaluate other UMDs with large existing markets and limited competition for feasibility of possible future NDAs. Avadel believes its strategy to create opportunities to commercialize UMD products in markets with a limited number of competitors may have a limited number of opportunities given the lack of patent protection from competition. Avadel believes this shorter-term strategy may provide us with near term revenue growth and provide cash flows that can be used to fund R&D and inorganic initiatives for the development of FT218 and, perhaps, other products.

Corporate Information

The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in Note 3: Subsidiary Bankruptcy and Deconsolidation), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French société par actions simplifiée, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities.

References in these unaudited condensed consolidated financial statements and the notes thereto to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires.

Key Business Trends and Highlights

In operating our business and monitoring our performance, we consider a number of performance measures, as well as trends affecting our industry as a whole, which include the following:

•

Healthcare and Regulatory Reform: Various health care reform laws in the U.S. may impact our ability to successfully commercialize our products and technologies. The success of our commercialization efforts may depend on the extent to which the government health administration authorities, the health insurance funds in the E.U. Member States, private health insurers and other third-party payers in the U.S. will reimburse consumers for the cost of healthcare products and services.

- 32 -

•

Competition and Technological Change: Competition in the pharmaceutical and biotechnology industry continues to be intense and is expected to increase. We compete with academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology companies, including other companies developing niche branded or generic specialty pharmaceutical products or drug delivery platforms. Furthermore, major technological changes can happen quickly in the pharmaceutical and biotechnology industries. Such rapid technological change, or the development by our competitors of technologically improved or differentiated products, could render our drug delivery platforms obsolete or noncompetitive.


•	Pricing Environment for Pharmaceuticals: The pricing environment continues to be in the political spotlight in the U.S. As a result, the need to obtain and maintain appropriate pricing for our products may become more challenging due to, among other things, the attention being paid to healthcare cost containment and other austerity measures in the U.S. and worldwide.


•	Generics Playing a Larger Role in Healthcare: Generic pharmaceutical products will continue to play a large role in the U.S. healthcare system. Specifically, we have seen, or likely will see, additional generic competition to our current and future products and we continue to expect generic competition in the future.


•	Access to and Cost of Capital: The process of raising capital and associated cost of such capital for a company of our financial profile can be difficult and potentially expensive. If the need were to arise to raise additional capital, access to that capital may be difficult and/or expensive and, as a result, could create liquidity challenges for the Company.


•	Net Loss from Operations in 2019: In part because we expect sales of our hospital products to significantly decline from 2018’s levels and we will incur substantial expenses to further the clinical development of FT218, we likely will incur a net loss in 2019 the amount of which is not known to us at this time.

Financial Highlights

Highlights of our consolidated results for the three and nine months ended September 30, 2019 are as follows:

•

Revenue was $14,229 and $48,220 for the three and nine months ended September 30, 2019, respectively, compared to $19,826 and $82,349 in the same periods last year, respectively. This year over year decrease was primarily the result of increased competition driving lower prices as noted above in our discussion of Key Business Trends and Highlights. We experienced price and unit volume declines across all our hospital products due to additional competition.

•

Operating loss was $4,147 and $16,765 for the three and nine months ended September 30, 2019, respectively, compared to operating loss of $14,095 and $29,505 and for the same periods last year, respectively. The decrease in operating loss for the three months ended September 30, 2019 was largely driven by lower selling, general and administrative (SG&A) expenses of $19,513 driven by the exit of Noctiva, partially offset by higher expense related to the changes in fair value of related party contingent consideration of $7,742 and lower gross margin of $5,300. The primary reasons for the decrease in operating loss for the nine months ended September 30, 2019 were (i) a $54,639 decline in SG&A expense and (ii) a $8,083 decline in research and development expense, partially offset by (iii) a $30,616 decline in gross margin (i.e., total revenues minus cost of products) and (iv) a $19,420 increase in expense related to the changes in fair value of related party contingent consideration.

•

Net loss was $8,864 and $30,487 for the three and nine months ended September 30, 2019, respectively, compared to net loss of $15,771 and $31,445 in the same periods last year, respectively. Included in the net loss during the nine months ended September 30, 2019 was a loss on the deconsolidation of Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”) of $2,840. As a result of Avadel Specialty Pharmaceuticals, LLC bankruptcy filing on February 6, 2019, the Company concluded that it no longer controls the operations of this subsidiary and accordingly deconsolidated this subsidiary.


•	Diluted net loss per share was $0.24 and $0.82 for the three and nine months ended September 30, 2019, respectively, compared to diluted net loss per share of $0.43 and $0.84 in the same period last year, respectively.


•	Cash and marketable securities decreased $27,461 to $72,454 at September 30, 2019, from $99,915 at December 31, 2018. This decrease was largely driven from $30,072 use of cash in operations.

- 33 -

Critical Accounting Estimates

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. To prepare these financial statements, management makes estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosures of contingent assets and liabilities. Actual results could be significantly different from these estimates.

Our significant accounting policies are described in Note 1 of the audited consolidated financial statements included in our Annual Report Form 10-K for the year ended December 31, 2018 (the “2018 Form 10-K”). The SEC suggests companies provide additional disclosure on those accounting policies considered most critical. The SEC considers an accounting policy to be critical if it is important to our financial condition and results of operations and requires significant judgments and estimates on the part of management in its application. Our estimates are often based on complex judgments, probabilities and assumptions that management believes to be reasonable, but that are inherently uncertain and unpredictable. It is also possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. For a complete discussion of our critical accounting policies, see the “Critical Accounting Policies” section of the MD&A in our 2018 Form 10-K. Effective January 1, 2019, the Company implemented ASC 842, Leases. The impact of adopting this new accounting standard required the Company to recognize $5,046 and $5,131 of assets and liabilities, respectively, related to the Company’s operating leases. See Note 9: Leases in the notes to the unaudited condensed consolidated financial statements for further information.

Results of Operations

The following is a summary of our financial results (in thousands, except per share amounts) for the three months ended September 30, 2019 and 2018, respectively:



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Comparative Statements of Loss	2019			2018			$			%

Product sales	$	14,229		$	19,826		$	(5,597	)	(28.2	)%
Total revenues	14,229			19,826			(5,597		)	(28.2	)%
Operating expenses:
Cost of products	2,823			3,120			(297		)	(9.5	)%
Research and development expenses	7,539			11,402			(3,863		)	(33.9	)%
Selling, general and administrative expenses	5,316			24,829			(19,513		)	(78.6	)%
Intangible asset amortization	205			1,620			(1,415		)	(87.3	)%
Changes in fair value of related party contingent consideration	627			(7,115		)	7,742			108.8	%
Restructuring costs	1,866			65			1,801			2,770.8	%
Total operating expenses	18,376			33,921			(15,545		)	(45.8	)%
Operating loss	(4,147		)	(14,095		)	9,948			70.6	%
Investment and other income, net	781			208			573			275.5	%
Interest expense	(3,125		)	(3,000		)	(125		)	(4.2	)%
Other (expense) income - changes in fair value of related party payable	(139		)	425			(564		)	(132.7	)%
Loss before income taxes	(6,630		)	(16,462		)	9,832			59.7	%
Income tax provision (benefit)	2,234			(691		)	2,925			423.3	%
Net loss	$	(8,864	)	$	(15,771	)	$	6,907		43.8	%
Net loss per share - diluted	$	(0.24	)	$	(0.43	)	$	0.19		44.2	%

- 34 -

The following is a summary of our financial results (in thousands, except per share amounts) for the nine months ended September 30, 2019 and 2018, respectively:



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Comparative Statements of Loss	2019			2018			$			%

Product sales	$	48,220		$	82,103		$	(33,883	)	(41.3	)%
License revenue	—			246			(246		)	(100.0	)%
Total revenues	48,220			82,349			(34,129		)	(41.4	)%
Operating expenses:
Cost of products	9,711			13,224			(3,513		)	(26.6	)%
Research and development expenses	25,160			33,243			(8,083		)	(24.3	)%
Selling, general and administrative expenses	22,520			77,159			(54,639		)	(70.8	)%
Intangible asset amortization	610			4,996			(4,386		)	(87.8	)%
Changes in fair value of related party contingent consideration	2,384			(17,036		)	19,420			114.0	%
Restructuring costs	4,600			268			4,332			1,616.4	%
Total operating expenses	64,985			111,854			(46,869		)	(41.9	)%
Operating loss	(16,765		)	(29,505		)	12,740			43.2	%
Investment and other income, net	2,548			845			1,703			201.5	%
Interest expense	(9,293		)	(7,577		)	(1,716		)	(22.6	)%
Loss on deconsolidation of subsidiary	(2,840		)	—			(2,840		)	n/a
Other (expense) income - changes in fair value of related party payable	(496		)	1,432			(1,928		)	(134.6	)%
Loss before income taxes	(26,846		)	(34,805		)	7,959			22.9	%
Income tax provision (benefit)	3,641			(3,360		)	7,001			208.4	%
Net loss	$	(30,487	)	$	(31,445	)	$	958		3.0	%
Net loss per share - diluted	$	(0.82	)	$	(0.84	)	$	0.02		2.4	%

The revenues for each of the Company’s significant products for the three months ended September 30, 2019 and 2018 were as follows:



						Three Months Ended
	Three Months Ended September 30,					Increase / (Decrease)
	Three Months Ended September 30,					2019 vs. 2018
Revenues:	2019			2018		$			%

Bloxiverz	$	1,466		$	3,656	$	(2,190	)	(59.9	)%
Vazculep	8,786			8,759		27			0.3	%
Akovaz	4,208			5,991		(1,783		)	(29.8	)%
Other	(231		)	1,420		(1,651		)	(116.3	)%
Product sales	14,229			19,826		(5,597		)	(28.2	)%
License revenue	—			—		—			n/a
Total revenues	$	14,229		$	19,826	$	(5,597	)	(28.2	)%

Total revenues were $14,229 for the three months ended September 30, 2019, compared to $19,826 for the same prior year period. Bloxiverz’s revenue declined $2,190 in the current quarter when compared to the same prior year period primarily due to lower net selling price and lower unit volumes sold driven largely by new competition which entered the market driving price and unit volumes lower. Vazculep’s revenue remained flat during the quarter when compared to the prior year period due primarily to slightly higher pricing, offset by lower volumes. Akovaz’s revenue declined $1,783 driven largely by lower net selling price due to new competition which entered the market driving lower prices. The decrease of other revenue is driven by lower net product sales related to Noctiva, as it was deconsolidated in February 2019.

- 35 -

The revenues for each of the Company’s significant products for the nine months ended September 30, 2019 and 2018 were as follows:



					Six Months Ended
	Nine Months Ended September 30,				Increase / (Decrease)
	Nine Months Ended September 30,				2019 vs. 2018
Revenues:	2019		2018		$			%

Bloxiverz	$	6,392	$	16,691	$	(10,299	)	(61.7	)%
Vazculep	27,669		33,097		(5,428		)	(16.4	)%
Akovaz	13,946		28,083		(14,137		)	(50.3	)%
Other	213		4,232		(4,019		)	(95.0	)%
Product sales	48,220		82,103		(33,883		)	(41.3	)%
License revenue	—		246		(246		)	(100.0	)%
Total revenues	$	48,220	$	82,349	$	(34,129	)	(41.4	)%

Total revenues were $48,220 for the nine months ended September 30, 2019, compared to $82,349 for the same prior year period. Bloxiverz’s revenue declined $10,299 when compared to the same period last year, primarily due to lower unit volumes and net selling prices driven largely by new competitors that entered the market. Vazculep’s revenue declined $5,428 compared to the same period last year, due primarily to lower unit volumes and net selling prices driven largely by new competitors that entered the market. Akovaz’s revenue declined $14,137 driven by lower unit volumes and net selling prices driven largely by new competitors that entered the market. The decrease in other revenues during the nine months ended September 30, 2019 is driven by the deconsolidation of Specialty Pharma on February 6, 2019 as well as a reduction in revenue related to the February 2018 divestiture of the pediatric products.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Cost of Products:	2019			2018			$			%

Cost of products	$	2,823		$	3,120		$	(297	)	(9.5	)%
Percentage of total revenues	19.8		%	15.7		%

Cost of products decreased $297 or 9.5% during the three months ended September 30, 2019 compared to the same prior year period. As a percentage of total revenue, cost of products sold was higher than the prior year period due to lower net selling prices of the Company’s hospital products.



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Cost of Products:	2019			2018			$			%

Cost of products	$	9,711		$	13,224		$	(3,513	)	(26.6	)%
Percentage of total revenues	20.1		%	16.1		%

Cost of products decreased $3,513 or 26.6% during the nine months ended September 30, 2019 compared to the same prior year period driven by lower sold units. As a percentage of total revenue, cost of products sold was higher than the prior year period primarily due to lower net selling prices of the Company’s hospital products.

- 36 -



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Research and Development Expenses:	2019			2018			$			%

Research and development expenses	$	7,539		$	11,402		$	(3,863	)	(33.9	)%
Percentage of total revenues	53.0		%	57.5		%

Research and development expenses decreased $3,863 or 33.9% during the three months ended September 30, 2019 as compared to the same period in 2018. This decline was a result of $600 of lower spending associated with the exit of Noctiva, lower payroll, benefits and share-based compensation of $1,100 due to the 2019 Corporate and French restructuring plans and $2,200 of cost reductions at the Company’s Lyon, France R&D center. The Company continues to invest a substantial portion of R&D in its FT218 development program.



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Research and Development Expenses:	2019			2018			$			%

Research and development expenses	$	25,160		$	33,243		$	(8,083	)	(24.3	)%
Percentage of total revenues	52.2		%	40.4		%

Research and development expenses decreased $8,083 or 24.3% during the nine months ended September 30, 2019 as compared to the same period in 2018. This decline was a result of $2,600 of lower spending associated with the exit of Noctiva, lower payroll, benefits and share-based compensation of $2,000 related to the 2019 Corporate and French restructuring plans and $3,400 of cost reductions at the Company’s Lyon, France R&D center. The Company continues to invest a substantial portion of R&D in its FT218 development program.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Selling, General and Administrative Expenses:	2019			2018			$			%

Selling, general and administrative expenses	$	5,316		$	24,829		$	(19,513	)	(78.6	)%
Percentage of total revenues	37.4		%	125.2		%

Selling, general and administrative expenses decreased $19,513 or 78.6% during the three months ended September 30, 2019 as compared to the same prior year period. This decrease was primarily due to a decrease of $16,000 of sales and marketing costs related to the exit of Noctiva that was incurred during the three months ended September 30, 2018. Also contributing to the decrease is lower other payroll and share-based compensation of $2,700 due to reduced headcount as a result of the 2019 Corporate and French restructuring plans.



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Selling, General and Administrative Expenses:	2019			2018			$			%

Selling, general and administrative expenses	$	22,520		$	77,159		$	(54,639	)	(70.8	)%
Percentage of total revenues	46.7		%	93.7		%

Selling, general and administrative expenses decreased $54,639 or 70.8% during the nine months ended September 30, 2019 as compared to the same prior year period. This decrease was primarily due to a decrease of $44,200 of sales and marketing costs related to the exit of Noctiva during the first quarter 2019 as well as $2,700 of decreased costs due to the 2018 divestiture of the pediatric products. Also contributing to the decrease is lower other payroll and share-based compensation of $7,700 due to reduced headcount as a result of the 2019 Corporate and French restructuring plans.

- 37 -



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Intangibles Asset Amortization:	2019			2018			$			%

Intangible asset amortization	$	205		$	1,620		$	(1,415	)	(87.3	)%
Percentage of total revenues	1.4		%	8.2		%

Intangible asset amortization expense decreased $1,415 or 87.3% during the three months ended September 30, 2019 driven by the impairment of the intangible asset related to Noctiva at December 31, 2018.



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Intangibles Asset Amortization:	2019			2018			$			%

Intangible asset amortization	$	610		$	4,996		$	(4,386	)	(87.8	)%
Percentage of total revenues	1.3		%	6.1		%

Intangible asset amortization expense decreased $4,386 or 87.8% during the nine months ended September 30, 2019 driven by the impairment of the intangible asset related to Noctiva at December 31, 2018.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Changes in Fair Value of Related Party Contingent Consideration:	2019			2018			$		%

Changes in fair value of related party contingent consideration	$	627		$	(7,115	)	$	7,742	108.8	%
Percentage of total revenues	4.4		%	(35.9		)%

We compute the fair value of the related party contingent consideration using several significant assumptions and when these assumptions change, due to underlying market conditions, the fair value of these liabilities change as well. Each of the underlying assumptions used to determine the fair values of these contingent liabilities can, and often do, change based on adjustments in current market conditions, competition and other factors. These changes can have a material impact on our unaudited condensed consolidated statements of loss and balance sheet.

As a result of changes in the underlying assumptions used to determine the estimated fair values of our acquisition-related contingent consideration earn-out payments - Éclat, we recorded a gain of $627 and expense of $7,115 and increased/lowered the fair value of the acquisition-related contingent consideration earn-out payments - Éclat for the three months ended September 30, 2019 and 2018, respectively. As noted in our critical accounting estimates included in the 2018 Form 10-K, there are numerous assumptions and estimates we use when determining the fair value of the acquisition-related earn-out payments - Éclat. These assumptions include estimates of pricing, market size, the market share the related products are forecast to achieve, the cost of goods related to such products and an appropriate discount rate to use when present valuing the related cash flows.

For the three months ended September 30, 2019, as a result of changes to these estimates when compared to the same estimates at June 30, 2019, we recorded an increase in the fair value of our contingent consideration liabilities due to changes in certain underlying market conditions of the acquisition-related contingent consideration earn-out payments - Éclat.

For the three months ended September 30, 2018, as a result of changes to these estimates when compared to the same estimates at June 30, 2018, we recorded a decrease in the fair value of our contingent consideration liabilities, largely due to changes in certain underlying market conditions of the acquisition-related contingent consideration earn-out payments - Éclat.

- 38 -



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Changes in Fair Value of Related Party Contingent Consideration:	2019			2018			$		%

Changes in fair value of related party contingent consideration	$	2,384		$	(17,036	)	$	19,420	114.0	%
Percentage of total revenues	4.9		%	(20.7		)%

As a result of changes in the underlying assumptions used to determine the estimated fair values of our acquisition-related contingent consideration earn-out payments - Éclat, we recorded an expense of $2,384 and a gain of $17,036 and increased/lowered the fair value of the acquisition-related contingent consideration earn-out payments - Éclat for the nine months ended September 30, 2019 and 2018, respectively. As noted in our critical accounting estimates included in the 2018 Form 10-K, there are numerous assumptions and estimates we use when determining the fair value of the acquisition-related earn-out payments - Éclat. These assumptions include estimates of pricing, market size, the market share the related products are forecast to achieve, the cost of goods related to such products and an appropriate discount rate to use when present valuing the related cash flows.

For the nine months ended September 30, 2019, as a result of changes to these estimates when compared to the same estimates at December 31, 2018, we recorded an increase in the fair value of our contingent consideration liabilities due to changes in certain underlying market conditions of the acquisition-related contingent consideration earn-out payments - Éclat.

For the nine months ended September 30, 2018, as a result of changes to these estimates when compared to the same estimates at December 31, 2017, we recorded a decrease in the fair value of our contingent consideration liabilities, largely due to changes in certain underlying market conditions of the acquisition-related contingent consideration earn-out payments - Éclat.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Restructuring Costs	2019			2018			$		%

Restructuring costs	$	1,866		$	65		$	1,801	2,770.8	%
Percentage of total revenues	13.1		%	0.3		%

During the first quarter of 2019, the Company announced a plan to reduce its Corporate workforce at our U.S. and Ireland sites by more than 50%. This reduction is an effort to align the Company’s cost structure with its ongoing and future planned projects and revenue stream. Additionally, during the second quarter of 2019, the Company announced a plan to reduce its French workforce. This reduction is an effort to align the Company’s cost structure with our ongoing and future planned projects. See Note 15: Restructuring Costs for further details. As a result of these actions, the Company recorded restructuring charges of $1,866 that are primarily related to the 2019 French and Corporate restructuring plans. These charges included severance costs and the termination payment for vacating the French office leases by the end of the year.

- 39 -



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Restructuring Costs	2019			2018			$		%

Restructuring costs	$	4,600		$	268		$	4,332	1,616.4	%
Percentage of total revenues	9.5		%	0.3		%

Restructuring charges of $4,600 were recognized during the nine months ended September 30, 2019. These charges were primarily related to the 2019 French and Corporate restructuring actions and included severance and legal costs, impairment of certain assets, the reversal of certain retirement indemnity obligations, share-based compensation and the termination payment for vacating the French office leases by the end of the year. See Note 15: Restructuring Costs for further details.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Investment and Other Income, net	2019			2018			$		%

Investment and other income, net	$	781		$	208		$	573	275.5	%
Percentage of total revenues	5.5		%	1.0		%

Investment and other income, net increased for the three months ended September 30, 2019 when compared to the same period in the prior year driven by the accrual of the 2018 employment tax audit in the prior year, which was paid by the Company in 2019.



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Investment and Other Income, net	2019			2018			$		%

Investment and other income, net	$	2,548		$	845		$	1,703	201.5	%
Percentage of total revenues	5.3		%	1.0		%

Investment and other income, net increased for the nine months ended September 30, 2019 when compared to the same period in the prior year driven by higher unrealized gains on our marketable equity securities during the current period when compared to the prior period.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Interest Expense	2019			2018			$		%

Interest expense	$	3,125		$	3,000		$	125	4.2	%
Percentage of total revenues	22.0		%	15.1		%

Interest expense for the three months end September 30, 2019 was largely comparable to the same period in the prior year. Interest expense represents the imputed interest on the 2023 Notes.

- 40 -



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Interest Expense	2019			2018			$		%

Interest expense	$	9,293		$	7,577		$	1,716	22.6	%
Percentage of total revenues	19.3		%	9.2		%

Interest expense increased $1,716 for the nine months end September 30, 2019 when compared to the same period in the prior year as a result of a nine months of interest recorded in 2019 versus 7.5 months of this amount in 2018 due to the 2023 Notes issued in February 2018.



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Loss on Deconsolidation of Subsidiary	2019			2018			$			%

Loss on deconsolidation of subsidiary	$	(2,840	)	$	—		$	(2,840	)	n/a
Percentage of total revenues	(5.9		)%	—		%

As a result of Avadel Specialty Pharmaceuticals, LLC bankruptcy filing on February 6, 2019, the Company concluded that it no longer controls its operations and accordingly deconsolidated this subsidiary. The Company recorded a loss on the deconsolidation as a result of removing the net assets and certain liabilities of this subsidiary from our unaudited condensed consolidated financial statements. See Note 3: Subsidiary Bankruptcy and Deconsolidation for more discussion.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Other (Expense) Income - Changes in Fair Value of Related Party Payable	2019			2018			$			%

Other (expense) income - changes in fair value of related party payable	$	(139	)	$	425		$	(564	)	(132.7	)%
Percentage of total revenues	(1.0		)%	2.1		%

We recorded expense of $139 and income of $425 to increase and reduce the fair value of these liabilities during the three months ended September 30, 2019 and 2018, respectively, due to the same reasons associated with the Éclat product sales forecasts as described in the section “Changes in Fair Value of Related Party Contingent Consideration” for these periods. As noted in our critical accounting estimates section included in the 2018 Form 10-K, there are a number of assumptions and estimates we use when determining the fair value of the related party payable payments. These estimates include pricing, market size, the market share the related products are forecast to achieve and an appropriate discount rate to use when present valuing the related cash flows. These estimates often do change based on changes in current market conditions, competition and other factors.



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Other (Expense) Income - Changes in Fair Value of Related Party Payable	2019			2018			$			%

Other (expense) income - changes in fair value of related party payable	$	(496	)	$	1,432		$	(1,928	)	(134.6	)%
Percentage of total revenues	(1.0		)%	1.7		%

We recorded expense of $496 and income of $1,432 to increase and reduce the fair value of these liabilities during the nine months ended September 30, 2019 and 2018, respectively, due to the same reasons associated with the Éclat product sales forecasts as described in the section “Changes in Fair Value of Related Party Contingent Consideration” for these periods. As noted in our

- 41 -

critical accounting estimates section included in the 2018 Form 10-K, there are a number of assumptions and estimates we use when determining the fair value of the related party payable payments. These estimates include pricing, market size, the market share the related products are forecast to achieve and an appropriate discount rate to use when present valuing the related cash flows. These estimates often do change based on changes in current market conditions, competition and other factors.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2019 vs. 2018
Income Tax Provision (Benefit):	2019			2018			$		%

Income tax provision (benefit)	$	2,234		$	(691	)	$	2,925	423.3	%
Percentage of loss before income taxes	33.7		%	(4.2		)%

The items accounting for the difference between the income tax provision (benefit) computed at the statutory rate and the Company’s effective tax rate for the three months ended September 30, 2019 and 2018, are as follows:



	Three Months Ended September 30,
	2019			2018

Statutory tax rate	12.5		%	12.5		%
International tax rates differential	(4.3		)%	7.0		%
Change in valuation allowance	(31.1		)%	(18.3		)%
Change in fair value of nondeductible contingent consideration	4.1		%	8.7		%
Nondeductible stock-based compensation	—		%	(3.5		)%
Unrecognized tax benefits	(8.8		)%	(3.5		)%
State and local income taxes, net of federal	(0.2		)%	0.1		%
Nondeductible interest expense	(4.5		)%	—		%
Other	(1.3		)%	1.2		%
Effective income tax rate	(33.6		)%	4.2		%

Income tax benefit - at statutory tax rate	$	(829	)	$	(2,058	)
International tax rates differential	283			(1,153		)
Change in valuation allowance	2,059			3,007
Change in fair value of nondeductible contingent consideration	(270		)	(1,431		)
Nondeductible stock-based compensation	1			578
Unrecognized tax benefits	581			578
State and local income taxes, net of federal	14			(13		)
Nondeductible interest expense	299			—
Other	96			(199		)
Income tax provision (benefit) - at effective income tax rate	$	2,234		$	(691	)

- 42 -



							Six Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Income Tax Provision (Benefit):	2019			2018			$		%

Income tax provision (benefit)	$	3,641		$	(3,360	)	$	7,001	208.4	%
Percentage of loss before income taxes	13.6		%	(9.7		)%

The items accounting for the difference between the income tax provision (benefit) computed at the statutory rate and the Company’s effective tax rate for the six months ended September 30, 2019 and 2018, are as follows:



	Nine Months Ended September 30,
	2019			2018

Statutory tax rate	12.5		%	12.5		%
International tax rates differential	4.1		%	6.9		%
Change in valuation allowance	(27.0		)%	(14.9		)%
Change in fair value of nondeductible contingent consideration	(0.1		)%	9.9		%
Nondeductible stock-based compensation	(0.2		)%	(2.6		)%
Unrecognized tax benefits	(3.3		)%	(3.1		)%
State and local income taxes, net of federal	(0.2		)%	0.2		%
Nondeductible interest expense	(2.6		)%	—		%
Other	3.1		%	0.8		%
Effective income tax rate	(13.7		)%	9.7		%

Income tax benefit - at statutory tax rate	$	(3,355	)	$	(4,351	)
International tax rates differential	(1,108		)	(2,394		)
Change in valuation allowance	7,242			5,188
Change in fair value of nondeductible contingent consideration	33			(3,436		)
Nondeductible stock-based compensation	50			914
Unrecognized tax benefits	873			1,086
State and local income taxes, net of federal	41			(70		)
Nondeductible interest expense	709			—
Other	(844		)	(297		)
Income tax provision (benefit) - at effective income tax rate	$	3,641		$	(3,360	)

The IRS commenced an examination of the Company's U.S. income tax returns for 2016 and 2017 during the second quarter 2019.

- 43 -

Liquidity and Capital Resources

The Company’s cash flows from operating, investing and financing activities, as reflected in the unaudited condensed consolidated statements of cash flows, are summarized in the following table:



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2019 vs. 2018
Net cash provided by (used in):	2019			2018			$			%

Operating activities	$	(30,072	)	$	(58,190	)	$	28,118		48.3	%
Investing activities	33,553			(53,188		)	86,741			163.1	%
Financing activities	14			112,735			(112,721		)	(100.0	)%

Operating Activities

Net cash used in operating activities of $30,072 for the nine months ended September 30, 2019 decreased $28,118 compared to the same prior year period. This decrease in cash used in operating cash flow is due to higher cash earnings (net loss adjusted for non-cash credits and charges) of $16,943 when compared to the same period last year. The decrease in cash used in operating cash flow was also due to lower cash used for accrued expenses of $9,281 when compared to the same period last year and lower cash payments for related party contingent consideration of $8,602 during the current period when compared to the prior period.

Investing Activities

Cash provided by investing activities was $33,553 for the nine months ended September 30, 2019, was related to net cash proceeds received from the excess of sales over purchases of marketable securities. Cash used in investing activities of $53,188 during the same prior year period was related to the use of cash to purchase marketable securities in excess of sales of marketable securities. The Company also made a payment of $20,000 during the second quarter of 2018 related to the Company’s purchase of developed technology as part of the ELAA with Serenity Pharmaceuticals, LLC.

Financing Activities

Cash provided by financing activities for the nine months ended September 30, 2019 was $14, which decreased $112,721 from the same prior year period. During the nine months ended September 30, 2018, $143,750 of cash was provided by financing activities through the issuance of the 2018 Notes. A portion of the proceeds from the offering of the 2018 Notes was used for share repurchases totaling $27,637 and to pay direct expenses of $6,190 associated with the issuance of the 2018 Notes.

Liquidity and Risk Management

The adequacy of our cash resources depends on the outcome of certain business conditions including the cost of our FT218 clinical development plan, our cost structure, our hospital products revenue stream and other factors set forth in “Risk Factors” within Part I, Item 1A of the 2018 Form 10-K and within Part II, Item 1A of this quarterly report on Form 10-Q. To complete the FT218 clinical development plan and to ensure an adequate and robust NDA for filing with the FDA we will need to commit substantial resources, which could result in future losses or otherwise limit our opportunities or affect our ability to operate our business. Our assumptions concerning the outcome of certain business conditions may prove to be wrong or other factors may adversely affect our business, and as a result we could exhaust or significantly decrease our available cash and marketable securities balances which could, among other things, force us to raise additional funds and/or force us to reduce our expenses, either of which could have a material adverse effect on our business. If available to us raising additional capital may be accomplished through one or more public or private debt or equity financings, collaborations or partnering arrangements. Any equity financing would be dilutive to our shareholders.

Borrowings

In February 2018, we issued the 2023 Notes. We received net proceeds of approximately $137,560 from the sale of the 2023 Notes, after deducting fees and expenses of $6,190.

Share Repurchase Programs

The Company fully completed its authorized share buyback program during the year ended December 31, 2018.

- 44 -

Other Matters

Litigation

Litigation Related to Noctiva

Tax Matters. On July 2, 2019, Specialty Pharma was made aware of a $50,695 claim made by the Internal Revenue Service (IRS) as part of the bankruptcy claims process against Specialty Pharma. On October 2, 2019 the IRS amended the original claim filed in July, reducing the claim to $9,302. Specialty Pharma files its U.S. federal tax return as a member of the Company’s consolidated U.S. tax group. As such, the IRS claim was filed against Specialty Pharma in the bankruptcy proceedings due to IRS tax law requirements for joint and several liability of all members in a consolidated U.S. tax group. Both Specialty Pharma and the Company disagree with the merits of the amended IRS claim and intend to defend their positions vigorously.

Material Commitments

- 45 -



Purchase Commitments:	Balance

2019	$	7,194
2020	1,320
2021	1,320
2022	1,320
2023	220
Thereafter	—
Total	$	11,374

Contractual Obligations

Disclosures regarding contractual obligations are included in Part II, Item 7 of the Company’s 2018 Annual Report on Form 10-K and updated in Note 10: Long-Term Related Party Payable to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this Report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Interest Rate Risk

The Company is subject to interest rate risk as a result of its portfolio of marketable securities. The primary objectives of our investment policy are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and competitive yield. Although our investments are subject to market risk, our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure from any single issue, issuer or certain types of investment. Our investment policy allows us to maintain a portfolio of cash equivalents and marketable securities in a variety of instruments, including U.S. federal government and federal agency securities, European Government bonds, corporate bonds or commercial paper issued by U.S. or European corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, tax-exempt obligations of states, agencies, and municipalities in the U.S and Europe, and equities.

ITEM 4. CONTROLS AND PROCEDURES.

Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of September 30, 2019, the end of the period covered by this quarterly report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to the Company’s management, including its Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Based on their evaluation, as of the end of the period covered by this Form 10-Q, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) were effective as of September 30, 2019.

Changes in Internal Control over Financial Reporting

During the nine months ended September 30, 2019, as part of our restructuring initiatives described in this Quarterly Report under Item 1 “Financial Statements - Note 15 (Restructuring Costs)” and Item 2 “Management Discussion and Analysis of Results of Operations and Financial Condition - Results of Operation,” we moved all of our Irish and a portion of our French accounting operations to St. Louis, Missouri. Further, as part of these restructuring initiatives, the Company completed the outsourcing of a majority of its Information Technology resources to a third party. These moves were made in order to consolidate our accounting

- 46 -

systems, gain efficiencies of scale, reduce costs and make internal control over financial reporting more consistent across our various entities. These moves were not made in response to any identified deficiency or weakness in the Company’s internal control over financial reporting. Other than these changes, there has been no change in our internal control over financial reporting during the quarter ended September 30, 2019 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION


ITEM 1.	LEGAL PROCEEDINGS.

The information contained in Note 19: Commitments and Contingencies to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this Report is incorporated by reference herein.

ITEM 1A. RISK FACTORS.

Except as set forth below, there have been no material changes in our risk factors from those disclosed in our annual report on Form 10-K for the year ended December 31, 2018 filed with the SEC on March 15, 2019.

The trading price of our American Depositary Shares (ADSs) could fall, causing them to be delisted from trading on Nasdaq, making it more difficult for investors to sell our ADSs.

The closing price of our American Depositary Shares (ADSs) was between $1.09 and $2.05 during the period from February 26, 2019 to June 6, 2019. Under Nasdaq Listing Rules 5550 (a)(2) and 5810(c)(3)(A), if the bid price of our ADSs closes below $1.00 for 30 consecutive business days, our ADSs could be subject to delisting from Nasdaq, after a grace period of 180 calendar days to regain compliance. To regain compliance, the closing bid price of our ADSs would need to meet or exceed $1.00 for a minimum of 10 consecutive business days during the grace period. If we do not regain compliance Nasdaq would provide notice that our ADSs will be subject to delisting. While the trading prices of our ADSs are currently above $3.00, such prices have been and continue to be volatile, and there is no assurance that our ADSs would not trade below $1.00 for 30 consecutive business days in the future and be subject to Nasdaq delisting. If our ADSs were to be delisted from Nasdaq, and not listed on another national securities exchange, trading of our ADSs could be conducted in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In that event, it may be more difficult to dispose of, or obtain accurate price quotations for, our ADSs, and there would likely also be a reduction in our coverage by security analysts and the news media, which could cause the price of our ADSs to decline further. As a result, the trading market for our ADSs could become limited, possibly impairing your ability to liquidate your investment in our company and causing the value of your investment to decline. Also, it may be difficult for us to raise additional capital if we are not listed on Nasdaq or another major exchange.

Although we recently announced an accelerated estimated timetable for completing our REST-ON clinical trial for FT218, we could experience unanticipated difficulties with enrolling the final patients or with other aspects of the clinical trial or the full FT218 development program, which could increase the cost of the program and further delay its completion.

Our FT218 product development program has become substantially more important to our success in the aftermath of the disappointing sales results for Noctiva and the Specialty Pharma bankruptcy filing. In September 2019, we announced FDA approval of amendments to the statistical analysis plan and protocol for our REST-ON phase 3 clinical trial for FT218, resulting in a lower sample size needed to demonstrate statistical significance. As a result of these amendments, we expect to complete enrollment in the REST-ON clinical trial by the end of 2019 and have topline data in the second quarter of 2020, which dates are earlier than we had previously estimated. As of November 12, 2019, we had enrolled 200 new patients in the REST-ON clinical trial, with an additional 5 patients needed to complete the sample size. Notwithstanding the new estimated timetable announced in September 2019, we could experience unanticipated difficulties in enrolling patients or with other aspects of the program, and as a result there is no assurance that we will complete enrollment by the end of 2019 as predicted, or that we will complete the clinical trial and collect all data before the end of the second quarter of 2020. Any such unanticipated difficulties could delay the completion of the REST-ON clinical trial and increase its cost.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

The Company fully completed its authorized share buyback program during the year ended December 31, 2018.

- 47 -

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.



Exhibit No.		Description

31.1*		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act
31.2*		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act
32.1**		Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**		Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

______________________

* Filed herewith.

** Furnished herewith.

- 48 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



	AVADEL PHARMACEUTICALS PLC
	(Registrant)

Date: November 12, 2019	By:	/s/ Michael F. Kanan
		Michael F. Kanan
		Senior Vice President and Chief Financial Officer
		(Duly Authorized Officer and Principal Financial and Accounting Officer)

- 49 -

EX-31.1 2 exhibit311q32019.htm EXHIBIT 31.1 Exhibit

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Gregory J. Divis, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Avadel Pharmaceuticals plc;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: November 12, 2019	/s/ Gregory J. Divis
	Gregory J. Divis
	Chief Executive Officer

EX-31.2 3 exhibit312q32019.htm EXHIBIT 31.2 Exhibit

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Michael F. Kanan, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Avadel Pharmaceuticals plc:

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date: November 12, 2019	/s/ Michael F. Kanan
	Michael F. Kanan
	Senior Vice President and Chief Financial Officer

EX-32.1 4 exhibit321q32019.htm EXHIBIT 32.1 Exhibit

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Avadel Pharmaceuticals plc (the “Company”) for the period ended September 30, 2019 (the “Report”), the undersigned hereby certifies in his capacity as Chief Executive Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: November 12, 2019	/s/ Gregory J. Divis
	Gregory J. Divis
	Chief Executive Officer

EX-32.2 5 exhibit322q32019.htm EXHIBIT 32.2 Exhibit

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Avadel Pharmaceuticals plc (the “Company”) for the period ended September 30, 2019 (the “Report”), the undersigned hereby certifies in his capacity as Chief Financial Officer of the Company pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: November 12, 2019	/s/ Michael F. Kanan
	Michael F. Kanan
	Senior Vice President and Chief Financial Officer

EX-101.INS 6 avdl-20190930.xml XBRL INSTANCE DOCUMENT 0001012477 2019-01-01 2019-09-30 0001012477 2019-11-08 0001012477 2019-07-01 2019-09-30 0001012477 2018-07-01 2018-09-30 0001012477 2018-01-01 2018-09-30 0001012477 us-gaap:ProductMember 2018-07-01 2018-09-30 0001012477 us-gaap:LicenseMember 2019-07-01 2019-09-30 0001012477 us-gaap:ProductMember 2018-01-01 2018-09-30 0001012477 us-gaap:LicenseMember 2019-01-01 2019-09-30 0001012477 us-gaap:ProductMember 2019-07-01 2019-09-30 0001012477 us-gaap:LicenseMember 2018-01-01 2018-09-30 0001012477 us-gaap:ProductMember 2019-01-01 2019-09-30 0001012477 us-gaap:LicenseMember 2018-07-01 2018-09-30 0001012477 2019-09-30 0001012477 2018-12-31 0001012477 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001012477 2018-04-01 2018-06-30 0001012477 2018-06-30 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001012477 2018-01-01 2018-03-31 0001012477 us-gaap:TreasuryStockMember 2017-12-31 0001012477 2018-03-31 0001012477 us-gaap:TreasuryStockMember 2018-06-30 0001012477 2018-09-30 0001012477 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001012477 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001012477 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001012477 us-gaap:CommonStockMember 2018-03-31 0001012477 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001012477 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001012477 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001012477 us-gaap:CommonStockMember 2018-09-30 0001012477 us-gaap:CommonStockMember 2017-12-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001012477 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001012477 us-gaap:RetainedEarningsMember 2017-12-31 0001012477 us-gaap:TreasuryStockMember 2018-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001012477 us-gaap:CommonStockMember 2018-06-30 0001012477 us-gaap:RetainedEarningsMember 2018-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001012477 us-gaap:RetainedEarningsMember 2018-09-30 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001012477 2017-12-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001012477 us-gaap:TreasuryStockMember 2018-09-30 0001012477 us-gaap:RetainedEarningsMember 2018-06-30 0001012477 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001012477 us-gaap:RetainedEarningsMember 2019-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001012477 us-gaap:CommonStockMember 2018-12-31 0001012477 2019-01-01 2019-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001012477 2019-04-01 2019-06-30 0001012477 us-gaap:CommonStockMember 2019-09-30 0001012477 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001012477 2019-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001012477 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001012477 us-gaap:TreasuryStockMember 2018-12-31 0001012477 us-gaap:TreasuryStockMember 2019-06-30 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001012477 us-gaap:TreasuryStockMember 2019-09-30 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001012477 us-gaap:CommonStockMember 2019-06-30 0001012477 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001012477 2019-06-30 0001012477 us-gaap:RetainedEarningsMember 2019-06-30 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001012477 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001012477 us-gaap:CommonStockMember 2019-03-31 0001012477 us-gaap:TreasuryStockMember 2019-03-31 0001012477 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001012477 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001012477 us-gaap:RetainedEarningsMember 2018-12-31 0001012477 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001012477 us-gaap:RetainedEarningsMember 2019-09-30 0001012477 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001012477 avdl:SpecialityPharamaMember avdl:DebtorinPossessionCreditandSecurityFacilityMember avdl:DIPCreditAgreementMember 2019-02-08 0001012477 avdl:SpecialtyPharmaMember 2019-09-30 0001012477 avdl:SpecialityPharamaMember 2019-04-26 2019-04-26 0001012477 avdl:DebtorinPossessionCreditandSecurityFacilityMember avdl:DIPCreditAgreementMember 2019-07-01 2019-09-30 0001012477 avdl:SpecialityPharamaMember us-gaap:InternalRevenueServiceIRSMember us-gaap:SubsequentEventMember 2019-10-02 0001012477 avdl:SpecialityPharamaMember us-gaap:InternalRevenueServiceIRSMember 2019-07-02 0001012477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:FixedIncomeSecuritiesMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-09-30 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:FixedIncomeSecuritiesMember 2019-09-30 0001012477 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-09-30 0001012477 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2018-12-31 0001012477 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-09-30 0001012477 avdl:FourPointFiftyPercentExchangeableSeniorNotesDue2023Member us-gaap:SeniorNotesMember 2019-09-30 0001012477 us-gaap:SeniorNotesMember 2019-09-30 0001012477 us-gaap:CorporateDebtSecuritiesMember 2019-09-30 0001012477 us-gaap:FixedIncomeSecuritiesMember 2019-09-30 0001012477 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-09-30 0001012477 avdl:DebtSecuritiesExcludingMoneyMarketFundsAvailableForSaleMember 2019-09-30 0001012477 us-gaap:EquitySecuritiesMember 2019-09-30 0001012477 us-gaap:MoneyMarketFundsMember 2019-09-30 0001012477 us-gaap:EquitySecuritiesMember 2019-01-01 2019-09-30 0001012477 us-gaap:FixedIncomeSecuritiesMember 2018-12-31 0001012477 us-gaap:MoneyMarketFundsMember 2018-12-31 0001012477 us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001012477 us-gaap:EquitySecuritiesMember 2018-12-31 0001012477 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001012477 us-gaap:EquitySecuritiesMember 2018-01-01 2018-12-31 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:VazculepMember 2019-09-30 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:VazculepMember 2018-12-31 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:VazculepMember 2018-01-01 2018-12-31 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:NoctivaMember 2019-09-30 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:NoctivaMember 2018-12-31 0001012477 us-gaap:DevelopedTechnologyRightsMember avdl:NoctivaMember 2018-01-01 2018-12-31 0001012477 2018-01-01 2018-12-31 0001012477 srt:MinimumMember 2019-01-01 2019-09-30 0001012477 srt:MaximumMember 2019-01-01 2019-09-30 0001012477 avdl:OperatingLeasesCommencedMember 2019-09-30 0001012477 avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember us-gaap:ScenarioForecastMember 2019-12-31 0001012477 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001012477 srt:MaximumMember 2019-09-30 0001012477 srt:MinimumMember 2019-09-30 0001012477 avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember 2019-01-01 2019-09-30 0001012477 avdl:BroadfinRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-07-01 2019-09-30 0001012477 avdl:DeerfieldRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-07-01 2019-09-30 0001012477 avdl:DeerfieldRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-06-30 0001012477 avdl:EarnOutPaymentsMember us-gaap:AcquisitionRelatedCostsMember 2019-06-30 0001012477 avdl:EarnOutPaymentsMember us-gaap:AcquisitionRelatedCostsMember 2019-07-01 2019-09-30 0001012477 avdl:BroadfinRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-06-30 0001012477 avdl:BroadfinRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-09-30 0001012477 avdl:EarnOutPaymentsMember us-gaap:AcquisitionRelatedCostsMember 2019-09-30 0001012477 avdl:DeerfieldRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-09-30 0001012477 avdl:EclatPharmaceuticalsMember 2012-03-01 2012-03-31 0001012477 avdl:BroadfinDebtFinancingMember 2013-12-01 2013-12-31 0001012477 avdl:DeerfieldCsfLlcMember srt:AffiliatedEntityMember 2013-02-01 2013-02-28 0001012477 avdl:BroadfinRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-01-01 2019-09-30 0001012477 avdl:DeerfieldRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2019-01-01 2019-09-30 0001012477 avdl:EarnOutPaymentsMember us-gaap:AcquisitionRelatedCostsMember 2019-01-01 2019-09-30 0001012477 avdl:EarnOutPaymentsMember us-gaap:AcquisitionRelatedCostsMember 2018-12-31 0001012477 avdl:DeerfieldRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2018-12-31 0001012477 avdl:BroadfinRoyaltyAgreementMember avdl:FinancingRelatedCostsMember 2018-12-31 0001012477 us-gaap:SeniorNotesMember 2018-12-31 0001012477 us-gaap:LoansPayableMember 2018-12-31 0001012477 us-gaap:LoansPayableMember 2019-09-30 0001012477 country:IE 2018-07-01 2018-09-30 0001012477 country:IE 2018-01-01 2018-09-30 0001012477 country:US 2018-07-01 2018-09-30 0001012477 country:US 2018-01-01 2018-09-30 0001012477 country:IE 2019-07-01 2019-09-30 0001012477 country:FR 2019-07-01 2019-09-30 0001012477 country:US 2019-01-01 2019-09-30 0001012477 country:FR 2018-01-01 2018-09-30 0001012477 country:FR 2018-07-01 2018-09-30 0001012477 country:FR 2019-01-01 2019-09-30 0001012477 country:US 2019-07-01 2019-09-30 0001012477 country:IE 2019-01-01 2019-09-30 0001012477 avdl:FSCMember us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember 2018-02-12 2018-02-12 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:CerecorMember us-gaap:SubsequentEventMember 2019-10-10 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember 2018-02-12 2018-02-12 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember us-gaap:ScenarioForecastMember 2021-01-01 2021-01-31 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember 2019-09-30 0001012477 us-gaap:DiscontinuedOperationsDisposedOfBySaleMember avdl:A2016MIPAMember 2018-02-12 0001012477 avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember 2018-12-31 0001012477 us-gaap:EmployeeSeveranceMember avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember 2019-01-01 2019-09-30 0001012477 avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember 2019-09-30 0001012477 avdl:LyonFranceWorkforceReductionMember 2018-01-01 2018-09-30 0001012477 avdl:LyonFranceWorkforceReductionMember 2019-01-01 2019-09-30 0001012477 avdl:LyonFranceWorkforceReductionMember 2019-09-30 0001012477 avdl:LyonFranceWorkforceReductionMember 2017-12-31 0001012477 avdl:LyonFranceWorkforceReductionMember 2018-12-31 0001012477 avdl:LyonFranceWorkforceReductionMember 2018-09-30 0001012477 us-gaap:EmployeeSeveranceMember avdl:CorporateWorkforceReductionMember 2019-09-30 0001012477 avdl:TwoThousandNineteenCorporateRestructuringObligationsMember 2019-01-01 2019-09-30 0001012477 avdl:RetirementIndemnityObligationMember avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember 2019-01-01 2019-09-30 0001012477 avdl:TwoThousandNineteenCorporateRestructuringObligationsMember 2019-07-01 2019-09-30 0001012477 us-gaap:EmployeeSeveranceMember avdl:TwoThousandNineteenCorporateRestructuringObligationsMember 2019-01-01 2019-09-30 0001012477 us-gaap:EmployeeSeveranceMember avdl:LyonFranceWorkforceReductionMember 2017-09-30 0001012477 us-gaap:AccruedLiabilitiesMember avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember 2018-12-31 0001012477 us-gaap:AccruedLiabilitiesMember avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember 2019-09-30 0001012477 avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember 2019-07-01 2019-09-30 0001012477 avdl:TwoThousandNineteenCorporateRestructuringObligationsMember 2019-09-30 0001012477 avdl:TwoThousandNineteenCorporateFrenchRestructuringObligationMember us-gaap:ScenarioForecastMember 2019-01-01 2019-12-31 0001012477 avdl:TwoThousandNineteenCorporateRestructuringObligationsMember us-gaap:ScenarioForecastMember 2019-01-01 2019-12-31 0001012477 avdl:TwoThousandNineteenCorporateRestructuringObligationsMember 2018-12-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-07-01 2019-09-30 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2018-06-30 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-30 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2017-12-31 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2018-07-01 2018-09-30 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2019-09-30 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-09-30 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-07-01 2018-09-30 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-01-01 2018-09-30 0001012477 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-06-30 0001012477 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0001012477 avdl:OtherProductsMember 2019-07-01 2019-09-30 0001012477 avdl:BloxiverzMember 2019-01-01 2019-09-30 0001012477 avdl:OtherProductsMember 2019-01-01 2019-09-30 0001012477 avdl:OtherProductsMember 2018-07-01 2018-09-30 0001012477 avdl:AkovazMember 2018-01-01 2018-09-30 0001012477 avdl:VazculepMember 2019-01-01 2019-09-30 0001012477 avdl:BloxiverzMember 2018-07-01 2018-09-30 0001012477 avdl:BloxiverzMember 2019-07-01 2019-09-30 0001012477 avdl:BloxiverzMember 2018-01-01 2018-09-30 0001012477 avdl:VazculepMember 2018-07-01 2018-09-30 0001012477 avdl:VazculepMember 2019-07-01 2019-09-30 0001012477 avdl:VazculepMember 2018-01-01 2018-09-30 0001012477 avdl:OtherProductsMember 2018-01-01 2018-09-30 0001012477 avdl:AkovazMember 2019-07-01 2019-09-30 0001012477 avdl:AkovazMember 2018-07-01 2018-09-30 0001012477 avdl:AkovazMember 2019-01-01 2019-09-30 0001012477 us-gaap:InventoriesMember 2019-09-30 0001012477 avdl:SpecialtyPharmaMember 2019-01-27 2019-01-27 xbrli:pure iso4217:USD xbrli:shares iso4217:USD xbrli:shares avdl:segment 2028000 1284000 3469000 0 1000000 3389000 1009000 482000 6541000 6244000 17456000 7024000 10432000 11042000 0 11042000 -17036000 2384000 139000 45000 94000 0 496000 166000 330000 0 2600000 2200000 0.15 645000 0 16254000 8640000 -0.035 -0.031 -0.088 -0.033 0 0 299000 709000 0.000 0.000 -0.045 -0.026 -1432000 496000 534000 560000 5697000 5271000 578000 1086000 581000 873000 1350000 749000 4000000 3000000 143000 378000 71000 339000 22000 350000 64000 211000 5894000 6494000 49000 49000 407000 0.2 0.0175 0.00834 0.15 1024000 0 11374000 0 220000 1320000 7194000 1320000 1320000 283000 270000 7272000 7694000 1000000 0.50 0.50 268000 2774000 -168000 10300000 603000 2911000 2905000 6000 false --12-31 Q3 2019 2019-09-30 10-Q 0001012477 37450300 Yes false Accelerated Filer AVADEL PHARMACEUTICALS PLC false false

3503000

3538000

11330000

8725000

21695000

17017000

-23416000

-22972000

433756000

434055000

26699000

2167000

2134000

2224000

2832000

351000

55000

-229000

3402000

4424000

1620000

4996000

205000

610000

18742

16647

19544

20512

190300000

155888000

124851000

88602000

62141000

28449000

48267000

11320000

411000

7000

22000

316000

66000

1009000

69000

26000

785000

129000

1180000

79000

13000

53000

79000

28000

1000

2000

91359000

6411000

9400000

52733000

12714000

58606000

4190000

1693000

43306000

5217000

342000

9629000

3360000

1669000

4600000

744000

605000

556000

49000

90590000

52996000

6339000

9409000

12701000

6339000

9409000

52996000

12701000

59587000

44091000

4258000

1718000

5344000

11320000

4258000

1718000

44091000

5344000

50695000

9302000

-7115000

-17036000

627000

2384000

98925000

38692000

28840000

1041000

2184000

25615000

24247000

866000

1799000

21582000

21706000

763000

1584000

19359000

9325000

12867000

16564000

17837000

9325000

12867000

1273000

3542000

-1750000

0.01

500000000

42720000

42857000

37313000

37450000

427000

428000

-15763000

68000

-60000

-31830000

-92000

-293000

-8988000

86000

-210000

-30043000

753000

-309000

3120000

13224000

2823000

9711000

33921000

111854000

18376000

64985000

1352000

923000

143750000

-26699000

0.045

0.0450

0.045

263000

28059000

23618000

2700000

-407000

-2840000

23029000

21636000

5625000

1690000

20337000

9439000

8264000

7588000

28840000

21706000

19401000

15983000

14118000

-0.43

-0.84

-0.24

-0.82

-0.43

-0.84

-0.24

-0.82

-84000

47000

0.042

0.097

-0.336

-0.137

0.125

-0.183

-0.149

-0.311

-0.270

0.070

0.069

-0.043

0.041

0.087

0.099

0.041

-0.001

-0.035

-0.026

0.000

-0.002

0.012

0.008

-0.013

0.031

0.001

0.002

-0.002

1396000

9145000

4176000

10101000

4200000

956000

24000

15000000

P5Y

P15Y

P3Y

815000

814000

85172000

73111000

12061000

1629000

1019000

-478000

18491000

5831000

6620000

15000000

5717000

5289000

5851000

6643000

66087000

598000

-16462000

79000

-18314000

1773000

-34805000

441000

-34203000

-1043000

-6630000

1720000

-14302000

5952000

-26846000

-2530000

-36625000

12309000

-691000

-3360000

2234000

3641000

3007000

5188000

2059000

7242000

-1153000

-2394000

283000

-1108000

-2058000

-4351000

-829000

-3355000

-1431000

-3436000

-270000

33000

578000

914000

1000

50000

-199000

-297000

96000

-844000

-13000

-70000

14000

41000

413000

140000

921000

594000

4312000

259000

-5059000

-2026000

-11660000

-2379000

-4675000

1333000

548000

-2465000

2216000

1399000

-2194000

1859000

1629000

1019000

3000000

7577000

3125000

9293000

3359000

6469000

3545000

4270000

1883000

4770000

2260000

500000

377000

4757000

1212000

208000

845000

781000

2548000

329000

963000

4975000

941000

690000

678000

670000

879000

1117000

513000

P7Y

P1Y

187520000

182851000

190300000

155888000

38383000

31763000

-18468000

2880000

820

115840000

115691000

120167000

120132000

106000

35000

76425000

115734000

120132000

1477000

1700000

90590000

59587000

-2889000

275000

112735000

14000

-53188000

33553000

-58190000

-30072000

-12236000

-3438000

-15771000

-31445000

-13018000

-8605000

-8864000

-30487000

2625000

28840000

21706000

-14095000

-29505000

-4147000

-16765000

411000

1150000

826000

4462000

5131000

1596000

2866000

411000

1115000

4385000

1000000

5046000

0.053

P4Y3M11D

5836000

1191000

695000

767000

1008000

1208000

967000

2798000

1559000

225000

175000

36146000

34927000

68000

-92000

86000

753000

18000

88000

5000

46000

-60000

-293000

-210000

-309000

-404000

11000

8000

213000

355000

-124000

8000

-385000

-124000

444000

3640000

1989000

14002000

13972000

594000

149000

43000

35000

425000

1432000

-139000

-496000

117000

-392000

27637000

2167000

668000

663000

1837000

2113000

2362000

1374000

19261000

3307000

148000

309000

2850000

10014000

444000

930000

8640000

20000000

341036000

23814000

167000

29000

0.01

50000000

8836000

5163000

2145000

2757000

143750000

-31000

-109000

308015000

57242000

250000

154000

3488000

123000

1911000

770000

15263000

6190000

11402000

33243000

7539000

25160000

65000

268000

1866000

1259

607000

4600000

1000000

2966000

168000

3198000

1570000

1000000

581000

11000

879000

884000

38000

895000

853000

879000

1737000

-19000

-10000

-42000

-357989000

-388476000

19826000

5991000

3656000

1420000

8759000

19826000

82349000

28083000

16691000

4232000

33097000

246000

82103000

14229000

4208000

1466000

-231000

8786000

14229000

48220000

13946000

6392000

213000

27669000

48220000

24829000

77159000

5316000

22520000

3500000

3000000

7190000

177000

41463000

2117000

42066000

4424000

42148000

5407000

42419000

5407000

42720000

5407000

42763000

5407000

42763000

5407000

42857000

5407000

3350000

24000

42000

12000

247000

1000

82000

127000

92000

31000

-3000

3000

-1000

1000

535000

534000

1000

85580000

-64000

-23266000

-23202000

393478000

414000

-262685000

-22361000

86639000

-23670000

427383000

420000

-274921000

-42573000

78546000

-224000

-23659000

-23435000

430141000

421000

-278359000

-49998000

65742000

-156000

-23651000

-23495000

433097000

424000

-294130000

-49998000

2780000

205000

-23416000

-23621000

433756000

427000

-357989000

-49998000

-9582000

-23203000

434199000

427000

-371007000

-49998000

-17777000

872000

-22848000

-23720000

434254000

427000

-379612000

-49998000

-26963000

958000

-22972000

-23930000

434055000

428000

-388476000

-49998000

82000

187000

5407000

2307000

983000

49998000

20212000

7425000

5315000

7717000

1378000

807000

36904000

37410000

37436000

37382000

36904000

37410000

37436000

37382000

3971000

2322000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nature of Operations.</font><font style="font-family:inherit;font-size:10pt;">  </font><font style="font-family:inherit;font-size:10pt;">Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company.  Our primary focus is on the development and potential U.S. Food and Drug Administration (“FDA”) approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.  The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted a new drug application (“NDA”) in March 2019 on a fourth sterile injectable drug which we refer to as AV001, for use in the hospital setting. AV001, if approved, could contribute revenues to Avadel starting in 2020. In May 2019, the FDA accepted the NDA for AV001, with a Prescription Drug User Fee Act (PDUFA) target action date of December 15, 2019. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current marketed products include: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Akovaz®</font><font> (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Bloxiverz®</font><font> (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Vazculep®</font><font> (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of our</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Akovaz</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bloxiverz</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vazculep</font><font style="font-family:inherit;font-size:10pt;"> products is used primarily in the hospital setting and was developed under our UMD program.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the U.S. Securities and Exchange Commission (“SEC”). These filings are also available to the public at www.sec.gov.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is the successor to Flamel Technologies S.A., a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">société anonyme</font><font style="font-family:inherit;font-size:10pt;"> (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “The Reincorporation Merger” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation</font><font style="font-family:inherit;font-size:10pt;">), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">société par actions simplifiée</font><font style="font-family:inherit;font-size:10pt;">, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various other assets and liabilities are summarized as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Prepaid Expenses and Other Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Valued-added tax recoverable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,378</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Prepaid and other expenses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,757</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee from Armistice (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">921</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Research and development tax credit receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Short-term deposit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,350</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">225</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation.</font><font style="font-family:inherit;font-size:10pt;"> The unaudited condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, which is derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 6, 2019, the Company’s indirect wholly-owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”), filed a voluntary petition for reorganization under Chapter 11 of the United States (“U.S.”) Code (the “Bankruptcy Code”). in the U.S. District Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case No. 19-10248. Specialty Pharma is operating and managing its business as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma’s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation. </font><font style="font-family:inherit;font-size:10pt;">Our results of operations for the period January 1, 2019 through February 6, 2019 include the results of Specialty Pharma prior to its February 6, 2019 voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Marketable Securities </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has investments in equity and available-for-sale debt securities which are recorded at fair market value. The change in the fair value of equity investments is recognized in our unaudited condensed consolidated statements of loss and the change in the fair value of available-for-sale debt investments is recorded as other comprehensive income (loss) in shareholders’ (deficit) equity, net of income tax effects. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market and mutual funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">785</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,091</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,718</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">58,606</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,009</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market and mutual funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,733</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,714</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine realized gains or losses on the sale of marketable securities on a specific identification method. We reflect these gains and losses as a component of investment and other income in the accompanying unaudited condensed consolidated statements of loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized gross realized gains of </font><font style="font-family:inherit;font-size:10pt;">$71</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$143</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. These realized gains were offset by realized losses of </font><font style="font-family:inherit;font-size:10pt;">$64</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$22</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized gross realized gains of </font><font style="font-family:inherit;font-size:10pt;">$339</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$378</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. These realized gains were offset by realized losses of </font><font style="font-family:inherit;font-size:10pt;">$211</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$350</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. We reflect these gains and losses as a component of investment and other income in the accompanying condensed consolidated statements of income (loss).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maturities</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less than 1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1-5 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">5-10 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Greater than 10 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,718</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has classified our investment in available-for-sale marketable debt securities as current assets in the unaudited condensed consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in our investment portfolio.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Debt</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt is summarized as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Principal amount of 4.50% exchangeable senior notes due 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: debt discount and issuance costs, net </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,618</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net carrying amount of liability component</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">     Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity component:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity component of exchangeable notes, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Divestiture of the Pediatric Assets</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 12, 2018, the Company, together with its subsidiaries Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics, LLC (“FSC Therapeutics”), and Avadel US Holdings, Inc. (“Holdings”), as the “Sellers,” entered into an asset purchase agreement (the “Purchase Agreement”) with Cerecor, Inc. (“Cerecor”). The transaction closed on February 16, 2018 wherein Cerecor purchased from the Sellers four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™, together with certain associated business assets – which were held by FSC.  The Company acquired FSC in February 2016 from Deerfield and certain of its affiliates. Pursuant to the Purchase Agreement, Cerecor assumed the Company’s  remaining payment obligations to Deerfield under the Membership Interest Purchase Agreement, dated as of February 5, 2016, between Holdings, Flamel Technologies SA (the predecessor of the Company) and Deerfield and certain of its affiliates, which payment obligations consist of the following (collectively, the “Assumed Obligations”): (i) a quarterly payment of </font><font style="font-family:inherit;font-size:10pt;">$263</font><font style="font-family:inherit;font-size:10pt;"> beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of </font><font style="font-family:inherit;font-size:10pt;">$2,625</font><font style="font-family:inherit;font-size:10pt;">; (ii) a payment in January 2021 of </font><font style="font-family:inherit;font-size:10pt;">$15,263</font><font style="font-family:inherit;font-size:10pt;">; and (iii) a quarterly royalty payment of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> on net sales of the FSC products through February 5, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$10,300</font><font style="font-family:inherit;font-size:10pt;">.  Cerecor also assumed certain contracts and other obligations related to the acquired assets, and in that connection Holdings agreed to pay Cerecor certain make-whole payments associated with obligations Cerecor is assuming related to a certain supply contract related to Karbinal™ ER. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In conjunction with the divestiture, the Company also entered into the following arrangements:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License and Development Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Also, in connection with the closing under the Purchase Agreement, Flamel Ireland Limited, an Irish limited company operating under the trade name of Avadel Ireland (“Avadel Ireland”) and a wholly-owned subsidiary of the Company, and Cerecor entered into a license and development agreement (the “License and Development Agreement”) pursuant to which, among other things:</font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avadel Ireland will provide Cerecor with four product formulations utilizing Avadel Ireland’s LiquiTime™ technology, and will complete pilot bioequivalence studies for such product formulations within 18 months;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cerecor will reimburse Avadel Ireland for development costs of the four LiquiTime™ products in excess of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate;</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon transfer of the four product formulations, Cerecor will assume all remaining development costs and responsibilities for the product development, clinical studies, NDA applications and associated filing fees; and</font></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:102px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:102px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon regulatory approval and commercial launch of any LiquiTime™ products, Cerecor will pay Avadel Ireland quarterly royalties based on a percentage of net sales of any such products in the mid-single digit range. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective October 25, 2019, Cerecor and Avadel Ireland agreed to terminate the License and Development Agreement.</font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deerfield Guarantee</font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the closing under the Purchase Agreement, the Company and Holdings provided their guarantee (the “Deerfield Guarantee”) in favor of Deerfield. Under the Deerfield Guarantee, the Company and Holdings guaranteed to Deerfield the payment by Cerecor of the Assumed Obligations under the Membership Interest Purchase Agreement between the Company and Deerfield dated February 5, 2016. The Assumed Obligations include (i) a quarterly payment of </font><font style="font-family:inherit;font-size:10pt;">$263</font><font style="font-family:inherit;font-size:10pt;"> beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of </font><font style="font-family:inherit;font-size:10pt;">$2,625</font><font style="font-family:inherit;font-size:10pt;">; (ii) a payment in January 2021 of </font><font style="font-family:inherit;font-size:10pt;">$15,263</font><font style="font-family:inherit;font-size:10pt;">; and (iii) a quarterly royalty payment of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> on net sales of the FSC products through February 6, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$10,300</font><font style="font-family:inherit;font-size:10pt;">. In addition, under the Deerfield Guarantee, the Company and Holdings guaranteed that Deerfield would receive certain minimum annual FSC Product Royalties through February 6, 2026 (the “Minimum Royalties”). Given the Company’s explicit guarantee to Deerfield, the Company recorded the guarantee in accordance with ASC 460. A valuation was performed, which was based largely on an analysis of the potential timing of each possible cash outflow described above and the likelihood of Cerecor’s default on such payments assuming an S&P credit rating of CCC+. The result of this valuation identified a guarantee liability of </font><font style="font-family:inherit;font-size:10pt;">$6,643</font><font style="font-family:inherit;font-size:10pt;">. This liability is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield. At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of this liability was </font><font style="font-family:inherit;font-size:10pt;">$5,851</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Armistice Guarantee</font></div><div style="line-height:120%;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the closing under the Purchase Agreement, Armistice Capital Master Fund, Ltd., the then majority shareholder of Cerecor, guaranteed to Holdings the payment by Cerecor of the Assumed Obligations, including the Minimum Royalties. A valuation of the guarantee asset was performed in accordance with ASC 460 and a guarantee asset of </font><font style="font-family:inherit;font-size:10pt;">$6,620</font><font style="font-family:inherit;font-size:10pt;"> was recorded. This asset is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield noted above. At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of this asset was </font><font style="font-family:inherit;font-size:10pt;">$5,831</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of the Avadel guarantee to Deerfield and the guarantee received by Avadel from Armistice largely offset and when combined are not material.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on management’s review of ASU 2014-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity</font><font style="font-family:inherit;font-size:10pt;">, the disposition of our pediatric assets and related liabilities did not qualify for discontinued operations reporting. Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC, prior to its February 16, 2018 disposition date.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:15px;text-align:left;padding-left:30px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recent Updates to Guarantees</font></div><div style="line-height:120%;text-align:justify;padding-left:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 10, 2019 Cerecor entered into a purchase and sale agreement with a Aytu BioScience, Inc (“Buyer”) pursuant to which the Buyer will purchase certain assets from Cerecor and assume certain of Cerecor’s liabilities, including all of Cerecor’s liabilities assumed as part of the Purchase Agreement noted above. As part of this transaction, on November 1, 2019, Armistice has agreed to deposit </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;"> in an escrow account governed by an escrow agreement between Armistice and Deerfield having the purpose of securing the </font><font style="font-family:inherit;font-size:10pt;">$15,000</font><font style="font-family:inherit;font-size:10pt;"> balloon payment due January 2021 as part of the Membership Interest Purchase Agreement. As part of the Cerecor transaction with the buyer, Deerfield contractually acknowledges and agrees that they will seek payment from the escrow funds before requesting payment from the Company pursuant to the Deerfield Guarantee discussed above. As a result, the Company is in process of assessing the impact this escrow deposit has on the fair values of the guarantees and will adjust such carrying values in the quarter ending December 31, 2019. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The net impact of this transaction was not material to the unaudited condensed consolidated statements of loss.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 820, “Fair Value Measurements and Disclosures,” defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques:  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income approach, which is based on the present value of a future stream of net cash flows. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:  </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 - Quoted prices for identical assets or liabilities in active markets. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 - Unobservable inputs that reflect estimates and assumptions. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 6</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market and mutual funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">62,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Related party payable (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A review of fair value hierarchy classifications is conducted on a quarterly basis.  Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the periods ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, there were no transfers in and out of Level 1, 2, or 3. During the three month periods ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, we did not recognize any other-than-temporary impairment loss.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Some of the Company’s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Debt</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate the fair value of our </font><font style="font-family:inherit;font-size:10pt;">$143,750</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of </font><font style="font-family:inherit;font-size:10pt;">4.50%</font><font style="font-family:inherit;font-size:10pt;"> exchangeable senior notes due 2023 (the “2023 Notes”), a Level 2 input, based on interest rates that would be currently available to the Company for issuance of similar types of debt instruments with similar terms and remaining maturities or recent trading prices obtained from brokers. The estimated fair value of the 2023 Notes at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> is </font><font style="font-family:inherit;font-size:10pt;">$76,425</font><font style="font-family:inherit;font-size:10pt;"> compared to a book value of </font><font style="font-family:inherit;font-size:10pt;">$120,132</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the Company’s other debt is reflected in the balance sheet at carrying value. The fair value of these loans is impracticable to estimate as these represent non-interest bearing grants from the French government and are repayable only if the research project is technically or commercially successful.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">11</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:normal;">Long-Term Debt</font><font style="font-family:inherit;font-size:10pt;"> for additional information regarding our debt obligations.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxe</font><font style="font-family:inherit;font-size:10pt;">s </font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of loss before income taxes are as follows: </font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss Before Income Taxes:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ireland</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(36,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(34,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,773</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,043</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">France</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(16,462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,846</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(34,805</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Income Tax Rate Reconciliation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Statutory tax rate </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">International tax rates differential</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(31.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of nondeductible contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State and local income taxes, net of federal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(33.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit - at statutory tax rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(829</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,058</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,355</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">International tax rates differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,059</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of nondeductible contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">914</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State and local income taxes, net of federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(199</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(844</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax provision (benefit) - at effective income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax provision was $2,234 for the three months ended September 30, 2019 and a benefit of $691 for the three months ended September 30, 2018. The increase in the income tax provision for the three months ended September 30, 2019 is primarily the result of a decrease in the amount of nontaxable gain from the revaluation of contingent consideration and an increase in the amount of valuation allowances recorded on foreign income tax losses.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The income tax provision was $3,641 for the nine months ended September 30, 2019 and a benefit of $3,360 for the nine months ended September 30, 2018. The increase in the income tax provision for the nine months ended September 30, 2019 is primarily the result of a decrease the amount of nontaxable gain from the revaluation of contingent consideration and an increase in the amount of valuation allowances recorded on foreign income tax losses. </font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The IRS commenced an examination of the Company's U.S. income tax returns for 2016 and 2017 during the second quarter 2019. </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td style="width:35%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maturities</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Debt Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less than 1 Year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1-5 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">5-10 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Greater than 10 Years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">556</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,360</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">342</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,600</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">744</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,669</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,718</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">605</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">342</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of lease costs, which are included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended September 30 were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease cost:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three months ended September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine months ended September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating lease costs </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sublease income </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total lease cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">Variable lease costs were immaterial for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;"> Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020. The Company also vacated portions of its office facility in St. Louis, Missouri during May 2019 and August 2019 and started receiving sublease income starting in May 2019 and August 2019 from two different tenants. The lease agreement ends in April 2025 and the sublease agreement that started in May 2019 ends in May 2020, with a one year renewal and the sublease agreement that started in August 2019 ends in July 2020, and can continue thereafter on a month-to-month basis.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of the Company’s operating lease liabilities were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maturities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Remaining three months of 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">678</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">941</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">513</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Present value of lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Leases</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. On January 1, 2019, the Company adopted the ASU using the modified retrospective transition approach and elected the transition option to recognize the adjustment in the period of adoption rather than in the earliest period presented. As of January 1, 2019, adoption of the new guidance resulted in the initial recognition of operating lease right-of-use assets of </font><font style="font-family:inherit;font-size:10pt;">$5,046</font><font style="font-family:inherit;font-size:10pt;"> and operating lease liabilities of </font><font style="font-family:inherit;font-size:10pt;">$5,131</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the balances of the operating lease right-of-use asset and total operating lease liability were </font><font style="font-family:inherit;font-size:10pt;">$4,385</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4,462</font><font style="font-family:inherit;font-size:10pt;">, respectively, of which </font><font style="font-family:inherit;font-size:10pt;">$1,596</font><font style="font-family:inherit;font-size:10pt;"> of the operating lease liability is current.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases certain facilities for office and manufacturing purposes, comprising approximately 99% of the total lease population. All leased facilities are classified as operating leases with remaining lease terms between </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">seven years</font><font style="font-family:inherit;font-size:10pt;">. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. For all of the Company’s leases, lease and non-lease components are accounted for as a single lease component, as all non-lease components are immaterial to break out separately. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of lease costs, which are included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended September 30 were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.8984375%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease cost:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three months ended September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine months ended September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating lease costs </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,150</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Sublease income </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">187</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total lease cost</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">329</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">963</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">Variable lease costs were immaterial for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;"> Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020. The Company also vacated portions of its office facility in St. Louis, Missouri during May 2019 and August 2019 and started receiving sublease income starting in May 2019 and August 2019 from two different tenants. The lease agreement ends in April 2025 and the sublease agreement that started in May 2019 ends in May 2020, with a one year renewal and the sublease agreement that started in August 2019 ends in July 2020, and can continue thereafter on a month-to-month basis.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company reduced its operating lease liabilities by </font><font style="font-family:inherit;font-size:10pt;">$411</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,115</font><font style="font-family:inherit;font-size:10pt;"> for cash paid. In addition, during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, new operating leases commenced resulting in the recognition of operating lease right-of-use assets and liabilities of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0</font><font style="font-family:inherit;font-size:10pt;">, respectively, as the entire lease payment was paid on March 31, 2019. There were no new leases during the three months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the Company is aware of one additional embedded lease that has not yet commenced and will not commence until the time of FDA approval of the product (if approved). Once FDA approval is given and the start date is determined, annual production suite fees of approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$4,000</font><font style="font-family:inherit;font-size:10pt;"> would commence and at that time an operating lease right-of-use asset and corresponding operating lease liability will be recorded. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the 2019 French Restructuring plan discussed in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 15: Restructuring Costs</font><font style="font-family:inherit;font-size:10pt;">, during the three months ended September 30, 2019, the Company came to an agreement with the landlord of the leased office space in France, to exit the lease by December 31, 2019 with an early termination payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$820</font><font style="font-family:inherit;font-size:10pt;">. The Company accounted for this change in the lease term as a modification of the original lease. As a result of this modification, the right-of-use asset and liability related to the French office lease that was remeasured, and the asset was subsequently tested for impairment as the fair value was less than the book value. Since the fair value was determined to be less than the book value, the Company recorded an impairment to the right of use asset of </font><font style="font-family:inherit;font-size:10pt;">$826</font><font style="font-family:inherit;font-size:10pt;">, which was recorded as a restructuring cost in the unaudited condensed consolidated statements of loss. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, our operating leases have a weighted-average remaining lease term of </font><font style="font-family:inherit;font-size:10pt;">4.3 years</font><font style="font-family:inherit;font-size:10pt;"> and a weighted-average discount rate of </font><font style="font-family:inherit;font-size:10pt;">5.3%</font><font style="font-family:inherit;font-size:10pt;">. Nearly all of Avadel’s lease contracts do not provide a readily determinable implicit rate. For these contracts, Avadel’s estimated incremental borrowing rate is based on information available at the inception of the lease.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Maturities of the Company’s operating lease liabilities were as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Maturities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Remaining three months of 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,117</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">670</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">678</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">690</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">941</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">513</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Present value of lease liabilities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the prior lease guidance, minimum rental commitments for non-cancelable leases as of December 31, 2018 were: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease Commitment:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">967</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Newly Issued Accounting Standards</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, “</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, “</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.</font><font style="font-family:inherit;font-size:10pt;">” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">“Financial Instruments - Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments(“ASU 2016-13”)</font><font style="font-family:inherit;font-size:10pt;">.” This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will be effective for the Company for fiscal years beginning on or after January 1, 2020, including interim periods within those annual reporting periods and early adoption is permitted. We are currently evaluating the impact of our adoption of ASU 2016-13 on our condensed consolidated financial statements.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Newly Issued Accounting Standards</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Guidance Not Yet Adopted</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, “</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement</font><font style="font-family:inherit;font-size:10pt;">” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU 2017-04, “</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.</font><font style="font-family:inherit;font-size:10pt;">” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">“Financial Instruments - Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments(“ASU 2016-13”)</font><font style="font-family:inherit;font-size:10pt;">.” This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will be effective for the Company for fiscal years beginning on or after January 1, 2020, including interim periods within those annual reporting periods and early adoption is permitted. We are currently evaluating the impact of our adoption of ASU 2016-13 on our condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Non-Current Liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Provision for retirement indemnity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,024</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer allowances </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">923</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,717</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee to Deerfield (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,289</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,717</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">594</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,002</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-Term Related Party Payable </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term related party payable and related activity are reported at fair value and consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Activity during the Nine Months Ended </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Changes in Fair Value of Related Party Payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-Term Related Party Payable: </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments to</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance, September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition-related contingent consideration:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Earn-out payments - Éclat Pharmaceuticals (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,640</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,359</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financing-related:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Deerfield (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,184</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(930</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Broadfin (c)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(444</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">166</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">763</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total related party payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total long-term related party payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,118</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term related party payable and related activity are reported at fair value and consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and June 30, 2019:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Activity during the Three Months Ended </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Changes in Fair Value of Related Party Payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-Term Related Party Payable: </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments to</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance, September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition-related contingent consideration:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Earn-out payments - Éclat Pharmaceuticals (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,582</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,850</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">627</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,359</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financing-related:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Deerfield (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Broadfin (c)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">866</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">763</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total related party payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,247</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">627</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">139</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total long-term related party payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,118</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s former CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of </font><font style="font-family:inherit;font-size:10pt;">$2,600</font><font style="font-family:inherit;font-size:10pt;"> in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of </font><font style="font-family:inherit;font-size:10pt;">$2,200</font><font style="font-family:inherit;font-size:10pt;"> in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a </font><font style="font-family:inherit;font-size:10pt;">0.834%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net sales of certain Éclat products until December 31, 2024.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, the fair value of each related party payable listed in (a), (b) and (c) above was estimated using a discounted cash flow model based on estimated and projected annual net revenues or gross profit, as appropriate, of each of the specified Éclat products using an appropriate risk-adjusted discount rate of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management’s revision of key assumptions, will be recorded in the unaudited condensed consolidated statements of loss in the line items entitled “Changes in fair value of related party contingent consideration” for items noted in (b) above and in “Other expense - changes in fair value of related party payable” for items (b) and (c) above. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 1: Summary of Significant Accounting Policies </font><font style="font-family:inherit;font-size:10pt;">under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K for more information on key assumptions used to determine the fair value of these liabilities. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for its royalty agreements detailed in items (b) and (c) above. These financing-related liabilities are recorded at fair market value on the unaudited condensed consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – change in fair value of related party payable” on the unaudited condensed consolidated statements of loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month periods ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Party Payable Rollforward:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of related party payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19,261</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value adjustments </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expiration of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,167</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Disposition of the pediatric assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of related party payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value adjustments </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2019 French Restructuring</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2019, the Company initiated a plan to substantially reduce all of its workforce at its Vénissieux, France site (“2019 French Restructuring”). This reduction is an effort to align the Group’s cost structure with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of calendar year 2019, and to result in employee severance, benefits and other costs of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$3,500</font><font style="font-family:inherit;font-size:10pt;">, which are likely to be recognized through December 31, 2019. Restructuring charges associated with this plan of </font><font style="font-family:inherit;font-size:10pt;">$1,259</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3,198</font><font style="font-family:inherit;font-size:10pt;"> were recognized during the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">. Included in the 2019 French Restructuring charges of </font><font style="font-family:inherit;font-size:10pt;">$3,198</font><font style="font-family:inherit;font-size:10pt;"> were charges for employee severance, benefits and other costs of </font><font style="font-family:inherit;font-size:10pt;">$2,774</font><font style="font-family:inherit;font-size:10pt;">, a charge of </font><font style="font-family:inherit;font-size:10pt;">$598</font><font style="font-family:inherit;font-size:10pt;"> related to fixed asset impairment, a charge of </font><font style="font-family:inherit;font-size:10pt;">$826</font><font style="font-family:inherit;font-size:10pt;"> related to the early termination penalty related to the office lease termination (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 9: Leases</font><font style="font-family:inherit;font-size:10pt;">) as well as a benefit of </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> related to the reversal of the French retirement indemnity obligation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth activities for the Company’s cost reduction plan obligations for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 French Restructuring Obligation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at September 30, </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2019 French Restructuring liabilities of </font><font style="font-family:inherit;font-size:10pt;">$884</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$11</font><font style="font-family:inherit;font-size:10pt;"> are included in the unaudited condensed consolidated balance sheet in accrued expenses and accounts payable at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2019 Corporate Restructuring</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2019, the Company announced a plan to reduce its Corporate workforce by more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> (“2019 Corporate Restructuring”). The reduction in workforce is primarily a result of the exit of Noctiva during the first quarter of 2019 (see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">3</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Subsidiary Bankruptcy and Deconsolidation</font><font style="font-family:inherit;font-size:10pt;">), as well as an effort to better align the Company’s remaining cost structure at our U.S. and Ireland locations with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of calendar year 2019, and to result in employee severance, benefits and other costs of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$3,000</font><font style="font-family:inherit;font-size:10pt;">, which are likely to be recognized through December 31, 2019. The restructuring charges associated with this plan of </font><font style="font-family:inherit;font-size:10pt;">$607</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1,570</font><font style="font-family:inherit;font-size:10pt;"> were recognized during the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, respectively. Included in the 2019 Corporate Restructuring expense of </font><font style="font-family:inherit;font-size:10pt;">$607</font><font style="font-family:inherit;font-size:10pt;"> for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> were charges for employee severance, benefit and other costs. Included in the 2019 Corporate Restructuring charges of </font><font style="font-family:inherit;font-size:10pt;">$1,570</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, were charges for employee severance, benefit and other costs of </font><font style="font-family:inherit;font-size:10pt;">$2,966</font><font style="font-family:inherit;font-size:10pt;">, as well as a benefit of </font><font style="font-family:inherit;font-size:10pt;">$1,396</font><font style="font-family:inherit;font-size:10pt;"> related to share based compensation forfeitures related to the employees affected by the global reduction in workforce. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth activities for the Company’s cost reduction plan obligations for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 Corporate Restructuring Obligation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">853</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 Corporate Restructuring liabilities of </font><font style="font-family:inherit;font-size:10pt;">$853</font><font style="font-family:inherit;font-size:10pt;"> are included in the unaudited condensed consolidated balance sheet in accrued expenses at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">2017 French Restructuring</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the first quarter of 2017, the Company announced a plan to reduce its workforce at the Venissieux, France site by approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> (“2017 French Restructuring”).  This reduction was an effort to align the Company’s cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council for our French operations and received approval from the French Labor Commission (DIRECCTE) to implement the plan. The reduction was substantially complete at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">. The 2017 French restructuring costs for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and 2018 were immaterial. The 2017 French Restructuring income of </font><font style="font-family:inherit;font-size:10pt;">$168</font><font style="font-family:inherit;font-size:10pt;"> and restructuring charges of </font><font style="font-family:inherit;font-size:10pt;">$268</font><font style="font-family:inherit;font-size:10pt;"> were recognized during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively. The following table sets forth activities for the Company’s cost reduction plan obligations for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 French Restructuring Obligation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at September 30, </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2017 French Restructuring accrual is included in the unaudited condensed consolidated balance sheet in other non-current liabilities at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue.</font><font style="font-family:inherit;font-size:10pt;"> Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (“R&D”) achievements. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">Accounting Standards Codification (“ASC”) Topic 606, </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">“Revenue from Contracts with Customers”</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer’s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales and Services </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Revenue </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">For a complete discussion of the accounting for net product revenue and license revenues, see </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">4</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">: Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Product Sales and Services </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective January 1, 2018, the Company implemented ASC 606, “</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue From Contracts With Customers</font><font style="font-family:inherit;font-size:10pt;">”. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product and the Company’s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Reserves to Reduce Gross Revenues to Net Revenues</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Product Returns</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">and other judgments and analysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Chargebacks, Discounts and Rebates </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Revenue from licensing arrangements</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The terms of the Company’s licensing agreements may contain multiple performance obligations, including certain R&D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments. Each of these payments results in license revenues. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">License of Intellectual Property</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Disaggregation of revenue</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company’s revenues by product, see </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">18</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: Company Operations by Product</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Contract Balances</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A receivable is recognized in the period the Company sells its products and when the Company’s right to consideration is unconditional. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">There were </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">no</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> material deferred contract costs at </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;font-weight:bold;">Transaction Price Allocated to the Remaining Performance Obligation</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accrued Expenses </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,322</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued social charges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">482</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,009</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued restructuring (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 15</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,737</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Customer allowances</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,244</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,541</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract research organization charges</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract manufacturing organization costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accrued contract sales organization and marketing costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,469</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,559</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,798</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">17,017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,695</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the components of accumulated other comprehensive loss for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, net of tax effects: </font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated Other Comprehensive Loss:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency translation adjustment:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,720</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,435</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,621</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,202</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other comprehensive loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(210</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,930</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,495</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrealized gain (loss) on marketable debt securities, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net other comprehensive income (loss), net of ($5), ($18), ($46) and ($88) tax, respectively</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">86</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">68</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">753</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(92</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at September 30,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">958</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">958</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(156</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Accumulated other comprehensive loss at September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(22,972</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,651</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term debt is summarized as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:58%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Principal amount of 4.50% exchangeable senior notes due 2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">143,750</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: debt discount and issuance costs, net </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(23,618</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net carrying amount of liability component</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,132</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">149</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">     Subtotal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: current maturities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(106</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">     Long-term debt</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">120,132</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">115,734</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity component:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity component of exchangeable notes, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,699</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows: </font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Loss Per Share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,864</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,771</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(30,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(31,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average shares:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,436</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,904</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,382</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,410</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effect of dilutive securities—employee and director equity awards outstanding and 2023 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,436</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,904</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,382</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">37,410</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.43</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.82</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.84</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss per share - diluted </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.43</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Income Tax Rate Reconciliation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Statutory tax rate </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">International tax rates differential</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(31.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(27.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of nondeductible contingent consideration</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State and local income taxes, net of federal</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible interest expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4.5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2.6</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Effective income tax rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(33.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> %</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax benefit - at statutory tax rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(829</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,058</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,355</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(4,351</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">International tax rates differential</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">283</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,108</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,394</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in valuation allowance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,059</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,007</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7,242</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,188</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of nondeductible contingent consideration</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,436</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">578</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">914</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unrecognized tax benefits</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,086</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">State and local income taxes, net of federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(70</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Nondeductible interest expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">299</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">96</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(199</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(844</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(297</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Income tax provision (benefit) - at effective income tax rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,641</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,360</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">As of December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value Measurements:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Marketable securities (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 6</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market and mutual funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,339</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,344</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,718</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,409</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,267</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11,320</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">62,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Related party payable (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 10</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s amortizable and unamortizable intangible assets at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows: </font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="29" rowspan="1"></td></tr><tr><td style="width:26%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:5%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Goodwill and Intangible Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Carrying</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Impairment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Net Carrying</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Amortizable intangible assets:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquired developed technology - Noctiva</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">73,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,024</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(66,087</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquired developed technology - Vazculep</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,432</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,629</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total amortizable intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,042</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(17,456</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(66,087</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,629</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Unamortizable intangible assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total unamortizable intangible assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18,491</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the prior lease guidance, minimum rental commitments for non-cancelable leases as of December 31, 2018 were: </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:81%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Lease Commitment:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,008</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">767</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">967</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total minimum lease payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,836</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of loss before income taxes are as follows: </font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:46%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss Before Income Taxes:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Ireland</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(14,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,314</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(36,625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(34,203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,952</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,773</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,309</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,043</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">France</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,530</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">441</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total loss before income taxes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,630</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(16,462</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(26,846</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(34,805</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal categories of inventories, net reserves of </font><font style="font-family:inherit;font-size:10pt;">$1,212</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4,757</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively, are comprised of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Inventory:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Finished goods</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">377</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,260</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,770</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other Non-Current Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Deferred tax assets, net</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,636</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">23,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Long-term deposits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,477</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Guarantee from Armistice (see </font><font style="font-family:inherit;font-size:9pt;font-style:italic;">Note 14</font><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,697</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Right of use assets at contract manufacturing organizations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,494</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,894</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">49</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total </font><font style="font-family:inherit;font-size:9pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34,927</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,146</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term related party payable and related activity are reported at fair value and consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Activity during the Nine Months Ended </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Changes in Fair Value of Related Party Payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-Term Related Party Payable: </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments to</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance, September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition-related contingent consideration:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Earn-out payments - Éclat Pharmaceuticals (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">25,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,640</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,384</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,359</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financing-related:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Deerfield (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,184</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(930</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Broadfin (c)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(444</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">166</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">763</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total related party payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,014</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">496</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,439</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total long-term related party payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,118</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term related party payable and related activity are reported at fair value and consist of the following at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and June 30, 2019:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Activity during the Three Months Ended </font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Changes in Fair Value of Related Party Payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Long-Term Related Party Payable: </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance,</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Payments to</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Parties</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Operating Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance, September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Acquisition-related contingent consideration:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Earn-out payments - Éclat Pharmaceuticals (a)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,582</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,850</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">627</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,359</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Financing-related:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Deerfield (b)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,799</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(309</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">94</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,584</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Royalty agreement - Broadfin (c)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">866</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(148</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">763</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total related party payable</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">24,247</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(3,307</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">627</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">139</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,264</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total long-term related party payable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">15,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,118</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s former CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to </font><font style="font-family:inherit;font-size:10pt;">20%</font><font style="font-family:inherit;font-size:10pt;"> of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of </font><font style="font-family:inherit;font-size:10pt;">$2,600</font><font style="font-family:inherit;font-size:10pt;"> in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a </font><font style="font-family:inherit;font-size:10pt;">1.75%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of </font><font style="font-family:inherit;font-size:10pt;">$2,200</font><font style="font-family:inherit;font-size:10pt;"> in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a </font><font style="font-family:inherit;font-size:10pt;">0.834%</font><font style="font-family:inherit;font-size:10pt;"> royalty on the net sales of certain Éclat products until December 31, 2024.</font></div></td></tr></table></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">-month periods ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:79%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Related Party Payable Rollforward:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">98,925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of related party payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19,261</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value adjustments </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(18,468</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expiration of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,167</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Disposition of the pediatric assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(20,337</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, September 30, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38,692</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,840</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments of related party payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Fair value adjustments </font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance, September 30, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">21,706</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:10pt;">Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth activities for the Company’s cost reduction plan obligations for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:72%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017 French Restructuring Obligation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">879</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(168</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(663</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(668</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at September 30, </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">38</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth activities for the Company’s cost reduction plan obligations for the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 Corporate Restructuring Obligation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,966</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2,113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at September 30, </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">853</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth activities for the Company’s cost reduction plan obligations for the three and </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019 French Restructuring Obligation:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at January 1,</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Charges for employee severance, benefits and other costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2,774</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,837</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Foreign currency impact</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(42</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance of restructuring accrual at September 30, </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">895</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents a summary of total revenues by these products: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenues by Product:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Bloxiverz</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,466</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,392</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">16,691</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Vazculep</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">27,669</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">33,097</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Akovaz</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,991</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13,946</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">28,083</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(231</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,420</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">213</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,232</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total product sales</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,229</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,103</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">License revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">246</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total revenues</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">14,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">19,826</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">48,220</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">82,349</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Estimated amortization of intangible assets for the next </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years is as follows: </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:86%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Estimated Annual Amortization Expense: </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">814</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2021</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2023</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Nature of Operations.</font><font style="font-family:inherit;font-size:10pt;">  </font><font style="font-family:inherit;font-size:10pt;">Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company.  Our primary focus is on the development and potential U.S. Food and Drug Administration (“FDA”) approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.  The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted a new drug application (“NDA”) in March 2019 on a fourth sterile injectable drug which we refer to as AV001, for use in the hospital setting. AV001, if approved, could contribute revenues to Avadel starting in 2020. In May 2019, the FDA accepted the NDA for AV001, with a Prescription Drug User Fee Act (PDUFA) target action date of December 15, 2019. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current marketed products include: </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Akovaz®</font><font> (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Bloxiverz®</font><font> (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery. </font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-style:italic;">Vazculep®</font><font> (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.</font></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of our</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Akovaz</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Bloxiverz</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Vazculep</font><font style="font-family:inherit;font-size:10pt;"> products is used primarily in the hospital setting and was developed under our UMD program.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the U.S. Securities and Exchange Commission (“SEC”). These filings are also available to the public at www.sec.gov.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is the successor to Flamel Technologies S.A., a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">société anonyme</font><font style="font-family:inherit;font-size:10pt;"> (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “The Reincorporation Merger” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation</font><font style="font-family:inherit;font-size:10pt;">), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">société par actions simplifiée</font><font style="font-family:inherit;font-size:10pt;">, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation.</font><font style="font-family:inherit;font-size:10pt;"> The unaudited condensed consolidated balance sheet as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;">, which is derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 6, 2019, the Company’s indirect wholly-owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”), filed a voluntary petition for reorganization under Chapter 11 of the United States (“U.S.”) Code (the “Bankruptcy Code”). in the U.S. District Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case No. 19-10248. Specialty Pharma is operating and managing its business as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma’s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note 3: Subsidiary Bankruptcy and Deconsolidation. </font><font style="font-family:inherit;font-size:10pt;">Our results of operations for the period January 1, 2019 through February 6, 2019 include the results of Specialty Pharma prior to its February 6, 2019 voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC Therapeutics and FSC Laboratories, Inc., (collectively “FSC”), prior to its February 16, 2018 disposition date. See </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">14</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">: </font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:normal;">Divestiture of the Pediatric Assets</font><font style="font-family:inherit;font-size:10pt;">, for additional information. All intercompany accounts and transactions have been eliminated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue.</font><font style="font-family:inherit;font-size:10pt;"> Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (“R&D”) achievements. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">Accounting Standards Codification (“ASC”) Topic 606, </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">“Revenue from Contracts with Customers”</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;"> applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer’s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales and Services </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">License Revenue </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">For a complete discussion of the accounting for net product revenue and license revenues, see </font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">Note </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">4</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;font-style:italic;">: Revenue Recognition</font><font style="font-family:inherit;font-size:10pt;color:#0d0d0d;">.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, respectively:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September 30, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market and mutual funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">785</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">44,091</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,190</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,217</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">129</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,344</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,718</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">58,606</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,009</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">59,587</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td style="width:48%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Marketable Securities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Equity securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">10,101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(956</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Money market and mutual funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,733</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">316</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(53</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">52,996</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Corporate bonds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,411</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Government securities - U.S.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,714</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(79</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">12,701</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other fixed-income securities</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,400</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">91,359</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">411</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(1,180</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">90,590</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></div>

EX-101.SCH 7 avdl-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2120100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Commitments and Contingencies - (Tables) link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Comprehensive Income (Loss) - Components (Details) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Comprehensive Loss - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Divestiture of the Pediatric Assets link:presentationLink link:calculationLink link:definitionLink 2415401 - Disclosure - Divestiture of the Pediatric Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2409404 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Goodwill and Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Income Taxes - Reconciliation of Tax Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Leases - Components of lease costs (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Leases - Maturities of operating lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Leases - Maturities of operating lease liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Long-Term Debt Schedule of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Long-Term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Long-Term Related Party Payable link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Long-Term Related Party Payable - Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Long-Term Related Party Payable - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Long-Term Related Party Payable (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Marketable Securities Marketable Securities - Schedule of Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Net Loss Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Newly Issued Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Other Assets and Liabilities link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Other Assets and Liabilities - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Other Assets and Liabilities - Other Non-Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Other Assets and Liabilities - Other Non-Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Other Assets and Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Restructuring Costs link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Restructuring Costs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Restructuring Costs - Severance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Revenue by Product link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Revenue by Product - Summary of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Revenue by Product (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Revenue Recognition - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Subsidiary Bankruptcy and Deconsolidation link:presentationLink link:calculationLink link:definitionLink 2403401 - Disclosure - Subsidiary Bankruptcy and Deconsolidation (Details) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY Statement link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 avdl-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 avdl-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 avdl-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Reorganizations [Abstract] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Specialty Pharma Specialty Pharma [Member] Specialty Pharma [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Speciality Pharama Speciality Pharama [Member] Speciality Pharama [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] DIP Credit Agreement DIP Credit Agreement [Member] DIP Credit Agreement [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Debtor in Possession Credit and Security Facility Debtor in Possession Credit and Security Facility [Member] Debtor in Possession Credit and Security Facility [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Equity method investments, fair value Equity Method Investments, Fair Value Disclosure Gain (loss) on deconsolidation of subsidiary Deconsolidation, Gain (Loss), Amount Aggregate cash proceeds of intangible assets and remaining inventory Proceeds from Sale of Intangible Assets DIP financing, amount arranged Debtor-in-Possession Financing, Amount Arranged Payments for debtor in possession financing Payments For Debtor In Possession Financing Payments For Debtor In Possession Financing Bankruptcy claims, amount of filed claims likely to be denied Bankruptcy Claims, Amount of Filed Claims Likely to be Denied Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Estimated useful life (in years) Finite-Lived Intangible Asset, Useful Life Estimated Annual Amortization Expense: Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] 2019 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year 2020 Finite-Lived Intangible Assets, Amortization Expense, Year Two 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Three 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Four 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Five Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Ordinary shares Common Stock [Member] Additional paid-in capital Additional Paid-in Capital [Member] Accumulated deficit Retained Earnings [Member] Accumulated other comprehensive (loss) income AOCI Attributable to Parent [Member] Treasury shares Treasury Stock [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (in shares) Shares, Outstanding Beginning balance Stockholders' Equity Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Vesting of restricted shares (in shares) Stock Issued During Period, Shares, Other Vesting of restricted shares Stock Issued During Period, Value, Other Employee share purchase plan share issuance (in shares) Stock Issued During Period, Shares, Employee Stock Ownership Plan Employee share purchase plan share issuance Stock Issued During Period, Value, Employee Stock Purchase Plan Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Exercise of warrants (in shares) Stock Issued During Period, Shares, Expiration Of Warrants Stock Issued During Period, Shares, Expiration Of Warrants Exercise of warrants Stock Issued During Period, Value, Expiration Of Warrants Stock Issued During Period, Value, Expiration Of Warrants Expiration of warrants Adjustments to Additional Paid in Capital, Other Equity component of 2023 Notes Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Share repurchases (in shares) Treasury Stock, Shares, Acquired Share repurchases Treasury Stock, Value, Acquired, Cost Method Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Ending balance (in shares) Ending balance Debt Disclosure [Abstract] Schedule of Debt Schedule of Long-term Debt Instruments [Table Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Marketable securities Marketable Securities, Current Accounts receivable Accounts Receivable, Net, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net Property, Plant and Equipment, Net Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Goodwill Goodwill Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Research and development tax credit receivable Research and Development Tax Credit Receivable Non Current The non current portion of tax credit receivable on research and development as on the balance sheet date. Other non-current assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND SHAREHOLDERS’ (DEFICIT) EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Current portion of long-term debt Long-term Debt, Current Maturities Current portion of long-term related party payable Due to Related Parties, Current Current portion of operating lease liability Operating Lease, Liability, Current Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt, less current portion Long-term Debt, Excluding Current Maturities Long-term related party payable, less current portion Due to Related Parties, Noncurrent Long-term operating lease liability Operating Lease, Liability, Noncurrent Other non-current liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Shareholders’ (deficit) equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; none issued or outstanding at September 30, 2019 and December 31, 2018, respectively Preferred Stock, Value, Issued Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 42,857 issued and 37,450 outstanding at September 30, 2019 and 42,720 issued and 37,313 outstanding at December 31, 2018 Common Stock, Value, Issued Treasury shares, at cost, 5,407 shares held at September 30, 2019 and December 31, 2018, respectively Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total shareholders’ (deficit) equity Total liabilities and shareholders’ (deficit) equity Liabilities and Equity Earnings Per Share [Abstract] Net Loss Per Share Earnings Per Share [Text Block] Investments, Debt and Equity Securities [Abstract] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Equity securities Equity Securities [Member] Money market and mutual funds Money Market Funds [Member] Corporate bonds Corporate Debt Securities [Member] Government securities - U.S. US Government Agencies Debt Securities [Member] Other fixed-income securities Fixed Income Securities [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Debt Securities, Trading, and Equity Securities, FV-NI [Abstract] Debt Securities, Trading, and Equity Securities, FV-NI [Abstract] Adjusted Cost Equity Securities, FV-NI, Cost Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Fair Value Equity Securities, FV-NI Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Adjusted Cost Debt Securities, Available-for-sale, Amortized Cost Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Fair Value Debt Securities, Available-for-sale Other Liabilities Disclosure [Abstract] Accrued Expenses Accrued Liabilities, Current [Abstract] Accrued compensation Workers' Compensation Liability, Current Accrued social charges Accrued Social Charges Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued social charges. Accrued restructuring (see Note 15) Restructuring Reserve, Current Customer allowances Accrued trade discounts and rebates Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued discounts and rebates Accrued contract research organization charges Accrued Contract Research Organization Charges Accrued Contract Research Organization Charges Accrued contract manufacturing organization costs Accrued Contract Manufacturing Organization Liabilities Accrued Contract Manufacturing Organization Liabilities Accrued contract sales organization and marketing costs Accrued Contract Research Organization Accrued Contract Research Organization Other Other Accrued Liabilities, Current Total Schedule of Earnings Per Share Reconciliation Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value Measurements, Recurring Fair Value, Measurements, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] 4.50% Exchangeable Senior Notes Due 2023 Four Point Fifty Percent Exchangeable Senior Notes Due 2023 [Member] Four Point Fifty Percent Exchangeable Senior Notes Due 2023 [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Senior Notes Senior Notes [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity securities Money market and mutual funds Total assets Assets, Fair Value Disclosure Related party payable Due to Related Parties Total liabilities Nonfinancial Liabilities Fair Value Disclosure Long-term debt Long-term Debt, Gross Debt instrument, interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Long-term debt, fair value Long-term Debt, Fair Value Book value of long-term debt Long-term Debt Restructuring and Related Activities [Abstract] Restructuring Costs Restructuring and Related Activities Disclosure [Text Block] Statement of Comprehensive Income [Abstract] Other comprehensive income (loss), tax Other Comprehensive Income (Loss), Available-for-sale Securities, Tax, Portion Attributable to Parent Inventory Disclosure [Abstract] Schedule of Inventory Schedule of Inventory, Current [Table Text Block] Marketable securities, realized gain Marketable Securities, Realized Gain Marketable Securities, Realized Gain Marketable securities, realized loss Marketable Securities, Realized Loss Marketable Securities, Realized Loss Long-Term Related Party Payable Related Party Transactions Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Amortization of premiums on marketable securities Marketable Securities, Gain (Loss) Remeasurement of related party acquisition-related contingent consideration Acquisition Related Contingent Consideration Remeasurement Represents the remeasurement of acquisition related contingent considerations Remeasurement of related party financing-related contingent consideration Financing Related Contingent Consideration Remeasurement Represents the remeasurement of financing related contingent considerations Amortization of debt discount and debt issuance costs Amortization of Debt Issuance Costs and Discounts Change in deferred tax and income tax deferred charge Increase (Decrease) in Income Taxes Stock-based compensation expense Share-based Compensation EX-101.PRE 11 avdl-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R74.htm IDEA: XBRL DOCUMENT

Comprehensive Loss - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stockholders' Equity Note [Abstract]
Other comprehensive income (loss), tax	$ (5)	$ (18)	$ (46)	$ (88)

XML 13 R70.htm IDEA: XBRL DOCUMENT

Restructuring Costs - Severance Obligation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,866,000	$ 65,000	$ 4,600,000	$ 268,000
2019 French Restructuring Obligation
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,259		3,198,000
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance			0
Payments			(1,837,000)
Foreign currency impact			(42,000)
Restructuring reserve, ending balance	895,000		895,000
2019 Corporate Restructuring Obligations
Restructuring Cost and Reserve [Line Items]
Restructuring costs	607,000		1,570,000
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance			0
Payments			(2,113,000)
Restructuring reserve, ending balance	853,000		853,000
Lyon France Workforce Reduction
Restructuring Cost and Reserve [Line Items]
Restructuring costs			168,000	268,000
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance			879,000	1,000,000
Charges for employee severance, benefits and other			(168,000)	268,000
Payments			(663,000)	(668,000)
Foreign currency impact			(10,000)	(19,000)
Restructuring reserve, ending balance	$ 38,000	$ 581,000	$ 38,000	$ 581,000

XML 14 R53.htm IDEA: XBRL DOCUMENT

Leases - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended
Leases - Narrative (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2019	Jan. 01, 2019
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	$ 4,385,000	$ 4,385,000
Operating lease liabilities	4,462,000	4,462,000
Current portion of operating lease liability	1,596,000	1,596,000
Operating lease payments	$ 411,000	$ 1,115,000
Operating lease, weighted average remaining lease term (in years)	4 years 3 months 11 days	4 years 3 months 11 days
Operating lease, weighted average discount rate, percent	5.30%	5.30%
Minimum
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	1 year	1 year
Lessee, operating lease, lease not yet commenced, operating lease expense	$ 3,000,000	$ 3,000,000
Maximum
Lessee, Lease, Description [Line Items]
Operating lease, term of contract	7 years	7 years
Lessee, operating lease, lease not yet commenced, operating lease expense	$ 4,000,000	$ 4,000,000
Operating Leases Commenced
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets	1,000,000	1,000,000
Operating lease liabilities	$ 0	0
Accounting Standards Update 2016-02
Lessee, Lease, Description [Line Items]
Operating lease right-of-use assets				$ 5,046,000
Operating lease liabilities				$ 5,131,000
2019 French Restructuring Obligation
Lessee, Lease, Description [Line Items]
Operating lease, impairment loss		$ 826,000
Scenario, Forecast \| 2019 French Restructuring Obligation
Lessee, Lease, Description [Line Items]
Early termination payment			$ 820

XML 15 R57.htm IDEA: XBRL DOCUMENT

Long-Term Related Party Payable - Narrative (Details) - USD ($) $ in Thousands	1 Months Ended
	Dec. 31, 2013	Feb. 28, 2013	Mar. 31, 2012	Sep. 30, 2019
Minimum
Line of Credit Facility [Line Items]
Discounted cash flow risk adjusted discount rate				15.00%
Broadfin Debt Financing
Line of Credit Facility [Line Items]
Cash consideration received on royalty agreement	$ 2,200
Percentage of royalty payable on net sales	0.834%
Affiliated Entity \| Deerfield FSC LLC
Line of Credit Facility [Line Items]
Cash consideration received on royalty agreement		$ 2,600
Percentage of royalty payable on net sales		1.75%
Eclat Pharmaceuticals
Line of Credit Facility [Line Items]
Percentage of earn-out payments			20.00%

XML 16 R36.htm IDEA: XBRL DOCUMENT

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Schedule of Components of Income Before Income Tax

The components of loss before income taxes are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Loss Before Income Taxes:	2019			2018			2019			2018

Ireland	$	(14,302	)	$	(18,314	)	$	(36,625	)	$	(34,203	)
United States	5,952			1,773			12,309			(1,043		)
France	1,720			79			(2,530		)	441
Total loss before income taxes	$	(6,630	)	$	(16,462	)	$	(26,846	)	$	(34,805	)

Schedule of Effective Income Tax Rate Reconciliation

The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Income Tax Rate Reconciliation:	2019			2018			2019			2018

Statutory tax rate	12.5		%	12.5		%	12.5		%	12.5		%
International tax rates differential	(4.3		)%	7.0		%	4.1		%	6.9		%
Change in valuation allowance	(31.1		)%	(18.3		)%	(27.0		)%	(14.9		)%
Change in fair value of nondeductible contingent consideration	4.1		%	8.7		%	(0.1		)%	9.9		%
Nondeductible stock-based compensation	—		%	(3.5		)%	(0.2		)%	(2.6		)%
Unrecognized tax benefits	(8.8		)%	(3.5		)%	(3.3		)%	(3.1		)%
State and local income taxes, net of federal	(0.2		)%	0.1		%	(0.2		)%	0.2		%
Nondeductible interest expense	(4.5		)%	—		%	(2.6		)%	—		%
Other	(1.3		)%	1.2		%	3.1		%	0.8		%
Effective income tax rate	(33.6		)%	4.2		%	(13.7		)%	9.7		%

Income tax benefit - at statutory tax rate	$	(829	)	$	(2,058	)	$	(3,355	)	$	(4,351	)
International tax rates differential	283			(1,153		)	(1,108		)	(2,394		)
Change in valuation allowance	2,059			3,007			7,242			5,188
Change in fair value of nondeductible contingent consideration	(270		)	(1,431		)	33			(3,436		)
Nondeductible stock-based compensation	1			578			50			914
Unrecognized tax benefits	581			578			873			1,086
State and local income taxes, net of federal	14			(13		)	41			(70		)
Nondeductible interest expense	299			—			709			—
Other	96			(199		)	(844		)	(297		)
Income tax provision (benefit) - at effective income tax rate	$	2,234		$	(691	)	$	3,641		$	(3,360	)

XML 17 R5.htm IDEA: XBRL DOCUMENT

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 12,867	$ 9,325
Marketable securities	59,587	90,590
Accounts receivable	8,725	11,330
Inventories	2,260	4,770
Prepaid expenses and other current assets	5,163	8,836
Total current assets	88,602	124,851
Property and equipment, net	770	1,911
Operating lease right-of-use assets	4,385
Goodwill	18,491	18,491
Intangible assets, net	1,019	1,629
Research and development tax credit receivable	7,694	7,272
Other non-current assets	34,927	36,146
Total assets	155,888	190,300
Current liabilities:
Current portion of long-term debt	35	106
Current portion of long-term related party payable	7,588	9,439
Current portion of operating lease liability	1,596
Accounts payable	3,538	3,503
Accrued expenses	17,017	21,695
Other current liabilities	1,989	3,640
Total current liabilities	31,763	38,383
Long-term debt, less current portion	120,132	115,734
Long-term related party payable, less current portion	14,118	19,401
Long-term operating lease liability	2,866
Other non-current liabilities	13,972	14,002
Total liabilities	182,851	187,520
Shareholders’ (deficit) equity:
Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; none issued or outstanding at September 30, 2019 and December 31, 2018, respectively	0	0
Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized; 42,857 issued and 37,450 outstanding at September 30, 2019 and 42,720 issued and 37,313 outstanding at December 31, 2018	428	427
Treasury shares, at cost, 5,407 shares held at September 30, 2019 and December 31, 2018, respectively	(49,998)	(49,998)
Additional paid-in capital	434,055	433,756
Accumulated deficit	(388,476)	(357,989)
Accumulated other comprehensive loss	(22,972)	(23,416)
Total shareholders’ (deficit) equity	(26,963)	2,780
Total liabilities and shareholders’ (deficit) equity	$ 155,888	$ 190,300

EXCEL 18 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( '5_;$\?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ =7]L3R?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " !U?VQ/=!=1NN\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+!3L,P#(9?!>7>NNDV!%&7"V@GD)"8!.(6)=X6K6FCQ*C=VY.& MK1."!^ 8^\_GSY(;[87N [Z$WF,@B_%F=&T7A?9K=B#R B#J SH5RY3H4G/7 M!ZO-)'M4>HJ^H6')(RBA1,P,+/1"8;HX4.J*@/9[S1,]Y_AC;#C 9L MT6%'$7C)@&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " !U?VQ/,P"_#GH" ! "0 & 'AL+W=OU?782)Z SF-I. MN/Y];<-1:B]] =O,[.PR+';1<_$J*TI5\-:P5F[#2JGN.8KDN:(-D4^\HZU^ M?P:@X:3IB'.Q^_1 M/]KB=3$G(NF!LY_U157;>/^)C@5E83!6_X4^*--PDXG6.',F M[34XWZ7BS1A%I]*0M^%>M_;>#T_29*3!!#P2\$3 ^7\)R4A()@)*;?%#9K;4 M#T21LA"\#\3@5D?,1X&>$_TRSV;1OCO[3%JCC(OH8<*,B/V P#,$FA"1 MCCT)8$A@CSTZ_E?@X",26" !*T@L/9G14YB>@O34TM,9/7->@(]8P0(9*)!Y M]-P1\!%K6& %"JP\^L81\!$HAA5R4"'W^@1W.?*;&+OF0YBE6N!61WXGXY6K F"65.!^1WX[8^\; M S!+*G#/([^C\=KY=IUF&V:K MT_%@A^U^]A<^G"V^$G&K6QFYT6MZ"3$#9)R]E_OTY(.3 S:7M3B/N,[==V/*_-_%C5WYNM]^WD M1UGLF[OIMFT/MU'4/&U]F3J[K,V_!8OT3-H?;YI@\JBPCCV$9E MOMM/%_.^[*%>S*O7MMCM_4,]:5[+,J__6_JB.MY-8?I>\&WWLFV[@F@Q/^0O M_D_?_G5XJ,-3=*YELRO]OME5^TGMG^^F]W"[5G$7T!-_[_RQN?@^Z:0\5M7W M[N&WS=TT[GKD"__4=E7DX>/-KWQ1=#6%?OP[5#H]M]D%7GY_K_V77GP0\Y@W M?E45_^PV[?9NZJ:3C7_.7XOV6W7\U0^"S'0RJ/_=O_DBX%U/0AM/5='T?R=/ MKTU;E4,MH2ME_N/TN=OWG\>A_O#GFW[.#6A.EZZ@K[V>G_%\:S":5O"TSG MT5M7SX L3PA>("J^1C*.P)F(0OOG3J#4B26R<+QN8,4)!:0/GU:R_K"2JVXJ M<:Q4'Z\NXU&.UV*\[N/U9;PB8WU";(_L3P.ID<[(2J!2AY8,"*>T0R13M^:4 M0Z5369<1=1D^+EJ.MV*\Y>-BR+B<$'/12PS=),/"(054;\:A- &REM8< H4X M(BH1125<%)F@9<):28RB<\TA !V3I9UQ"@U8.M><4@JUDF4Y49;CLA(BR[%6 MC *B?<4A#*N3B,\$"@U;PIQ*$C C2S@59:5 _(90&5A8(LE3!='%,J19HT M!0U/O =P+S("9#X'2=$XSJ2J=6JI*,#)ZS#^#;#Z NP^Z,RR! MNX&9M?3$LI(PL-I28R5Q85NGX[F6.*7=Z 8BVQ#@/H2^T$L0C @J3?5Q:F93 MMOUS2EF:FR71-F3(/JA;29A-8TW52;4IKDYL%,9> M/=F6(+ ]LL7.RAG7!1. M^VR$DR_=[4B8<+DC8-+MCH YA'CDR(]RVD6>=LW8WBCG-4R_/,)*3A]*.,W2 M$59\'Z=I_W,D^QQ9"PAJ>H*-+JY@2U^_]/?AS>2I>MVWW5!J;:NRO]Y]KJK6A[['-^%UV?I\ MR_ MJ ( " ) 8 >&PO=V]R:W-H965T&ULC59M;YLP$/XK MB.\M+S9O41*ID$R;M$E5JVV?W<1)4 $SVTFZ?S_;4$KM6[:\ MO#+^+$Z42N^E;3JQ\D]2]HL@$+L3;8FX93WMU)<#XRV1:LJ/@>@Y)7M#:IL@ M#L,T:$G=^>NEL=WS]9*=95-W])Y[XMRVA/\N:<.N*S_R7PT/]?$DM2%8+WMR MI(]4?N_ON9H%DY=]W=).U*SS.#VL_+MHL2TTW@!^U/0J9F-/*WEB[%E/ONQ7 M?J@3H@W=2>V!J->%5K1IM".5QJ_1IS^%U,3Y^-7[)Z-=:7DB@E:L^5GOY6GE MY[ZWIP=R;N0#NWZFHY[$]T;Q7^F%-@JN,U$Q=JP1YNGMSD*R=O2B4FG)R_"N M._.^COY?:3 A'@GQ1%"Q/R*@D8#>"/A# AX)^'\C)",AL2($@W93S V19+WD M[.KQ83OT1.^Z:)&HY=IIHUD=\TW54RCK99VDR^"B_8R0H7 2*K!S^Z63[H9-W:2*P5LCPT;Q6&H"D!M(9R$V>I]BJ!H"*DBRS*P+ 4(CSS"H+!(LP3F!I"2@M<4N3P_P4 MY*=.:1*[- ,DF:<91]9&K !0:F]6 (-"*]H6BE8@6%(&2LH<278F9>8$R:W# M5[F0-+?TN) L098<%W-3Q+":'%23NVJL[5;F;HPHMK>N"[+EN B,+2];(!3* M_[)A"U!/X>JQ?A=E 9S%(K?2K0"4.HNIM0 ; (;"$-OK!,&B?/:_':0%L]][ M2_G1]%KA[=BYD_H8SJQ3.[^+=7NP[&6TJ"+ OE'M?^C6;^Z'N\,WPH]U)[PG M)E53,JWCP)BD*OOP5JW(25U7IDE##U(/,S7F0],>)I+UXWTDF"Y%ZS]02P,$ M% @ =7]L3QJM_CP& @ B 4 !@ !X;"]W;W)K]=>)JR3I&[@P!W148KYWQT0UF]=W[TX7NJR MDMJ!TJ3%)?P ^;,]<&6A4>544VA$S1J'0[%U'_W-4Z3Q!O"KAEY,[HZNY,C8 MJS:^GK:NIQ," KG4"E@=9\B $"VDTOAC-=TQI"9.[Q?U9U.[JN6(!62,_*Y/ MLMJZ:]3MX)R:A54:E0_#:< M=6/.WNI?:,N$P!*"D:!BWR.$EA"^$Z*[A,@2HH]&B"TAGD5 0^VFF7LL<9IP MUCM\&(<6ZZGS-['Z7+EVFJ]CWJE^"N4]IZLP06>M8R&[ 1),(*%W#=G?0OP1 M@53\,8E@*8E=<$,/K@-DMXC0G^7P7Y&GNR)7:8:+O0H-/YSV*EKF1XO\R/"C M*3^>]7J K RD,9!/,TBV /'7LUXL8*+5K!L+F/5Z5@Z:C!$%7II_6C@YZQJI M.S'QCFOC,=!C.//O_$WF+_CW:LT,6^%=?MA1WS$OZT8X1R;5\)L1+1B3H%+W M'M305VHMC@:!0NKK9W7GPW(8#,E:N_?0N'S3?U!+ P04 " !U?VQ/A\B6 M[W4$ "Y%0 & 'AL+W=O&P 1M0W+#ML]NH37!VG-EN<_OWLQTW<$CJ[DMCNR^E ME[+TB-;J7#??VGT(W>)[51[;A^6^ZT[W2=(^[T-5M)_J4SCV_WFIFZKH^MOF M-6E/32AV8U!5)FA,EE3%X;A$8'IM%^U951?/?)I3U^6$) MRX\'7P^O^VYXD*Q7I^(U_!FZOTZ/37^77%O9':IP; _U<=&$EX?E+W"_I7P( M&!5_'\*YG5TOAE2>ZOK;A#,_=T$31_[R';2C+H:7>Q[]3H\MK MGT/@_/JC]2]C\GTR3T4;MG7YSV'7[1^6;KG8A9?BK>R^UN=?PY10NEQ,V?\> MWD/9RP8'H!3 %X#P/XP M@*8 8@')Q=F8ZN>B*]:KICXOFLO;.A7#I(![Z@?S>7@XCMWXOS[;MG_ZOLZR M5?(^M#-)-A<)SB1XJ]A*199?)4G?_]4$JB9PC*=YO-/C28VG,=[.XSU+XB+) M1LEQE "ZF4ND% MF)=4].+R6<(7*U($0!2QDJE6,FF%3:)-)GI!S-C8;:7(YGG$2:XZR:438DYR M^8(@8Z*M%#E'F>[$J4Z<=&*9$Z=TDAF^_*0*T+H4=#->->.E&38--EYTD_.Y MO94:\! Q D8GDI%6!)*,G ?D(@L5(N0#V4_.^P&9C[,>./]^)KOUHT,04/IQ MW _*C@QX;D=19>@C;G2D@F1JSIDZ:6YF1.8M=Z.H<+;Z;]WH5 6)5<>Q"I*8 M9#URKFJR#&QDY8).5I!H=1RMH& S39USW)"B\X9,A&J@ Q8RL8>ZV!CK8 1) M1L?)"))ZQ'<+10,F-KPZ&4&BT7$T@J1>GLK!E2IO*;84=#2"9*/C; 0%?*F/ M9(TZ^%""SW'PH00?I<2S5E6&(FYT/*+$(Z]1-JAP+S? EYPB0\A\!-<8J1$E M'OG;WJ "/N\X'A4593:RW%#'(TH\\GXV*,%'D(M"0I,YFD)$E*STE)DH&\6/VAY-:'SDB2C/2@Y'TF2[\YZSW7;G^MN'46^RB4CO?@LE_"S9$W*BPI51WD:69ND4Y(D M)<%P3)+$WQTY9_E'R%85IOE\P[DUI8.2)"C!<%*21. =HD2&JB,+L7'264F2 ME<"_.C+2"6]-I!7A;]-\ZM/;AV)WO2G#2S=0=XV^B)$1Z[S5MQ,HOI6R7 (A] M26HL7EA+&C5S9+S&4G7Y"8B6$WPP034%(80IJ''5^$5NQK:\R-E9TJHA6^Z) M%[(AE&HGQ?%W,/7' MG#KPNOWA_L44KXK984$VC/ZI#K)<^9GO'<@1GZE\9=U7,A24^-Y0_7=R(53) M-8G*L6=4F&]O?Q:2U8.+0JGQ>_^L&O/L^AF$AC!W0#@$A&- $-\-B(: R H M/9DI]3.6N,@YZSS>[U:+]4L1+".UF'L]:-;.S*EJA1J]% &,XI)A#("8'F$(&58HV>>4\>B"8HF1,EVWU^49Y01J MX81:.*"L'_MZ,4L5AUF"YDPN(0IO(P70?41!!U1DGU%PEBQ"<>)8*:RAP=;+KJ_8'YJ>J$=Z.275)F*/\R)@DRA2^ M*+M2W>YCAY*CU$VDVKR_XOJ.9.UP?8/Q/T3Q'U!+ P04 " !U?VQ/ Z<4 M7&0( !R- & 'AL+W=OXS;9?;:(#R MV>^?=38-KMBOBRP/,P-NZ3 MD:?R[^J5XO=K\TS_6F_9?' M9KM>[-N/VZ_CW?.V7CP<&ZU78UL4<;Q>+#?#FZOCWSYO;ZZ:;_O5%1OC3-'X-JO_+1_V M3]?#GI?ZV_UZL6?F#2]G'?K';'_P_NO^WV MS?H4I:6R7OSY^G.Y.?Y\.<7_T8P;V%,#^]; ]#=PIP;N9X/8V\"?&OBW!C;U M-@BG!N%G@WY*\=0@OC7P_932J4$2SS!^'=WC=,T6^\7-U;9Y&6Q?5]SSXK"P MS:?4+HC[PQ^/\W_\MW;&=NU?O]\8$Z[&WP^!3IC)*\9V,+&+F1(F=3$SC:FJ M+N06PA1%%S.GKLHNYHXP/_L:MT/R-BX6Q\4> _CW :P@,GW%A"-F<\1XXZ,3 M5#3*OA^:#A>'7!QP,6*.7C'Q72]E"*5DK%$M8S%+&N,JYY,8X5L-&]EH8RD6 MSYQPSD:Q?NX(9ETT/$X>Q\D?8[C..%D.$#! 4 /MQ0*=!#6;(W,@*D;G+*S# M)B*;"-,N%M %TAOI,3J#OT M44GT&5273L92#- I)1VC.XI1^L'L+*Q+B+7@BZF0HZ79C;P-*2-$ADW MD M(6S=:X2D3 5@^%3'L!(:L0"8C1LL\92,G6'\Z K$P'P$<)R0(A(P$V/6E M)(;MRI27)R6&SRE5=B/T>@B\'(T=+L M1KZJJC(S7IFB!8S.R>3(0MD"8D^PK-A;]D-+?BCS**O]D,3>0NVBQ!YBH=@# MCL4>@2#VP*Y/["V;M?U !6/97^T%-8P%!W/>244]"^OR8?^REU0Q5AN3S*3G M_9@N%;8N>TD58Z%"L5HGSJ"Z=-@9+%4R2D5U*5.5N47%]F&AF%%)J07_:#4T M2#JZGNG"NJ<9[#*.7$8H[-1I^R@S.\&Q>3@R#UF&.*W/02FFT^(L5N<,XV36 M@V/Q=B3>4@4=B;?Q\O@+8'GS=9E3)Q!O+]>-T_J8RN#EZ: C\59C".+M"N,% M[A9PK7B7+HC!FB.P-5^YR8!=G_DZ%F_W ?%V+-[N O%V=+044LIHH6-9=I?( MLM.26\HA[H-TB; H.Q!E.>-3!W+K*TVJH3U%*M%2?7L8XR MRDBV8\EV(-E>YN$.3HXRBN-9B#T(L9>&Z+40J\.EV1E0EPS+M:=3(T4&CH-* M>7PP.X?JTF$U]J3&<@H\J;$NA0"65V//:NPIE5;#HP6/2B%/:BQ3'(B%I1#@ MN!1"()1"P*Y/C7WF+@#.O;PT=D_G7DE6%7< ZYD_EG8/YU[2)B=>:WMK;%*" M/!U[J1T)QU[.I2 O*@ W9UX>Q[79<0>Y"GCEZ;KM7M8X^1D](.Z9-AC/'F,-%ZO/2:39P2V MF$ 6(VTW:/#[ D!/$'Y9=!B7TF#ZL=TJ; =!+H3 M5E2TXCHIM[,SH"X9UMI 6BL+NH!:J\ZH 9;7VI"YQB6ME95? #VK0BF],EPB MMA#+M]*HWFZ@/ETR12$"S@EHG2W4:'U,; .+;8!B0'EE@#L&\$J ]@ MFD!Z98":0'ME@"L&/7TZ%'HEX-@K"4A>">QZIX]M)7S@BB&P&80+KA@"73$4 MOLS,;61#B&0(\I0CTA5#&<2\W0$LO]8B6T<$ZPCRE"/2*7ZLI'A-(]TQ".&9 M0;!6+(H@-MPM=>K*TB>QBN;(SE9)7B@#N[[5%MD$(YB@-)5II,)(BSW >B:0 MG3""$P:9842H/4#L(Q5&4BT@%HH]]8EB3T 2>V#7.W]LUO$#QU21_35><$P5 MP<'*6*A%?@[6Y9-Y4>JB-Z6T,3FYY^9G0%TR;%[QDEN&J U"MA#V]=OP;Q^V#?/IV_XC-^^9G3S-U!+ P04 " !U?VQ/;)@>3E0% M !K&P & 'AL+W=O9*2=/]^DNRXSMW+YD-LR2_)]RCR MX5&\?FV[;_U3C,/B^VZ[[V^63\-PN%JO^[NGN&OZ#^TA[L=?'MINUPSC9?>X M[@]=;.[G0KOMFK*L6.^:S7YY>SW?^]3=7K?/PW:SCY^Z1?^\VS7=?U7'YC'^%8+4^UW*_V<5]OVGWBRX^W"P_NJM: MPE1@5OR]B:_]Q??%%,K7MOTV7?Q^?[/,)D=Q&^^&J8IF_'B)==QNIYI&'_^> M*EV>VYP*7GY_J_W7.?@QF*]-'^MV^\_F?GBZ68;EXCX^-,_;X7/[^EL\!90O M%Z?H_X@O<3O*)R=C&W?MMI__+^Z>^Z'=G6H9K>R:[\?/S7[^?#W5_U8,%Z!3 M 3H7&-O^60$^%> ?!60._NAL#O679FANK[OV==$=G]:AF0:%N^*Q,^^FFW/? MS;^-T?;CW9=;E^?7ZY>IHI.F.FKH4G-6K,?:STT0:J(B4YS>-U!;!2=:8!@$ MS^7Y71 %KD!@!3)7(!<52*DZX2@I9LE^EJPXD^!5*$CF1'+L)H=N4%)6+QT(H'5G37>M.*>&6WMIH,VPC01K V M"A5L%4P3*_)J+M161"&4V$H)K93 BE-62ML*!U%6K&CE?,:)@>\R//\S8(0PZ!Q;/SKPZB1ZY\=K3@&1=V5B3CE,30>P:=8. 69RS1F@2EG! MR'0Y>%#&2VX? 9=Z,0(JYQ+X=9B_KK $+U+S$G/367!Z30EGH4@9F7EI57F6 M)Y#E,#Z=Y:IUCU$CE.$],!<(()810K_U8.)+I'" 2=@F"$B8H68+JG*DB@$9B MW8,J%**QA63CZIFGQ@_&*%F,CJF8=F0).0X- MKQ<])",N4L\,PY0 3+W.E@C U'%I'AJ0$;D$# GSE$!":VA(-ED=,_1,]3W8RA2B I-1PCE)6:3@:BRSG_W@V&*H&\5 ^OBBPN76[& MH!4E^I8Q4!GDI#H1K]BR4D]/(%E1-OXEW&">,N"I+[0;B\KH$KV((U>#TTT(Z%I?<1W!B"PZPJC=Q%5M>,N>Y3I6!;)6S"XDL M@3%66< ,3:0]C$'( (1!@Y MX34( 4B<7K\K2^. M*':Q>YQ/<_K%7?N\'Z;#@(N[YQ.CCS0=<:C[E;NJC^<^/ZHY'D/]V72/FWV_ M^-H.0[N;CSD>VG:(H\?LP]A73[&Y/U]LX\,P??7C]^YX_'.\&-K#Z6AK?3Y? MN_T?4$L#!!0 ( '5_;$^Q=H&PO=V]R:W-H965T M&UL?5/;;IPP$/T5RQ\0[P)ITQ4@95-5K=1(JU1-GKTP@!5? MJ&V6Y.\[-H30%O7%]HSGG#DS'N>CL<^N _#D14GM"MIYWQ\809BSH MGKXY'D3;^>!@9=[S%GZ _]F?+%IL8:F% NV$T<1"4]#;_>&8A?@8\"A@=*LS M"96ZH+L@""14/C!PW"YP!U(&(I3Q:^:D2\H 7)_?V+_$VK&6,W=P M9^23J'U7T!M*:FCX(/V#&;_"7,\U)7/QW^$"$L.#$LQ1&>GB2JK!>:-F%I2B M^,NT"QWW<;K)TAFV#4AF0+( ;F(>-B6*RC]SS\O/J' MPFR;(-LDR")!]M\2MV*N_TK"5CU58-LX38Y49M!QDE?>96!OD_@F[^'3M-]S MVPKMR-EX?-G8_\88#RAE=X4CU.$'6PP)C0_'CWBVTYA-AC?]_(/8\HW+WU!+ M P04 " !U?VQ/YB?'R;4! #2 P &0 'AL+W=O<.3,>9X-US[X%".1%*^-SVH;0G1CS90M:^#O;@<&;VCHM M IJN8;YS(*H$THKQS>:>:2$-+;+DN[@BLWU0TL#%$=]K+=S/,R@[Y'1+7QU/ MLFE#=+ BZT0#7R!\[2X.+3:S5%*#\=(:XJ#.Z 1E(I$*./'Q$GGE!&X/+^ROT^U8RU7X>'1JN^R M"FU.CY144(M>A2<[?("IGC>43,5_@ALH#(]*,$=IE4\K*7L?K)Y84(H6+^,N M3=J'\>9PG&#K #X!^ PXICQL3)24OQ-!%)FS W%C[SL1GWA[XMB;,CI3*](= MBO?HO17;M_<9NT6B*>8\QO!ES!S!D'U.P==2G/D_<+X.WZTJW"7X[@^%AW6" M_2K!/A'L_UOB6LSQKR1LT5,-KDG3Y$EI>Y,F>>&=!_:!IS?Y'3Y.^V?A&FD\ MN=J +YOZ7UL; *5L[G"$6OQ@LZ&@#O%XP+,;QVPT@NVF'\3F;US\ E!+ P04 M " !U?VQ/[)?>U[0! #2 P &0 'AL+W=OC;%H? M'*S(>M' 3_"_^I-%BRTJE=30.6DZ8J'.Z=WN<$P#/@*>)(QN=2:ADK,Q+\'X M5N4T"0F!@M('!8';!>Y!J2"$:?R>->D2,A#7YS?UAU@[UG(6#NZ->I:5;W-Z M0TD%M1B4?S3C5YCK^43)7/QWN(!">,@$8Y1&N;B2Z%D%4]'B==IE%_=Q MNDGY3-LF\)G %\)-C,.F0#'S+\*+(K-F)';J?2_"$^\.''M3!F=L1;S#Y!UZ M+\7N]C9CER T8XX3AJ\Q"X*A^A*";X4X\@]TODW?;V:XC_3]FIXDVP+IID : M!=+_EO@1PY-_BV2KGFJP39PF1THS='&25]YE8._B([)W^#3M/X1M9.?(V7A\ MV=C_VA@/F$IRA2/4X@=;# 6U#\?/>+;3F$V&-_W\@]CRC8N_4$L#!!0 ( M '5_;$\!$@B2M $ -(# 9 >&PO=V]R:W-H965T( 7J=_WP$[KMM: M>0%FF'/FS#!DH[$OK@7PY$U)[7+:>M\?&'-E"TJX*].#QIO:6"4\FK9AKK<@ MJ@A2DO$DN69*=)H66?2=;)&9PGRQ:;&&I.@7:=483"W5.[W:'8QKB8\"/#D:W.I-0R=F8EV!\KG*: M!$$@H?2!0>!V@7N0,A"AC->9DRXI W!]?F=_C+5C+6?AX-[(GUWEVYS>4E)! M+0;IG\WX!',]GRB9B_\"%Y 8'I1@CM)(%U=2#LX;-;.@%"7>IKW3<1^GF_1F MAFT#^ S@"^ VYF%3HJC\07A19-:,Q$Z][T5XXMV!8V_*X(RMB'&UL?5/; M;MP@$/T5Q <$+^M]P?&7-F"$N[*]*#QIC96"8^F;9CK+8@J@I1D M/$ENF!*=ID46?2=;9&;PLM-PLL0-2@G[=@1IQISNZ(?CJ6M:'QRLR'K1P#/X M[_W)HL46EJI3H%UG-+%0Y_1^=SBF(3X&_.A@=*LS"9645%"+0?HG M,WZ!N9YK2N;BO\$%)(8')9BC--+%E92#\T;-+"A%B==I[W3(MG.XW99'C3SS^(+=^X> =02P,$% @ =7]L3X B M@SBV 0 T@, !D !X;"]W;W)K&UL?5/;;M0P M$/T5RQ]0)]XM+*LD4K<(@032JHCR[$TF%]678#N;\O>,G30$&O7%]HSGG#DS M'F>CL4^N!?#D64GM09LQI2E\<#UW3^N!@1=:+!KZ#_]&? M+5IL8:DZ!=IU1A,+=4[OTN-I'^)CP&,'HUN=2:CD8LQ3,+Y4.4V"()!0^L @ M<+O"/4@9B%#&KYF3+BD#<'U^8?\4:\=:+L+!O9$_N\JW.3U04D$M!ND?S/@9 MYGIN*9F+_PI7D!@>E&".TD@75U(.SALULZ 4)9ZGO=-Q'Z>;VW2&;0/X#. + MX!#SL"E15/Y1>%%DUHS$3KWO17CB],BQ-V5PQE;$.Q3OT'LM>'+(V#40S3&G M*8:O8M(E@B'[DH)OI3CQ5W"^#=]M*MQ%^.X?A1^V"?:;!/M(L'^SQ(V8-/DO M"5OU5(%MXC0Y4II!QTE>>9>!O>/Q3?Z&3]/^3=BFTXY7C?VOC?& 4I(; M'*$6/]AB2*A].+['LYW&;#*\Z>&PO=V]R:W-H965TIVF3-NG4:>MG+G$25, 9D$OW[P@NB3B"M&-_MWC,M MI*%EGGQG6^8X>"4-G"UQ@];"_CJ!PK&@&7UU/,JV\]'!RKP7+7P#_[T_VV"Q MA:66&HR3:(B%IJ#WV?%TB/$IX(>$T:W.)%9R07R.QN>ZH+LH"!14/C*(L%WA M 92*1$'&SYF3+BDC<'U^9?^8:@^U7(2#!U1/LO9=0>\HJ:$1@_*/.'Z"N9YW ME,S%?X$KJ! >E80<%2J75E(-SJ.>68(4+5ZF79JTC]/-GL^P;0"? 7P!W*4\ M;$J4E'\07I2YQ9'8J?>]B$^<'7GH316=J17I+HAWP7LM;WG.KI%G#CE-(7P5 MDBT1+) O&?A6AA-_ ^?;\/VFP'V"[]?P[!_Y#YL$AT1P^%^%;T-X]K=(MNJH M!MNF67*DPL&D.5YYEW&]3T_(_H1/L_Y5V%8:1R[HP[NF[C>('H*4W4T8H"Y\ MK\50T/AXO UG.PW99'CLY__#ED]<_@902P,$% @ =7]L3X^)ZT6T 0 MT@, !D !X;"]W;W)K&UL?5-ACYP@$/TKA!]P MK.BVEXV:W%[3M$F;;*YI^YG54FS?#D$]HGFT' MX,B+5KTM:.?<<&+,5AUH8>]P@-[?-&BT<-XT+;.# 5%'D%:,'PYOF!:RIV4> M?1=3YC@Z)7NX&&)'K87Y>0:%4T$3^NIXDFWG@H.5^2!:^ +NZW QWF(K2RTU M]%9B3PPT!7U(3N ;Q(FNSF34,D5\3D8'^N"'H(@4%"YP"#\=H-'4"H0 M>1D_%DZZI@S [?F5_7VLW==R%18>47V7M>L*>D])#8T8E7O"Z0,L]1PI68K_ M!#=0/CPH\3DJ5#:NI!JM0[VP>"E:O,R[[.,^S3?'=('M _@"X"O@/N9A.+DQ'UOJN",K8AW7KSUWEO)DS1GMT"TQ)SG&+Z)2=8( MYMG7%'POQ9G_ ^?[\'1781KAZ1\*LWV";)<@BP39?TOJK!M'&: M+*EP[.,D;[SKP#[P^":_P^=I_RQ,*WM+KNC\R\;^-X@.O)3#G1^ASG^PU5#0 MN'!\Z\]F'K/9<#@L/XBMW[C\!5!+ P04 " !U?VQ/5"&U\+0! #2 P M&0 'AL+W=O2V2O=@_(WC3:2.6^:EMC> *LC2 I"-YMK(AE7N,RC[V3* M7 ].< 4G@^P@)3-_CB#T6. ,OSD>>=NYX"!EWK,6?H+[U9^,M\C,4G,)RG*M MD(&FP+?9X;@+\3'@-X?1+LXH5'+6^CD8W^H";X(@$%"YP,#\=H$[$"(0>1DO MB1//*0-P>7YC_QIK][6,4O'?X0+" MAPEA8TKJ@;KM$PL7HIDK]/.5=S'=+-/L'4 30 Z _8Q#YD21>7WS+$R M-WI$9NI]S\(39P?J>U,%9VQ%O//BK?=>2II=Y^02B%+,<8JABYALCB">?4Y! MUU(TOCF[R'3]/^@YF6*XO.VOF7C?UOM';@I6RN_ AU_H/-AH#&A>.- M/YMIS";#Z3[](#)_X_(O4$L#!!0 ( '5_;$^*\+LHM $ -(# 9 M>&PO=V]R:W-H965TF;XT$VK0\.5F2]:. 7^-_]R:+%%I5*:NB<-!VQ4.?T M+CT<]P$? 8\21K,L$8 MI5$NKJ0$NTG=K.D^V!?:; OLHL/^PQ T,_[=(MNJI!MO$:7*D-$,7)WGE M70;V+CXB>X=/T_Y3V$9VCIR-QY>-_:^-\8"I)%&UL?5-A;]P@#/TKB!]0M#*NH)WW_9$Q M5W6@A;O!'DRX:=!JX8-I6^9Z"Z).(*T8S[+W3 MI:)DGW]F6.0Y>20-G2]R@ MM;"_3J!P+.B.OCJ>9-OYZ&!EWHL6OH+_UI]ML-C"4DL-QDDTQ$)3T/O=\72( M\2G@NX31K4S,5_ABNH$!Z5A!P5*I=6 M4@W.HYY9@A0M7J9=FK2/TPV_G6'; #X#^ *X2WG8E"@I?Q1>E+G%D=BI][V( M3[P[\M";*CI3*])=$.^"]UIRSG-VC41SS&F*X:N8W1+! ON2@F^E./'_X'P; MOM]4N$_P_5\*LVV"PR;!(1$@I3L)HQ0%S[88BAH?#S>AK.=QFPR//;S M#V++-RY_ U!+ P04 " !U?VQ/E<\&DK0! #2 P &0 'AL+W=OX4]=/ZF1J.%\Z9IF.T-B"J"M&)\M[MA6LB.%EGTG4R1X>"4[.!DB!VT%N;U M" K'G.[IF^-1-JT+#E9DO6C@![B?_RN_ BU_H,MAH+:A>,G?S;3F$V&PW[^06SY MQL4?4$L#!!0 ( '5_;$\3NIK_M $ -(# 9 >&PO=V]R:W-H965T M<"CKM_/\".ZVW6O@!WW'OW[CC2 =.JM1EMG.L.C-FB 2WL#7;0 M^IL*C1;.FZ9FMC,@R@C2BO'-YB/30K8T3Z/O9/(4>Z=D"R=#;*^U,+^.H'#( MZ)9>'8^R;EQPL#SM1 T_P/WL3L9;;&8II8;62FR)@2JC=]O#,0GQ,>!)PF 7 M9Q(J.2.^!.-KF=%-$ 0*"A<8A-\N< ]*!2(OXW7BI'/* %R>K^Q?8NV^EK.P M<(_J69:NR>B>DA(JT2OWB,,#3/5\H&0J_AM<0/GPH,3G*%#9N)*BMP[UQ.*E M:/$V[K*-^S#>)%?8.H!/ #X#]A' QD11^6?A1)X:'(@9>]^)\,3; _>]*8(S MMB+>>?'6>R\YY[8XQO!%S':.8)Y]3L'74ASY/W"^#M^M*MQ%^.X/ MA?MU@F25((D$R7]+7(OY]%<2MNBI!E/':;*DP+Z-D[SPS@-[Q^.;O(>/T_Y= MF%JVEIS1^9>-_:\0'7@IFQL_0HW_8+.AH'+A>.O/9ARST7#833^(S=\X_PU0 M2P,$% @ =7]L3S"BM1*T 0 T@, !D !X;"]W;W)K&UL?5/;;MLP#/T501]0.4K2%8%MH.DP=, &!!VV/BLV?4%U\20Y M[OY^E.RZ;N?U11(IGL-#BDH'8Y]< ^#)LY+:9;3QOCLPYHH&E'!7I@.--Y6Q M2G@T;09LCHAKXX M'MJZ\<'!\K03-?P _[,[6;38S%*V"K1KC286JHS>;@['78B/ ;]:&-SB3$(E M9V.>@O&US&@2!(&$P@<&@=L%[D#*0(0R?D^<=$X9@,OS"_N76#O6ZOC/HPW^_T$6P?P"6C,0._:^$^&)-P>.O2F",[8B MWJ%XA]Y+SK=)RBZ!:(HYCC%\$;.9(QBRSRGX6HHC_P?.U^';587;"-^^4?B? M_+M5@ETDV'U8XEK,>Y5LT5,%MH[3Y$AA>ATG>>&=!_:6QS=Y#1^G_;NP=:L= M.1N/+QO[7QGC :4D5SA"#7ZPV9!0^7#\A&<[CMEH>---/XC-WSC_"U!+ P04 M " !U?VQ/R7H!K[4! #2 P &0 'AL+W=O9NQ%$BF>PT.*RD9CGUT+X,FKDMKEM/6^/S+FRA:4<#>F!XTWM;%*>#1M MPUQO0501I"3CN]T'ID2G:9%%W]D6F1F\[#2<+7L*^G4":,:=[^NYXZIK6 M!P S@"^ 0\S#ID11^2?A19%9,Q([];X7X8GW1XZ]*8,SMB+>H7B' MWFO!DR1CUT TQYRF&+Z*V2\1#-F7%'PKQ8G_ ^?;\&1381+AR1\*TVV"=),@ MC03I?TO(T.5*:0<=)7GF7@;WC\4U^AT_3_BALTVE'+L;C MR\;^U\9X0"F[&QRA%C_88DBH?3A^Q+.=QFPRO.GG'\26;US\ E!+ P04 M" !U?VQ/N83M@+0! #2 P &0 'AL+W=O:6*=%JFJ?1=S)YBKV3K8:3(;972IA?1Y X9'1+KXZGMFY<<+ \ M[40-S^!^="?C+3:SE*T";5O4Q$"5T?OMX;@+\3'@9PN#79Q)J.2,^!J,KV5& M-T$02"A<8!!^N\ #2!F(O(RWB9/.*0-P>;ZR?XFU^UK.PL(#RI>V=$U&]Y24 M4(E>NB<<'F&JYQ,E4_'?X +2AP!TL:5%+UUJ"86+T6)]W%O==R'\2:Y MPM8!? +P&;"/ #8FBLH_"R?RU.! S-C[3H0GWAZX[TT1G+$5\<4?"W%D?\#Y^OP9%5A$N')'PKOU@EVJP2[2+#[ M;XEK,?N_DK!%3Q68.DZ3)07V.D[RPCL/[#V/;_([?)SV[\+4K;;DC,Z_;.Q_ MA>C 2]G<^!%J_ >;#0F5"\<[?S;CF(V&PV[Z06S^QOD'4$L#!!0 ( '5_ M;$]D##!KM $ -(# 9 >&PO=V]R:W-H965T&,"*S5#;+.G?US:$H@;EQ?:, MSSES\3B?T#S9#L"19ZUZ6]#.N>'(F*TZT,+>X "]OVG0:.&\:5IF!P.BCB2M M&$^2]TP+V=,RC[ZS*7,)1MYX*#E?D@6O@. M[L=P-MYBJTHM-?168D\,- 6]/QQ/6)YWF4?]VF^26\7VCZ! M+P2^$NYB'#8'BIE_%$Z4N<&)F+GW@PA/?#ARWYLJ.&,KXIU/WGKOM>3IAYQ= M@]"".Y@ MLO^+9)N>:C!MG"9+*AS[.,D;[SJP]SR^R3_X/.W?A&EE;\D%G7_9V/\&T8%/ M);GQ(]3Y#[8:"AH7CK?^;.8QFPV'P_*#V/J-R[]02P,$% @ =7]L3V.R M$BFT 0 T@, !D !X;"]W;W)K&UL?5/;;M0P M$/T5RQ]0[WH#E%42J5N$0 )I500\>Y-)8M678#N;\O>,G32$-N+%]HSGG#DS M'N>C=8^^ PCD22OC"]J%T!\9\U4'6O@;VX/!F\8Z+0*:KF6^=R#J!-**\=WN M+=-"&EKFR7=V96Z'H*2!LR-^T%JXWR=0=BSHGCX['F3;A>A@9=Z+%KY!^-Z? M'5IL8:FE!N.E-<1!4]"[_?&4Q?@4\$/"Z%=G$BNY6/L8C<]U07=1$"BH0F00 MN%WA'I2*1"CCU\Q)EY01N#X_LW],M6,M%^'AWJJ?L@Y=06\IJ:$1@PH/=OP$ ME6".RBJ?5E(-/E@]LZ 4+9ZF79JTC],-?S_#M@%\!O % M<)ORL"E14OY!!%'FSH[$3;WO17SB_9%C;ZKH3*U(=RC>H_=:\HSG[!J)YIC3 M%,-7,?LE@B'[DH)OI3CQ5W"^#3]L*CPD^.$?A8=M@FR3($L$V7]+W(K)7B1A MJYYJ<&V:)D\J.Y@TR2OO,K!W/+W)W_!IVK\*UTKCR<4&?-G4_\;: "AE=X,C MU.$'6PP%38C'=WAVTYA-1K#]_(/8\HW+/U!+ P04 " !U?VQ/O&.@ +4! M #2 P &0 'AL+W=O9NQ%$BF>PT.*2@=C M7UT#X,F[DMIEM/&^.S#FB@:4<%>F XTWE;%*>#1MS5QG0901I"3CF\TU4Z+5 M-$^C[V3SU/1>MAI.EKA>*6%_'4&:(:-;^NEX;NO&!P?+TT[4\ +^>W>R:+&9 MI6P5:-<:32Q4&;W;'HY)B(\!/UH8W.),0B5G8UZ#\:7,Z"8( @F%#PP"MPO< M@Y2!"&6\39QT3AF R_,G^V.L'6LY"P?W1OYL2]]D]):2$BK12_]LAB>8ZME3 M,A7_%2X@,3PHP1R%D2ZNI.B=-VIB02E*O(][J^,^C#=[/L'6 7P"\!EP&_.P M,5%4_B"\R%-K!F+'WG\EYLD_9)1!-,<3_P/DZ?+>J,! ! M!0 &0 'AL+W=O8T[9#>>I\ M9YFGXJI9V\%9!NK*.95_3L#$D*$(O3N>VKK1UH'SM*$K3/4D*)B* M_PXW8 9N,S$:A6#*?8/BJK3@$XM)A=.W<6T[MP[C21)/8?X ,@60.6#O=/ H MY#+_0C7-4RF&0(Z][ZG]Q=&1F-X4UNE:X#/5==NIX"*T&01W72LA-)A4PCO3U<:\1[/! MH-)VNS-[.4[E:&C13P\.GE^]_"]02P,$% @ =7]L3S6R8WZW 0 T@, M !D !X;"]W;W)K&UL;5/;;MP@$/T5Q <$+WM) MM+(M95-5J=1*JT1MGUE[?%&X.(#7Z=]GP([KIGX!9CCGS(4A'8Q]<0V )V]* M:I?1QOONR)@K&E#"W9@.--Y4QBKAT;0UB];#6=+7*^4L'].(,V0T0W]<#RU=>.#@^5I)VIX!O^S.UNTV*Q2M@JT:XTF M%JJ,WF^.IUW 1\"O%@:W.)-0R<68EV!\*S.:A(1 0N&#@L#M"@\@91#"-%XG M33J'#,3E^4/]:ZP=:[D(!P]&_FY+WV3TCI(2*M%+_V2&1YCJV5,R%?\=KB 1 M'C+!&(61+JZDZ)TW:E+!5)1X&_=6QWT8;V[W$VV=P"<"GPEW,0X; \7,OP@O M\M2:@=BQ]YT(3[PY9\OT_9-0A-F-.(X0O,9D8P5)]# M\+40)_X?G:_3MZL9;B-]NZ0GAW6!W:K +@KL_BGQ\*G$-ATG>>&=!_:>QS?Y"Q^G_8>P=:L=N1B/+QO[7QGC 5-);G"$&OQ@LR&A M\N&( T'L.&:CX4TW_2 V?^/\'5!+ P04 " !U?VQ/UDX=#L4! W! M&0 'AL+W=OSCGW Z[YI/2KZ0 L>I.B M-P7NK!V.A)BJ \G,G1J@=R>-TI)99^J6F$$#JP-)"D*3Y)Y(QGM-S"@ET[]/(-14X!2_.YYYVUGO(&4^L!:^@_TQG+6SR*I2N)V_Z[^*=3N:KDP T]*_.2U[0I\P*B&AHW"/JOI,RSU9!@MQ7^%*P@' M]YFX&)42)GQ1-1JKY*+B4I'L;5YY']9I/LEV"RU.H N!KH1#B$/F0"'SC\RR M,M=J0GKN_<#\%:='ZGI3>6=H13ASR1OGO98T.^3DZH46S&G&T TF71'$J:\A M:"S$B?Y'IW'Z+IKA+M!W6WKR$!?81P7V06#_3XD/-R5&,/=)/$@6#9)%!-*; M(#',;2O(YN(DZ#8\68,J-?9A7#;>=2H>:;CXO_!YI+XQW?+>H(NR[OF$2VZ4 MLN!22>Y<+IV;XM40T%B__>#V>G[+LV'5L(PI6?\5Y1]02P,$% @ =7]L M3^/Q6FBV 0 T@, !D !X;"]W;W)K&UL=5/; M;MP@$/T5Q >$-7;2:&5;RJ:J6JF55JG:/K/V^*( XP)>IW]?P([KINX+,,,Y M9RX,^83FV78 CKPHJ6U!.^>&(V.VZD )>X,#:'_3H%'">=.TS X&1!U)2C)^ M.-PQ)7I-RSSZSJ;,<72RUW VQ(Y*"?/K!!*G@B;TU?'4MYT+#E;F@VCA*[AO MP]EXBZTJ=:] VQXU,= 4]"$YGK* CX#O/4QV< M/L)2SRTE2_&?X0K2PT,F/D:%TL:55*-UJ!85GXH2+_/>Z[A/\TW*%]H^@2\$ MOA+N8QPV!XJ9OQ=.E+G!B9BY]X,(3YP]-%9RQ%?'.)V^]]UKRNS1GUR"T M8$XSAF\PR8I@7GT-P?="G/@_=+Y/3W&PO=V]R:W-H965TBOH?I^1FQ>:,><) M0U>8=$$0I[Y8T)C%F?Y'IW'Z)IKA)M W:WJZC0MLHP+;(+#]I\3#78DQS#%N MLHN:["("'^Y,(IA#3!Y=*Z+EX6 FKKIP&PO=V]R:W-H965TAY? G=^7NX(1S)(]:9K (/>!6]UBFMCNB,A.J]!,'TG.VCMEU(JP8P- M545TIX 5GB0XH9M-3 1K6IPE/G=662)[PYL6S@KI7@BF/D[ Y9#B"-\2+TU5 M&Y<@6=*Q"E[!_.K.RD9D5BD: :UN9(L4E"E^B(ZGV.$]X'<#@U[LD>OD(N6; M"[X7*=ZX@H!#;IP"L\L5'H%S)V3+^#MIXMG2$9?[F_J3[]WV@A2LC5"4V8TXBA"\P7@ECUV8*&+$[T/SH-T[?!"K>>OEW2HT-88!<4V'F! MW3\MTE6+(T0H"H_%QKE MLF_]3"ZR\^@]4'^[ON#CW/YDJFI:C2[2V#OJ;U(II0%;RN;.-ES;IV(..)3& M;0]VK\:!&0,CN^DM(/.#E'T"4$L#!!0 ( '5_;$\:$:9BMP$ -(# 9 M >&PO=V]R:W-H965TI5"V MP)US_8$06W4@F;W2/2A_TV@CF?.F:8GM#; ZDJ0@-$ENB&1<]:^ GN5W\RWB*+2LTE*,NU0@:: M M^EAV,6\!'PS&&TJS,*E9RU?@G&M[K 24@(!%0N*#"_7> >A A"/HT_LR9> M0@;B^ORF_AAK][6JXQFHO_#A<0'AXR M\3$J+6Q<4358I^6LXE.1['7:N8K[.-UDZ4S;)M"90!?"/L8A4Z"8^0-SK,R- M'I&9>M^S\,3I@?K>5,$96Q'O?/+6>R\EO=WGY!*$9LQQPM 5)ET0Q*LO(>A6 MB"/]1*?;]-UFAKM(WZWI--D6R#8%LBB0O2OQRX<2-S#[CT'(JJ<23!NGR:)* M#RI.\LJ[#.P=C6_R'SY-^P]F6JXL.FOG7S;VO]':@4\EN?(CU/D/MA@"&A>. MM_YLIC&;#*?[^0>1Y1N7_P!02P,$% @ =7]L3XE& #6U 0 T@, !D M !X;"]W;W)K&UL;5/;;MP@$/T5Q <$+[M)5BO; M4C91E$JMM$K5YIFUQQ<%& ?P.OW[ G8<-_4+,,,Y9RX,Z8#FU38 CKPKJ6U& M&^>Z V.V:$ )>X4=:']3H5'">=/4S'8&1!E)2C*>)#=,B5;3/(V^D\E3[)UL M-9P,L;U2POPY@L0AHQOZX7ANZ\8%!\O33M3P$]RO[F2\Q6:5LE6@;8N:&*@R M>KY!RB#DTWB;-.D< M,A"7YP_UQUB[K^4L+-RC?&E+UV1T3TD)E>BE>\;A":9ZKBF9BO\.%Y >'C+Q M,0J4-JZDZ*U#-:GX5)1X'_=6QWT8;_CM1%LG\(G 9\(^QF%CH)CY@W B3PT. MQ(R][T1XXLV!^]X4P1E;$>]\\M9[+SG?;U)V"4(3YCAB^ +SB6!>?0[!UT(< M^7]TOD[?KF:XC?3MDLZ3=8'=JL N"NS^*9%_*7$-L_T2A"UZJL#4<9HL*;#7 M<9(7WGE@[WA\DT_X..T_A*E;;&UL;53K;ML@%'X5Q .4A,1M%-F6FE;5 M)FU2U&G;;V(?VZAQA\#A^]R#G"G""*S@; M9 ADHO6;V'QN2[P)B0$ BH7%)@?KO $0@0AG\:O61,OEH&X MGG^HO\3:?2T79N%)BY^\=EV!#QC5T+!!N%<]?H*YG@RCN?@O< 7AX2$3[U%I M8>,758-U6LXJ/A7)WJ>1JSB.TTZVFVEI IT)="$J3^;*@3C4<0]G[SUT6M)#_N<7(/0C#E-&+K";!<$\>J+!4U9G.A_ M=)JF[Y(9[B)]MZ;3+"VP3PKLH\#^GQ*SFQ)3F/NT298TR1("#S.3M:C2@XKMLHHN7?%(X\7_A4\M]969EBN++MKYYQ,ON=':@4]E<^=S MZ7P7+PL!C0O3!S\WTUN>%D[W&UL=53KCIP@%'X5 MP@,L#J/C[$1-=K9IVJ1-)MNT_YWCUICA1(@N6Q!,/\@!>KM22R68L:%JB!X4L,J3!"9S%U5D\F9XU\-%(7T3@JG?9^!RS/$.OR=>NJ8U+D&*;& -? /S?;@H&Y%% MI>H$]+J3/5)0Y_AI=SJG#N\!/SH8]6J.7"=7*5]=\+G*<>0* @ZE<0K,#G=X M!LZ=D"WCUZR)%TM'7,_?U3_ZWFTO5Z;A6?*?767:'!\QJJ!F-VY>Y/@)YGX2 MC.;FO\ =N(6[2JQ'*;GV7U3>M)%B5K&E"/8VC5WOQW%:2>*9%B;0F4 7PM'[ MD,G(5_Z!&59D2HY(37L_,/>+=R=J]Z9T2;\5?LT6KVWV7M#C8T;N3FC&G"<, M76%V"X)8]<6"ABS.]!\Z#=/WP0KWGKY?T^DQ+! '!6(O$*\%'J--BR',?YI, M@B9)0(!N3$*8?=CD$#0Y! 3BC4D(DX1-TJ!)&A X;$Q"F'1C0E9'4(!J_.73 MJ)2WWE_\57:YWT_4'^&_\.EQ^,I4T_4:7:6Q%\$?UUI* [:4Z,'N:FO?HR7@ M4!LW3>U<3;=R"HP'+*]>\0=02P,$% @ =7]L3^B 7\"X 0 T@, M !D !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0LX:T MFQ4@91-5J91(JU1MG[TP@!5?B&V6].]K&T)IPHOM&9]SYN)Q/FKS8CL A]ZD M4+; G7/]@1!;=2"9O=(]*'_3:".9\Z9IB>T-L#J2I" T2;X0R;C"91Y])U/F M>G""*S@99 @+-<* M&6@*?+L['+. CX!?'$:[.J-0R5GKEV!\KPNY B"#DTWB= M-?$2,A#7YW?U;[%V7\N96;C3XC>O75?@/48U-&P0[EF/#S#7,C$QZBTL'%%U6"=EK.*3T6RMVGG*N[C=)/M9]HV@/4E M!-T*<:2?Z'2;GFYFF$9ZNJ:GV;9 MBF018'LOQ)O/I3X&9,FR8<@9-53"::- MTV11I0<5)WGE70;VEL8W^0>?IOV)F98KB\[:^9>-_6^T=N!32:[\"'7^@RV& M@,:%XU=_-M.838;3_?R#R/*-R[]02P,$% @ =7]L3U"B_SVV 0 T@, M !D !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0LX8F MT0J0LJFJ5FJE5:JVSUX8P(J-J6V6].\[-H30E!?;,S[GS,7C?#+VV74 GKQH MU;N"=MX/1\9B5[.%LB1NU%O;/"929"GJ@KXXGV78^.%B9#Z*%[^!_#&>+%EM5:JFA=]+T MQ$)3T(?#\90%? 3\E#"YS9F$2B[&/ ?C2UW0)"0$"BH?% 1N5W@$I8(0IO%[ MT:1KR$#8?(.O=4,P5%]# M\+T0)_X?G>_3T]T,TTA/M_3T;E\@VQ7(HD#V3XG\78E[F/1=$+;IJ0;;QFER MI#)C'R=YXUT']H''-WF#S]/^3=A6]HY7C?UOC/& J20W.$(=?K#54-#X M<+S#LYW';#:\&98?Q-9O7/X%4$L#!!0 ( '5_;$_>0OPQMP$ -(# 9 M >&PO=V]R:W-H965TQ168& MKV0'%TO$T:W.)%1R->8Y&%^JG"8A(5!0^J @<+O!(R@5A#"-W[,F M74(&XOK\JOXIUHZU7(6#1Z-^R53 5+5ZF779Q'Z>;PW&F;1/X3. +X1CCL"E0S/RC\*+( MK!F)G7K?B_#$NQ/'WI3!&5L1[S!YA]Y;L4_2C-V"T(PY3QB^PNP6!$/U)03? M"G'F_]'Y-GV_F>$^TO=K>IIL"Z2; FD42/\I\?"NQ"W,_;L@;-53#;:)T^1( M:88N3O+*NPSL X]O\@:?IOV;L(WL'+D:CR\;^U\;XP%32>YPA%K\8(NAH/;A M^ '/=AJSR?"FGW\06[YQ\1=02P,$% @ =7]L3\TC-,>W 0 T@, !D M !X;"]W;W)K&UL;5/;;IPP$/T5RQ\0LX8DVQ4@ M95-5J=1(JU1MG[TP@!5?B&V6Y.]K&T)IPHOM&9]SYN)Q/FKS;#L AUZE4+; MG7/]@1!;=2"9O=(]*'_3:".9\Z9IB>T-L#J2I" T26Z(9%SA,H^^DRES/3C! M%9P,LH.4S+P=0>BQP#O\[GCB;>>"@Y1YSUKX">Y7?S+>(HM*S24HR[5"!IH" MW^T.QRS@(^ WA]&NSBA4]+C \SU7&,T%_\#+B \/&3B M8U1:V+BB:K!.RUG%IR+9Z[1S%?=QNKFA,VV;0&<"70C[&(=,@6+F7YEC96[T MB,S4^YZ%)]X=J.]-%9RQ%?'.)V^]]U*FR6U.+D%HQAPG#%UA=@N">/4E!-T* M<:2?Z'2;GFYFF$9ZNJ9GZ;9 MBF018'LOQ+W'TKBK!M'&:+*KT MH.(DK[S+P-[%1R3_X-.T/S+3-L4IX-&W+W&!!U!&D).-)4Z#4M\^@[VS(WHY>] MAK,E;E1*V#\GD&8J:$I?'4]]V_G@8&4^B!:^@_\QG"U:;&6I>P7:]483"TU! M']+C*0OQ,>!G#Y/;G$FHY&+,]0O$/OM3RD2*K!MG"9'*C/J M.,D;[SJP#SR^R5OX/.W?A&U[['S9V/_&& \H);G!$>KP@ZV&A,:'XP<\ MVWG,9L.;8?E!;/W&Y5]02P,$% @ =7]L3]*@:,G1 @ .0P !D !X M;"]W;W)K&ULE5==;YLP%/TKB/<5VWQ72:0U_90V MJ6JU[=E-G 05,,-.TOW[V<9! 2XIS4/ YIQS?6_N,<[LR.MWL6-,.A]%7HJY MNY.RNO8\L=JQ@HHK7K%2/=GPNJ!2#>NM)ZJ:T;4A%;E'$(J\@F:ENYB9N>=Z M,>-[F6ZX=L2\*6O^[83D_SEWLGB9>LNU.Z@EO,:OHEKTR^:MZKM7(:U76 M6<%*D?'2J=EF[G['UT^$:()!_,[849S=.SJ5-\[?]>!I/7>17A'+V4IJ":HN M![9D>:Z5U#K^6E&WC:F)Y_QV?]@!Y8KN%Z)BK'BN3#?SFHO)"^LBEI*03^::U::Z]'JGV@P@5@" M:0DXN$CP+<&?2@@L(9A*""TAG$J(+"&:2H@M(9Y*2"PAF4I(+2'M$;SF]S,- M<4LE7%C?^8=M)#%W#08TL$$ M7HRW@0Z%*U+WVW\+B/U!+ P04 " !U?VQ/5U^G79L! M !8 P &0 'AL+W=O.BT"AF[/_.A =*E(*\:+XI9I(0UM MJI3;NJ:RAZ"D@:TC_J"U+#J779AJ.D/2CKHQ4&%%SO]@GF>&TKF MX9_@" KA40GV:*WRZ4O:@P]6SRPH18O/;*5)=LHGUW=SV>4"/A?PI8#G67*C MI/Q1!-%4SD[$Y=V/(E[Q:LUQ-VU,IE6D,Q3O,7MLRG)5L6,DFC&;C.%G&+Y@ M&/(O3?C%)CP1E"<$O"@O$Y07")$#/O,E4-"'Z-ZA[_)EYR#8<7[';/F9FO]02P,$ M% @ =7]L3XT@Y;0Q! ^Q8 !D !X;"]W;W)K&ULE5C;CJ,X%/P5Q <,V#[FTDHB;;):[4HS4FM6N_M,)TX'#9UE4[=H_==WY*0C:_4F56?NI M/JM*_W.LFS+K]&7S&K3G1F6'85!9!#P,HZ#,\LK?K(9[S\UF5;]U15ZIY\9K MW\HR:WYL55%?UC[S/VY\S5]/77\CV*S.V:OZ6W7_G)\;?17 MHXYK_S?VM)/4#Q@0_^;JTMZ=>WTJ+W7]K;_XZ[#VPYZ1*M2^ZT-D^O"N=JHH M^DB:Q_]C4/_VS'[@_?E']#^&Y'4R+UFK=G7Q7W[H3FL_\;V#.F9O1?>UOORI MQH2D[XW9?U;OJM#PGHE^QKXNVN'7V[^U75V.4325,OM^/>;5<+R,\3^&X0%\ M',!O Q@]'"#& <(8$%R9#:G^GG799M74%Z^YOJUSUD\*]B1T,??]S:%VPW\Z MVU;??=\(0:O@O0\T8K97#+_#\"EB9R.B^ 8)-($;"PY9\&&\F+"0.(" <00 M@"8!(B.-*R8:,-6 D:E,8B,5&Y6&,@TQ&8)D") Q'K.]8N3=8Q@/662R 3 F M$W+0D9".!'02'""" :+Y;R>& 6+ (#4*$EMU9R1B&1H%^25L0B>!=!*;#AG/ MV2(,,[@\QDR(I)!(.F.BI';">J((4X$ QF24.NBP$"\&($-B<%8'A)4&XZH_%SH#:B1PA ML-S9 KTS+'@&%$^6K<16PL3BR+06&Y4RK(B6.M<@;>DBLGAW$O<&Z.9/<(FI2%R\2L MBHV*[IUF2@=KE0.MDJNN6(-<+B@*UB"/YA0ELB>!);,=0#$>AXZUDF-!BL!):@6&"7 DM0 MV$Z8&,O%=L1,Y)-PJ]L$L(@SEZT*1RN.;-556*Q!00NJ@C4H'OO@6!8YQX$ MRNU NM9 #V[FE:!)2CB!47!$A2/?7 L2C++@0#L@0,)+&@!!"T=TXVP""F< M7Q;"(B3;!RT%C9CIEYC@YN<)@/&$7-.?L*()]+;2T082%B&)!55Q?,6BIM6< M+&0WK<"7 SE7;+"GP9H-R^++&>)>AKI2LC+$&YH*^56((2^*"T MBF)WK)S%H6E!"):XMX&PH*4MZ-1TQ!$3_8H/@ $^P=TN9+\M_"5K7O.J]5[J MKJO+8=OQ6->=TB'#3SJYD\H.MXM"';O^--;GS74[]GK1U>=QJSFX[7=O?@)0 M2P,$% @ =7]L3X;CC]4N @ 6@8 !D !X;"]W;W)K&ULC57;CILP$/T5Q >L >/<1) VEZJ56BG:JNVS0R8!K<'4=L+V M[VL;EB4&I7T)]G#.F3EC/$D:+EYE#J"\MY)5+/V M0_\]\%)<H'OH'[4!Z%WJ%U'YB"@$&FC +5CQML@3$CI,OXW6GZ?4I#'*[?U3]9[]K+ MD4K8F7JA3>?H?-#?*\S_Q5NP#3<5*)S9)Q)^^ME5ZEX MV:GH4DKZUCZ+RCZ;]LULV=&F"5%'B'I"2!X2<$? 'X3X(2'N"/'_9B =@3@9 M4.O=-G-'%4T3P1M/M)]#3ZGU)';RDF\P3=C%"'V;28 M:(@)[B&[,23L$4@7T%<1356QB4;TZ#[!=HS H5/#/T7V#T7NRL23S<*6CX<9 M@N6T0#PI$%N!^*[;"Z?;+69F,97%S!VGVS$DC+'3C3$&XZ73CPG,?#'MATSZ M(1-^G"0;,DHRBQT_8TCD'-UN A(Z;=F/,9@$CATTN!@EB(N=4M++^+52YF@' MT7X0/D?F8CGQ3;C:AA/QG1Z<[9S[D&^G[C=ZT/<;!F=EEG.]%NVX:S>*U]TD1_W?2?H74$L#!!0 ( '5_;$^D*E(* M#00 , 3 9 >&PO=V]R:W-H965T#&&41)J9JMJ5MM*HJ]T^,XGSH0+. IFT_WX-83*)?=Q2C31@Y_CZ MV#X^7'M^TLVW=J=4%WRORKI=A+NN.]Q'4;O:J:IH/^B#JLTO&]U416>*S39J M#XTJUD.CJHPHCM.H*O9UN)P/=<_-J*IH?CZK4IT4HPK>* M+_OMKNLKHN7\4&S5WZK[Y_#5ZIN][H.&K59A _B_HFSOL& ^'>O M3NW5>] /Y47K;WWAS_4BC'M&JE2KK@]1F,>K>E)EV4#>2E:]:3+K_MUMUN$LS!8JTUQ++LO^O2'&@@L0%=&IB^?]: QP;\WB = M!G]F-@SU8]$5RWFC3T%S7JU#T8M"W+.9S%5?.,O.I&Q'%N<7%! MB?"L7 J9I(")M)BD3B=W-+.( (P0LQA3R2"5#%"QYOXQ<[J1N9QE%AD7E<9!T 31CJ!;U28V%0#*9>IA@YU)\ 3=CJ#;C9K9S@)0 MN4BDAP[V.0&,CGTCPNXDY'2S%=A6!/(51[NN:23,CM\"F*2,V4,(FXM [N*( MUS6.;"9M.BZ(A6^"L;D(X"ZN@&>_WDDNY$[ZY@7;E,BGJ#=W%RJ)-<&&2 M\MPS-X1=CX#K^;8 8:,B,5V_A"V&D,78^B77/1*1VXL$4*GW(TW88PAYC*U> M5B;R'D+8YR7>.0).PT"J $9<*3!A$V&$(&XTC7 M=0Y!CG9=4.J97L;>PBBCLL7+;JYT9Y]F$,8G7L8FQ2B;LL7+;JHDK_/0D8V+ M,NODR^X8.QX#QTM\1S3/&>TW#FF,[86G'-/8M0Z1YFS/BHO*D]B3:3)V&)YR M4&/7.\C.81#&-S/877C*28W1,I(&Q3?&4H]H(NCXGBTS8Q@M09I7L MK11=W8=4JMD.5T=ML-+'>KBWNJJ]7$\]T'"?\@X_WVU]+IKMOFZ#%]UUNAKN M3C9:=\J0B3^82=FI8GTIE&K3]:^9>6_.=TKG0J&PO=V]R:W-H965T?,2XB M^'JB?P(VYW[F''^LKJ)][4Z<2^^M*NMN[9^D;.Z#H-N=>)5W=Z+AM?IR$&V5 M2S5LCT'7M#S?:Z.J#" ,65#E1>UO5GKNL=VLQ%F61_GW@I;BN M?>*_3SP5QY/L)X+-JLF/_">7OYK'5HV"T/"]_RLNP]J3S^&*?^&+,WG+Z_ M>_^BBU?%O.0=WXKR=[&7I[6?^MZ>'_)S*9_$]2LW!<6^9ZK_SB^\5/ ^$Q5C M)\I._WJ[C?]W,]P C &,!B3ZKP$U!G1F$ R9Z5(_ MYS+?K%IQ]=KAWVKRGA3DGJIF[OI)W3O]357;J=G+AK)T%5QZ1P;S,&!@@H%; MQ-9&L&2$!"J!,0M LP!M3V^RR' '%'5 M8/HQ@&;E3%@F,;4&A-G<9K,2K%1 M61AG(9Y,A"83VX@1AW$R]O!4 ?,SB )9^T8,/&T'3'#@R1HD 0)0F9! M$BL(I!!,C1(A@2ALR"9%<11!PEQI84+.&I TR@1 MQ.E<;C:*4>I@"'$(GR L=?S_!%2#+P4$60LBQSY#<*&3;#EE =Q]$"SAK0 LX"+G3 A#[G+"P6.N!"!T3H%F/!%CI)R'R--:B;@T 4NEJ+ M+P> +0<.#0*N=6 ?("PN8\ V:HNPMD!9Z#BT "Y/P+9JB['V7ITQY<9RDN=8I(W3Z]$HN/A%"8ZR.8'/S[F]B/ MO#T6=>>]"*GN$/JD?Q!" M,3?_ %!+ P04 " !U?VQ/!@,/GA8" 8!@ &0 'AL+W=O M GZU,,K5/#!.CIP_F^#K>1]&1A P."G#0/5PAQH8,T1:QI^9,UQ*FL3U_)7] ML_6NO1RIA)JSW^U9-?NP"(,S7.B-J2<^?H'93Q8&L_EO< >FX4:)KG'B3-K? MX'23BGD=(X152.$(PWIZBPCD@<9QOU-8N*"5. M3]#JCIHW\SL5U[:7P9$K?=WMI;QPKD 31@_:5:.?Z25@<%%F2O1<3(_5%"@^ MS.\P6CX&U3]02P,$% @ =7]L3Q;8'(T& P [@P !D !X;"]W;W)K M&ULE5=M;YLP$/XKB.\MG'FODDA-IFF3-JGJU.VS MFS@)*F &3M+]^QGC4L!'0[\$VWGN[CES/#XO+KQZJ8^,">LUSXIZ:1^%*.\< MI]X>64[K6UZR0OZSYU5.A9Q6!ZE#?;;PF-Z.(IFP5DM2GI@OYAX*A\J.7,Z+[LT9T6= M\L*JV'YIW\/=AGB-@4+\3MFE[HVM)I5GSE^:R??=TG8;1BQC6]&XH/)Q9AN6 M98TGR>.O=FIW,1O#_OC-^U>5O$SFF=9LP[,_Z4XSK>7J M>>7%L'#.C2.-6;<8TL>$[QA'^N^"$"S(FA@.PF@88V-""![!0]/PE+DW2&/" M@8\Z$4#?^# &^U#BPD5IE"8.("(C#(Q44#D>"$(HGG"!:P]\0GP 5Q^8(S\:U,\W\@",;3%A M4^$5Q^8(S^ "$OD$G],QH1-D<&U!^:(#WQ.?0"7'YBC/V!JB_&1? 09$L'% M!V*$R(1\ 2X_D,RO28)K!L$T8UR3Q!2$X6FG3_=KL"$A7#L(IAWCNB2F*-S( M\\X;G](H;OI@)+AZ$$P]QM6I03/J@> "0[P9A:E!@[[#/!DQE'DT.KWN,6?5 M037:M;7EIT)U^;W5KIF_)ZK[?(>W-X&?M#JD16T]&PO=V]R:W-H965TRE)X%*6O8,8N?JPJS?TL@]+JP/?O-\%2>"J$,3I8V^ 2_0#PW M.R9/3J]R*"NH>4EKB\%Q83]Z\VVB\!KPNX0K'^PMETA=U^'Y8V*X*" CD M0BE@N5Q@!80H(1G&WT[3[ETJXG#_IK[5N$TO=GA* C!#="^"DA[ CAO1ZBCA#=ZP%U!'0C(-V/MEBZ^FLL<)8R M>K58>W\:K*ZI-T>RO[DRZG;J?[(!7%HO69"XJ7-10AUFV6+\(68$64\AWGO$ MUB"";AA'!ME'ZILB7?H3 ?^]B]44$8RB6'\ILOE:9#N%H)DYD\!8\T#S@V$0 M7F@6"(T"H18(AS'&HYZU$*0A=>O#C4;UFF(\Y(\[.P4A;X393#%ADB!S1I$Q MHVA2DB#YX'8@HP":EB09M7:+IJD@-_Z@=3.CFYG!36 6B(T"\?V))D:!Y(Y$ MD[L2=09O1 7LI%]X;N7T7 L5XL#:#Y%'7[TQ(_O2FZ\\@WWMS3?MC+C)MQ/K M)V:GLN;6G@KYLNGWYTBI !F\^R#O0B&'9'\@&ULC57MCILP$'P5Q ,<-E\A48*47%6U4BM%5[7][9!-0 >8 MVDZXOGUM0V@"BY0_L;W,SNQ"QKMNN7B7.8!R/JJREALW5ZI9>9[,Q4K:C==V]A>I&M^4651PUXX\E)53/S= M0KO *96F8=!U_>E)WT#2)]_L; M^V?;O&[FP"2\\O)W<53YQDUNF$;.6?F&+I6O#6$=W+ M;YCYQG3EZW>3F:!]%?:9+E[JZ#4-EN':NQJB'K/K,/X=A@X(3[,/$CXFL?,G MZ4'@XP0!6F-@"8*'&F%#78EOK/&X3B%J/!$Q9!0"$) M9G1P)]*IS4(R\^>BN,\H9K2Y;G>:G5D&ZGH)",S>;=W;,5B+.=,-+)^*6V MX^TN.DRQK6_OZ?_P;@1^9^)WLGGSA7H&LA+[KG7$_=X5#"29GM M0N]%-WJZ@^)-/U:]8;:G_P!02P,$% @ =7]L3S=IVV9J P $! !D M !X;"]W;W)K&ULE5AM;YLP$/XKB!]0[#-OJ9)( M39IIDS:IZM3M,TV\^KUGN>)]6=./!"O=F*,D^D>BQW7G4H>;+11GGF 2&AER=I MXNRIG$_%469IP9]*ISKF>5+^7?!,G&&4?#MS'^C]BFD#C?B5\G/5NW?JI;P*\58_?-O,7%(S MXAE?R]I%HBXGON195GM2//ZT3MUNSMJP?__A_8M>O%K,:U+QIW-- M"WT]-V\BOS7##: U@,X @HL&K#5@MQKXK8'?&=#+E(+6(# ,O&;M.IB/B4SF MTU*E1H]S7T23KU3[:C%+!H,]#",#"%+ M&T([A*<(="P 8[$ RQR,":XB'FV$3Z(A9H5A8IPH0\/%M ,V<##!'?BH U\[ M\'L.(C/<#234D**9@\4!(6;,K^,&? *43V#Q\:DQT:+!!/V)_!!L0M=Q T(A M2BBT",6!P2>TYJ'!)+3Y7,<-^$0HGP@)$#4(178F*+7YV#!*Z7C"8I1/C/ Q M2F&!89A!YC)F0&2"$ID@#GR#"(8QLKF\C!D0H037,&*[(##B8D0&Z>V%35$- M>Z" +,224@P4F6)Z&30D@^L498B+V"3#K ^2$?UG$KH.')+"M8_:XN<3?\0% M+E<(&AML(@><) $S,LET%#,KBZ4$Q>K#PA^H+GZ3IP2 J7&(IH XRY MP,6!3F[/$^!5#7956UMEBQE(/!J9&X!#3KA, +UANVQ!_2Q8=*A%9XP(+C: M2 2,';EPB8!/G&4 +VBX?II9@7U,"8@_O@L#7OAPPT%EU8(&S","#/#JY61VQ?,\.)B M2'&!<5IX9'9QQ98V>;WN)^?E3K>BE;,6QT+WP;W1KMU] -T]_86\"JEZ,-TI;8607'$A=^ISVZOVO'O(^%;6MY&Z+YL>M7F0XM#VWU[W(\#\ M'U!+ P04 " !U?VQ/.;%$5P4" !^!0 &0 'AL+W=OVS0R8!K8U9 MVX3MW]<70@FX^X(]XW-FS@SV9#WC;Z("D-X')8W(_4K*=HN0*"N@6#RP%AIU MH&#MP3':68_]D!87WN MA_[-\5)?*JD=J,A:?(&?('^U!ZXL-$8YU10:4;/&XW#._:=PNT\UW@!>:^C% M9._I2HZ,O6GCVRGW RT(")121\!JN<(>"-&!E(SW(:8_IM3$Z?X6_=G4KFHY M8@%[1G[7)UGE_L;W3G#&'9$OK/\*0SV)[PW%?XK&\T-R$:"-%(4+D_(\0#(9X1D%5F2OV")2XRSGJ/VY_5 M8GTGPFVLFEEJI^F=.5/5"N6]%JLHS=!5!QHP.XN))I@XN(?LEY!P1" E8%01 MN53LH@4]FB7X#'&7(':6&1MZ/*6':W> E3/ R@18W?5I/>N3Q:0&TUA,&,[J M6&+", G<2A*GDL2A9#-38C')),MFWM E)-S\IR.I4T?JT/$XTY$NJHWGF/T2 M\YC&,R%H8J3/QCL/E*3+/X1_<3J8?F%_J1GA')M6C,E?_ MS)@$)25X4.VHU# <#0)GJ;=KM>=V)%A#LG:8=F@&PO=V]R:W-H965T M7N$GJ%_]4>@5FE7.30N=;'CG";CL_4]X=\#6P5J\-C#(Q=PSJ9PX?S.+;^>] M'YB(@$&EC 35PQV>@3&CI./X,XGZ,],X+NW YD?D_-&^,=T7=3F4U[%?9,!R_U M[KV,PJ! =R,TV1Q&&[*P"4,RVR"M/T.($T*L0+@0(#AU"X1.@= *1/]%B5=1 MCC:)M>FL#<:/*)&3$FTH89ZM**--O*!D:>Z&Q$Y([(#D*TB\@21IX(8D3DBR MO:]@_:J) Y*Y(:D3DCH@ZT=)MY#\02:9$Y(Y7IZL(-D&DD?8#0 M? .)\C1V4W#@KK7 P8G6Q19L0#$.'W >U#3>;,=CYP/B[J &D\]G23A1N+66_0TA4-;1$/+$>.O7F MS'A+I KY!8F> SF9I)8B['DQ:DG3N65NU@Z\S-E5TJ:# W?$M6T)_[L'RH;" M]=W[PFMSJ:5>0&7>DPO\ OF[/W 5H=GEU+30B89U#H=SX7[Q=_M,ZXW@K8%! M+.:.[N3(V+L.OI\*U],% 85*:@>BAAL\ Z7:2)7Q,7FZ,U(G+N=W]Q?3N^KE M2 0\,_JG.3K554C6 M3BZJE)9\CF/3F7&8_.]I]@0\)> Y 8^]C"!3^5Z$_L[[#: MFTHOFJTP[U3Q0JW>RC"(4T/-6E'A#2>('7R6Q0A(+Q%]!D@TDSB([)+5"TBTDP"M(NH%D MCSK)K)#, DE6D&SS@T7IYAB@Q;G3U]I/PB]-)YPCD^H(FX-V9DR",O2>5,&U MNDGG@,)9ZFFBYGR\3\9 LGZZ*M%\7Y?_ %!+ P04 " !U?VQ/V52 J'8" M "_" &0 'AL+W=O)$98\IY+8M*KMQ,J7J)D$PS5E+YP&M6Z2]'+DJJ]%2UZ$ M2II7;A);VY-(8GY615ZQ)^'(A9ZA7.>0EJV3.*T>PX\I=X^4CC@S!(G[FK)%78\>DLN?\Q4R^'%:N9R)B M!4N5D:#Z=6%;5A1&2Y^&>#U^4_]DD]?)[*ED6U[\R@\J6[ESUSFP M(ST7ZIDWGUF74.@Z7?9?V845&FXBT3Y27DC[=-*S5+SL5'0H)7UMWWEEWTW[ M9;;H:##![PA^3]"^/R($'2%X)Y /":0CD'L)84<(1P34YFZ+N:.*)K'@C2/: M]5!3L^SP,M2_*S5&^W?L-UU/J:V7A 3S&%V,4(?9M!A_@%GT&*3U>R<^Y&3C MWPH0;^AD"V'P$+.#,/X0\WB+\>%0 [ >@:63:Q?>A !!8@5" 8Q!K! " J$ MMQ$0,DH2PH2PDPAT$@$"$2PP P5F]ZED 7L;+&\),+&_LP4WDW4J$$W'BB3[$]Q<4@UVVQOZ_2[KM0(.:1E,UQ7"/ M8*!)QE7=0J 03_B!6PD30&*B&3'<3#C\C[+"K8*!7@F#TRYTD>&W=B/ MG"NF8_0>="TR?9OH)P4[*C.&UL ME5A=CZLV$/TKB/>]X \,1$FD3=C=5FJEU:W:/K.)DZ +. 6RN?WW->";"YXA MH2\).&?&9\8SQXZ75U5]JT]2-L[W(B_KE7MJFO/"\^K=219I_46=9:E_.:BJ M2!O]6AV]^ES)=-\9%;E'?5]X19J5[GK9C;U7ZZ6Z-'E6RO?*J2]%D5;_;F2N MKBN7N#\&OF;'4],.>.OE.3W*/V3SY_F]TF_>S#9:4/Y4.I;^_+K?N7Z+2.9RUW3NDCUUZ?_QBG[FW. MUG#X_,/[:Q>\#N8CK>56Y7]G^^:TLF;K^KZBS0!!:YCHO]-?LI< MPULF>HZ=RNONT]E=ZD85QHNF4J3?^^^L[+ZO_2]A9,QP VH,Z,U SWW/@!D# M]M. WS7@QH#/G2$P!L'<&80Q$',-0F,06@9>G]UNN9*T2=?+2EV=JJ^X<]H6 M-EF$NB!V[6"W_MUO>L5J/?JYYD&P]#Y;1P:SZ3%T@&'^&)) "+DA/$W@QH)B M+#84F-/Q!%N(8,3B\-#)RV,GKQ#" S'&O$&,"/%H&9ISUMFST1P3#CCJ@'<. M^,A!9"U:CQ$=INRSP2D/K9PAJ"CBUNJ^0%0TPPF.:) M,=^FC*"([Q-N<<9@,14392E0T@*2%E9N-@+,(ZA%>2M _IY"0JPV2Z GRB([ M+ AZ(J'/!!Y6B(85(F%9?; )P3R$6>N50 R/)XA$*)$((6+U[":"6=$!6RVY MC4"&621BRU+(RN<;!HNY/]'P9&([ M)$AX$T)'T+WLF=#Y\D[P#8*P&0)O0.-J#B*[YC%8(,A43/B&0[ =QY9O QK5 M*HT"<%1 8)$8[#EC0OAV0I#]!$@S@7L T.8$ 8UD=\P&WR<(ME'8BDJ@=(/4 MW(.,B>#*3C!IMQ65(-H>,WLYDX>P,2%!Y#K31/CMYNT9]I>FUCC&[+8 M$F0\(8N7_I[LI_O^VN[WM#IF9>U\J*9117>ETEEX>F M?0SU<]5?E_4OC3J;JT#O=A^Y_@]02P,$% @ =7]L3Z2D@+MP @ Q@< M !D !X;"]W;W)K&ULC55=CYLP$/PKB/<[P'Q' M!.D25+52*YVN:OOL$">@,YC:3G+]][4-X8CMM/<"]C*S,[N M[@0^LH:A+CS MUN&>K=V&\V'E>:QN4 ?9(QE0+YX<".T@%UMZ]-A $=PK4H<]X/N)U\&V=\M" MQ9YI69 3QVV/GJG#3ET'Z9\-PN2R=@/W&GAICPV7 :\L!GA$WQ'_,3Q3L?/F M+/NV0SUK2>]0=%B[3\&JRB5> 7ZVZ,(6:T=6LB/D56Z^[->N+PTAC&HN,T!Q M.Z,MPE@F$C9^3SG=65(2E^MK]D^J=E'+#C*T)?A7N^?-VLU<9X\.\(3Y"[E\ M1E,]L>M,Q7]%9X0%7#H1&C7!3%V=^L0XZ:8LPDH'W\9[VZO[9E-!#LN"DHM#Q[<[0/D1!:M(=+^60=5L M]4RTAXGHN8R2K/#.,M&$V8P8L,"$_BUD:T*"&>$) [,+8'.Q 08=: +_150F M(KSC(;1V(E3\\*83N3U!9$T0J031,D&LMW+$) K3CV5$($JU8BVH+(NTGER#R$H:];MJ "WP\BS;,-EH/DSHM*K*83B^E MLY,8.J*#>@--T$.0+3__&S.IU4QJF F UILJ-75 D*1VFE23@CDU.?5< M_O*+Z#R,GH \#;7X5@RI<::\IQDGW#=(CVW/G!WAXJQ5)^*!$(Z$2?]1]+01 M0W7>8'3@/[O(O4$L#!!0 ( '5_;$^0_GO,I ( M . ) 9 >&PO=V]R:W-H965TW4:2V1]XP=2,ZWIHO>R$;IDU7'B+52/W;TTO6CTLJL:WJI*M('D^W7X&=V6B%H#I_A=\8N:M ,;RI,0S[;S?;<. M8TO$:[[5U@4SKS,O>5U;3X;C[^ T'.>TAM/VJ_>O+G@3S!-3O!3UGVJGC^LP M#X,=W[-3K1_$Y1L? B)A,$3_@Y]Y;>26Q,RQ%;5RSV![4EHT@Q>#TK"7_EVU M[GWIO]!L,(,-DL$@&0U0^J8!'@RP9Q#U9"[4+TRSS4J*2R#[U>J8W13H%IMD M;NV@RYW[9J)59O2\23.\BL[6T:"YZS7)1)/,%>520;-1$AF D2(!*1)GCV<4 M*>P @PZP3J\ADWE2 M+_'E4D***VDA( MT5S&+CN(:#PY=3AZI5P9/0YJ_M_JU[ M(30W#N,;$]S17+?&3LWWVC8STY;]G:/O:-$-]ZEHO-1M_@-02P,$% @ M=7]L3^IG2CT. @ D 4 !D !X;"]W;W)K&UL MC53;CILP$/T5Q'O7@ G=1@1IUC4,(H'1? ML#T^Y\R%\:0-%Z^R %#>.Z.57/B%4O4<(9D7P(A\X#54^N; !2-*'\41R5H MV5L2HR@*@@0Q4E9^EEK;5F0I/RE:5K 5GCPQ1L3?)5#>+/S0OQB>RV.AC %E M:4V.\ +J5[T5^H0ZE7W)H)(EKSP!AX7_%,XWL<%;P.\2&MG;>R:3'>>OYO!] MO_ #$Q!0R)51('HYPPHH-4(ZC#>GZ7%0O_ MT??V<" GJIYY\PU1:!\YI])^O?PD%6=.18?"R'N[EI5= MF_8FN="F"9$C1!U!^[Y'P(Z KX3X+B%VA/BC'F:.,!MX0&WNMIAKHDB6"MYX MHFV'FIBN"^DIM/6?Q8YBBLQ%RF&6+B7H8'-Q"UF/(503I M +HHHJDHEM&('MTZ6(T1>!#F^K\BF[LB-V'BR6)AR\=]#]%L6B">%(BM0'Q3 M[4&Q6TAB(97S@>-!-<:@3\F783W&()S$ ]!F0@GC)!@DA7KMQ$ <[=N67LY/ ME3(%Z5F[\?$4F78. MYYR8L4='(5_5CG,=O%5EK<;A3NMF&$5JM>,54X^BX;5YLQ&R8MI,Y392C>1L M[9*J,L)QG$85*^IP,G*Q)SD9B;TNBYH_R4#MJXK)/S->BN,X1.$I\%QL=]H& MHLFH85O^G>L?S9,TLZAG61<5KU4AZD#RS3B1'B MU4Z^K,=A;"OB)5]I2\',X\#GO"PMDZGC=T<:]FO:Q//QB?V3$V_$O##%YZ+\ M5:SU;ASF8;#F&[8O];,X?N:=H"0,.O5?^8&7!FXK,6NL1*G<;[#:*RVJCL64 M4K&W]EG4[GGL^$]I< +N$G"?8-;^*(%T">0]@7Z80+L$>N\*29>0>"M$K79G MYH)I-AE)<0QDNQ\:9K<=&B;FXVV*2"]\HB?WM!L%R@CRV!0 C:8H3SUX(1G%\0UP. MBLL!<2E,, )!O?;BV*X5\1W&-R!SL4F@\3W%T"A+"-^5P%0F,0#SUX ]H!B M>DOV1Y\1D:SA$07]@[B3OBWNG; M"\TW)K=%K8(7H&PO=V]R:W-H M965T[2E2>=TIM/[X94??^S*[AX_^;T\J-76>O M#MDU;[[HVV_*&)*N8]S_H=Y5WN)=3]IG['1>]W^=W;5N=&%4VJX4V??A\USV MG[?A/U%DFN$&W#3@]P;MLY\U$*:!^-D@>-H@, V"CSY!F@:2/,$;O/>#NNN]E7I_]?.YYU>_=]'<3QTGOOA RS&1C^P A_ MC&QMA-T)K^W O1<<]6+#K>9\_(#$)@0C??BE2/I49-1- 0=+].W%:+#F6"" M D$O$#P*S,E0;A!#K"8?8+8?8-+GS,B0A(8D$""COD&,((80$Q!#B)'$$&)" M;"B$AD(@$!%#B"&_F00QI!"$:2Q#BU!:"Z!R$T-0DQ&'-!)"P)B&" M0FH+05:U$!136PB:V$$PO(5@@;4)D6)BO6$XM)F=DI+NIC8&"GNH[*%9S*V) M#"CN2[KL($P(2=,;88&0$WG'<((S%+TT\0PD'Y[$8[HI =",,4E3#V-TZ4T1 MQL5\:E+C-&$ WUH!J5\9XPAK.=8;"UJI; M# 8Q\JDU0+' >F$ F+ 6(B E C&QIV0XX1F*9KIG,=#CDZSUU49D9/W6 &2E MALW,IS*>XXSG*$_I(F*@45]BZ@I!EBL Q1$M%H#:W^%$K3@.>8Y2E\:&@48/ M"J@MFYG1O=860 %]24-"T<2*SW'$?"FH(V-0NM@P) B=">A4!+B) 6S7LX>"I4=>Q/ 6MGIZ]ET^U:'N[>3QI? M>'=P1>YOV")AX/Z6+=+A'/&G_'"L^6=6'<]E[;SIIM%%?ZAUT+I1;>_]3VU) M3BK;WR]R=6BZKU'[O1J.$X>+1E_,4:EW/Z]=_P]02P,$% @ =7]L3_3/ MT]A0 @ EP< !D !X;"]W;W)K&UL?97MCIP@ M%(9OQ7@!BXKXL7%,.M,T;=(FDVVZ_T%YNPD7)X!D <&])A\<0&TJLW9\8[+-607X 8.,$G$]11 MD$11!CK<]F%=F;D]KRMVE;3MR9X'XMIUF/_=$LK&31B']XF7]M)(/0'J:L 7 M\I/(7\.>JQ%87$YM1WK1LC[@Y+P)/\7/NSC2 4;QVI)1K/J!+N7 V)L>?#MM MPD@3$4J.4EM@U=S(CE"JG13'G]DT7'+JP'7_[O[%%*^*.6!!=HS^;D^RV81% M&)S(&5^I?&'C5S(7A,)@KOX[N1&JY)I$Y3@R*LPS.%Z%9-WLHE Z_#ZU;6_: M=23 M9NW,.U6M4+.W&D%8@9LVFC7;29.L-,FC8NBL3$PP>*U&\ MO0;0&*0/!L@J8])D1M,;31'E5B&N)H9YX2=)O22IAR2S2"8-6F5)$1Q MBOPHR(N"/"A6EBURLJ LLD@\FH^^3N8%R3P@A062N4G*U )Q-642^T%R+TCN M@.2EQ9%[OHV](!Y- ?TC\"R(#5(X26P,5P$ABOPC=#D2*\NV=++$ MN;6U=JXF23[X5=69[SV'(@!G$U00U$4!!@UI&[]LC![!UX6["9IW<*!>^+6-(3_V0%E M_=8/_M_R%\WN=:;P0_ M:^C%;.[I2HZ,O>K%E_/6#S004#A)[4#4<(<]4*J-%,;OT=.?4NK ^?SA_LG4 MKFHY$@%[1G_59UEM_=SWSG A-RI?6/\9QGI2WQN+_PIWH$JN252.$Z/"/+W3 M34C6C"X*I2%OPUBW9NQ'_T>8.R : Z(I($S>#8C'@-@*0 .9*?4CD:0L..L] M/GRLCN@[$3['ZC!/>M.B!4KF1,G6*)%]Z;-5EF1C@;PK66#D3HQ\A1&&UG7< MY:OK&">;R+XH#A4.$VS!H%E3T$WZ&^'7NA7>D4G57TP7N# F03D&3ZJL2OT7 MI@6%B]333,WYT!V'A63=V/C1]/&UL?99OKYL@%,:_BO$# M7 7\V]@FJ\NR)5O2W&5WKVE+J[DH#FB]^_8#M*8%NC<5\#G/^1U :#4R_BX: M0F3PT=%>K,-&RF$51>+0D Z+%S:07KTY,=YAJ;K\'(F!$WPT01V-8!QG48?; M/MQ49FS'-Q6[2-KV9,<#<>DZS/]N"67C.@3A;>"U/3=2#T2;:L!G\I/(7\.. MJUZTN!S;CO2B97W R6D=?@*K&I@ HWAKR2CNVH$N9<_8N^Y\.Z[#6!,12@Y2 M6V#UN)*:4*J=%,>?V31<-7,A>4AL%<_7=R)53)-8G*<6!4F-_@_,<9_];F#\ MS@%P"0#)?P/0'("L@&@B,Z5^QA)O*L[&@$^K-6"]*< *JLF3=(JNFJC6;.=-/!. Q\5M:O(\D42*8"% GHIH(E'#Q29WP!Y#9 Q2!X, M)J0!R7?I+42Y)Z M2$J+)'6SY,B:N=H5%?D3DLQ+DKDD:6R19$Z2#":)1>(1I;3'39U)!OF^SE:_B1L_@%02P,$% @ =7]L3Z5IKY0G @ MA 8 !D !X;"]W;W)K&UL?97;CML@$(9?Q?(# M+ 8?$SF6-EE5K=1*T5;=7I.$Q-9BXP*)MV]?P([E -N;5R6[2MIT9,\#<6U;S/]N"67#)H3A?>.UN=12;X"J[/&%_"3R5[_G M:@5FEU/3DDXTK LX.6_"9[C>%5IO!&\-&<1B'NA*#HR]Z\6WTR:,-!"AY"BU M U;#C>P(I=I(8?R9/,,YI0Y#D2#X>593MJTD66%8HM$E<#XQ3Y25(O2>J2 M0&B1I$Z6/(>YA>**TAA^!Y3&ULE5;M;ILP%'T5Q ,4VV!#JB32VB[:I$VJ.G7[[29.@@J8V4[2 MO?V,H2C@RT;_%.RE5>#2FOHTBO3V*DNL;68O* M_K*7JN3&#M4ATK42?.=(91$1A%A4\KP*UTLW]ZC62WDR15Z)1Q7H4UER]>=. M%/*R"G'X/O&4'XZFF8C6RYH?Q ]AGNM'94=1K[++2U'I7%:!$OM5^ G?;H@C M.,3/7%STU7O0M/(BY6LS^+I;A:BI2!1B:QH);A]G<2^*HE&R=?SN1,/>LR%> MO[^K;USSMID7KL6]+'[E.W-GPKS)"]?1-<0#8.N^V_B+ H+;RJQ M'EM9:/Z"4!2TF 4A)8@((" M=/YB,%" 170T?EA7I_D:L$&)BEHD@(F;&328NC A%#8)0-=,L E';EDG@M& M",$N"]!E\?_3<[?P7!A+QD?,!]&,8K@4C.#P(Z 8+_W(VS[&"!KGUD?1+)XJ M9^);A(%R%A,2<+CQ!]*-X7AC/]])XBT*!)HX;1C.+@;"FZ*Q3^(M*T;QU(G# M<,@Q!9RFM@:..68?6%)'&WD'<36$O MI1%6$MW8_P502P,$% @ M=7]L3XF _85L! /!< !D !X;"]W;W)K&UL ME5C;0FVI^8M'Q7')(GR_QY- MG)VF'O$^!W[LM[NR'O!GDT.T-7^9\N_#6UZ]^6>6]3XQ:;'/TE%N-E/O@8Q? MN:@-&L0_>W,J+IY'=2KO6?:S?GE=3[V@CLC$9E76%%'U\V'F)HYKIBJ.7Y;4 M._NL#2^?/]F?F^2K9-ZCPLRS^-_]NMQ-/>6-UF83'>/R1W9Z,38AX8UL]M_- MAXDK>!U)Y6.5Q47S=[0Z%F666)8JE"3ZW?[NT^;W9/D_S7 #:@WHV8"(JP;, M&K O W[5@%L#/M2#L 9BJ =I#>27@;QJ$%J#<*@'90W44 -M#73/P&_7KRF( M151<F>G49Y6].'J&X=,M95R:WJP:;"FO]5-5%4HQ\S$8J)_U$360Y4HI%^D@! >VZF$,$ZT6QN$GR=)OD&4)X$'8Q M2XB1/<@+A(A0=C&O&";$9XVAZ\L: M8A4#@!1PEX0\ [R?;JHX7(!I*VBZ^D M#((>;@YQ4@#4 J)XS=7'/4$H2UDE.H,D)D!S3O8)8"ABU#%3H]"113Q). M(Z4X08@2A,,74J$$ZO9"MA!QN9!4Z-[Z0! CVCWQ&@U&WY[XA0:.Q!4_),#U M+4 FGO75*P"N%)5N5PXI)<"5"'5?2PETI9$N&(A;(CA7U*BL/A *HU8N"EQC MR!TB0W"5(5!FA );"&QY)KK2T/6%-SV!72^4HQ<)WLU$WI$QWL\D'%(M(:P" MQ9%J&89;(CA"W/.'"PF!2B(4&-3I+'[>D9A7\L@A-.'X(@( MW85%<0&@0P2 (HTM&!+3,-P2P;FBQ@6 8@+ ^]%0.$-,NR62XDI!&>)+."AP MI:#\CM+!!8!B @ .>7#?9\$5L:&X4E"X\0LE'12X4M [MGZ*MRR]O?DO*++[ M=P]4]H ,<=<.7A17 I/ $*%_9#@$> //"8(O!83PR6%04F!_6M!G;J $JF^&*QQ#%4X[29+C\,#J\NIGC&P>J M"JANBQ&#$\;5AV'G%.V@P-6'B3L2QD6%8:+2;QX+ZGP@A2%W9XRK#T/.*=I% M@:L/4W=DC,L%0^1"DWYK8J#^5\4-4/>+&-<)CNB$=AR .-XXG-SQ78XW#H?[ M-JAZB^G4@);N;9OC#<:1;5MS!X7C&N&.;9OCC<.1;;M? Z\HJ+^\_L7M6&+R M;7/=6HQ6V3$M:]N+T?.5[@.M;]=ZXX]D/"?(^(*,G[#Q9S)>MA>Y7V[;>^4_ MHWR[3XO1>U:66=+=B=;GE]ALROHQK)[S]CZW?2FS@[VK M]L\7YK/_ 5!+ P04 " !U?VQ/'49TCHL# %$ &0 'AL+W=O.4 MFX/(XO)1'D6N_]G)(HN5?BSV3GDL1+RMC;+4H:X;.%F_!3JU_&YT$].R[)-,I&7 MB7V]-/\$GC'##:@Q MH*V!]GW-P#,&WJ>!?]7 -P;^O1Z8,6 ##TZ3>UW,5:SB^;20%ZMHSL,QKHX= MF3"]79MJL=Z=^C]=SU*OGNPA B/#&*X2;*^2M(+TT.+Y=7V7K=8(<<)?)3 KPG\#H$_J.2B@00U M)&\JR8/ =0>X)<0%#*!6$.577$/<&N)HP+NP7G(,38[!Y"C%"0*4(+B_O"%* M$-XN;P-AW?)2%@VJ!D$>B<;+P=%@.,PF"G""""6(0#8L"@>11B#2D1B)B\O? M19SPH;A=X.6!<"\<+0@9Z34$<3:LO0'UG/ETW!7:4)X(!:Z"X:%?&%#7%8\0 M$=W&]4/"FP?Q8/;<&Z' VP?Q[U<(P45*$)6"NC"0;^"&2%T@CK#0'2\,+GN" MZ'Y,*007/H'*AUHA4-9C@>**)OP>L7!X?BDAWGA5?8(I+FT)I#T_PBD+%DO[[S'P00-RU]Q[%E4V1 M[X*Q TQQ95/X90 /L 'U=C&,D*P@CKCNN"XIWBHH;!6,@YA@#WC 2PV!5TN- M]PH:W"%! ^K%% 10%FL<>"4HO/M0K/L,WVL4=I\'@GR)H;AH/"2\55'8JF#W M,*#N5Y\'=VZ)P!@GL,G<1[>^3=+*V-/.6J$EMGM9U9GV@U M @W6%V2R),CZ2L^XS43Z2=\,R#_B8I_DI?4JE1Z\ZO%H)Z42.GSW4>_,0<_D M[4,J=JJZ#?5]T0RFS8.21S-T.^WD/_\/4$L#!!0 ( '5_;$]Z9WJ^_0( M /<+ 9 >&PO=V]R:W-H965TN[IXV78KOCX=Z255\;>Y&*Y MGKA(9D1+NN)2(A>7 YW1LI1*(H^_6M0]QY3$X?U)_5&9%V9>\X[.6/FG6//= MQ$U<9TTW^;[D+^RXH-I0Z#K:_7=ZH*6 RTQ$C!4K._7KK/8=9Y56$:E4^7M_ M+6IU/6K]$PTF!)H0G DB]C4"U@3\02!7"403R*V$4!/"6PF1)D2W$F)-B&\E M))J0W'I*J2:D1@2OKY]JB(>G 98&8C2!A=8AYL M3(0,G;F-P8;=1T@&7V*>( PQSN1+4\NKR5P<&P:+AQ4?#R/@&!8@H !1 F1X MJJE1_!X2*4BM(-^2)#*\SB!4A$*C0 #*Q\A/C!I!L#".S3H!,$RP(?8$B04! M-GIG 8DADL1&Q2"83T@('WH('GIH56UX4A<"$2@0656+D.$GZS'A(%$<$]/U M'$!%J=7(D!9.S&8&(_H(-A:#QF+ F%&!++;"&.^B^9>(Q9>(Y37$A9$$-)( M1HS&S)*;*@2@@ I!6G:%P(B?52@%C:66L= XNJR'Q,-'!-T%1L9S$$6,U^P" M1%F^8!2!?8G)#/P.(MN9]1U$-UF#898W&&:9^P1FNO,&'_R*MELU07;.BNUK M+E\V@]WSE'H?R('!V,_\T9,/["_D5*L&C _Y?B3^D;?;HNZ<5\;%F**&B0UC MG(KLT9WHMIV8PL^+DFZXO(W%?=N/HOV"LT:/V=YYUI_^!U!+ P04 " !U M?VQ/.I$4B!(" "4!0 &0 'AL+W=OZ%/J%!Y5@S:&3-&T] L?:?P]4+-G@+^%E#)T=[SU1RX/S-'+X< MUWY@# &%7!D%HI\(!3E1][_6C5T[ MIW^AS1,B1X@&@LY]CQ [0OQ!P'<)V!'P_V9('"&99$!][;:9.Z)(E@K>>:*_ M#BTQMRY<)?ISY29HOXY]I_LI=?2<+8*G%)V-D,-L>DPTPL3!-61W"PD'!-(& M!A?1G(M-=$./KA-L;Q%Q./'P3Y&7NR)7-N/99L66'X\SQ,MY 3PK@*T 'G<[ MG+1RTV,2BVGZ5CXE&$_Z,8-Z7.))P;M;5!0DX;0M,UJ+!9X6AD97BH$H[?\M MO9R?&F6:,HH.(^0Y,E=R$M^$JVTX$]_ID=-/B _Y?EY](Z*L&^D=N-(_@KVN M!><*M/G@0?NN](@<#A0*9;9+O1?]H.@/BK=N!J)A$&=_ 5!+ P04 " !U M?VQ/?%BSRI[N5!%/K-5I9YHO1C MN7.J0RF231.49PYU7>[D25K8\VDS]EC.I_*HLK00CZ55'?,\*?\M1";/,YO8 M;P-/Z6ZOZ@%G/CTD._%3J%^'QU(_.1>639J+HDIE895B.[,?R"2F;AW0('ZG MXEQ=W5NUE&DTHL9?8GW:C]S YM:R.VR3%33_+\572"F&UUZK^+D\@TO,Y$S[&6 M6=7\M];'2LF\8]&IY,EK>TV+YGINWP2\"\,#:!= +P%Z[H\"O"[ >P_P/PSP MNP!_[ RL"V!@!J?5WA1SE:AD/BWEV2K;_7!(ZFU')DPOU[H>;%:G>:?K6>G1 MTYP3,G5.-5&'6;08>H7QW#YD94+>21R=P"4+BF6QH$8X[4^P-!$>2'-UDR3^ MD*27IH<6RVOBO5ZQ*$[@HP1^0^#W"#Q0[1;#&TS18.Y(H/] 04Q8$#*?@YJ8 M*!J$8/%B$Q0R=H7J"6.H,(8(\X&P%L.NA851& )="(JP@(,JK1"8Y[H^@,48 MC(3>@#:.:N.(-@:T<7,>RB.8]=*$<1;X8)NNQI'%M\AZT@)46H!(XSA!B!*$ MX[^(""6(1GP1$5(/+Z!@&R]1F.^!I5JA,$[!:1*C,.H.B",N?KJZ([Z+#M2? MBD!U&(H;QS "\MP(2$,GC+P!90.^049\%1T(%#&"[K'$<7X$EVXD7WR;KR\1 M-:4'0A&)P0 %;ACD$XY!<,L@8SRC UT+#@-HH0CHCE(?UMA$49?! B-4W!_0 MA3L&&6,9Q#R_0PYEF1@>0E$F)F#P/$5 =]'08N%60<9X!3$/[HA!&T1 V@>A MO8^ABF]1]87A1D$PIQBJ#6X5Y!->07"S(&/<@F G-PU]H\*X$; (UACW%<)A MF7''X .%IKAC4,PQX [J0+PO,3*^>!2G)1J_G,?QQ;?Y6HG.5?>1BW+7M(*5 MM9;'0M4[X&KTTFX^T+I[ >,+,ED29'REV].VF7RG;WO;'TFY2XO*>I9*]TQ- M9[.54@F=OGNOUV:OV^G+0R:VJKX-]'W9]I3M@Y*'KE]V+DW[_#]02P,$% M @ =7]L3V;:0J() @ B@4 !D !X;"]W;W)K&ULC53;CILP$/T5Q'O7W!M%@+1)MFJE5HJV:OOLD$E :V-JF[#]^_JV+"$H M[0NVQ^>YL>UYF;->DJ:%/?=$3RGF?S9 V%#XH?]F>&[.M=0& M5.8=/L-WD#^Z/5]&' M+\?"#W1 0*"26@&KY0);($0+J3!^.TU_=*F)T_V;^B>3N\KE@ 5L&?G5'&5= M^"O?.\()]T0^L^$SN'Q2WW/)?X4+$ 77D2@?%2/"?+VJ%Y)1IZ)"H?C5KDUK MUL'>9)FC+1,B1XA&@O)]CQ [0OQ.2.X2$D=(_M=#Z@CIS .RN9MB[K#$9<[9 MX'';#AW671>N4_53NEOF%^;EKA'9A4[6^:],28!!5Z M\*#:OE:#<3P0.$F]_:CVW(X'>Y"L.W_ M02P,$% @ =7]L3S<] MV9U5 P < X !D !X;"]W;W)K&ULE5?;CILP M$/T5Q'L7/+8)1$FDS:5JI59:M6K[S"9.@A9P"DZR_?N:R[+$'I+L"]CFS/', MP3JV)V=9O)1[(93SFJ5Y.77W2AW&GE>N]R*+RP=Y$+G^LI5%%BO=+79>>2A$ MO*F#LM0#WP^\+$YR=S:IQYZ*V40>59KDXJEPRF.6Q<6_N4CE>>H2]VW@1[+; MJVK FTT.\4[\%.K7X:G0/:]CV229R,M$YDXAME/WD8Q7P*J &O$[$>>RUW:J M4IZE?*DZ7S=3UZ\R$JE8JXHBUJ^36(@TK9AT'G];4K>;LPKLM]_8/]?%ZV*> MXU(L9/HGV:C]U U=9R.V\3%5/^3YBV@+XJ[35O]-G$2JX54F>HZU3,OZZ:R/ MI9)9RZ)3R>+7YIWD]?O!O MC1F\IO9:S&6LXMFDD&>G:-;#(:Z6'1ES_;O6U6#]=^IO6L]2CYYF 8DFWJDB M:C'S!@,]#/4O(4L;0CJ$IQ/HL@ LBSG8,U"XG&)A8P(PT\ PY!*SNLYSD2Q% M):,U >T1 *,X 4,)6$W +C(PJETV&%YC\FN"R&C#RB,&PP)[U XM,K]!)28"MLH[=#6UFVC@%!37QO$H+=%7Q:&&Q^Q MG8\/6"_@)@/^_>H";C) ;JO;8@S=K)T-@R%;&P+#]C8$%@+QAZK#_0]L_^,# M)@RXRX!]NAF6&'<9L,\WML3,VLI]4]Z;D.5MR J! #-=T^N=EC-1[.JK2^FL MY3%7E1:]T>YZ] C5:=L8GY/Q@B#C2WV=:D[G[_3-7>Q[7.R2O'2>I=)G_/HD MOI52"9V[_Z 7PUY?_[I.*K:J:HYTNVCN0$U'R4-[O_.Z2^;L/U!+ P04 M" !U?VQ/X"!M@:H! "; P &0 'AL+W=OT;U]?*$H[ M]@7['/_/[URPRU&;)]L#./0LA;(5[IT;]H38I@?)[$H/H/Q)IXUDSIOF3.Q@ M@+4Q2 I"LZP@DG&%ZS+ZCJ8N]<4)KN!HD+U(R*[S&;XY'?NY=<)"Z M'-@9?H+[-1R-M\A,:;D$9;E6R$!7X<_K_6$3]%'PF\-H;_8H='+2^BD8W]L* M9Z$@$-"X0&!^N<(]"!% OHR_$Q//*4/@[?Z-_C7V[GLY,0OW6OSAK>LKO,.H MA8Y=A'O4XS>8^OF$T=3\#[B"\/)0B<_1:&'C%S47Z[2<*+X4R9[3RE5^>*M]U[K M@FY+<@V@27-(&OI.LYLUQ//G)'0Q"8V S0T@IW?+@'P1D$= _JZ"_P VBX#- M/Q44>?:AS:3918V*FO5J^R$)N9EKN+8/S)RYLNBDG?]%<9"=U@X\+UOYN]#[ MES(; CH7MEN_-^F^),/I87H*9'Z/]2M02P,$% @ =7]L3T&TZL#\ 0 MNP4 !D !X;"]W;W)K&ULE931CILP$$5_!?$! M:S )A(@@-5M5K=1*T5;=/CLP!+0VIK83MG]?VQ!$P7G8E]AC[MPSX]C.>B[> M9 V@O'=&6WGP:Z6Z/4*RJ($1^<0[:/67B@M&E [%! M;O ,E!HC7<:?T=.?D"9Q/K^[?[&]ZU[.1,(SI[^;4M4'?^=[)53D2M4+[[_" MV,_6]\;FO\,-J):;2C2CX%3:7Z^X2L79Z*)+8>1]&)O6COWH?T]S)^ Q 4\) M>.AE -G*/Q-%\DSPWA/#WG?$_,7A'NN]*HMCZ,P0S=C-&J. M@P;/-%&$)PW2_A,$.R'8&D3_01X81$Z#R!IL9@;A;E'D((FMI+62)$PW;LC& M"=FL(%&ZI R:[8P21CAP4[9.RM9!21>4[0&UL[+WI<]OXF2#\>?>O0"5.AJH%&=Z'/3-5:DGN:.,KDMV]4UOO!Y"$ M)+1!@ %(R^R_?I_S=^"@*+N3S.Z\54F;(H'?^=SGOY;E+OBZ2;/RWW[WL-MM M7_[I3^7J(=Y$92_?QAG\F?-E&2 M_2[89\G?]O%%OL]V__:[Z6CTNW__US+Y]W_=_?MEOMIOXFP7G&?KX"K;);M# M<)WQF$F>!=V@?(B*N/S7/^W^_5__A._P>XO@;9[M'DIX9QVOJ[_>QMM>,.J' MP; _6%1_?)=_Z07]>?./3ZWG?Y\ORUT1K7;_7_5->?@FOD_P"1CB7;2)JT^= M_W1^>?4F^/#G\YNWYQ=7GSY>7YR_N0T^O+EH&>\"%E-$*2QB'7\-_A(?JL_U M^_U!?S 9V4*QCA/^*HP.,*+J-=;5W=[F#8'0U:%O$Z2>,B MN(#W[O.BMH+SU2J&W^'7-3_9>J@?#]O:S(-^]Z^M+WR(BR1?MZY:[_F__[?_ M=O0RW1-X#5_6P.F4MV4MC>__=50[%'AUS:^GT7WUU[LH+6N[T1N7:[N)MWFQ M2[+[X'87[>IS_D<=*V2$JTU.]\3 MSS_$:?K$,_#K!K#E=I>O/H?P!J)P\'Z_*W=1MH8IJJ]]>G?^Z?+ZX]5E75NUO^=/O^S?7E.7Y]^Q'^>7OU[N-M\/YU\.;][2V0AD^WET'GQ9F0B"#) M@H\/^;Z$*.']79UP=#+]F%=_O(F_Q-D^+E]6?_B8[P!,"OFY^NO[+:(( M'F_\%2AGV3# 10[$-K\+MD6^WJ]VM2%NXA(@>/40P(Z"-^":(/@\2O1P=K* M'^!9OH*[*"F"+U&ZCW$K19P27=A&!8#%"LX_?T-S!$ X*]CW%^>)FMF&W 2Y7X)&TZB.OU\3[-V9,@SF1_@>W7:J6ZC M0P37U+B690R\*]8A=]'7IHO6WQ#POB0E+KBS!(BY2W9G->X)D-!TDOB]S-+! MW\\".'C&3-C),BJ35="!C:SS-(V*TO[:.$/[2.LDW>/63QOKYSBY?\#'HR\ M!O=QD.TW2W@:[X.)1FZ)DK=._OF[!W27VS+D!\;VH(S2^N6\258(%$I5OI-N M7KQ_^^'FZL_PW/5/5U4J>IQ@,I BU2_B!U@2D@Z!G Y"VED8? 0(:I>/>("5 M-X#) B372^!J@.+G/@A4QQ]4A0!&K3!F[[D'&E+&:@"EOF-D#,#-S MY\4$_NB\&,SIG_'TC,A"Y\5\?H;+"N$>RFV\0L*9UO!82-+)L\& S4/X+S=A MVW?=^_4[^/L*K@WN_RSH?(A0W'B(=PE(.62S&Y^U]V7 M<$D+)QPE:Y"'G:JHC7R>[(B3(P9GG6/>64FG]3*$F3:)FD M=+=U4)%G2,IFF2#-L_LN2!0;6/6RMJVC+YPD C2,D%V','.?GTZD#UY D<>8 4 MJ(<\!7FY_./OY\/![%7068-\M@()C;!Q=ZC!&Y"#NQCF7HO@ :B3@^0/,QDY M\D6_UQ]8\>E5,.F'_7Y?19EHOWL 2O-KO'Z%6P$:799XY7GA23G1+@"%"9@! M"D)J=2%F:<3FC63B>]$]<.[P^ M&_8KKX\&H^KKM3W6;K< 4-D[NXIVI-*$P20<]V>Z=-"JU[_=49ZO@>@!*,/A M(4_H O];1=L$X*P!C_>;/>.&@-2Q1YK$FR8)A6&Z/ %PG\0&VO^WC/1<@:$N M"KT(_M1B@/3$G]< I=DJ02-17B9/& J?PDM4%?;E^HA64Q^A!O['%8Z6UP76 MO^55%RF.O/\$AC^]]=H S]IYV]M/;[SMS1/W;6D 6\1H6#]?&:J3'IBCNX0IU_0:O,-Z<(M1ZNIK7*R2DA@H MK !]$^4QJ&MZOO[,-BF,;:OU*=X_+A+$!Z:5P_YP%+S+=RU2#G"U[1YD^0@5 MF".+K#U.KR->+..]2)/L-S3:YA3+WPV(9"C> M&)7"-U=$*YB9-8NN_G*Z,^WHT'>LNV3WSQZXNFFTRN#9D=U(;''PC:%ZC7X\ M]APB7*U5M4"K';YMG5;V-R"&Q7V+"2^RH-3D!G"\:6S$HTF.6%VJ%K#@C]%F M^ZIB43WR_E549%U0$/!]!O"[O#C1(XJKC+^NT#@%)^M>_QK>=MR!M=O.#U'* M!JZV.74[WA2@/-V3)M8^M)SR26?W3C%VCU(JS-2$K4\1D(2\LT]@^ Z_3;-A7&@ZET8/1>.= M-+U=.]2[NWA%5/NNZ@$%W&7:B9%7AKKE&4]TBD_*4L4@><9KK3XODD&B;(]G M. B?]9IG]:SI>OOM-B7V!1B*# ;D@GW!*+%24(4MF#"]&FR:N TTAC:H\B8X MHO&!V_UF@WN"Z6[A"I*[9(7Q?<(?\ (_Y&FR:F-L FWK!^9=H':?!!X#?3;2*]V3'A#VEJZ#S+BK7T=]>!N<_7;XY"SIH'QKV M7_$;(?TU>$6T4'Z1 "_SDWS]&%>_R?>%^0I04+[=E_(=4!RXX6 ):(1PCR;K MA#F4MTHR$L!\O>#]O@ T2>@D[C#8#@< L"8Z[3CW$)2V^0X^HN'U4^^V%[S. MO+<[.T:(L(B5P/5O[ZXW P#QX?DM4#3HER AXE MT/A1L$IA*%PF*('R.*YG5\313N4JH!VK/(VW);)80&8$[7(/"$Q13$1NF-^B MA6<='78)0%V9QO$VR9 +=ZXN;\\$0W810/Q7.(UK6(78\L/@,186 ),7J"," M5"?$R7\!*D%\80T[+PW7Q34^Y"49_H%E[ B(>(>/@!!ZGO#P'FX'W3KV C,^ M'/B-YT3_ RN5]WY]/;R#.G9?1%M>J 5Q!H3B(?W$$?KOP$A0+2CE5SNEW"$ M87"-# $):[)[4*$ #0ID.^L%;W(0=,+@+=!E6$M"I_'F@'M_72"=QCLN@@W' M-!E\#P'$R1B'T4N[X/'QL1<18/< J@Q:P+)DOW@*=-LA3* <\3X2APDH('$W M0Z=UBA!8D,E2H[CR- #J7;QZR/(TOS^$S8 $<."# 9Y.&TA9J.L)!"?&H0GK7\84 M'8<"'?'A8U"]PD#0=7!S=?NQ^_Y=!?9VS@67^^4FV5$8%'"[1]X?@ L0)Q_7 MWCFX!C._)2\]^;10'8/=[PL @Q8P-H :D-H 7(>_I< M4NXBA8&'G8'_;I&-Y&!UHV'P-0$ M*V19:_H"MDD+DCD)MN&4@>.LBH2,7TR1/I6PC=> N.? TSL?+C^]/L>X(M!H M=B0#H.Z)8 4P8/Q]@PGK\TP85>TP**FQHJ@MI?MU_)+Q=_HJ./\,E.U7@=( M3%F)#C+ 0"1;VP<<$U5'P#\294BXVSU$.Z:A:P0)6&SR(FS>!<)-(?H"_AV3F$8""?K\U_$V3Z,B M^167FL5[P--]N0(R4@3+-%]]-@<%1/_=VQ_.T=ISMT.GUQY@H3C8#?T4_0KO MQ4I(.G"+V2&58X>C6H,T^Y""\K:N[$CO(()@60LS0>PVYXJK^%EP&"&TA3OL.2!=-.^1YIT9" MUAB_[]-&+]9;DO M69" PP$HHW4#&OZ $!<,^MT!'BLP49"[UN4N?\Q@N[+!X /0$_@9KWJ5Y\2I MF6,3_1&FK9Q4?(O \1XP*D1"8&'6_F#0'4U&W4%W/)]T!\-^GQ?[&"^!+Z/E MNL*;@58^H!Q"@LUG4)^_1 TR #N4+Y!$"2##]U600D*@#)$@N"6(LVQ*/'J MBWB7G^&)@82P*7'#?PGQOW^E.YAW_X(G7^;(>## #@ T@YE 5D-9'*" N0?;(D@LH?_L"<.@!64!.H$72AS).@#N@,S ,R6-#E([KES(#*)0$S$4DX9KWKWF,]4$;\(W?8K M%#9S8IRO4SBL-/BHH@>N[[9WWD/:]QKU2>#"^2KYX^^'H]&K'?\#&\BS [HA M57*F073-(9XC$T,D DH*64[K[O*NBGH ]*!?E3L5#C [A4.F957,+\GB)[O4 MK2!"I'$5 <68/@TZCK[RED:U!WK-]("_)M&9;V)-L"28!M+3)G:8?Y/F1%&4 M\,HO<*\ED$L325?<1YF:/V$(V>XKG"HJR_T&T2]-:17-1C-[!*^83-D(*T K M69)OE0!&GI#I89T ,4@9)R) M[8]!$TE_C$08!X@+'-.):N!IS4I#VA/Z?*T6L<(;!]1 ,-R7Q'R:%\_Q#@T[ M*-!,7P(FLV4$!T!=*-G (29 G^ I@YIRI6)+VC/^F0$8]/%641SG>#X@DHD: M - 4"9?) 4,!$$&>D5E'NF:XC*J[]E8"I)>1RBZF%]R@B IXQ ;FW0,@X7F6 M[6%JSJM2PD1T"5_^^RC@1OLVWU#P%/ 7%#XPAK'$O<$5+E'[BS=\?$N1L7D# MEEYX6Q5D%/!WD6N?41@E/P0G_56"[A\32EV LX:S!^YA@]+6(%TF@$BV& MSJWBL6.V$< B$ 4XRNM=#(WP1"C;^S]F+E<9?F6H4+5"MX'S5\@F_ DQQX1YZ34H)7W##R.@RY,A,Z MF4^Z!S-Z9VT>X\BVV*S@$F2V^XQ$BW,V6A[,^Y0J$=M7B1'HMH+;\]O>D=U& M,'0:/>+U.S<9*C-[D%%BSB_$7(W$S'1K;$H5^AT&;]YKYO72@_;)MU$&JH)0+P,?MA3E@[QJ^ MF/>M?5"?X"/_EAMNO8S*6!?180,T7 "JUP+&0<8!LU_^?[^0>B /&'(0>/. MT$)U0Q[,2\??T .X+1.21#XP Z4C9>*VSZ+]6A03N)^, \X4JI%Q2NP!9?PC M@J#ENAZ_'%JC*MQR@B9%XWEC#G/ S&R,,0F<&>T\=R:^MM3HQ9)5*QR">'NR M>7JY3<,$5O! %0(5GX<(J#?!RQ8S:L2 &:T Y-:T7997K55>=#%TZTFB+1Z[ M&HA$.ON4T=(H_!)T&%(6?CP_1\,+"]'$)7E-*'<(,V+MY1SDF!4H 8,^_G83 MWZM)\K;[OP(B[;A1&(+(7!BLU/?)NH)1XC^O>G0)UC:N1K>HM M DB2K8\$FX@N <;X99^Q^&Y8^\G@1M=@#\U,)[=;%2X(EG\3">.[CH/WJ'$, MOB#$DJ$CD*BQX@X)'MVM$U$!7!0=MA(/EZ4'MG7A7:-92:QTS@MG; 0$] GU MD-#P+M+CQG U])>BGLKNG@*MPAB!L'6H49L$9W>^E;#[4)31TDEU0G)KW([B MU!9CUYIPD1Q)5-S!H08 F' @"\QF<:)QJC2: Z4*! FHBI9MZ0C1IL.L5'4 M#7A-=Z2K,;'2"5'@05350V!3%EGE4(B4G>NN6%3'.%^*1%QS@CP_@9561'\A M,5DLQ41:">$+,IK<[9/\5>BNS(H$S'HF+'##$M2$X,AS^ M9HT)2L.1/%XF' D:>$_OBYT!*_,$V?%%JFV=!]ZT>[] Z_.[O!<,%MU!?SB> M]VKG2>Y0&TV3K1F9R$CNZ@+ CF4ZC(K(B[*;9%U E#(F,Y1J1U;RJAHX\+O: M'ME,4^.&1&?8 83&*E-(H&P<"%D26E4*!UZK,P$"HM_8&I>: (8@T\*)([BS M)8V(;@V\'Q'E*)=2S A%3HXOIE&&:#3,^8H-C1B+0<.X=1X0V*I7Q7X!1&1S M2O4UJARC=!EC( OB+43(C9Z&+M+J!(Y:C,5#T,6!6'T;Q\_74=A6VTQ %;29 M;#A1'BSAJ3Q:/6N/#SDCU_9A# VXY]HHWTD)$&LK\/?->YW7]RJ*QKQMLZBD M 2@ MPV S6RYAI'>&3&^)W\D+RNYH,>7&EC MXRK!(>KW"8.4"F*0]SL6D86=O*C7;H!SE#LTGE9BT%KRPY4KB%YDPT)6#PD\ M1B/TW/B;6[2*HOL$@8CB]%99+>D^UP@V8E06R/* M< %B4[Z1W$8RVR$Q95L<2F(K__&5/AY22,EV)_*Z/J2B%SVM[K<5P#B!.IE? M2]U*B)Z"!V07%$-1HK@&HCS2=E0KTI2AE *H,1CNWA6(C00&[^R*O9S8)\)$ M. W>/V@ HLXB:;L'A"6U@T_C\4$4"DRKCX H $2_V8HRTR+LA#+%R,XC@B&QZ@ MRS:$QSL'.FN7?B\!UN'%LO4"S,$\FEV+ 3\%\91@&UE&N8NW:"5,SH+K-1[@ MW<&86/&:.R!C2ZB!'@Y SP+=Q$GUG;;#E:7ID*_$]G3I'8F#TDA]5K&9!LU, M*?L:FY\T;JO3YI>!U81UH^#B0TL'KX 4C%@!2T$!18;FN7Q[K4$O/'8X["X> M=K#)48"%)5M,(E7'P*BK.B'Y=AR>IW.+F4/0-4A MU(@N^)ZB5PTQ.32K@0;9+8K^3YZT-80D7:'V_1#]Y#:1#VT4@M48[Y'W:-H$/ACL$+(4ELSV JU5=4M\&C=_ MJYMWMU7&:5K:8 T;I&'MECD, (,4HIL+=-(]E['W.\.,BVUU#E.XK'7K%M3" M#9@#7EM,-NPD7^Y <2ZKK**J_LJ@:LJDP"18VV$KL0'[+87#K.($F+$X%"UF MG)<*0[,"?E]@>I*_.8)H\6<0['V). *1\A@01%P3 M3D('@NE5WK@:CN"_S,(M"H\;TJEMI4(8"N3)#$0'#M=81JO/ M$<(828GJ,2+PKA),36)(,([0=87D?N1PCL*.]/:AEF"HIL>Q%[] %IV7M#! M@9P;6;%=UB0&3,!VT4A%@A0#"!M1')&?I" #LW9]O^S7]U;BT17T BW-IF*= MBP!LWDXXMH#^W40'I+=47A"^R_>[KA5EH_LB%FF"P>L)R4'XB5C5=R(4QT*2 MDX+3+9!LKN("P5OYDF@-9I=BD&IP<>!NV%W,"('0X$D]!O(5,/2V*R$<*' " M#=:H74$O(^J\I( Y4*EA2UR19[^%T\O,IDC.?^6*[0A%9 #/"PFP9VOHQGY)ZHK\M9)@.RP8C8?]L]0&5;'!3KS M-O%C7GPF@CM\938O\.P\>F-]-9PXT#R3JG*"TABL9A'2NDPJKI\O@-AO$-C1 MX, ?AAP&3Y]';BE0)[&3:;8;$H>79L^%*:HQ1^&R[[BN,1J(T3^JJU9MS^VMVTKQ95!-]!Z6*?"H? ''U4!!V1P]@?QPQ, M5^P7@8V$@;/['-,>\'Y(3@)*3=MD^1'$C\R=3$(J70^9D8^4B8KDN3P(]'+@ MC3,@?,6J:[Y,RNYUY93'H">%A6>+EDGM&"C9' M5Q%XC3"C"^CQO=TK04%EQX-]3\N0\+FD@$N0I!6I5-)'UN !?%):F/<<.N1> M(7]?VP67SMUBR*"D88H3BK#.MS7.*D')M'.RW_/I(#3>6T22#'>+7SOO#."D M1/1Q8<%5"TM&OCTP3PRO;,8\=$[@KRZMM?6OKJT9"-#P@FLOOB&G@U#>T7 * MA/>MGY+N/XA&^Z81K9GMDR[!F-MZ'L*J<-+DSJ1*2^! MZ:.N0<(WM42;#_!K+Q'(D4IQ:)#&V8XFWCCTX2;6)VG"D&/QQFXIRIX"H$%: M6D4E&2#M?AD(EE52[H+S$=+.KO\&4!OV0Y'C.-?"]U$:231'*=#UY5/T@WHR M,5VZ'5EZP<\Q,:$3& -&:)I!2.RU!Y!G$L![LC.$BZ=[!&IEU)P'0['4SE/ M#0QS?GYM_4'5IT[UA9WH 1-7+=F88G0U2?VT'8./<2B2PTH=BB((51UUS.)D M1.O71P,7DG/B&KB*UC7;:"03**!APR :%J6?W(# B#&C=<^DY'+V_+64XND_ M8$@Z_/.$AR^$F4!CS2F29OQ"M*,0>FA$!!%A-O4"UW"S?4>G F.L$9US<(@%*1@)0O]HBZB_4U MTPY2/Y 2E623IDUC'18.<2'^ZD!,BIY&QUQ2/T+QQN_SQ"J"B,&G,?XS<;"'8W*N,_%;DXG1F;3A M'#RIB<0@XP]W,@)4):AD!M2V0+'VP#-S$T"'A/";@O3,GHQP+_D'QO>,0S_A M>T;;(VS!FFE\^?1%/R##%UGI6YXY899'@KA',I]'G&B+JO0RSS_+.*VQ^94N M#*&WP8BK\V)0D.882:KH5UHJ#/9B&,['?<-@,THBY+8A,26S-]5J+3'PD[9J M *VA&T1UFSURTW, 7\ORFU'MD9EJQ=APPKGN2T4R)W* B\V8H98@@6"2K2"_ MH8JQEG@[@M9/!U, HAO_D(-]C)84F70.UPGJKV%;M1'@=#1,HE(H7,0K#(IB MD8;+IA_(3(JQ M$=3L0ZA#&9'6I^D.C^OHCOJ<*&U.]@I:I.4^0F(I@U#FHS\'N6FU"-E MG%#,7,N!J%S5F-A0*A[BB#A;&CWZ-BG$@U_R1&INE*C%.Q6:B3FC*L4[D\(9 M1S?R0PZ4L7LZ@0LE#]&:!H697V Y=>MJ;SH.(Y'8UTNQJ:BDR[[Q M?98FGVG-^%V=X*$:OHTPY'#U62Q:468S27F-M""3?6)%#Y_ I:9R M?'^N5XVRX85+ZC!2,JRDC!)6PU5CD+2>%A?>$6?]E=&&*M&-E?B+C=3=(MO? MA1?-9ICW:S^<[6KDF]"S'4EFBBG,*F%"I9;Q[C)\(ZA.3-OP?Y)K" *S9/$Y@ MP,(ZS4JT@F.P&QLBEJ([V,>T)&9IZ#*9Q5,00Q**9J4H,#P5U9RC>E\P"5)3 M02VQ56HKA,%$"&N(G!0M]R?5^NS1 MG42BEO-%DP4HSU0]Q@G9#85!-,$JVFU)^/9C(;%VU1?4V.\ ,O*B-.'0 M303R:?<. =A>>JVB(+8GLX.K4(5*\ ME>BJ6S.[Z@77=SJT$^C#>@UAP!?*27QR(%]F8GY65N#0H,TC^;DC+NO:%A.$ M!(0TN\2$QF,F"@$FJ.!)*EW%/O+1H&? M!9U(,1UT9A!325( F22P\OP]L32X;)M>MLH0>KT6-<.UA<1'>#S M F$KU$C,?,C*2O9WZXM,90P=Y<5INHE[JBY)KEZ&)QRV5?RP2_47YQGT_ZGR MPPG1C!X\(4ZZ4X;%$V)5X*P* 2S*MMDG$@IQBKNKE MLX"T:ZQS)S^Q;$'&(;20&RW"U1RLZB)N@:IOG4SS1&3( MV.U*$HW4$2/)T5)0O5S5%)20>2-X;C(4?!>4-O>X/:WK9']I1M"H1IZ4\6-ZDK^D:&UW7ILK>3< MM 38/AU?^PW1LT[T-+QV[9HO3)_9:S&.R7/^UH\7:&'-K9)TLJ;:!0"CAN\P M06S-3-+<$X,TSB7YO+.>U29:5^OYX[G7LS9TKT83U2^P-HRDW13V<2/^*24Q M7V!*B C0U'.7RKE2/W>[>QF;8P!L +EJ3@T9+Y)^4Y%W]CM@<;AUY2Q59J49?->[*[,54T0A=$=0;R#DY)K@^O7>R'*G*@7H#*M+3QP8TU'KM6+2; MBY$Z3.14XZJK68*VQ%5T2%"VWE%B7&@G!U!<&8TMHLPTWH^)4V+ "T5V#"5< MDNT&&.9.!)K-6"[;LF5"NL$0UEBNDBG5.P;KJ&1C47QYLMI")Y1_,@Y?F MKIV:7/"P2NX]:_/^@6,V_*PJXWXO:FF1R)'77[2119)]R9.5%H3PS1D[C9HA MD3S+ [?K#\W-WN!><.Y9&SPK:5V ]BV[7HX)1994$BC]?,F@II.3 \;$2F), MUT>I$TOE4MS()VT,9/(JL>E'2R-=&,;)H?M ,M9YE0K?&.?'!P=AWEM2\]I1 M;LB&XQ-$JRC9I-1DUVX!=O-\/+&LV1)I-3VUI[G70MMDPUK+=)9*8O8?Y0EY MBUU3<= M1H[E^]+&@,84.&S<.YSL:2*7A'T0\#5P9&OQH+DXDI18R]/+K!!I MZUWA>Z.,7]O?G(3%YBQD5!&:F8D0]JBTXB;I'D=S= M*$6)TYIOJ9"#DD,Y%*\CA-#IEE73>9YV8-;9W2[MU7R=S0E!1YZZ= JHM7LX M6_*,7,A*G'IN3J2[ EE+'>)HYSB!PT *])+K*4&!@&M\&:^J5),J;<2:$S.6 M%U9&82H1?XW0CTBQ:BB..O[F^.N..]YJDGTECHT14R4>W45CU8F0![#2FC[= MVF*MVF)W3(J M902DFO?8+#LR02Q:/-\LANZ>U(3\$6W!-!"3]^W>]G>PY_" MP<+=6PU-B;31!M?8)V:)1??)54]#20L2Y#+**Q!& M*IC#/D9X1,@0$";0?9 MUC$&.4NDOJ,PB=Z-_5\DQDK65QE=N@*Y<@FY'EFY7W%0?F."54C'0L7^26>!1S!G)79)Z\ZPS@FRP%G)9 M G5H +>1I)9S!N0:.:O2T;4O)W +)UO[D_''#\_B(8AX/9%/[5Y'3WTR(-O[T%+G!0@*-*D7M2 MRSAN5C_G0S#Q6):^]KVBEGF^+9^/PZ'DWGMZ6DX&BW,7S^B#I<1 M'W9VU>6X8#-O.!J/:P,-,/#4+E+[;GZ-UUWI#^R,:%X*9X/ZFA;AN&_7])%S MBYFZP '/P^%T!A\&@W T['O'.1W""0_@PW >CL<+Y[>;QL:Z]CH'_>"LY=:& ML,A^VY7"1)AYPFMTZ=ZWCW6NR6 X(THJ9B[4K6PU(KBXKC4W&CL*A>ITU#K M0Y!!74B3B0IWT980&N44R5L0)Y(_*[/?FIC?PK8OW40Q-E.TY^5P4F4%K\FK MM=5RBR%;QXR5R9:Z2MA&@"HE;,O2+B+V(V\E+'A3FM!IJVI<"&:T)>N*M8]\ M/KC$+K*S+@R&&%DFU7CRO!3.)GTGV-WVTK)Q!N/>I/\'DPHD!#O#Y#(N (ZK&?:'(Z^N+WV!B&^: MGV)# .4!A .ATS-2>](48O;'IDZJH-CP@EH+*-<9[?8O-EU>#ELVQ7$W9(>1 MD\7-;P;CITEM\"PE [&@:\Y(QEX;?W8I ;$:P+$L\L_J>&Y-\\-5V[-I,NT,^&2!&9JELI M.=B?*"1@GM,^#);KAI_LQ!>O.A-Z@\RE+V,N['%/_:6MB4_:1]Q;EJD1@MB, M@!D,%25,3&EP+FX*6$,QNN@L)+6$;:VL (G[%NV\W!;L;I^ZE6$' <@R>7;? M_8@H1:C47@(6W<-1P3KK7H[7L9O5S&&.T'/;VK;<-J3! !0<$O8JJV_).R>^NI'M8=?&3^MKTV+$A35AB7$#6+^(&M=H&(8!V+ M&VF5@H5!!XTUJV1W)KNF#NEL2]+&V]I LU%)P8Y5^6,C?C=LP]Z6SL_N4#HX M+,C#03K[K(BCE(Z:DN8:OI=2(!1T:0\/5#8_Z]5D4XI=[=#>".44(>1ETXN- MH UZC.[L E-X/]FE_TB1?,X74EG%T6.:M8QAWQ=].\,Q2;"L?SRA3XS"$4BA ML_G$*@>L8E1U!QAMT0^FBZ S@-%9@SBJ(TQ"N$G0!>"-(;S!JL)Q76 03A>C M8#CE.5@C8'GZ13"9AU.2EP=AO[^@;(B5M:,7@&K88!Q, MI_**J&7'KP 5KGXP',(5X%I8_]([6(">-<&SQY7 -@?A8,[:TJ(?3@ \?G:L MM(&/K*0)F%I!;FC!IE&_)NW%N+XTLL>TH^2:^3\;D548-T]%OA*A!*54_(,[ MR(2"&>QW;95T$-]DJ6C*W/O9J]#%9*IZ'B 7S0:T!I1O;3=?JXP0BJ!!,7,QWS8N#R?[.UG'@.",LT]V@V?U[MAK_#.0P' M%H9$,>ZR[W@?2',Z*%B&XP:Q8"JY$8: MK;5-+OU2ZDA!1?<$=JX^DO@#D9MX.^O+Q1^S K29K\RV3S2H=!XXU03X&G'>*C'LT'GK,XP36:NUX M4R#6^M<,^.LI7':\0$8[7=3M=A[#G?8GQ,&FPX59)4YAS&U5*=VYJGHMDX;K M;@<7LFE(>H[8D4Y-H_;-QIH2Y R=F>ALMW,UP.2^C"DH3WWQH4E]UZ78%'B- M;6(7!B([-0_BW"^?NW&$E9E>= 3G<-!3#CB8Y#4=[-H40'$*F;;K4OJX:E#6 M1*+>8XWV,<^Q6&\BSTE5![&-BY>^&(>SR:Q%\S_--L>M04'[H!+P]6!GL\-& M";K!II](^VZNY(["X'P^8J29]8.;Z-&$F97!:#8+)OV^ >AA."2$@VW-]%MO M^^MXA26UF-2\&(43D-V,8Y\?.!C03C5&1F#0D5-K\ M_0"T7ZO\-/L,[*?9*!RP@#X+^Z(,=J;3L ]JDNO:>&J^GZ)?5_LTWJ+FT)\. M0-X'W6L\)-4,3]]\W0_'(_S:,A)D&A^U$NP1>'BA@[QP1G\AX[\(YA/088?T MXRP@O/?8)Y*^!J;=%Q@ MPQ \3M!(-1;V^*)(N 6NSBH'G%S_F8)^BWS+ TY![A&V@>KK;R,X.TZ:.ZRL M]6"*_7+E"R=@3&NTKB*N[9%BF')H"#(%1F'A%XI_06<]#'RW1R,I4_V >D0S MAJ'U=U4D$C^RAB4EXIQP^O2Z3)P"TCF2OK1)^-02,G;2M7Q;M1<@%)*C#9U' M2TQF33E'%J5 SL+R"DF9.B.F.'&4U6I3V_1%K4E=YD[,:HPV/$WGBKU>FZ; M+LM)6@_%B."R8!,*% 4-AS)Q/!SO3^&XU/1RN4<'CZR!NA+?)013MC"L6^L,[HA; M)DC8AU. _2A_8W[.3Y@0<7(,6A439'!$20R;-VAD8^0*KO#'7A>D5RB@)W<[ M3+*DLLF]X,HF(;JDDF/<*^LQ%"K^NN/N75Q[.2D]L<,.*;V!/8Y_Q43XI;+X MH3"NP81*8L&',7ZPT1#PQ]#]8Z1_5*6Q-]39K?G;(T*;;(*Y:VA_Y9?^UN* M]9O*WRG6]M(B!NI*9X #>*FX +D'GE.<@AQ#\BWC^YTTOK;=\C3ITU;_U=^D M/1OYJ>\]O7XH?(RK*_KM-*L%!;@)!GZ'YVP+=VZH!R%E<.U HM2.3Q2VP''+ M&FK)507$^6E2)"2V>5N/Y">R8PKS5/)]W(+SL%\37B=/80WP!'F&/.ZV5":Y MH;9;M]0W(]&C+5O/X2+Q4^'9E;/GQ*)N?M?=EY[,,@&Y<,I&L,H;E?*[\.1@ M- C:"J>%K@/9Y!0_O0IF%R3WM2W@P(9%D'U&\XF*0>/IL*81FUI\((!-0$QJ M6813:<680OQ\% 97&W@3K?0@J)CLW5TB*8- Q?>8="?YD)("&:I>3B'07E74 MQ>(/)BN'@YEH2=M\*QWLN9UHRJJR,W&]9$P5NQBY;.P"C\Q1#9HNCU'06K-2 MZ'K@;]VX&$KJ(FKSR$@4$;S?">1A'1VWPX]-".Y59&R,M*(,7T$O(C^4[8"V M()J1Q!E.).4RX)CNT@2V;=/+XC"]CKI-V.ZS&/^]]1HLVL,QN7@'\6-+!X*# MFXFTC/%$MV25AK /_90S1I5NIV#'>:L.\RN-4Y@+G;!W* MIJ.1< E;^4PA6MKC3PSW[FOH5)&A2C_C-%&!$;W87,$A5'F!N@>&,V\Q*V>HK>]>X4'>I]A81P4F5G<&;\ M=8-P,.ECT>I4]!WV!0S/@OD0U,Z9QBZ:U]'N2];?Q71$(_VDN5GN%)4TPV>? MD$GTQ)7<:.0-JCO^0DW)()W@2\3JE1 [H41410]K5J3Y#M'U78YJXT54P*UF MD:GI$SDY0:8F+'9XIF^%SU9*R4\9-BW&F"4ZY2<,I<"WC:+ ]5%=@D.E)G4+ MD@UIJBDU;.D6"-:;')86!F]!A -=,U'KY-OH8/5HVW5KH?6L"DX9Q^/C@M;^ MP=(34B2D=2@6NQ]S4T<%MLQ-0#[P\G1NNJGYJD^LA*W67H M,/P%9A^)?(9L ID#[ MD#\'W$T=W]Z43<+5LFH$C*34+C?MZ J&B%BRD3A,H M8V\*#AF5R-I:0.G)H%\M38%EN[BNW3&!!XW48_55 FZ#RD&AN%3S/$K6U/= MH\'"9UNR0Y+I:AR< M.R%0&44UQ&%?QGBG?5K$;V0/3[8DKJUST*XI6$FRD4 MZ+34RB,5Z4W(YO&6XNM$/5]4<]%Q9[*?=?76GJ93)U8Y1FE$2ZN34&,#\_"] M-8XO/%[+;:%5XX"96.:0C:A ?5GDZP#3+5->LQ39>7UY;KJI5/*8@TXBA>^! M>)ZA\@(C>,]CRRER5Q@<0EQAIZI7EP5Q(]O;^@]XT^4>;6-4':5>8']$=XG% MJ,?TB6-ES3Z(1PM^2I6/4^5QRL$IMWG6I,:Y>1&EX M8+G%I$=D6](,GD389.<(E$ VJN:KA1#53)I!*0NC9'Q!KOK=SH?]BF#NRXE4 MVLT/:'1$6D[])&UX%;DBLBGP3P_7&B?0J.Y[?'@M4&+AH&*@DXN68W/0\)$J M>6KZ5&A0@L?$7VT.-1U5:;K*6:.A4"G'&DHM44PL >FA)D2Z%]PFV:H6_(ZO MU$HBM8U1KV[$]DS?+)S;L\*SM&>%='<^G :N>.0ⅅ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
YM;(O;DXWE_Y1OG!=1IO M,2WAU)=L2P1'KE=DS,&8[L5^R385%/_RN"X3XQ-+FM0UF4+(X U=MZ?=)]P8 MR*8F60Y:+NZ."9!C4J+8C'[+N?1;ZCYI1 +E&HE2V YIGD4I2*-5*\-AZ-5Y M"1UJT=B_(XF6;H5]AKE-]HMYX0@W5>2'#B%2G MSIPKV'MK+FD2>0+0W&W-"^DF%8RF95>C_.S&0I#I^MWLZ\A@"-O[)!Y_RLDF MNK$1KB@4R=[S<\)^OJ-.]+WE!W760\8B#-ER>XAF7")EHE[]258B0:M" 7H0 M^W&1_>;"PC#)82ZS4GS&6#N,BK(!PD&K*;'H>EWGZ!A&16Z"=@Z\4]0&@1^S M)*HQ%"XNR792:'-O:'+0:1Q7>2(Z5:$E5RUP4U2J4TU2NHMMKJ,&A])S$EVC M\H+06NLY:3*> A^XDC#2NZX/\[4+9TSK(6@H;R*'O9'\:Z!H4&)_ &))8V!C MX70 S@IID P/T7U M-(%'BFD*?ZMI"W_91(.'BHZ@5] X0 IW L/ MER"Y,,VZ K!33PQ&S!/KW6 M>"Q1TK?(J/"?B-R99EK#WTG";VNI:Z^M!KK=9OY)H,_ABL.)-U,UNM P 8_G M,"-/J)F,^SJM\#]&7:JL)YPAD=T*?*J9-G2G?#(7H\RY([0)&6-NPW!8>@LI M?GFS7)!_6[XVH1'I;YDS%J5\2"$ UH?>;XQ%]%U?X;-DDG(/4VHVIU>!U U_ M]3XT=@F1SR3/N;&"'IJD.2FX&#"Z$@704529-3F%>5)@*GY(^."-\Q89Y#!I9G0ZYW&2U%$=9T4&K#)M MFL>2XP0#TZ@W18X#R7,<7Y$C0QQ)D&E4UDT$@D<+?#Y,>V7#-S;(V>.DJ8ZC M-FB;HVC1Y$U]/D!C6:O#'VLCS8'IJD4QF,[X24/V\TG6UK20'HX[$8-XPI2R M#%(>1?'E!9TV;4HD O(594I,.!C4.5JX.X%B#M(SR?>/S@9KK;Q(0!INLA4SM)S3X_?1!J_-,IA+C:&?B;;A'2:VL MA8,G MY"UJ5XR:7?F4Q5C))Y=EQ$1:F IY$Y;!0S\_@<5T48'!4Y3'(6] /KC=R]DP MIK7D3)"\IEB*"X60H;$!*SA:"OA;%JG1*3'+JBJ&5>]#]@.HN6FI)XG[:'B! MA-J5QEE3X"F7->[3PIIF/L4%=S"JGP!EJ V]KXJJE?LJ+N'=ULEZ5C;30R&%RE9ZQL9-4X.=!:M#/1B4]H M1Y^([7*)U=#)/0>6[>@54XG$ MQZ\6\[LL;JO*6"Z0>DA$?L@J-*"5_/L6X,C07#'#X[;/7[$.=5T8ZY""S%8/ M[1A*E',-;G$D13/S9LOR+ &^-W; 0#3^BGH1$\V$I M!GA&\!-S.=R\)@4;Q,TV*?!;#A(<7@1&RE8-@C+'&:6B3G9"=_:SHDV>>*P& MB13+5N\98ZV84\JG$(@%K\EYT,\)[/]_)I9R1&]?.ZL-&C(3Q0E9A,3$)5,R MX-*G)E.?"N%M<)J0U#2R$5^BQW;Y$?$*M9EV@@O_9%Q"OY'=)13:<(NC1)"/ M6.YTY]CR9\:+)$,Q7_2@A(]A/ZTRK*! R):,'[&S#DT93I5_KSE,DB('1%UE M[9N$/;3\L%JO&5B%.><)^:_0&_!$?"[R4GVNLE1]SL@=@;06G.9)QG),17\Y M@FR2M>9YZF'(V'B;&QUH=0?JTAA'K:LF'&*5+XS:_G8XC?.^49J1IJG4NYSI[K@4*2)K#<&([P=LG@C=<*7_!2 MHRG%D=OJ&*Z@$HUFPL1&:'L[$6FHX?)V'+\EHD9^P&:]-AH7_?7OS:>WFZ^( MJ_8':19%Q4GM%26W5W'>DKY7D>M7I8HV<0T$ G]1[:XI"SW/XZ2MH_-/F\^S M/PADHT%''SR%6F-182A$TN32Y)_EC%A1P,;.0*"%!_),*)IVM030-;.LQ8C1 M)JL(L0;31$ ,3G(%H2KARD+'70;O?V?/^8EL^$0V?2(;/\'F\Z+U'#DJZ0+W MSH4TN,\YJ3^70)I1$\HU.E#"?1K$KHJ=3)B=@R8<(X.YFWVE_)/_V<\0WTWB M4LSL@@4"))OQ]C[*2M^4 [6Z,1!<^0F.)5U^E8C'5&%QQO%INE=QSP6KSGI. MJ^6SW; 5G45OY!H8!*?CJD2<3QVG;2%S3DB(^9_IA'2-1&5HX-!L5 M$'7AL,:QM8RCR3,"!NW0=?+KVV=PICA;X/Q^.XTR46/8,:TA.&"2^7_\97\; M_O'%\CW\V/A_?"JKM#NN#Z"\9+]?(4=%.NV<[*R7]D&^Z$T HG*K MV7(V[N6;Z((]!^"@!+!V*7"?#52@V/ [ MAX0ML^;<:?0:^T":K6(.3F^6]U/%QP-LXYD?VW8DV&3@\ND0?*2/F0&+7&$A M/6&Q"+_]2+Q*O.OU9KWM]6"($0TB8SF[9;/Y9"2[6F%V[FI0Z"%9#X9C(=TU MPOA(!9P9:R_]EJH14' MZ-A!*G.E. L RD7O"2,]^7U) 6"G<<3=Q08A?9?(FX]Y%CX=G(,CVSN*6H]H MV_$\'?,L?#JPE$>V=LS*']GTGT4HN49I9>[N67;XU^N]"BL7ET@0@CH'6$0S3Z_?Q]1Z>A M;6<+56K 4F%\?UV^OIR8"#^M0@NHF'% M,8 MCE^Z$6LS>#SW808=TI"H@_T?- BAJ5.2J" ML,?BN(,H@$=/H\+44[A^GLCZK4"'T0K#P-T2H\\A20N-S^%J)AC?D7![IQ86 M'(EJ'JRWX^=F&!W.77W5!T\0DA>>SID\A5;G\RKV!N3RA&',-9<0/1ASWR6F MWW\!L"UP_5/O<81\]5HV_YL.!T^,? M'K5N9=\M;_:W;.>:P"-DG7(4LI*OAYL9 H/K/X7&*\\U1XI% M_N7T-5M/HR3P(QXE2Y $Z+V87-C- MMZO[@Y:J/D#; 14_U:9/'[@OCCZTO> &V92:HD4KC 1%<+TF4O_9II&B]FW M![Q8Y;ZQJBET3(=HI[FK8#J-4Z8&AS"H%Z'EFG3;XYG HMS?,-<.RP? MMYYC$<$^KM;2#]E8^\G0@6BZD"U[S@>9@?06HP0H9.#7>X)81IBY4S> ;TP MSL%YU!S0*XB_A15"UT-,3F$LXPL<\2$O?C[#_&P)A$>12$S P9T;Q(9\P''A M!4+TF-!-##S'7]A#0@QV?#3*VVB^/PS)YG%L"M_!T!!"_,-&8@L.\K$8:V.' M;K+D)L"VAS#+O":F :RRQXDEZ0%=4H_%.0[).9(U_A]!(5!/.GR SA=,9V53 MM+0^#QX\LF#NTJ@?%VU7W2==FL+BUNZY.TU<+JU@)$C#>1%R:%S@&_LUS054 M!'[NPS\XOA1EG*1(/7&[S$Z'%A3<0_])1H=P>*\$NP'EE\M)?3?"KA$ ].KJ MPID!A!QQN)P/:&FX^P[.C,OF?5-]F(X5:-;Q9/S+?JV-_>Y)=00FU2C+%<9Q M]F)IG#D+ VR%>7T 7MF"WQK9P27'[05ZQSSSPD:2"ANWO:@*CYIFM 8?HB,/ M>M?W8?RN![<@^<"Q1'N8J.4GZ5X_GK8/8Z($:"^(A^$UO#E 'AX.? C;)#Q] M;$'J@6(\U()VJ;Q!@T?&>! *_X;S>:-"D!/^^T8!:#@L^3'0$^X*S-:=)!J/ ME4SC3SQ.CN@U9O ?'ON*H75GZ4KX,SQ #D[#C#KAVJ8,4 EGRVQ];+4W M"]=.L+M"-3A^^&,Q(^)('-<#YF\7+\$1%C*?UW1,BGK_&<112'YR1.#:)R,4 MT]2]6$U;]^)@HKO3!81D\/2!$!I\US/JG>?^ OOB!N ]*G^^WUHSK=WQ(LR# MY\VM;V[&Y=R[DJ9G01#DP3<1R33SSMNT\EP.YA ZSS?3QM=L[E^EW#LEQR " MN'/@H3\:Z_ <]X$#/'O -XUTS+A$YAUMZNM%[N]OXUX,(EVXLYI[%['PO9]@ M,;QDZ2'A\0Q,.#_"_&L\_L; D\=C,_C%A$!,SNEX<(,'G ;C@1/Z3PY!)(3> MXF(D].\,)>0/S+_&.7"VL -W<.3,AW *'F*("T$>N)*I']P@K%5)9 -'X'\X M4,&1\^0 #3S W]AK(O3[T-'C!R4(W15&)G /9C>W/=R_,0 %!Y\^A%%PL(%Q M, 6/W@]77J/NPS>%"5;@ZV]#KCSTYT2O+M^< MHYW1_XY8]&M)11"AF[ZP#R>6DY%B8;F$#2@.VO$1E(9 >;>,'KP6WV=F\#WI MV\ QH76'6H+0.]OEZN[]?MLM90=0V\9 F\U-<*[\Y@XTO)*SZ8=,UO6 F3B6 M"2?.T1EP?_V8'BWO#:!9,<_^<-]>%#L&12Y1T-@^L@O/N_EV\R4D%O@00A[A M4:^=81DQY4^9>1)1 M G;XE\WV$S3FRJ=CNSQJHJ^^89893_6_Y!NA3=$1CQGA2.P(EX[4V7JI('^L M57N0)USV11/.#VQ(3_:(*4(ID]9VO:=T-F 4TB;=1M6T03K(PGXS7< M*".OK2,\S >0L+>Q(^G!S\UT@\;"CF!L=FN**Z$? 0D8'0GC^-(1SB_G@/2# MF8Q\[;!+RX-AXK/ /E5P(Q*CXF)V.]_?!N<11,2_2QP+X!QH%8:C2E]0PF-\ M.!1](%;+<& ZDJ;YI/-C""^D?Y\%'X+!4_S1H9,QZ"&;>]YQ.(T*!-^$"QEH MOP<-,G"G=T7]ASFWX"A7(&1X!B%2:F5B,6,A*P)92E ; WU&.(\&^CH$%V)% M!CU(PSX,B^&L]J$M.H1CX9#$X,8;"[[A,PL_",AB>.Z)8AZG]GD 'JQ,#OG[ MV) @4VP,A03YTA4[1HQPEDZ=?3I42]PJ]I/X@OFD@38&P2@&956%Y^ :%OUA MU0S9X%FT0; #W_K1++]:W=[Z3EQ2Q[-Z,-^3:,-^TV"Z!=ZNW#;S;Z!@SNYF M**)UFSTPW=B?ZG=H:+[\>XM*S>R(86QEU%7*U?.UWV-FXT5L&]Q6 1AUGHDEPI77].@B:K ).F@M9@S"10BI.M'%5&32U I(W M-HFS8!Z&RX 3*G :BY;?IU+$* (VQ5MCO[_O,K_ M6/'EJS^7["Z50\%/J-%VJ!,0N3@%DD[5Y9>WQF]P<"M(R?6>GZ(()GNSW5GBT'$>M M1HH$3_8'R&G+KUS!Z2F7?@502P,$% @ =7]L3Z(0;P7-!0 T3( \ M !X;"]W;W)K8F]O:RYX;6S%FUU3VSH00/^*)D_M S>)/UL&F*&$]F8& D,H MKW<46R$:;"DCV5#ZZ[MR2)# [-R7;9Y(9,<^EJT]JY4Y>M+F8:'U _M55\H> M#U9-LSX<#FVQ$C6W_^BU4+!EJ4W-&_AJ[H=V;00O[4J(IJZ&T6B4#6LNU>#D M:'NL:S/TO^A&%(W4"AI=PYT43_9UN_O*..SP*&[YXG@P&C#>-OJ[K!IA)KP1 M/XQNUU+='P_& [:4QC9S=^YNSUHJ6>EIOK:J#'7F&9.92PP4S+L0.G@_PY._TYF=Z>3]C9U6QR M/IMO/LVO+J:3T]MS#S)"(*,]0OX7>9 Q AGO$S+V(!,$,MDG9.)!I@ADND_( MU(/,$,ALGY"9!YDCD/D^(7,/\@L"^846@TB&VSHUX%*H5[ :@X(Z_U2&FFC&Q:[YS:=@=KX#N4G#; M&N%^X--ACAD32^:2FP1_IFT01"),#1&Q&F9PW MM+?2;8?,5-_Y( MC3 O1,1>.-/UVHB54!9NVC]BE@@:-X7 M5MDPF\3$-@GSOMY>Q)02$RO%3P![X3"KQ,16P3)!@/4Q,:_$Q%[IR;)ZNQ*3 M2DPLE??I5B\B)I286"AAWO7R8'YRT)\=JU^1QHR2$!OE?1+6UY,))I:$6"QH M-L8.?$Q,+ FQ6-#J7Q#!$TPT";%H>JI_[(#-N#'/B2DH(U;0&\QP M)OG-3]@S3$$9L8+>8+KI!4S0*MGMR?SPGF$6RH@MA!9A#OPJ9899*".V$(H9 M9'$99J&,V$(XIA_>,_1ML7U6WH+PGF$6RH@MA"[#AC<=LU!&;*&^ F%_!2'# M+)016Z@?(9%3A8^98Q;*B2W44\KTHZ>/B5DH)[90+^:K,GU,S$(YL86P MJBO,/'Q,S$(YL87>+\I_V)N8A7)B"_44AWE>QXJ2U+V2M6RK MZ@S:KM2%YJZ].\;VOTE._@!02P,$% @ =7]L3ZUB_WAQ @ '"X !H M !X;"]?O]2$[6:_- M]=,9U=/C=.;J>;>I^N>=KU8_Z_Z0ATWEWL_NK>U?RS'GH;CKC[\;%QC_\M'E M_UF^W>]/V_R]W?ZZY&;XI.+O I7[/$CF@X0>I/-!2@\*\T&!'A3G@R(]R.:# MC!Z4YH,2/>A^/NB>'O0P'_1 #_)K(..:GX2PYFOM =>>[[4'8'N^V!Z0[?EF M>X"VYZOM =N>[[8'<'N^W![0[?EV>X"WY^LM0&_AZRU ;UG@71N];//U%J"W M\/46H+?P]1:@M_#U%J"W\/46H+?P]1:@M_#U%J"W\/56H+?R]5:@M_+U5J"W M+K!7@C9+^'HKT%OY>BO06_EZ*]!;^7HKT%OY>BO06_EZ*]!;^7H'H'?@ZQV MWH&O=P!Z![[> >@=%MCK1IO=?+T#T#OP]0Y [\#7.P"] U_O /0.?+T#T#OP M]8Y [\C7.P*](U_O"/2.?+TCT#OR]8Y [[C MTKTL9*O=P1Z1[[>$>@=^7I' MH'?DZQV!WI&OMP&]C:^W ;V-K[AM?[P3T3GR]$] [\?5.0._$USL!O1-?[P3T3GR]$] [ M\?5.0.^TP%E!=%B0KW>:Z%V.=9]W/X;^U!S*K4O^&?YES03N,GR<\^TSKE._ M/#LY47H85\GN>KTYA->I?R+7!E&ULS=K?;ILP% ;P5XFXG8+C_]O4 M]&;M[59I>P$/3@(*8,MVN_3M9V@[:54F=6HB?37JQV.@M#J. MPY2V59=S^,Q8:CH:7:I]H*E4=CZ.+I?3N&?!-0>W)R8V&\,:/V6:\CK//:KK MJQO:N?LAK[X\79];;RL7PM W+O=^8@]3^ZKI^KEA'6E8UJ2N#^E#65"M;H^E M2RK7ME6IIHJ]8<+K&^?S^OER") <$B2' LFA07(8D!P6),='D!R?0'+P#4H0%%$Y"JD< MQ52.@BI'496CL,I17.4HL'(4606*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL M D56B2*K1)%5HL@J4625*+)*%%DEBJP215:)(JM$D56AR*I09%4HLBH4616* MK I%5H4BJT*15:'(JE!DU2BR:A19-8JL&D56C2*K1I%5H\BJ4635*+)J%%D- MBJP&15:#(JM!D=6@R&I09#4HLAH460V*K 9%5HLBJT61U:+(:E%DM2BR6A19 M+8JL]H*R+L=Z=/WTKR0_O3^\S&?+?YZO?P-02P$"% ,4 " !U?VQ/'R// M \ 3 @ "P @ $ 7W)E;',O+G)E;'-02P$"% ,4 M " !U?VQ/)^B'#H( "Q $ @ 'I 9&]C4')O M<',O87!P+GAM;%!+ 0(4 Q0 ( '5_;$]T%U&Z[P "L" 1 M " 9D! !D;V-0&UL4$L! A0#% @ =7]L3S, OPYZ @ 0 D !@ ( ! M^ @ 'AL+W=OE'\ 0 ,48 8 " :@+ !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ M=7]L3QJM_CP& @ B 4 !@ ( !K!, 'AL+W=O@5 !X;"]W;W)K&PO=V]R M:W-H965T&UL4$L! A0#% @ =7]L3P.G%%QD" &PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3^8GQ\FU 0 T@, !D ( ! M*RT 'AL+W=OU[0! #2 P &0 @ $7+P >&PO=V]R:W-H965T&UL4$L! A0#% M @ =7]L3PLX!?ZU 0 T@, !D ( ![3( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3X^)ZT6T M 0 T@, !D ( !L3@ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3QRGZZVT 0 T@, !D M ( !&PO=V]R M:W-H965T&UL M4$L! A0#% @ =7]L3S"BM1*T 0 T@, !D ( !,T0 M 'AL+W=O1@ >&PO=V]R:W-H965T&UL4$L! A0#% @ M=7]L3V0,,&NT 0 T@, !D ( !]4D 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3X/\^_7C 0 M 04 !D ( !MT\ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3^/Q6FBV 0 T@, !D M ( !NU4 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ =7]L3QH1IF*W 0 T@, !D ( !IUL 'AL M+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L M3SI_I*#? 0 04 !D ( !?&$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3]Y"_#&W 0 T@, M !D ( !;F< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3]*@:,G1 @ .0P !D M ( !-VT 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ =7]L3X;CC]4N @ 6@8 !D ( !>78 'AL+W=O M> >&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3P8# M#YX6 @ & 8 !D ( !@X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3PBNJ M. @ YP< !D M ( !EX@ 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ =7]L3PQSK68? @ C 8 !D ( ! M^9 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ =7]L3^B8OHI,! FQ0 !D ( !,)@ 'AL+W=O&UL4$L! A0#% @ =7]L3^IG2CT. M @ D 4 !D ( !-:( 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3_3/T]A0 @ EP< !D M ( !VJL 'AL+W=O&PO=V]R M:W-H965TT*:; ( # ( M 9 " <"P !X;"]W;W)K&UL M4$L! A0#% @ =7]L3Z5IKY0G @ A 8 !D ( !8[, M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M=7]L3QU&=(Z+ P !1 !D ( !6+T 'AL+W=O&UL4$L! A0#% @ =7]L3WQ7*@)^ P MP \ !D ( !E\8 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ =7]L3^ @;8&J 0 FP, !D M ( !&- 'AL+W=O&PO=V]R:W-H M965T-P( -<) - " 7%G 0!X;"]S='EL M97,N>&UL4$L! A0#% @ =7]L3Z(0;P7-!0 T3( \ M ( !TVD! 'AL+W=O"4&P( /LL 3 " M 79R 0!;0V]N=&5N=%]4>7!E&UL4$L%!@ !6 %8 C!< ,)T 0 ! $! end XML 19 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2019

Nov. 08, 2019

Document And Entity Information [Abstract]

Entity Registrant Name AVADEL PHARMACEUTICALS PLC

Entity Central Index Key 0001012477

Current Fiscal Year End Date --12-31

Entity Filer Category Accelerated Filer

Document Type 10-Q

Document Period End Date Sep. 30, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q3

Amendment Flag false

Entity Current Reporting Status Yes

Entity Emerging Growth Company false

Entity Smaller Reporting Company false

Entity Shell Company false

Entity Common Stock, Shares Outstanding 37,450,300

X

- References
No definition available.
+ Details

Name: avdl_DocumentAndEntityInformationAbstract

Namespace Prefix: avdl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

XML 20 R32.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Intangible Assets (Tables)
9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets
The Company’s amortizable and unamortizable intangible assets at September 30, 2019 and December 31, 2018 are as follows:

September 30, 2019

December 31, 2018
Goodwill and Intangible Assets:

Gross
Value

Accumulated
Amortization

Net Carrying
Amount

Gross
Value

Accumulated
Amortization

Impairment

Net Carrying
Amount

Amortizable intangible assets:

Acquired developed technology - Noctiva

$
—

$
—

$
—

$
73,111

$
(7,024
)

$
(66,087
)

$
—

Acquired developed technology - Vazculep

12,061

(11,042
)

1,019

12,061

(10,432
)

—

1,629

Total amortizable intangible assets

$
12,061

$
(11,042
)

$
1,019

$
85,172

$
(17,456
)

$
(66,087
)

$
1,629

Unamortizable intangible assets:

Goodwill

$
18,491

$
—

$
18,491

$
18,491

$
—

$
—

$
18,491

Total unamortizable intangible assets

$
18,491

$
—

$
18,491

$
18,491

$
—

$
—

$
18,491

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
Estimated amortization of intangible assets for the next five years is as follows:
Estimated Annual Amortization Expense:

Amount

2019

$
815

2020

814

2021

—

2022

—

2023

—

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275
+ Details

Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
Summary of Significant Accounting Policies
Nature of Operations.  Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company. Our primary focus is on the development and potential U.S. Food and Drug Administration (“FDA”) approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted a new drug application (“NDA”) in March 2019 on a fourth sterile injectable drug which we refer to as AV001, for use in the hospital setting. AV001, if approved, could contribute revenues to Avadel starting in 2020. In May 2019, the FDA accepted the NDA for AV001, with a Prescription Drug User Fee Act (PDUFA) target action date of December 15, 2019.

Our current marketed products include:
•
Akovaz® (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

•
Bloxiverz® (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

•
Vazculep® (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Each of our Akovaz, Bloxiverz and Vazculep products is used primarily in the hospital setting and was developed under our UMD program.

The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the U.S. Securities and Exchange Commission (“SEC”). These filings are also available to the public at www.sec.gov.

The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “The Reincorporation Merger” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in Note 3: Subsidiary Bankruptcy and Deconsolidation), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French société par actions simplifiée, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities.

Basis of Presentation. The unaudited condensed consolidated balance sheet as of September 30, 2019, which is derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.
The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.
On February 6, 2019, the Company’s indirect wholly-owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”), filed a voluntary petition for reorganization under Chapter 11 of the United States (“U.S.”) Code (the “Bankruptcy Code”). in the U.S. District Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case No. 19-10248. Specialty Pharma is operating and managing its business as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma’s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See Note 3: Subsidiary Bankruptcy and Deconsolidation. Our results of operations for the period January 1, 2019 through February 6, 2019 include the results of Specialty Pharma prior to its February 6, 2019 voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code.
Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC Therapeutics and FSC Laboratories, Inc., (collectively “FSC”), prior to its February 16, 2018 disposition date. See Note 14: Divestiture of the Pediatric Assets, for additional information. All intercompany accounts and transactions have been eliminated.
Revenue. Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (“R&D”) achievements.
Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer’s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Sales and Services

The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis.

License Revenue

The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.

For a complete discussion of the accounting for net product revenue and license revenues, see Note 4: Revenue Recognition.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.19.3

Subsidiary Bankruptcy and Deconsolidation
9 Months Ended

Sep. 30, 2019

Reorganizations [Abstract]

Subsidiary Bankruptcy and Deconsolidation
Subsidiary Bankruptcy and Deconsolidation

Bankruptcy Filing and Deconsolidation

As a result of Specialty Pharma’s bankruptcy filing on February 6, 2019, Avadel has ceded authority for managing the business to the Bankruptcy Court, and Avadel management cannot carry on Specialty Pharma’s activities in the ordinary course of business without Bankruptcy Court approval. Avadel manages the day-to-day operations of Specialty Pharma, but does not have discretion to make significant capital or operating budgetary changes or decisions and purchase or sell significant assets, as Specialty Pharma’s material decisions are subject to review by the Bankruptcy Court. For these reasons, we have concluded that Avadel has lost control of Specialty Pharma, and no longer has significant influence over Specialty Pharma during the pendency of the bankruptcy. Therefore, we deconsolidated Specialty Pharma effective with the filing of the Chapter 11 bankruptcy in February 2019.

In order to deconsolidate Specialty Pharma, the carrying values of the assets and certain liabilities of Specialty Pharma were removed from our unaudited condensed consolidated balance sheet as of February 5, 2019, and we recorded our investment in Specialty Pharma at its estimated fair value of $0. As the estimated fair value of our investment in Specialty Pharma was lower than its net book value immediately prior to the deconsolidation, we recorded a non-cash charge of approximately $2,840 for the nine months ended September 30, 2019 associated with the deconsolidation of Specialty Pharma. Subsequent to the deconsolidation of Specialty Pharma, we are accounting for our investment in Specialty Pharma using the cost method of accounting because Avadel does not exercise significant influence over the operations of Specialty Pharma due to the Chapter 11 filing.

On April 26, 2019, Specialty Pharma sold its intangible assets and remaining inventory to an unaffiliated third party in exchange for aggregate cash proceeds of approximately $250, pursuant to an order approving such sale which was issued by the Bankruptcy Court on April 15, 2019. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business.

On July 2, 2019, Specialty Pharma was made aware of a $50,695 claim made by the Internal Revenue Service (IRS) as part of the bankruptcy claims process against Specialty Pharma. On October 2, 2019 the IRS amended the original claim filed in July, reducing the claim to $9,302. Specialty Pharma files its U.S. federal tax return as a member of the Company’s consolidated U.S. tax group. As such, the IRS claim was filed against Specialty Pharma in the bankruptcy proceedings due to IRS tax law requirements for joint and several liability of all members in a consolidated U.S. tax group. Both Specialty Pharma and the Company disagree with the merits of the amended IRS claim and intend to defend their positions vigorously.

DIP Financing – Related Party Relationship

In connection with the bankruptcy filing, Specialty Pharma entered into a Debtor in Possession Credit and Security Agreement with Avadel US Holdings (“DIP Credit Agreement”) dated as of February 8, 2019, in an aggregate amount of up to $2,700, of which the funds are to be used by Specialty Pharma solely to fund operations through February 6, 2020. As of September 30, 2019, the Company had funded $407 under the DIP Credit Agreement. As the Company has assessed that it is unlikely that Specialty Pharma will pay back the loan to Avadel, the $407 has been recorded as part of the loss on deconsolidation of subsidiary within the unaudited condensed consolidated statements of loss. At September 30, 2019 the fair value of the remaining commitment under the DIP Credit Agreement is not material.

X

- Definition
The entire disclosure for the description and amounts of reorganization under Chapter 11 of the US Bankruptcy Code.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-URI http://asc.fasb.org/topic&trid=2209115
+ Details

Name: us-gaap_ReorganizationUnderChapter11OfUSBankruptcyCodeDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReorganizationsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R15.htm IDEA: XBRL DOCUMENT v3.19.3

Inventories
9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Inventories
Inventories
The principal categories of inventories, net reserves of $1,212 and $4,757 at September 30, 2019 and December 31, 2018, respectively, are comprised of the following:
Inventory:

September 30, 2019

December 31, 2018

Finished goods

$
1,883

$
4,270

Raw materials

377

500

Total

$
2,260

$
4,770

Total net reserves decreased by $3,545 during the nine months ended September 30, 2019 largely driven by the deconsolidation of Specialty Pharma.

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-URI http://asc.fasb.org/topic&trid=2126998
+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R19.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Debt
9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Long-Term Debt
Long-Term Debt
Long-term debt is summarized as follows:

September 30, 2019

December 31, 2018
Principal amount of 4.50% exchangeable senior notes due 2023

$
143,750

$
143,750

Less: debt discount and issuance costs, net

(23,618
)

(28,059
)
Net carrying amount of liability component

120,132

115,691

Other debt

35

149

     Subtotal

120,167

115,840

Less: current maturities

(35
)

(106
)
     Long-term debt

$
120,132

$
115,734

Equity component:

Equity component of exchangeable notes, net of issuance costs

$
(26,699
)

$
(26,699
)

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R23.htm IDEA: XBRL DOCUMENT v3.19.3

Restructuring Costs
9 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

Restructuring Costs
Restructuring Costs
2019 French Restructuring
During the second quarter of 2019, the Company initiated a plan to substantially reduce all of its workforce at its Vénissieux, France site (“2019 French Restructuring”). This reduction is an effort to align the Group’s cost structure with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of calendar year 2019, and to result in employee severance, benefits and other costs of up to approximately $3,500, which are likely to be recognized through December 31, 2019. Restructuring charges associated with this plan of $1,259 and $3,198 were recognized during the three and nine months ended September 30, 2019. Included in the 2019 French Restructuring charges of $3,198 were charges for employee severance, benefits and other costs of $2,774, a charge of $598 related to fixed asset impairment, a charge of $826 related to the early termination penalty related to the office lease termination (see Note 9: Leases) as well as a benefit of $1,000 related to the reversal of the French retirement indemnity obligation.
The following table sets forth activities for the Company’s cost reduction plan obligations for the three and nine months ended September 30, 2019:
2019 French Restructuring Obligation:

2019

Balance of restructuring accrual at January 1,

$
—

Charges for employee severance, benefits and other costs

2,774

Payments

(1,837
)
Foreign currency impact

(42
)
Balance of restructuring accrual at September 30,

$
895

The 2019 French Restructuring liabilities of $884 and $11 are included in the unaudited condensed consolidated balance sheet in accrued expenses and accounts payable at September 30, 2019, respectively.

2019 Corporate Restructuring

During the first quarter of 2019, the Company announced a plan to reduce its Corporate workforce by more than 50% (“2019 Corporate Restructuring”). The reduction in workforce is primarily a result of the exit of Noctiva during the first quarter of 2019 (see Note 3: Subsidiary Bankruptcy and Deconsolidation), as well as an effort to better align the Company’s remaining cost structure at our U.S. and Ireland locations with our ongoing and future planned projects. The reduction in workforce is projected to be substantially complete by the end of calendar year 2019, and to result in employee severance, benefits and other costs of up to approximately $3,000, which are likely to be recognized through December 31, 2019. The restructuring charges associated with this plan of $607 and $1,570 were recognized during the three and nine months ended September 30, 2019, respectively. Included in the 2019 Corporate Restructuring expense of $607 for the three months ended September 30, 2019 were charges for employee severance, benefit and other costs. Included in the 2019 Corporate Restructuring charges of $1,570 for the nine months ended September 30, 2019, were charges for employee severance, benefit and other costs of $2,966, as well as a benefit of $1,396 related to share based compensation forfeitures related to the employees affected by the global reduction in workforce.

The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2019:
2019 Corporate Restructuring Obligation:

2019

Balance of restructuring accrual at January 1,

$
—

Charges for employee severance, benefits and other costs

2,966

Payments

(2,113
)
Balance of restructuring accrual at September 30,

$
853

2019 Corporate Restructuring liabilities of $853 are included in the unaudited condensed consolidated balance sheet in accrued expenses at September 30, 2019.
2017 French Restructuring
During the first quarter of 2017, the Company announced a plan to reduce its workforce at the Venissieux, France site by approximately 50% (“2017 French Restructuring”). This reduction was an effort to align the Company’s cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council for our French operations and received approval from the French Labor Commission (DIRECCTE) to implement the plan. The reduction was substantially complete at September 30, 2019. The 2017 French restructuring costs for the three months ended September 30, 2019 and 2018 were immaterial. The 2017 French Restructuring income of $168 and restructuring charges of $268 were recognized during the nine months ended September 30, 2019 and 2018, respectively. The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2019 and 2018:
2017 French Restructuring Obligation:

2019

2018

Balance of restructuring accrual at January 1,

$
879

$
1,000

Charges for employee severance, benefits and other

(168
)

268

Payments

(663
)

(668
)
Foreign currency impact

(10
)

(19
)
Balance of restructuring accrual at September 30,

$
38

$
581

The 2017 French Restructuring accrual is included in the unaudited condensed consolidated balance sheet in other non-current liabilities at September 30, 2019 and 2018.

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-URI http://asc.fasb.org/topic&trid=2175745
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R27.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies
9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
Commitments and Contingencies
Litigation
The Company is subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At September 30, 2019 and December 31, 2018, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s unaudited condensed consolidated financial position, results of operations, cash flows or liquidity.

Litigation Related to Noctiva

Note 3: Subsidiary Bankruptcy and Deconsolidation briefly describes the Chapter 11 bankruptcy case which our subsidiary Specialty Pharma commenced on February 6, 2019, and which on April 26, 2019 resulted in the bankruptcy court-approved sale of all of Specialty Pharma’s intangible assets and inventory to an unaffiliated third party. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business. During the pendency of the bankruptcy case, all pending litigation against Specialty Pharma is automatically stayed and any new litigation against Specialty Pharma is precluded unless the bankruptcy court orders otherwise. Below are descriptions of a litigation to which Specialty Pharma is a party and a contract dispute involving Specialty Pharma, both of which matters are subject to the automatic stay during the bankruptcy case.

Ferring Litigation. Some of the patents covering the Noctiva^TM product (the “Noctiva Patents”) are the subject of litigation initiated by Ferring Pharmaceuticals Inc. and two of its foreign affiliates, who manufacture a competing product known as Nocdurna. Nocdurna was approved by the FDA in June 2018 and commercially launched in the U.S. in November 2018. In this litigation, Ferring seeks to invalidate and disputes the inventorship of the Noctiva Patents, seeks damages for various alleged breaches of contractual and common law duties, and seeks damages for alleged infringement by Noctiva^TM of Ferring’s “Nocdurna” trademark. Specialty Pharma and certain other parties including Serenity Pharmaceuticals, LLC (“Serenity”) (the licensor of the Noctiva Patents) have defended this litigation, and have made counterclaims against Ferring, including for infringement of the Noctiva Patents and a declaratory judgment of noninfringement with respect to Ferring’s “Nocdurna” trademark. The court dismissed Ferring’s inventorship claim and its claims for alleged breaches of contractual and common law duties, although these dismissals may be appealed by Ferring. On February 15, 2019, Specialty Pharma and its co-defendants moved to stay the litigation pending completion of the bankruptcy proceeding of Specialty Pharma. On May 15, 2019, that motion was denied due to an impending settlement of the litigation with respect to just Ferring and Specialty Pharma.

Contract Dispute. On January 21, 2019, Serenity gave notice to Specialty Pharma of an alleged breach of the parties’ Noctiva license agreement. Serenity alleges that Specialty Pharma breached its contractual obligation to devote commercially reasonable efforts to the commercialization of Noctiva and seeks unspecified damages. On January 27, 2019, Specialty Pharma notified Serenity of a claim for $1.7 million in damages as a result of Serenity’s breach of its contractual obligation to pay the costs of the Ferring Litigation. Serenity’s notice to Specialty Pharma invoked the dispute resolution provisions of the Noctiva license agreement, which culminate in arbitration, but neither party has yet initiated an arbitration proceeding or filed suit.

Material Commitments
Due to the Chapter 11 bankruptcy case of Specialty Pharma, the Company’s various commitments to purchase finished product from suppliers has changed from what was included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K. As of September 30, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:

Purchase Commitments:

Balance

2019

$
7,194

2020

1,320

2021

1,320

2022

1,320

2023

220

Thereafter

—

Total

$
11,374

Other than commitments disclosed in Note 15: Contingent Liabilities and Commitments to the Company’s audited consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt obligations which are disclosed in Note 10: Long-Term Debt, respectively, to the Company’s consolidated financial statements included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K and long-term contingent consideration payable as disclosed in Note 10: Long-Term Related Party Payable, to the Company’s unaudited condensed consolidated financial statements included in Part I, Item 1 of this report.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R61.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Income Tax Disclosure [Abstract]

Income tax provision (benefit) $ 2,234 $ (691) $ 3,641 $ (3,360)

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 28 R65.htm IDEA: XBRL DOCUMENT v3.19.3

Other Assets and Liabilities - Other Non-Current Assets (Details) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Other Non-Current Assets:

Deferred tax assets, net $ 21,636 $ 23,029

Long-term deposits 1,477 1,477

Guarantee from Armistice 5,271 5,697

Right of use assets at contract manufacturing organizations 6,494 5,894

Other 49 49

Total $ 34,927 $ 36,146

X

- Definition
Guarantee, Noncurrent
+ References
No definition available.
+ Details

Name: avdl_GuaranteeNoncurrent

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Operating Lease, Right-Of-Use Asset, Contract Manufacturing, Noncurrent
+ References
No definition available.
+ Details

Name: avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amount of other noncurrent receivables.
+ References
No definition available.
+ Details

Name: avdl_OtherNoncurrentReceivables

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b),(c)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319
+ Details

Name: us-gaap_DeferredTaxAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.12)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of noncurrent assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 29 R69.htm IDEA: XBRL DOCUMENT v3.19.3

Restructuring Costs - Narrative (Details) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2019

Dec. 31, 2018

Dec. 31, 2017

Sep. 30, 2017

Restructuring Cost and Reserve [Line Items]

Restructuring costs $ 1,866,000 $ 65,000 $ 4,600,000 $ 268,000

Fixed asset impairment $ 66,087,000

2019 French Restructuring Obligation

Restructuring Cost and Reserve [Line Items]

Restructuring costs 1,259 3,198,000

Fixed asset impairment 598,000

Operating lease, impairment loss 826,000

Restructuring reserve 895,000 895,000 0

2019 French Restructuring Obligation | Scenario, Forecast

Restructuring Cost and Reserve [Line Items]

Severance costs $ 3,500,000

2019 French Restructuring Obligation | Accrued Liabilities

Restructuring Cost and Reserve [Line Items]

Restructuring reserve 884,000 884,000 11,000

2019 Corporate Restructuring Obligations

Restructuring Cost and Reserve [Line Items]

Restructuring costs 607,000 1,570,000

Restructuring reserve 853,000 853,000 0

Share-based compensation forfeitures related to the employees affected by the global reduction in workforce 1,396,000

2019 Corporate Restructuring Obligations | Scenario, Forecast

Restructuring Cost and Reserve [Line Items]

Severance costs $ 3,000,000

Lyon France Workforce Reduction

Restructuring Cost and Reserve [Line Items]

Restructuring costs 168,000 268,000

Charges for employee severance, benefits and other (168,000) 268,000

Restructuring reserve $ 38,000 $ 581,000 38,000 $ 581,000 $ 879,000 $ 1,000,000

Retirement Indemnity Obligation | 2019 French Restructuring Obligation

Restructuring Cost and Reserve [Line Items]

Restructuring costs 1,000,000

Employee Severance | 2019 French Restructuring Obligation

Restructuring Cost and Reserve [Line Items]

Charges for employee severance, benefits and other $ 2,774,000

Employee Severance | Corporate Workforce Reduction

Restructuring Cost and Reserve [Line Items]

Expected number of positions eliminated (as a percent) 50.00% 50.00%

Employee Severance | 2019 Corporate Restructuring Obligations

Restructuring Cost and Reserve [Line Items]

Restructuring costs $ 2,966,000

Employee Severance | Lyon France Workforce Reduction

Restructuring Cost and Reserve [Line Items]

Expected number of positions eliminated (as a percent) 50.00%

X

- Definition
Restructuring And Related Costs, Expected Number Of Positions Eliminated, Percent
+ References
No definition available.
+ Details

Name: avdl_RestructuringAndRelatedCostsExpectedNumberOfPositionsEliminatedPercent

Namespace Prefix: avdl_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Restructuring Charges Before Gain (Loss) Due to Curtailment
+ References
No definition available.
+ Details

Name: avdl_RestructuringChargesBeforeGainLossDuetoCurtailment

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense for employee benefit and equity-based compensation.
+ References
No definition available.
+ Details

Name: us-gaap_EmployeeBenefitsAndShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of loss from impairment of right-of-use asset from operating lease.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 25
-Paragraph 6
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=77888369&loc=SL77918431-209957
+ Details

Name: us-gaap_OperatingLeaseImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_RestructuringCostAndReserveLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringReserve

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_SeveranceCosts1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_RestructuringPlanAxis=avdl_TwoThousandNineteenCorporateFrenchRestructuringObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringPlanAxis=avdl_TwoThousandNineteenCorporateRestructuringObligationsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringPlanAxis=avdl_LyonFranceWorkforceReductionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=avdl_RetirementIndemnityObligationMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RestructuringPlanAxis=avdl_CorporateWorkforceReductionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R46.htm IDEA: XBRL DOCUMENT v3.19.3

Marketable Securities - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Investments, Debt and Equity Securities [Abstract]

Marketable securities, realized gain $ 71 $ 143 $ 339 $ 378

Marketable securities, realized loss $ 64 $ 22 $ 211 $ 350

X

- Definition
Marketable Securities, Realized Gain
+ References
No definition available.
+ Details

Name: avdl_MarketableSecuritiesRealizedGain

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Marketable Securities, Realized Loss
+ References
No definition available.
+ Details

Name: avdl_MarketableSecuritiesRealizedLoss

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R42.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies - (Tables)
9 Months Ended

Sep. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Contractual Obligation, Fiscal Year Maturity Schedule
Due to the Chapter 11 bankruptcy case of Specialty Pharma, the Company’s various commitments to purchase finished product from suppliers has changed from what was included in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K. As of September 30, 2019, commitments for these arrangements, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:

Purchase Commitments:

Balance

2019

$
7,194

2020

1,320

2021

1,320

2022

1,320

2023

220

Thereafter

—

Total

$
11,374

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the aggregate amount of payments due on known contractual obligations for the five years following the date of the latest balance sheet and the combined aggregate amount of maturities of known contractual obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher SEC
-Name Regulation S-K (SK)
-Number 229
-Section 303
-Paragraph a
-Subparagraph 5
+ Details

Name: us-gaap_ContractualObligationFiscalYearMaturityScheduleTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 32 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 33 R22.htm IDEA: XBRL DOCUMENT v3.19.3

Divestiture of the Pediatric Assets
9 Months Ended

Sep. 30, 2019

Discontinued Operations and Disposal Groups [Abstract]

Divestiture of the Pediatric Assets
Divestiture of the Pediatric Assets

On February 12, 2018, the Company, together with its subsidiaries Avadel Pharmaceuticals (USA), Inc., Avadel Pediatrics, Inc., FSC Therapeutics, LLC (“FSC Therapeutics”), and Avadel US Holdings, Inc. (“Holdings”), as the “Sellers,” entered into an asset purchase agreement (the “Purchase Agreement”) with Cerecor, Inc. (“Cerecor”). The transaction closed on February 16, 2018 wherein Cerecor purchased from the Sellers four pediatric commercial stage assets – Karbinal™ ER, Cefaclor, Flexichamber™ and AcipHex® Sprinkle™, together with certain associated business assets – which were held by FSC. The Company acquired FSC in February 2016 from Deerfield and certain of its affiliates. Pursuant to the Purchase Agreement, Cerecor assumed the Company’s remaining payment obligations to Deerfield under the Membership Interest Purchase Agreement, dated as of February 5, 2016, between Holdings, Flamel Technologies SA (the predecessor of the Company) and Deerfield and certain of its affiliates, which payment obligations consist of the following (collectively, the “Assumed Obligations”): (i) a quarterly payment of $263 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625; (ii) a payment in January 2021 of $15,263; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 5, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300. Cerecor also assumed certain contracts and other obligations related to the acquired assets, and in that connection Holdings agreed to pay Cerecor certain make-whole payments associated with obligations Cerecor is assuming related to a certain supply contract related to Karbinal™ ER.

In conjunction with the divestiture, the Company also entered into the following arrangements:

License and Development Agreement

Also, in connection with the closing under the Purchase Agreement, Flamel Ireland Limited, an Irish limited company operating under the trade name of Avadel Ireland (“Avadel Ireland”) and a wholly-owned subsidiary of the Company, and Cerecor entered into a license and development agreement (the “License and Development Agreement”) pursuant to which, among other things:

•
Avadel Ireland will provide Cerecor with four product formulations utilizing Avadel Ireland’s LiquiTime™ technology, and will complete pilot bioequivalence studies for such product formulations within 18 months;

•
Cerecor will reimburse Avadel Ireland for development costs of the four LiquiTime™ products in excess of $1,000 in the aggregate;

•
Upon transfer of the four product formulations, Cerecor will assume all remaining development costs and responsibilities for the product development, clinical studies, NDA applications and associated filing fees; and

•
Upon regulatory approval and commercial launch of any LiquiTime™ products, Cerecor will pay Avadel Ireland quarterly royalties based on a percentage of net sales of any such products in the mid-single digit range.

Effective October 25, 2019, Cerecor and Avadel Ireland agreed to terminate the License and Development Agreement.

Deerfield Guarantee

In connection with the closing under the Purchase Agreement, the Company and Holdings provided their guarantee (the “Deerfield Guarantee”) in favor of Deerfield. Under the Deerfield Guarantee, the Company and Holdings guaranteed to Deerfield the payment by Cerecor of the Assumed Obligations under the Membership Interest Purchase Agreement between the Company and Deerfield dated February 5, 2016. The Assumed Obligations include (i) a quarterly payment of $263 beginning in July 2018 and ending in October 2020, amounting to an aggregate payment obligation of $2,625; (ii) a payment in January 2021 of $15,263; and (iii) a quarterly royalty payment of 15% on net sales of the FSC products through February 6, 2026 (“FSC Product Royalties”), in an aggregate amount of up to approximately $10,300. In addition, under the Deerfield Guarantee, the Company and Holdings guaranteed that Deerfield would receive certain minimum annual FSC Product Royalties through February 6, 2026 (the “Minimum Royalties”). Given the Company’s explicit guarantee to Deerfield, the Company recorded the guarantee in accordance with ASC 460. A valuation was performed, which was based largely on an analysis of the potential timing of each possible cash outflow described above and the likelihood of Cerecor’s default on such payments assuming an S&P credit rating of CCC+. The result of this valuation identified a guarantee liability of $6,643. This liability is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield. At September 30, 2019, the carrying value of this liability was $5,851.

Armistice Guarantee

In connection with the closing under the Purchase Agreement, Armistice Capital Master Fund, Ltd., the then majority shareholder of Cerecor, guaranteed to Holdings the payment by Cerecor of the Assumed Obligations, including the Minimum Royalties. A valuation of the guarantee asset was performed in accordance with ASC 460 and a guarantee asset of $6,620 was recorded. This asset is being amortized proportionately based on undiscounted cash outflows through the remainder of the contract with Deerfield noted above. At September 30, 2019, the carrying value of this asset was $5,831.

The fair values of the Avadel guarantee to Deerfield and the guarantee received by Avadel from Armistice largely offset and when combined are not material.

Based on management’s review of ASU 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, the disposition of our pediatric assets and related liabilities did not qualify for discontinued operations reporting. Our results of operations for the period January 1, 2018 through February 16, 2018 include the results of FSC, prior to its February 16, 2018 disposition date.

Recent Updates to Guarantees
On October 10, 2019 Cerecor entered into a purchase and sale agreement with a Aytu BioScience, Inc (“Buyer”) pursuant to which the Buyer will purchase certain assets from Cerecor and assume certain of Cerecor’s liabilities, including all of Cerecor’s liabilities assumed as part of the Purchase Agreement noted above. As part of this transaction, on November 1, 2019, Armistice has agreed to deposit $15,000 in an escrow account governed by an escrow agreement between Armistice and Deerfield having the purpose of securing the $15,000 balloon payment due January 2021 as part of the Membership Interest Purchase Agreement. As part of the Cerecor transaction with the buyer, Deerfield contractually acknowledges and agrees that they will seek payment from the escrow funds before requesting payment from the Company pursuant to the Deerfield Guarantee discussed above. As a result, the Company is in process of assessing the impact this escrow deposit has on the fair values of the guarantees and will adjust such carrying values in the quarter ending December 31, 2019.

The net impact of this transaction was not material to the unaudited condensed consolidated statements of loss.

X

- References
No definition available.
+ Details

Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-URI http://asc.fasb.org/topic&trid=2155823

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2122178
+ Details

Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 34 R26.htm IDEA: XBRL DOCUMENT v3.19.3

Revenue by Product
9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Revenue by Product
Revenue by Product
The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer based technology. The Company’s Chief Operating Decision Maker is the CEO. The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the Company’s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.
The following table presents a summary of total revenues by these products:

Three Months Ended September 30,

Nine Months Ended September 30,
Revenues by Product:

2019

2018

2019

2018

Bloxiverz

$
1,466

$
3,656

$
6,392

$
16,691

Vazculep

8,786

8,759

27,669

33,097

Akovaz

4,208

5,991

13,946

28,083

Other

(231
)

1,420

213

4,232

Total product sales

14,229

19,826

48,220

82,103

License revenue

—

—

—

246

Total revenues

$
14,229

$
19,826

$
48,220

$
82,349

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510
+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R68.htm IDEA: XBRL DOCUMENT v3.19.3

Divestiture of the Pediatric Assets - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended

Feb. 12, 2018

Jan. 31, 2021

Oct. 10, 2019

Sep. 30, 2019

Dec. 31, 2018

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Guaranty liabilities $ 5,289 $ 5,717

2016 MIPA | Discontinued Operations, Disposed of by Sale

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Debt instrument, periodic payment, interest $ 263

Noncash or part noncash acquisition, debt assumed 2,625

Research and development reimbursement, in excess of 1,000

Guaranty liabilities 6,643 5,851

Guaranty assets $ 6,620 $ 5,831

FSC | 2016 MIPA | Discontinued Operations, Disposed of by Sale

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Percentage of royalty payable on net sales 15.00%

Royalty payable on net sales, maximum $ 10,300

Scenario, Forecast | 2016 MIPA | Discontinued Operations, Disposed of by Sale

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Repayments of assumed debt $ 15,263

Subsequent Event | Cerecor | Discontinued Operations, Disposed of by Sale

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Guaranty assets $ 15,000

Escrow deposit $ 15,000

X

- Definition
The percentage of royalty that has to be paid by the company as per the royalty agreement.
+ References
No definition available.
+ Details

Name: avdl_PercentageOfRoyaltyPayableOnNetSales

Namespace Prefix: avdl_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Research and Development Reimbursement, In Excess Of
+ References
No definition available.
+ Details

Name: avdl_ResearchandDevelopmentReimbursementInExcessOf

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Royalty Payable on Net Sales, Maximum
+ References
No definition available.
+ Details

Name: avdl_RoyaltyPayableonNetSalesMaximum

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the required periodic payments applied to interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentPeriodicPaymentInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_EscrowDeposit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The carrying amount of the contractual right to receive fees, as compensation in exchange for providing a guarantee to a third party, over life of the guarantee.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_GuarantyAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 25
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913062&loc=d3e11019-110243

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 25
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=82913062&loc=d3e11049-110243
+ Details

Name: us-gaap_GuarantyLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of debt that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586
+ Details

Name: us-gaap_NoncashOrPartNoncashAcquisitionDebtAssumed1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow from the repayments of a long-term debt originally issued by another party but is assumed by the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfAssumedDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=avdl_A2016MIPAMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=avdl_FSCMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=avdl_CerecorMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R60.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Debt Schedule of Debt (Details) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Debt Instrument [Line Items]

Net carrying amount of liability component $ 120,167 $ 115,840

Other debt 43 594

Less: current maturities (35) (106)

Long-term debt, less current portion 120,132 115,734

Senior Notes

Debt Instrument [Line Items]

Long-term debt 143,750 143,750

Less: debt discount and issuance costs, net (23,618) (28,059)

Net carrying amount of liability component 120,132 115,691

Equity component of exchangeable notes, net of issuance costs $ (26,699) $ (26,699)

Debt instrument, interest rate, stated percentage 4.50% 4.50%

Loans Payable

Debt Instrument [Line Items]

Other debt $ 35 $ 149

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870
+ Details

Name: us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of unamortized debt discount (premium) and debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19,20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebtNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of long-term debt classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_OtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R64.htm IDEA: XBRL DOCUMENT v3.19.3

Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Prepaid Expenses and Other Current Assets:

Valued-added tax recoverable $ 807 $ 1,378

Prepaid and other expenses 2,757 2,145

Guarantee from Armistice 560 534

Income tax receivable 594 921

Research and development tax credit receivable 270 283

Short-term deposit 0 3,350

Other 175 225

Total $ 5,163 $ 8,836

X

- Definition
Guarantee, Current
+ References
No definition available.
+ Details

Name: avdl_GuaranteeCurrent

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Research And Development Tax Credit Receivable, Current
+ References
No definition available.
+ Details

Name: avdl_ResearchAndDevelopmentTaxCreditReceivableCurrent

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.5(c))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.10)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_IncomeTaxesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of current assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6787-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 10
-Section 05
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316
+ Details

Name: us-gaap_PrepaidExpenseCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(6))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(5))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(1)(g))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(2))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.8)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ValueAddedTaxReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 38 R47.htm IDEA: XBRL DOCUMENT v3.19.3

Marketable Securities - Summary of Marketable Securities (Details) - USD ($)
$ in Thousands
9 Months Ended 12 Months Ended

Sep. 30, 2019

Dec. 31, 2018

Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]

Adjusted Cost $ 58,606 $ 91,359

Unrealized Gains 1,009 411

Unrealized Losses (28) (1,180)

Fair Value 59,587 90,590

Equity securities

Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]

Adjusted Cost 4,200 10,101

Unrealized Gains 0 0

Unrealized Losses (24) (956)

Fair Value 4,176 9,145

Money market and mutual funds

Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]

Adjusted Cost 43,306 52,733

Unrealized Gains 785 316

Unrealized Losses 0 (53)

Fair Value 44,091 52,996

Corporate bonds

Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]

Adjusted Cost 4,190 6,411

Unrealized Gains 69 7

Unrealized Losses (1) (79)

Fair Value 4,258 6,339

Government securities - U.S.

Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]

Adjusted Cost 5,217 12,714

Unrealized Gains 129 66

Unrealized Losses (2) (79)

Fair Value 5,344 12,701

Other fixed-income securities

Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]

Adjusted Cost 1,693 9,400

Unrealized Gains 26 22

Unrealized Losses (1) (13)

Fair Value $ 1,718 $ 9,409

X

- Definition
Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740
+ Details

Name: us-gaap_EquitySecuritiesFvNi

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.
+ References
No definition available.
+ Details

Name: us-gaap_EquitySecuritiesFvNiCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714
+ Details

Name: us-gaap_EquitySecuritiesFvNiUnrealizedGain

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 321
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84241550&loc=SL75117546-209714
+ Details

Name: us-gaap_EquitySecuritiesFvNiUnrealizedLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_FixedIncomeSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R43.htm IDEA: XBRL DOCUMENT v3.19.3

Subsidiary Bankruptcy and Deconsolidation (Details) - USD ($)
3 Months Ended 9 Months Ended

Apr. 26, 2019

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Oct. 02, 2019

Jul. 02, 2019

Feb. 08, 2019

Business Acquisition, Contingent Consideration [Line Items]

Gain (loss) on deconsolidation of subsidiary $ 0 $ 0 $ (2,840,000) $ 0

DIP Credit Agreement | Debtor in Possession Credit and Security Facility

Business Acquisition, Contingent Consideration [Line Items]

Gain (loss) on deconsolidation of subsidiary (407,000)

Payments for debtor in possession financing 407,000

Speciality Pharama

Business Acquisition, Contingent Consideration [Line Items]

Aggregate cash proceeds of intangible assets and remaining inventory $ 250,000

Speciality Pharama | Internal Revenue Service (IRS)

Business Acquisition, Contingent Consideration [Line Items]

Bankruptcy claims, amount of filed claims likely to be denied $ 50,695,000

Speciality Pharama | Internal Revenue Service (IRS) | Subsequent Event

Business Acquisition, Contingent Consideration [Line Items]

Bankruptcy claims, amount of filed claims likely to be denied $ 9,302,000

Speciality Pharama | DIP Credit Agreement | Debtor in Possession Credit and Security Facility

Business Acquisition, Contingent Consideration [Line Items]

DIP financing, amount arranged $ 2,700,000

Specialty Pharma

Business Acquisition, Contingent Consideration [Line Items]

Equity method investments, fair value $ 0 $ 0

X

- Definition
Payments For Debtor In Possession Financing
+ References
No definition available.
+ Details

Name: avdl_PaymentsForDebtorInPossessionFinancing

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of bankruptcy claim filed with bankruptcy court that are likely to be denied.
+ References
No definition available.
+ Details

Name: us-gaap_BankruptcyClaimsAmountOfFiledClaimsLikelyToBeDenied

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_BusinessAcquisitionContingentConsiderationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount debtor-in-possession financing arranged (but not necessarily all borrowed).
+ References
No definition available.
+ Details

Name: us-gaap_DebtorInPossessionFinancingAmountArranged

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684
+ Details

Name: us-gaap_DeconsolidationGainOrLossAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Fair value portion of investments accounted under the equity method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 25
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=66022186&loc=d3e32014-111567
+ Details

Name: us-gaap_EquityMethodInvestmentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=avdl_DIPCreditAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CreditFacilityAxis=avdl_DebtorinPossessionCreditandSecurityFacilityMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: dei_LegalEntityAxis=avdl_SpecialityPharamaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=avdl_SpecialtyPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R75.htm IDEA: XBRL DOCUMENT v3.19.3

Revenue by Product - Summary of Revenue (Details)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

USD ($)

Sep. 30, 2018

USD ($)

Sep. 30, 2019

USD ($)

segment

Sep. 30, 2018

USD ($)

Segment Reporting [Abstract]

Number of operating segments (in segments) | segment 1

Segment Reporting Information [Line Items]

Total revenues $ 14,229 $ 19,826 $ 48,220 $ 82,349

Bloxiverz

Segment Reporting Information [Line Items]

Total revenues 1,466 3,656 6,392 16,691

Vazculep

Segment Reporting Information [Line Items]

Total revenues 8,786 8,759 27,669 33,097

Akovaz

Segment Reporting Information [Line Items]

Total revenues 4,208 5,991 13,946 28,083

Other

Segment Reporting Information [Line Items]

Total revenues (231) 1,420 213 4,232

Product sales

Segment Reporting Information [Line Items]

Total revenues 14,229 19,826 48,220 82,103

License revenue

Segment Reporting Information [Line Items]

Total revenues $ 0 $ 0 $ 0 $ 246

X

- Definition
Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.
+ References
No definition available.
+ Details

Name: us-gaap_NumberOfOperatingSegments

Namespace Prefix: us-gaap_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_SegmentReportingInformationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=avdl_BloxiverzMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=avdl_VazculepMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=avdl_AkovazMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=avdl_OtherProductsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R71.htm IDEA: XBRL DOCUMENT v3.19.3

Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Sep. 30, 2019

Sep. 30, 2018

Earnings Per Share [Abstract]

Net loss $ (8,864) $ (8,605) $ (13,018) $ (15,771) $ (3,438) $ (12,236) $ (30,487) $ (31,445)

Weighted average shares:

Basic shares (in shares) 37,436 36,904 37,382 37,410

Effect of dilutive securities—options and warrants outstanding (in shares) 0 0 0 0

Diluted shares (in shares) 37,436 36,904 37,382 37,410

Net income (loss) per share - basic (in dollars per share) $ (0.24) $ (0.43) $ (0.82) $ (0.84)

Net income (loss) per share - diluted (in dollars per share) $ (0.24) $ (0.43) $ (0.82) $ (0.84)

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 42 R52.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Intangible Assets - Estimated Future Amortization (Details)
$ in Thousands
9 Months Ended

Sep. 30, 2019

USD ($)

Finite-Lived Intangible Assets [Line Items]

Estimated useful life (in years) 5 years

Estimated Annual Amortization Expense:

2019 $ 815

2020 814

2021 0

2022 0

2023 $ 0

Minimum

Finite-Lived Intangible Assets [Line Items]

Estimated useful life (in years) 3 years

Maximum

Finite-Lived Intangible Assets [Line Items]

Estimated useful life (in years) 15 years

X

- Definition
Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R56.htm IDEA: XBRL DOCUMENT v3.19.3

Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details)
$ in Thousands

Dec. 31, 2018

USD ($)

Leases [Abstract]

2019 $ 1,191

2020 1,208

2021 1,008

2022 767

2023 695

Thereafter 967

Total minimum lease payments $ 5,836

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 10
-Section 55
-Paragraph 40
-Subparagraph (Note 3)
-URI http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697
+ Details

Name: us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 239 398 1 false 65 0 false 5 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.avadel.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS Statements 2 false false R3.htm 1002000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 3 false false R4.htm 1002501 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveIncomeLossParenthetical UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedBalanceSheets UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 1003501 - Statement - UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedBalanceSheetsParenthetical UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? (DEFICIT) EQUITY Statement Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfShareholdersDeficitEquityStatement UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? (DEFICIT) EQUITY Statement Statements 7 false false R8.htm 1005000 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.avadel.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 8 false false R9.htm 2101100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.avadel.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2102100 - Disclosure - Newly Issued Accounting Pronouncements Sheet http://www.avadel.com/role/NewlyIssuedAccountingPronouncements Newly Issued Accounting Pronouncements Notes 10 false false R11.htm 2103100 - Disclosure - Subsidiary Bankruptcy and Deconsolidation Sheet http://www.avadel.com/role/SubsidiaryBankruptcyAndDeconsolidation Subsidiary Bankruptcy and Deconsolidation Notes 11 false false R12.htm 2104100 - Disclosure - Revenue Recognition Sheet http://www.avadel.com/role/RevenueRecognition Revenue Recognition Notes 12 false false R13.htm 2105100 - Disclosure - Fair Value Measurement Sheet http://www.avadel.com/role/FairValueMeasurement Fair Value Measurement Notes 13 false false R14.htm 2107100 - Disclosure - Marketable Securities Sheet http://www.avadel.com/role/MarketableSecurities Marketable Securities Notes 14 false false R15.htm 2108100 - Disclosure - Inventories Sheet http://www.avadel.com/role/Inventories Inventories Notes 15 false false R16.htm 2109100 - Disclosure - Goodwill and Intangible Assets Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 16 false false R17.htm 2110100 - Disclosure - Leases Sheet http://www.avadel.com/role/Leases Leases Notes 17 false false R18.htm 2111100 - Disclosure - Long-Term Related Party Payable Sheet http://www.avadel.com/role/LongTermRelatedPartyPayable Long-Term Related Party Payable Notes 18 false false R19.htm 2112100 - Disclosure - Long-Term Debt Sheet http://www.avadel.com/role/LongTermDebt Long-Term Debt Notes 19 false false R20.htm 2113100 - Disclosure - Income Taxes Sheet http://www.avadel.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2114100 - Disclosure - Other Assets and Liabilities Sheet http://www.avadel.com/role/OtherAssetsAndLiabilities Other Assets and Liabilities Notes 21 false false R22.htm 2115100 - Disclosure - Divestiture of the Pediatric Assets Sheet http://www.avadel.com/role/DivestitureOfPediatricAssets Divestiture of the Pediatric Assets Notes 22 false false R23.htm 2116100 - Disclosure - Restructuring Costs Sheet http://www.avadel.com/role/RestructuringCosts Restructuring Costs Notes 23 false false R24.htm 2117100 - Disclosure - Net Loss Per Share Sheet http://www.avadel.com/role/NetLossPerShare Net Loss Per Share Notes 24 false false R25.htm 2118100 - Disclosure - Comprehensive Loss Sheet http://www.avadel.com/role/ComprehensiveLoss Comprehensive Loss Notes 25 false false R26.htm 2119100 - Disclosure - Revenue by Product Sheet http://www.avadel.com/role/RevenueByProduct Revenue by Product Notes 26 false false R27.htm 2120100 - Disclosure - Commitments and Contingencies Sheet http://www.avadel.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 27 false false R28.htm 2201201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.avadel.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.avadel.com/role/SummaryOfSignificantAccountingPolicies 28 false false R29.htm 2305301 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.avadel.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.avadel.com/role/FairValueMeasurement 29 false false R30.htm 2307301 - Disclosure - Marketable Securities (Tables) Sheet http://www.avadel.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.avadel.com/role/MarketableSecurities 30 false false R31.htm 2308301 - Disclosure - Inventories (Tables) Sheet http://www.avadel.com/role/InventoriesTables Inventories (Tables) Tables http://www.avadel.com/role/Inventories 31 false false R32.htm 2309301 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssetsTables Goodwill and Intangible Assets (Tables) Tables http://www.avadel.com/role/GoodwillAndIntangibleAssets 32 false false R33.htm 2310301 - Disclosure - Leases (Tables) Sheet http://www.avadel.com/role/LeasesTables Leases (Tables) Tables http://www.avadel.com/role/Leases 33 false false R34.htm 2311301 - Disclosure - Long-Term Related Party Payable (Tables) Sheet http://www.avadel.com/role/LongTermRelatedPartyPayableTables Long-Term Related Party Payable (Tables) Tables http://www.avadel.com/role/LongTermRelatedPartyPayable 34 false false R35.htm 2312301 - Disclosure - Long-Term Debt (Tables) Sheet http://www.avadel.com/role/LongTermDebtTables Long-Term Debt (Tables) Tables http://www.avadel.com/role/LongTermDebt 35 false false R36.htm 2313301 - Disclosure - Income Taxes (Tables) Sheet http://www.avadel.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.avadel.com/role/IncomeTaxes 36 false false R37.htm 2314301 - Disclosure - Other Assets and Liabilities (Tables) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesTables Other Assets and Liabilities (Tables) Tables http://www.avadel.com/role/OtherAssetsAndLiabilities 37 false false R38.htm 2316301 - Disclosure - Restructuring Costs (Tables) Sheet http://www.avadel.com/role/RestructuringCostsTables Restructuring Costs (Tables) Tables http://www.avadel.com/role/RestructuringCosts 38 false false R39.htm 2317301 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.avadel.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.avadel.com/role/NetLossPerShare 39 false false R40.htm 2318301 - Disclosure - Comprehensive Income (Loss) (Tables) Sheet http://www.avadel.com/role/ComprehensiveIncomeLossTables Comprehensive Income (Loss) (Tables) Tables 40 false false R41.htm 2319301 - Disclosure - Revenue by Product (Tables) Sheet http://www.avadel.com/role/RevenueByProductTables Revenue by Product (Tables) Tables http://www.avadel.com/role/RevenueByProduct 41 false false R42.htm 2320301 - Disclosure - Commitments and Contingencies - (Tables) Sheet http://www.avadel.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies - (Tables) Tables http://www.avadel.com/role/CommitmentsAndContingencies 42 false false R43.htm 2403401 - Disclosure - Subsidiary Bankruptcy and Deconsolidation (Details) Sheet http://www.avadel.com/role/SubsidiaryBankruptcyAndDeconsolidationDetails Subsidiary Bankruptcy and Deconsolidation (Details) Details http://www.avadel.com/role/SubsidiaryBankruptcyAndDeconsolidation 43 false false R44.htm 2404401 - Disclosure - Revenue Recognition - Narrative (Details) Sheet http://www.avadel.com/role/RevenueRecognitionNarrativeDetails Revenue Recognition - Narrative (Details) Details 44 false false R45.htm 2405402 - Disclosure - Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) Sheet http://www.avadel.com/role/FairValueMeasurementFairValueMeasurementMeasuredOnRecurringBasisDetails Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) Details 45 false false R46.htm 2407402 - Disclosure - Marketable Securities - Narrative (Details) Sheet http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails Marketable Securities - Narrative (Details) Details 46 false false R47.htm 2407403 - Disclosure - Marketable Securities - Summary of Marketable Securities (Details) Sheet http://www.avadel.com/role/MarketableSecuritiesSummaryOfMarketableSecuritiesDetails Marketable Securities - Summary of Marketable Securities (Details) Details 47 false false R48.htm 2407404 - Disclosure - Marketable Securities Marketable Securities - Schedule of Maturities (Details) Sheet http://www.avadel.com/role/MarketableSecuritiesMarketableSecuritiesScheduleOfMaturitiesDetails Marketable Securities Marketable Securities - Schedule of Maturities (Details) Details 48 false false R49.htm 2408402 - Disclosure - Inventories (Details) Sheet http://www.avadel.com/role/InventoriesDetails Inventories (Details) Details http://www.avadel.com/role/InventoriesTables 49 false false R50.htm 2409402 - Disclosure - Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssetsGrossValueAndNetCarryingAmountDetails Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) Details 50 false false R51.htm 2409403 - Disclosure - Goodwill and Intangible Assets - Narrative (Details) Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssetsNarrativeDetails Goodwill and Intangible Assets - Narrative (Details) Details 51 false false R52.htm 2409404 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization (Details) Sheet http://www.avadel.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationDetails Goodwill and Intangible Assets - Estimated Future Amortization (Details) Details 52 false false R53.htm 2410402 - Disclosure - Leases - Narrative (Details) Sheet http://www.avadel.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 53 false false R54.htm 2410403 - Disclosure - Leases - Components of lease costs (Details) Sheet http://www.avadel.com/role/LeasesComponentsOfLeaseCostsDetails Leases - Components of lease costs (Details) Details 54 false false R55.htm 2410404 - Disclosure - Leases - Maturities of operating lease liabilities (Details) Sheet http://www.avadel.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails Leases - Maturities of operating lease liabilities (Details) Details 55 false false R56.htm 2410405 - Disclosure - Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) Sheet http://www.avadel.com/role/LeasesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) Details 56 false false R57.htm 2411402 - Disclosure - Long-Term Related Party Payable - Narrative (Details) Sheet http://www.avadel.com/role/LongTermRelatedPartyPayableNarrativeDetails Long-Term Related Party Payable - Narrative (Details) Details 57 false false R58.htm 2411403 - Disclosure - Long-Term Related Party Payable - Activity (Details) Sheet http://www.avadel.com/role/LongTermRelatedPartyPayableActivityDetails Long-Term Related Party Payable - Activity (Details) Details 58 false false R59.htm 2411404 - Disclosure - Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) Sheet http://www.avadel.com/role/LongTermRelatedPartyPayableLongTermRelatedPartyPayablePayableBalanceDetails Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) Details 59 false false R60.htm 2412402 - Disclosure - Long-Term Debt Schedule of Debt (Details) Sheet http://www.avadel.com/role/LongTermDebtScheduleOfDebtDetails Long-Term Debt Schedule of Debt (Details) Details 60 false false R61.htm 2413402 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.avadel.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 61 false false R62.htm 2413403 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details) Sheet http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails Income Taxes - Income (Loss) Before Income Taxes (Details) Details 62 false false R63.htm 2413404 - Disclosure - Income Taxes - Reconciliation of Tax Rate (Details) Sheet http://www.avadel.com/role/IncomeTaxesReconciliationOfTaxRateDetails Income Taxes - Reconciliation of Tax Rate (Details) Details 63 false false R64.htm 2414402 - Disclosure - Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesPrepaidExpensesAndOtherCurrentAssetsDetails Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) Details 64 false false R65.htm 2414403 - Disclosure - Other Assets and Liabilities - Other Non-Current Assets (Details) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesOtherNonCurrentAssetsDetails Other Assets and Liabilities - Other Non-Current Assets (Details) Details 65 false false R66.htm 2414404 - Disclosure - Other Assets and Liabilities - Accrued Expenses (Details) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesAccruedExpensesDetails Other Assets and Liabilities - Accrued Expenses (Details) Details 66 false false R67.htm 2414405 - Disclosure - Other Assets and Liabilities - Other Non-Current Liabilities (Details) Sheet http://www.avadel.com/role/OtherAssetsAndLiabilitiesOtherNonCurrentLiabilitiesDetails Other Assets and Liabilities - Other Non-Current Liabilities (Details) Details 67 false false R68.htm 2415401 - Disclosure - Divestiture of the Pediatric Assets - Narrative (Details) Sheet http://www.avadel.com/role/DivestitureOfPediatricAssetsNarrativeDetails Divestiture of the Pediatric Assets - Narrative (Details) Details 68 false false R69.htm 2416402 - Disclosure - Restructuring Costs - Narrative (Details) Sheet http://www.avadel.com/role/RestructuringCostsNarrativeDetails Restructuring Costs - Narrative (Details) Details 69 false false R70.htm 2416403 - Disclosure - Restructuring Costs - Severance Obligation (Details) Sheet http://www.avadel.com/role/RestructuringCostsSeveranceObligationDetails Restructuring Costs - Severance Obligation (Details) Details 70 false false R71.htm 2417402 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) Sheet http://www.avadel.com/role/NetLossPerShareReconciliationOfBasicAndDilutedCalculationDetails Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) Details 71 false false R72.htm 2417403 - Disclosure - Net Loss Per Share - Narrative (Details) Sheet http://www.avadel.com/role/NetLossPerShareNarrativeDetails Net Loss Per Share - Narrative (Details) Details 72 false false R73.htm 2418402 - Disclosure - Comprehensive Income (Loss) - Components (Details) Sheet http://www.avadel.com/role/ComprehensiveIncomeLossComponentsDetails Comprehensive Income (Loss) - Components (Details) Details http://www.avadel.com/role/ComprehensiveIncomeLossTables 73 false false R74.htm 2418403 - Disclosure - Comprehensive Loss - Narrative (Details) Sheet http://www.avadel.com/role/ComprehensiveLossNarrativeDetails Comprehensive Loss - Narrative (Details) Details 74 false false R75.htm 2419402 - Disclosure - Revenue by Product - Summary of Revenue (Details) Sheet http://www.avadel.com/role/RevenueByProductSummaryOfRevenueDetails Revenue by Product - Summary of Revenue (Details) Details 75 false false R76.htm 2420402 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.avadel.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 76 false false R77.htm 2420403 - Disclosure - Commitments and Contingencies - Purchase Commitments (Details) Sheet http://www.avadel.com/role/CommitmentsAndContingenciesPurchaseCommitmentsDetails Commitments and Contingencies - Purchase Commitments (Details) Details 77 false false All Reports Book All Reports avdl-20190930.xml avdl-20190930.xsd avdl-20190930_cal.xml avdl-20190930_def.xml avdl-20190930_lab.xml avdl-20190930_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true XML 45 R8.htm IDEA: XBRL DOCUMENT v3.19.3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Cash flows from operating activities:

Net loss $ (30,487) $ (31,445)

Adjustments to reconcile net loss to net cash provided by operating activities:

Depreciation and amortization 1,690 5,625

Loss on disposal of property and equipment 478 0

Amortization of premiums on marketable securities (275) 2,889

Remeasurement of related party acquisition-related contingent consideration 2,384 (17,036)

Remeasurement of related party financing-related contingent consideration 496 (1,432)

Amortization of debt discount and debt issuance costs 4,424 3,402

Change in deferred tax and income tax deferred charge 1,333 (4,675)

Stock-based compensation expense 177 7,190

Loss on deconsolidation of subsidiary 1,750 0

Other adjustments (392) 117

Net changes in assets and liabilities

Accounts receivable 2,026 5,059

Inventories 2,465 (548)

Prepaid expenses and other current assets (1,859) 2,194

Research and development tax credit receivable (749) (1,350)

Accounts payable & other current liabilities 259 4,312

Accrued expenses (2,379) (11,660)

Earn-out payments for related party contingent consideration in excess of acquisition-date fair value (8,640) (16,254)

Royalty payments for related party payable in excess of original fair value (1,374) (2,362)

Other assets and liabilities (1,399) (2,216)

Net cash used in operating activities (30,072) (58,190)

Cash flows from investing activities:

Purchases of property and equipment (29) (167)

Proceeds from the disposal of property and equipment 154 0

Purchase of intangible asset 0 (20,000)

Proceeds from sales of marketable securities 57,242 308,015

Purchases of marketable securities (23,814) (341,036)

Net cash provided by (used in) investing activities 33,553 (53,188)

Cash flows from financing activities:

Earn-out payments for related party contingent consideration 0 (645)

Proceeds from debt issuance 0 143,750

Payments for debt issuance costs 0 (6,190)

Share repurchases 0 (27,637)

Proceeds from issuance of ordinary shares and warrants 123 3,488

Other financing activities, net (109) (31)

Net cash provided by financing activities 14 112,735

Effect of foreign currency exchange rate changes on cash and cash equivalents 47 (84)

Net change in cash and cash equivalents 3,542 1,273

Cash and cash equivalents at January 1, 9,325 16,564

Cash and cash equivalents at September 30, 12,867 17,837

Supplemental disclosures of cash flow information:

Interest paid 6,469 3,359

Income taxes paid $ 140 $ 413

X

- Definition
Represents the remeasurement of acquisition related contingent considerations
+ References
No definition available.
+ Details

Name: avdl_AcquisitionRelatedContingentConsiderationRemeasurement

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the amount of acquisition earn out payment made.
+ References
No definition available.
+ Details

Name: avdl_EarnOutPayment

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the Earn Out Payment In Excess Of Acquisition Date Fair Value
+ References
No definition available.
+ Details

Name: avdl_EarnOutPaymentInExcessOfAcquisitionDateFairValue

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Represents the remeasurement of financing related contingent considerations
+ References
No definition available.
+ Details

Name: avdl_FinancingRelatedContingentConsiderationRemeasurement

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in research and development tax credit receivable.
+ References
No definition available.
+ Details

Name: avdl_IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399
+ Details

Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_CashDivestedFromDeconsolidation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_DepreciationAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 230
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906
+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_IncomeTaxesPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 17
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3367-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of unrealized and realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).
+ References
No definition available.
+ Details

Name: us-gaap_MarketableSecuritiesGainLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).
+ References
No definition available.
+ Details

Name: us-gaap_OtherOperatingActivitiesCashFlowStatement

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow to reacquire common stock during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for royalties during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585
+ Details

Name: us-gaap_PaymentsForRoyalties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash outflow for purchase of marketable security.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562
+ Details

Name: us-gaap_PaymentsToAcquireMarketableSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities classified as other.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3151-108585

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585
+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 46 R4.htm IDEA: XBRL DOCUMENT v3.19.3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Parenthetical) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Statement of Comprehensive Income [Abstract]

Other comprehensive income (loss), tax $ (5) $ (18) $ (46) $ (88)

X

- Definition
Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 47 R37.htm IDEA: XBRL DOCUMENT v3.19.3

Other Assets and Liabilities (Tables)
9 Months Ended

Sep. 30, 2019

Other Liabilities Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Current Assets
Various other assets and liabilities are summarized as follows:
Prepaid Expenses and Other Current Assets:

September 30, 2019

December 31, 2018

Valued-added tax recoverable

$
807

$
1,378

Prepaid and other expenses

2,757

2,145

Guarantee from Armistice (see Note 14)

560

534

Income tax receivable

594

921

Research and development tax credit receivable

270

283

Short-term deposit

—

3,350

Other

175

225

Total

$
5,163

$
8,836

Schedule of Other Assets, Noncurrent
Other Non-Current Assets:

September 30, 2019

December 31, 2018

Deferred tax assets, net

$
21,636

$
23,029

Long-term deposits

1,477

1,477

Guarantee from Armistice (see Note 14)

5,271

5,697

Right of use assets at contract manufacturing organizations

6,494

5,894

Other

49

49

Total

$
34,927

$
36,146

Schedule of Accrued Liabilities
Accrued Expenses

September 30, 2019

December 31, 2018

Accrued compensation

$
2,322

$
3,971

Accrued social charges

482

1,009

Accrued restructuring (see Note 15)

1,737

879

Customer allowances

6,244

6,541

Accrued contract research organization charges

3,389

1,000

Accrued contract manufacturing organization costs

1,284

2,028

Accrued contract sales organization and marketing costs

—

3,469

Other

1,559

2,798

Total

$
17,017

$
21,695

Schedule Of Long Term Liabilities
Other Non-Current Liabilities:

September 30, 2019

December 31, 2018

Provision for retirement indemnity

$
—

$
1,024

Customer allowances

923

1,352

Unrecognized tax benefits

7,717

5,315

Guarantee to Deerfield (see Note 14)

5,289

5,717

Other

43

594

Total

$
13,972

$
14,002

X

- Definition
Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.
+ References
No definition available.
+ Details

Name: avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock

Namespace Prefix: avdl_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of other noncurrent liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_OtherNoncurrentLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accrued liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of noncurrent assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.17)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R33.htm IDEA: XBRL DOCUMENT v3.19.3

Leases (Tables)
9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Components of lease costs
The components of lease costs, which are included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the three and nine months ended September 30 were as follows:
Lease cost:

Three months ended September 30, 2019

Nine months ended September 30, 2019

Operating lease costs ⁽¹⁾

$
411

$
1,150

Sublease income ⁽²⁾

82

187

Total lease cost

$
329

$
963

⁽¹⁾Variable lease costs were immaterial for the three and nine months ended September 30, 2019.
⁽²⁾ Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020. The Company also vacated portions of its office facility in St. Louis, Missouri during May 2019 and August 2019 and started receiving sublease income starting in May 2019 and August 2019 from two different tenants. The lease agreement ends in April 2025 and the sublease agreement that started in May 2019 ends in May 2020, with a one year renewal and the sublease agreement that started in August 2019 ends in July 2020, and can continue thereafter on a month-to-month basis.

Maturities of operating lease liabilities
Maturities of the Company’s operating lease liabilities were as follows:
Maturities:

Operating Leases

Remaining three months of 2019

$
1,117

2020

879

2021

670

2022

678

2023

690

Thereafter

941

Total lease payments

4,975

Less: interest

513

Present value of lease liabilities

$
4,462

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]
Under the prior lease guidance, minimum rental commitments for non-cancelable leases as of December 31, 2018 were:
Lease Commitment:

Operating Leases

2019

$
1,191

2020

1,208

2021

1,008

2022

767

2023

695

Thereafter

967

Total minimum lease payments

$
5,836

X

- Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_LeaseCostTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 840
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717
+ Details

Name: us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R18.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Related Party Payable
9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Long-Term Related Party Payable
Long-Term Related Party Payable
Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2019 and December 31, 2018:

Activity during the Nine Months Ended
September 30, 2019

Changes in Fair Value of Related Party Payable

Long-Term Related Party Payable:
Balance,
December 31, 2018

Payments to
Related Parties

Operating Expense

Other
Expense

Balance, September 30, 2019

Acquisition-related contingent consideration:

Earn-out payments - Éclat Pharmaceuticals (a)
$
25,615

$
(8,640
)

$
2,384

$
—

$
19,359

Financing-related:

Royalty agreement - Deerfield (b)
2,184

(930
)

—

330

1,584

Royalty agreement - Broadfin (c)
1,041

(444
)

—

166

763

Total related party payable
28,840

$
(10,014
)

$
2,384

$
496

21,706

Less: current portion
(9,439
)

(7,588
)
Total long-term related party payable
$
19,401

$
14,118

Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2019 and June 30, 2019:

Activity during the Three Months Ended
September 30, 2019

Changes in Fair Value of Related Party Payable

Long-Term Related Party Payable:
Balance,
June 30, 2019

Payments to
Related Parties

Operating Expense

Other
Expense

Balance, September 30, 2019

Acquisition-related contingent consideration:

Earn-out payments - Éclat Pharmaceuticals (a)
$
21,582

$
(2,850
)

$
627

$
—

$
19,359

Financing-related:

Royalty agreement - Deerfield (b)
1,799

(309
)

—

94

1,584

Royalty agreement - Broadfin (c)
866

(148
)

—

45

763

Total related party payable
24,247

$
(3,307
)

$
627

$
139

21,706

Less: current portion
(8,264
)

(7,588
)
Total long-term related party payable
$
15,983

$
14,118

(a) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s former CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.
(b)
As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products.
(c)
As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.
At September 30, 2019, the fair value of each related party payable listed in (a), (b) and (c) above was estimated using a discounted cash flow model based on estimated and projected annual net revenues or gross profit, as appropriate, of each of the specified Éclat products using an appropriate risk-adjusted discount rate of 15%. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management’s revision of key assumptions, will be recorded in the unaudited condensed consolidated statements of loss in the line items entitled “Changes in fair value of related party contingent consideration” for items noted in (b) above and in “Other expense - changes in fair value of related party payable” for items (b) and (c) above. See Note 1: Summary of Significant Accounting Policies under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements in Part II, Item 8 of the Company’s 2018 Annual Report on Form 10-K for more information on key assumptions used to determine the fair value of these liabilities.
The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for its royalty agreements detailed in items (b) and (c) above. These financing-related liabilities are recorded at fair market value on the unaudited condensed consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – change in fair value of related party payable” on the unaudited condensed consolidated statements of loss.
The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the nine-month periods ended September 30, 2019 and 2018, respectively:
Related Party Payable Rollforward:

Balance

Balance, December 31, 2017

$
98,925

Payments of related party payable

(19,261
)
Fair value adjustments ⁽¹⁾

(18,468
)
Expiration of warrants

(2,167
)
Disposition of the pediatric assets

(20,337
)
Balance, September 30, 2018

$
38,692

Balance, December 31, 2018

$
28,840

Payments of related party payable

(10,014
)
Fair value adjustments ⁽¹⁾

2,880

Balance, September 30, 2019

$
21,706

⁽¹⁾Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-URI http://asc.fasb.org/topic&trid=2122745
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R10.htm IDEA: XBRL DOCUMENT v3.19.3

Newly Issued Accounting Pronouncements
9 Months Ended

Sep. 30, 2019

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

Newly Issued Accounting Pronouncements
Newly Issued Accounting Standards
Recent Accounting Guidance Not Yet Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.

In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments(“ASU 2016-13”).” This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will be effective for the Company for fiscal years beginning on or after January 1, 2020, including interim periods within those annual reporting periods and early adoption is permitted. We are currently evaluating the impact of our adoption of ASU 2016-13 on our condensed consolidated financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394
+ Details

Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R14.htm IDEA: XBRL DOCUMENT v3.19.3

Marketable Securities
9 Months Ended

Sep. 30, 2019

Investments, Debt and Equity Securities [Abstract]

Marketable Securities
Marketable Securities
The Company has investments in equity and available-for-sale debt securities which are recorded at fair market value. The change in the fair value of equity investments is recognized in our unaudited condensed consolidated statements of loss and the change in the fair value of available-for-sale debt investments is recorded as other comprehensive income (loss) in shareholders’ (deficit) equity, net of income tax effects.
The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of September 30, 2019 and December 31, 2018, respectively:

September 30, 2019
Marketable Securities:

Adjusted Cost

Unrealized Gains

Unrealized Losses

Fair Value

Equity securities

$
4,200

$
—

$
(24
)

$
4,176

Money market and mutual funds

43,306

785

—

44,091

Corporate bonds

4,190

69

(1
)

4,258

Government securities - U.S.

5,217

129

(2
)

5,344

Other fixed-income securities

1,693

26

(1
)

1,718

Total

$
58,606

$
1,009

$
(28
)

$
59,587

December 31, 2018
Marketable Securities:

Adjusted Cost

Unrealized Gains

Unrealized Losses

Fair Value

Equity securities

$
10,101

$
—

$
(956
)

$
9,145

Money market and mutual funds

52,733

316

(53
)

52,996

Corporate bonds

6,411

7

(79
)

6,339

Government securities - U.S.

12,714

66

(79
)

12,701

Other fixed-income securities

9,400

22

(13
)

9,409

Total

$
91,359

$
411

$
(1,180
)

$
90,590

We determine realized gains or losses on the sale of marketable securities on a specific identification method. We reflect these gains and losses as a component of investment and other income in the accompanying unaudited condensed consolidated statements of loss.
We recognized gross realized gains of $71 and $143 for the three months ended September 30, 2019, and 2018, respectively. These realized gains were offset by realized losses of $64 and $22 for the three months ended September 30, 2019, and 2018, respectively.
We recognized gross realized gains of $339 and $378 for the nine months ended September 30, 2019, and 2018, respectively. These realized gains were offset by realized losses of $211 and $350 for the nine months ended September 30, 2019 and 2018, respectively. We reflect these gains and losses as a component of investment and other income in the accompanying condensed consolidated statements of income (loss).
The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of September 30, 2019:

Maturities
Marketable Debt Securities:

Less than 1 Year

1-5 Years

5-10 Years

Greater than 10 Years

Total

Corporate bonds

$
556

$
3,360

$
342

$
—

$
4,258

Government securities - U.S.

—

4,600

—

744

5,344

Other fixed-income securities

49

1,669

—

—

1,718

Total

$
605

$
9,629

$
342

$
744

$
11,320

The Company has classified our investment in available-for-sale marketable debt securities as current assets in the unaudited condensed consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in our investment portfolio.

X

- Definition
The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-URI http://asc.fasb.org/topic&trid=2122426

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-URI http://asc.fasb.org/topic&trid=2196928
+ Details

Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 52 R20.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes
9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes
Income Taxes
The components of loss before income taxes are as follows:

Three Months Ended September 30,

Nine Months Ended September 30,
Loss Before Income Taxes:

2019

2018

2019

2018

Ireland

$
(14,302
)

$
(18,314
)

$
(36,625
)

$
(34,203
)
United States

5,952

1,773

12,309

(1,043
)
France

1,720

79

(2,530
)

441

Total loss before income taxes

$
(6,630
)

$
(16,462
)

$
(26,846
)

$
(34,805
)

The items accounting for the difference between the income tax provision computed at the statutory rate and the Company’s effective tax rate are as follows:

Three Months Ended September 30,

Nine Months Ended September 30,
Income Tax Rate Reconciliation:

2019

2018

2019

2018

Statutory tax rate

12.5
%

12.5
%

12.5
%

12.5
%
International tax rates differential

(4.3
)%

7.0
%

4.1
%

6.9
%
Change in valuation allowance

(31.1
)%

(18.3
)%

(27.0
)%

(14.9
)%
Change in fair value of nondeductible contingent consideration

4.1
%

8.7
%

(0.1
)%

9.9
%
Nondeductible stock-based compensation

—
%

(3.5
)%

(0.2
)%

(2.6
)%
Unrecognized tax benefits

(8.8
)%

(3.5
)%

(3.3
)%

(3.1
)%
State and local income taxes, net of federal

(0.2
)%

0.1
%

(0.2
)%

0.2
%
Nondeductible interest expense

(4.5
)%

—
%

(2.6
)%

—
%
Other

(1.3
)%

1.2
%

3.1
%

0.8
%
Effective income tax rate

(33.6
)%

4.2
%

(13.7
)%

9.7
%

Income tax benefit - at statutory tax rate

$
(829
)

$
(2,058
)

$
(3,355
)

$
(4,351
)
International tax rates differential

283

(1,153
)

(1,108
)

(2,394
)
Change in valuation allowance

2,059

3,007

7,242

5,188

Change in fair value of nondeductible contingent consideration

(270
)

(1,431
)

33

(3,436
)
Nondeductible stock-based compensation

1

578

50

914

Unrecognized tax benefits

581

578

873

1,086

State and local income taxes, net of federal

14

(13
)

41

(70
)
Nondeductible interest expense

299

—

709

—

Other

96

(199
)

(844
)

(297
)
Income tax provision (benefit) - at effective income tax rate

$
2,234

$
(691
)

$
3,641

$
(3,360
)

The income tax provision was $2,234 for the three months ended September 30, 2019 and a benefit of $691 for the three months ended September 30, 2018. The increase in the income tax provision for the three months ended September 30, 2019 is primarily the result of a decrease in the amount of nontaxable gain from the revaluation of contingent consideration and an increase in the amount of valuation allowances recorded on foreign income tax losses.

The income tax provision was $3,641 for the nine months ended September 30, 2019 and a benefit of $3,360 for the nine months ended September 30, 2018. The increase in the income tax provision for the nine months ended September 30, 2019 is primarily the result of a decrease the amount of nontaxable gain from the revaluation of contingent consideration and an increase in the amount of valuation allowances recorded on foreign income tax losses.

The IRS commenced an examination of the Company's U.S. income tax returns for 2016 and 2017 during the second quarter 2019.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680
+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 53 R24.htm IDEA: XBRL DOCUMENT v3.19.3

Net Loss Per Share
9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Net Loss Per Share
Net Loss Per Share
Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during each period. Diluted net (loss) income per share is calculated by dividing net (loss) income by the diluted number of shares outstanding during each period. Except where the result would be anti-dilutive to net loss, diluted net loss per share would be calculated assuming the impact of the conversion of the 2023 Notes, the exercise of outstanding equity compensation awards, ordinary shares expected to be issued under our employee stock purchase plan (“ESPP”) and the exercise of contingent consideration warrants, all which have been exercised or have expired during the first quarter of 2018.

We have a choice to settle the conversion obligation under the 2023 Notes in cash, shares or any combination of the two. We utilize the if-converted method to reflect the impact of the conversion of the 2023 Notes, unless the result is anti-dilutive. This method assumes the conversion of the 2023 Notes into shares of our ordinary shares and reflects the elimination of the interest expense related to the 2023 Notes.

The dilutive effect of the warrants, stock options, RSU’s and ordinary shares expected to be issued under or ESPP has been calculated using the treasury stock method.
A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:

Three Months Ended September 30,

Nine Months Ended September 30,
Net Loss Per Share:

2019

2018

2019

2018

Net loss

$
(8,864
)

$
(15,771
)

$
(30,487
)

$
(31,445
)

Weighted average shares:

Basic shares

37,436

36,904

37,382

37,410

Effect of dilutive securities—employee and director equity awards outstanding and 2023 Notes

—

—

—

—

Diluted shares

37,436

36,904

37,382

37,410

Net loss per share - basic

$
(0.24
)

$
(0.43
)

$
(0.82
)

$
(0.84
)
Net loss per share - diluted

$
(0.24
)

$
(0.43
)

$
(0.82
)

$
(0.84
)

Potential common shares of 19,544 and 18,742 were excluded from the calculation of weighted average shares for the three months ended September 30, 2019 and 2018, respectively, because their effect was considered to be anti-dilutive. Potential common shares of 20,512 and 16,647 were excluded from the calculation of weighted average shares for the nine months ended September 30, 2019 and 2018, respectively. For the three and nine months ended September 30, 2019 and 2018, the effects of dilutive securities were entirely excluded from the calculation of net loss per share as a net loss was reported in this period.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-URI http://asc.fasb.org/topic&trid=2144383
+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 R28.htm IDEA: XBRL DOCUMENT v3.19.3

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Nature of Operations
Nature of Operations.  Avadel Pharmaceuticals plc (Nasdaq: AVDL) (“Avadel,” the “Company,” “we,” “our,” or “us”) is a branded specialty pharmaceutical company. Our primary focus is on the development and potential U.S. Food and Drug Administration (“FDA”) approval for FT218 which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program. The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit www.avadel.com.

Avadel is developing FT218, an investigational once-nightly formulation of sodium oxybate based on its propriety Micropump® drug delivery technology, for the treatment of EDS and cataplexy in patients suffering from narcolepsy. FT218 is currently being evaluated in a Phase 3 clinical trial called REST-ON. In addition, the Company submitted a new drug application (“NDA”) in March 2019 on a fourth sterile injectable drug which we refer to as AV001, for use in the hospital setting. AV001, if approved, could contribute revenues to Avadel starting in 2020. In May 2019, the FDA accepted the NDA for AV001, with a Prescription Drug User Fee Act (PDUFA) target action date of December 15, 2019.

Our current marketed products include:
•
Akovaz® (ephedrine sulfate injection, USP), an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

•
Bloxiverz® (neostigmine methylsulfate injection), a cholinesterase inhibitor, is indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) after surgery.

•
Vazculep® (phenylephrine hydrochloride injection), an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

Each of our Akovaz, Bloxiverz and Vazculep products is used primarily in the hospital setting and was developed under our UMD program.

The Company was incorporated on December 1, 2015 as an Irish private limited company, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our principal place of business is located at Block 10-1, Blanchardstown Corporate Park, Ballycoolin, Dublin 15, Ireland. Avadel’s phone number is 011-353-1-485-1200. Our website is www.avadel.com, where we make available free of charge our reports (and any amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the U.S. Securities and Exchange Commission (“SEC”). These filings are also available to the public at www.sec.gov.

The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the France-to-Ireland redomestication merger of Flamel with and into the Company completed on December 31, 2016 (the “Merger”). In the Merger, we changed our company name to Avadel Pharmaceuticals plc and our jurisdiction of organization to Ireland; we assumed all the assets and liabilities of Flamel; and we issued one Avadel ordinary share (either directly or in the form of an American Depositary Share (ADS)) in exchange for each formerly outstanding share of Flamel, all of which were canceled. Thus, an Avadel ordinary share held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger. References in this Annual Report on Form 10-K to “Avadel,” the “Company,” “we,” “our,” “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires. Additional details about the Merger are set forth in Item 1 under the caption “The Reincorporation Merger” of the Company’s Annual Report on Form 10-K filed with the SEC on March 15, 2019.

The Company currently has five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Specialty Pharmaceuticals, LLC (currently the subject of a voluntary Chapter 11 bankruptcy proceeding as noted in Note 3: Subsidiary Bankruptcy and Deconsolidation), (ii) Avadel Legacy Pharmaceuticals, LLC, (iii) Avadel Management Corporation, (iv) FSC Holding Company and (v) Avadel Operations Company, Inc. Avadel Finance Ireland Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Flamel Ireland Limited (operating under the trade name Avadel Ireland) is an Irish corporation which, since December 16, 2014, has been the owner of substantially all of Avadel’s intellectual property. Avadel France Holding SAS, a French société par actions simplifiée, is the holding entity of Avadel Research SAS through which Avadel conducts substantially all of its R&D activities.

Basis of Presentation
Basis of Presentation. The unaudited condensed consolidated balance sheet as of September 30, 2019, which is derived from the prior year 2018 audited consolidated financial statements, and the interim unaudited condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the unaudited condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2018 Annual Report on Form 10-K filed with the SEC on March 15, 2019.
The unaudited condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.
On February 6, 2019, the Company’s indirect wholly-owned subsidiary, Avadel Specialty Pharmaceuticals, LLC (“Specialty Pharma”), filed a voluntary petition for reorganization under Chapter 11 of the United States (“U.S.”) Code (the “Bankruptcy Code”). in the U.S. District Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), Case No. 19-10248. Specialty Pharma is operating and managing its business as “debtors-in-possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and order of the Bankruptcy Court. As a result of Specialty Pharma’s voluntary bankruptcy filing on February 6, 2019, we no longer controlled the operations of Specialty Pharma; therefore, we deconsolidated Specialty Pharma effective with the bankruptcy filing and the Company recorded its investment in Specialty Pharma under the cost method. See Note 3: Subsidiary Bankruptcy and Deconsolidation. Our results of operations for the period January 1, 2019 through February 6, 2019 include the results of Specialty Pharma prior to its February 6, 2019 voluntary petition for reorganization under Chapter 11 of the U.S. Bankruptcy Code.

Revenue
Revenue. Revenue includes sales of pharmaceutical products, licensing fees, and, if any, milestone payments for research and development (“R&D”) achievements.
Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer’s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

Product Sales and Services

The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product, which occurs typically upon receipt by the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates of product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, future expectations for such products and other judgments and analysis.

License Revenue

The Company from time to time may enter into out-licensing agreements which are within the scope of ASC 606 under which it licenses to third parties certain rights to its products or intellectual property. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, upfront license fees; development, regulatory, and commercial milestone payments; and sales-based royalty payments. Each of these payments results in license revenue.

For a complete discussion of the accounting for net product revenue and license revenues, see Note 4: Revenue Recognition.
Revenue Recognition

The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.

Product Sales and Services

Effective January 1, 2018, the Company implemented ASC 606, “Revenue From Contracts With Customers”. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product and the Company’s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

Reserves to Reduce Gross Revenues to Net Revenues

Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

Product Returns

Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products and other judgments and analysis.

Chargebacks, Discounts and Rebates

Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.

Revenue from licensing arrangements

The terms of the Company’s licensing agreements may contain multiple performance obligations, including certain R&D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments. Each of these payments results in license revenues.

License of Intellectual Property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Disaggregation of revenue

The Company’s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company’s revenues by product, see Note 18: Company Operations by Product.

Contract Balances

The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.

A receivable is recognized in the period the Company sells its products and when the Company’s right to consideration is unconditional.

There were no material deferred contract costs at September 30, 2019.

Transaction Price Allocated to the Remaining Performance Obligation

For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.

For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product.

The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.

Newly Issued Accounting Pronouncements
Newly Issued Accounting Standards
Recent Accounting Guidance Not Yet Adopted

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13.

In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments(“ASU 2016-13”).” This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will be effective for the Company for fiscal years beginning on or after January 1, 2020, including interim periods within those annual reporting periods and early adoption is permitted. We are currently evaluating the impact of our adoption of ASU 2016-13 on our condensed consolidated financial statements.

X

- Definition
Disclosure of accounting policy for nature of business.
+ References
No definition available.
+ Details

Name: avdl_NatureOfBusinessPolicyPolicyTextBlock

Namespace Prefix: avdl_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R49.htm IDEA: XBRL DOCUMENT v3.19.3

Inventories (Details) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Inventory Disclosure [Abstract]

Inventory reserves $ 1,212 $ 4,757

Increase in inventory reserves 3,545

Inventory:

Finished goods 1,883 4,270

Raw materials 377 500

Total $ 2,260 $ 4,770

X

- Definition
Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=66092785&loc=d3e4492-108314

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryAdjustments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryFinishedGoods

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a)(4))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryRawMaterials

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of valuation reserve for inventory.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.BB)
-URI http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SX 210.12-09)
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.6(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_InventoryValuationReserves

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 56 R45.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds $ 59,587 $ 90,590

Book value of long-term debt 120,167 115,840

Senior Notes

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Long-term debt $ 143,750 $ 143,750

Debt instrument, interest rate, stated percentage 4.50% 4.50%

Book value of long-term debt $ 120,132 $ 115,691

4.50% Exchangeable Senior Notes Due 2023 | Senior Notes

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Debt instrument, interest rate, stated percentage 4.50%

Long-term debt, fair value $ 76,425

Book value of long-term debt 120,132

Equity securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Equity securities 4,176 9,145

Money market and mutual funds

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds 44,091 52,996

Corporate bonds

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds 4,258 6,339

Government securities - U.S.

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds 5,344 12,701

Other fixed-income securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds 1,718 9,409

Fair Value Measurements, Recurring | Level 1

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total assets 48,267 62,141

Fair Value Measurements, Recurring | Level 1 | Equity securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Equity securities 4,176 9,145

Fair Value Measurements, Recurring | Level 1 | Money market and mutual funds

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds 44,091 52,996

Fair Value Measurements, Recurring | Level 2

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Total assets 11,320 28,449

Fair Value Measurements, Recurring | Level 2 | Corporate bonds

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds 4,258 6,339

Fair Value Measurements, Recurring | Level 2 | Government securities - U.S.

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds 5,344 12,701

Fair Value Measurements, Recurring | Level 2 | Other fixed-income securities

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Money market and mutual funds 1,718 9,409

Fair Value Measurements, Recurring | Level 3

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Related party payable 21,706 28,840

Total liabilities $ 21,706 $ 28,840

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258
+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DebtInstrumentCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.17)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15(3),(4))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_DueToRelatedPartiesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740
+ Details

Name: us-gaap_EquitySecuritiesFvNi

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_LongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermDebtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value of obligations not classified as financial liabilities. Includes, but is not limited to, accounts payable and accrued liabilities, commitments, obligations, and other liabilities.
+ References
No definition available.
+ Details

Name: us-gaap_NonfinancialLiabilitiesFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=avdl_FourPointFiftyPercentExchangeableSeniorNotesDue2023Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_FixedIncomeSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 57 R41.htm IDEA: XBRL DOCUMENT v3.19.3

Revenue by Product (Tables)
9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, Revenue by Product
The following table presents a summary of total revenues by these products:

Three Months Ended September 30,

Nine Months Ended September 30,
Revenues by Product:

2019

2018

2019

2018

Bloxiverz

$
1,466

$
3,656

$
6,392

$
16,691

Vazculep

8,786

8,759

27,669

33,097

Akovaz

4,208

5,991

13,946

28,083

Other

(231
)

1,420

213

4,232

Total product sales

14,229

19,826

48,220

82,103

License revenue

—

—

—

246

Total revenues

$
14,229

$
19,826

$
48,220

$
82,349

X

- Definition
Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599
+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R62.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Income Taxes [Line Items]

Total income before income taxes $ (6,630) $ (16,462) $ (26,846) $ (34,805)

Ireland

Income Taxes [Line Items]

Total income before income taxes (14,302) (18,314) (36,625) (34,203)

United States

Income Taxes [Line Items]

Total income before income taxes 5,952 1,773 12,309 (1,043)

France

Income Taxes [Line Items]

Total income before income taxes $ 1,720 $ 79 $ (2,530) $ 441

X

- References
No definition available.
+ Details

Name: avdl_IncomeTaxesLineItems

Namespace Prefix: avdl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: srt_StatementGeographicalAxis=country_IE

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_US

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_StatementGeographicalAxis=country_FR

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 59 R66.htm IDEA: XBRL DOCUMENT v3.19.3

Other Assets and Liabilities - Accrued Expenses (Details) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Accrued Expenses

Accrued compensation $ 2,322 $ 3,971

Accrued social charges 482 1,009

Accrued restructuring (see Note 15) 1,737 879

Customer allowances 6,244 6,541

Accrued contract research organization charges 3,389 1,000

Accrued contract manufacturing organization costs 1,284 2,028

Accrued contract sales organization and marketing costs 0 3,469

Other 1,559 2,798

Total $ 17,017 $ 21,695

X

- Definition
Accrued Contract Manufacturing Organization Liabilities
+ References
No definition available.
+ Details

Name: avdl_AccruedContractManufacturingOrganizationLiabilities

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Contract Research Organization
+ References
No definition available.
+ Details

Name: avdl_AccruedContractResearchOrganization

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accrued Contract Research Organization Charges
+ References
No definition available.
+ Details

Name: avdl_AccruedContractResearchOrganizationCharges

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued social charges.
+ References
No definition available.
+ Details

Name: avdl_AccruedSocialCharges

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for accrued discounts and rebates
+ References
No definition available.
+ Details

Name: avdl_AccruedTradeDiscountsAndRebates

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AccruedLiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765
+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(2))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringReserveCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_WorkersCompensationLiabilityCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 60 R50.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) - USD ($)
$ in Thousands
12 Months Ended

Dec. 31, 2018

Sep. 30, 2019

Amortizable intangible assets:

Gross Value $ 85,172 $ 12,061

Accumulated Amortization (17,456) (11,042)

Impairment (66,087)

Net Carrying Amount 1,629 1,019

Unamortizable intangible assets:

Gross Value 18,491 18,491

Accumulated Amortization 0 0

Net Carrying Amount 18,491 18,491

Developed technology | Noctiva

Amortizable intangible assets:

Gross Value 73,111 0

Accumulated Amortization (7,024) 0

Impairment (66,087)

Net Carrying Amount 0 0

Developed technology | Vazculep

Amortizable intangible assets:

Gross Value 12,061 12,061

Accumulated Amortization (10,432) (11,042)

Impairment 0

Net Carrying Amount $ 1,629 $ 1,019

X

- Definition
Represents the amount of accumulated amortization of goodwill.
+ References
No definition available.
+ Details

Name: avdl_AccumulatedAmortizationGoodwill

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_BusinessCombinationGoodwillAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNetAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266
+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267
+ Details

Name: us-gaap_GoodwillImpairedAccumulatedImpairmentLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=avdl_NoctivaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_TitleOfIndividualAxis=avdl_VazculepMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 61 R54.htm IDEA: XBRL DOCUMENT v3.19.3

Leases - Components of lease costs (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2019

Leases [Abstract]

Operating lease costs $ 411 $ 1,150

Sublease income 82 187

Total lease cost $ 329 $ 963

X

- Definition
Amount of lease cost recognized by lessee for lease contract.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_LeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of sublease income excluding finance and operating lease expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_SubleaseIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 62 R58.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Related Party Payable - Activity (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Jun. 30, 2019

Dec. 31, 2018

Acquisition-related contingent consideration:

Related party payable, beginning balance $ 24,247 $ 28,840 $ 98,925

Payments to Related Parties (3,307) (10,014) (19,261)

Operating Expense 627 $ (7,115) 2,384 (17,036)

Other Expense 139 496

Related party payable, ending balance 21,706 $ 38,692 21,706 $ 38,692

Less: Current portion (7,588) (7,588) $ (8,264) $ (9,439)

Long-term related party payable 14,118 14,118 $ 15,983 $ 19,401

Acquisition-related contingent consideration: | Earn-out payments

Acquisition-related contingent consideration:

Related party payable, beginning balance 21,582 25,615

Payments to Related Parties (2,850) (8,640)

Operating Expense 627 2,384

Other Expense 0 0

Related party payable, ending balance 19,359 19,359

Financing-related: | Royalty agreement - Deerfield

Acquisition-related contingent consideration:

Related party payable, beginning balance 1,799 2,184

Payments to Related Parties (309) (930)

Operating Expense 0 0

Other Expense 94 330

Related party payable, ending balance 1,584 1,584

Financing-related: | Royalty agreement - Broadfin

Acquisition-related contingent consideration:

Related party payable, beginning balance 866 1,041

Payments to Related Parties (148) (444)

Operating Expense 0 0

Other Expense 45 166

Related party payable, ending balance $ 763 $ 763

X

- Definition
This element represents financing-related costs incurred to effect a business combination which costs have been expensed during the period.
+ References
No definition available.
+ Details

Name: avdl_BusinessCombinationFinancingRelatedCosts

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Business Combination, Liabilities Arising from Contingencies, Amount Recognized [Roll Forward]
+ References
No definition available.
+ Details

Name: avdl_BusinessCombinationLiabilitiesArisingfromContingenciesAmountRecognizedRollForward

Namespace Prefix: avdl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460
+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.23)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
+ Details

Name: us-gaap_DueToRelatedPartiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=avdl_EarnOutPaymentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_NonrecurringAdjustmentAxis=avdl_FinancingRelatedCostsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=avdl_DeerfieldRoyaltyAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_BusinessAcquisitionAxis=avdl_BroadfinRoyaltyAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 63 R77.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies - Purchase Commitments (Details) - Inventories
$ in Thousands

Sep. 30, 2019

USD ($)

Long-term Purchase Commitment [Line Items]

2019 $ 7,194

2020 1,320

2021 1,320

2022 1,320

2023 220

Thereafter 0

Total $ 11,374

X

- Definition
Purchase Commitment, Maximum
+ References
No definition available.
+ Details

Name: avdl_PurchaseCommitmentMaximum

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Purchase Commitment, Maximum, Due After Fifth Year
+ References
No definition available.
+ Details

Name: avdl_PurchaseCommitmentMaximumDueAfterFifthYear

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Purchase Commitment, Maximum, Due in Fifth Year
+ References
No definition available.
+ Details

Name: avdl_PurchaseCommitmentMaximumDueinFifthYear

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Purchase Commitment, Maximum, Due in Fourth Year
+ References
No definition available.
+ Details

Name: avdl_PurchaseCommitmentMaximumDueinFourthYear

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Purchase Commitment, Maximum, Due in Next Twelve Months
+ References
No definition available.
+ Details

Name: avdl_PurchaseCommitmentMaximumDueinNextTwelveMonths

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Purchase Commitment, Maximum, Due in Second Year
+ References
No definition available.
+ Details

Name: avdl_PurchaseCommitmentMaximumDueinSecondYear

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Purchase Commitment, Maximum, Due in Third Year
+ References
No definition available.
+ Details

Name: avdl_PurchaseCommitmentMaximumDueinThirdYear

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermPurchaseCommitmentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 64 R73.htm IDEA: XBRL DOCUMENT v3.19.3

Comprehensive Income (Loss) - Components (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Accumulated Other Comprehensive Loss:

Beginning balance $ (17,777) $ 78,546 $ 2,780 $ 85,580

Net other comprehensive loss (8,988) (15,763) (30,043) (31,830)

Ending balance (26,963) 65,742 (26,963) 65,742

Foreign currency translation adjustment:

Accumulated Other Comprehensive Loss:

Beginning balance (23,720) (23,435) (23,621) (23,202)

Net other comprehensive loss (210) (60) (309) (293)

Ending balance (23,930) (23,495) (23,930) (23,495)

Unrealized gain (loss) on marketable debt securities, net

Accumulated Other Comprehensive Loss:

Beginning balance 872 (224) 205 (64)

Net other comprehensive loss 86 68 753 (92)

Ending balance 958 (156) 958 (156)

Accumulated Other Comprehensive Loss:

Accumulated Other Comprehensive Loss:

Beginning balance (22,848) (23,659) (23,416) (23,266)

Ending balance $ (22,972) $ (23,651) $ (22,972) $ (23,651)

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 67 R12.htm IDEA: XBRL DOCUMENT v3.19.3

Revenue Recognition
9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

Revenue Recognition
Revenue Recognition

The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property.

Product Sales and Services

Effective January 1, 2018, the Company implemented ASC 606, “Revenue From Contracts With Customers”. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product and the Company’s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

Reserves to Reduce Gross Revenues to Net Revenues

Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.

Product Returns

Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products and other judgments and analysis.

Chargebacks, Discounts and Rebates

Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer.

Revenue from licensing arrangements

The terms of the Company’s licensing agreements may contain multiple performance obligations, including certain R&D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments. Each of these payments results in license revenues.

License of Intellectual Property

If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.

Disaggregation of revenue

The Company’s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company’s revenues by product, see Note 18: Company Operations by Product.

Contract Balances

The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets.

A receivable is recognized in the period the Company sells its products and when the Company’s right to consideration is unconditional.

There were no material deferred contract costs at September 30, 2019.

Transaction Price Allocated to the Remaining Performance Obligation

For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial.

For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product.

The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_RevenueFromContractWithCustomerTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 68 0001012477-19-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001012477-19-000012-xbrl.zip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
&XG87-*%J,>J%Q06DC,GPW+PC L.ZO$L)5B MV"L1Z[&;39.6AHQ=X^GF#)P3GFC'U<, >JXJ-N=@O$^EDP<"DTDT>;I/$>$F?=5O@.3;<^ 6?.G=VCK#K.0LW&^]REOMJ1%3\XKY[JY&G@T09^D": M)18 NSHQI#R8LGP<#90]D>K^*_8Q]$XT%23W$=Z/Q M>"\@!*"RG=3!P[T<1 M #Y,A\ 5Z)_HV6HBT ,H_+3O870?8JP,V@R0#WG)_"V^8_=P03$;07 MYSAS_4\:"NUK&(>P<.C0X.=IZ(UF$QRF\L._O\!CM)N"MY7?]Q&O [HK^QZY M$)00WQ5R%9 =-]:^?F/&@8:/\VE.C>1D<=DBUYIWD,8*'"#@2+1>S*3_/)#\X?)<(@=$'I2!-D=%D1 M@MD(SEDI\V#12E9""0.)^P*#Q&7M6)H8]7! ESE&5HT'"K.D";7F+O@U>+Z MJ>DBB!SVZ=,%.RJU([]R#JT:V4"LX&FBF[M2H]X:?]870S1?_&45QG;J2\;0 M*S04L'1Q%CK)38Y,2,ZLZ;.>HS;-:='J=F36@0]V"@WX5?JG6YP=&P&G:/TQYH<09#: M?#)Z4_!Z;K1FUK(.I"S9N*7XR0HK'TQ):-]G7FZ:#K.,(_T\Y&BPGG$-QD]% M9N?+XN-:8Z-F U5@DK90!>Y ["I9D<;9E_ MH'__ _8$PJ/I%O#(&?86*2X$9?2T]BW!1J^(+4![9DQJXBY11<%NAGT!N[>Q MT/H+0"C>:9Z6Q7V7WIC11X[6&7]$@Z#D=_GB#F,2<[9+$;?44F0!HBFLR::&86G,Q+L/<@P: 0]8U%/[6W:.@2^?%O[DF/P8 % MQF8L[ X^[[LO3FF:@6>"?UPJDXS%3$0Z&Z<5K@5;_9I'% '=U>]ZHA2%"PN- MCH+4<"68F5+E3G)YHEM2!2=S:[TT&,N0:U>X'*T&]S=-P,N7A75@UJNG(BF9 MVGSNGCD:QL1..%_@DD>%.*\6?N^JA<-M4N'JE;W/^:)#:?%U>ZN*%1W[2V,P M/!$1715ZM"XYW1YG65(OZ=9#JTBYO^>5UM^1\=+8&V%'A[B\A?-&[B4/XV@, M'#"9!!*C9SKN.>(ASF/ZIWN'D*!XSMW'\OR8JJPE]<=W/F>L$S@W&]N5QS#-+'PUCL!+Y M#SE.Q^S/%*S5;*L-^@O)W!0PB8%BX57@2>K&QF#>@S!TN'58A'YF"[AF63-W MMC"D>L_EG?#+K7)TS(-CZP*]VI:U$EB8@S"-TU1:NCS;,<]6FE1+1 !S(0!U MG>TR%> M_OGY&WW D;R5H6DD!J/S+\RV7OW-O?23T=GIZ4FW<=KJ=7[*MQUZH%E\HL19 M_L>2@S!K?3D=0;$5L;,RL\3Z"0U,P_KN3T_O=5RYZ]+:;K][>,S)7[%CMW5YL+7?#XJF2K+Y$@;[><"CL^03]']]V8S[;K2M)#O91ZIO>.SE#)OWTM -AOV#BP2]>YM@1:K!UL/ MFCT.Q=1KNF3J58AO]BSFW_ M]TWR1G/\8*D_SWR1^;AT-$.G[W$[9[-DA0G[5,HE9O(86CM:8_;RYV=35AR= M*.4#6Y4%3"7PA9'.9LYF+*98*_+1F5-&Y>&)TD1)OSA%83;:K\Q+]WG5[5D6 MA0=ORSO(@@@G @$-U,E59\?Z5'9<3B>CV9JN-,[8)VS1#;;H$EID12><_+RR MO!/!U'E,17:E&AH+L\$H)=_#%H$FY <.^92;?$V[&I4\B]I7?4+RJVF/LW'L M/B.;WZ.#E8V5:\9*8D)*'(QG9]5]5EK@C1]#0*U *3\GA6[? M?=\][7_HGS;;G4Z[V7[?[EYK!7]>\JU-E'TYPD Y >&Z'#TZ>;FA[T_(TWX(GP1O@A? ME<;7DV'4+0JQ#H*KC+!(XPY!XRR$Z?OU]GK>BUL9ZI),@^?5:*A^?&+GF+0N MGVJHC+7\!)OKL6WS\:C9_+ZMM1T[67^_NU,MMG4B34$FKMH;9+H"70$FCK!=I6PUXE8D(MH990 MNQ4#^=1>T25"K>6HP7YM^##;/!A/*/'0[LM=;"#94/WCMNN*J!YQW=/6UMRH M0V!PXA_B'^*?9_!/^]3:OA3B'^(?XA_B'[)_B'^(?ZJF0L0_9/]4-()6X6!X M7ID$PWH59RX2XO-6%VIV%+)20JR,X$@321.K(3C21-+$:@B.-/&0-='"&G;- M4[7]'L8"'OR7\-DMER$[PIWM;[%:[IC'WX6I[:>K%2OAI;$N):VK&5*0Q3Z. MG]K#4[.M./9GAD-)"$6@(% 0* @4+[;X=F/8[5P^I#^D/]MU!M9TK>J^TW53 MJ85LG&J<]M[75' RA,\B6SC7 M2^,L&K*COW7@P]'?W+[^3[O[EO'0A[_Z_;_KKA MQD\O;#EBU+7&@(3@8G ]"B8>IVM)60B-!&:]AQ- M1Z?V5@;I#"95\=Y=>C,*65;HW/W!A#1?F]*Q^B'/T\[6O!=:=B$.(PXC#K-O MY;J=K<4S#WI=APB."(X(CHPT,M*(PXC#B,/(2*N@D?;ZS3?N5MAM/4LP;0HE GR^C&M!^L^F<6CR?MJYD]IGAB8*( M@HB"GI6,N-MQB8*(@HB"B(+("JJT^A %$041!9$55 <**H7:?M;)3U==OT&T MEZ01R% J$CF<6N6CFY%@8C@47H+I7Q/X=!&-8;"FING] MIMM[IU@:\M27&(?SHA H49F_=+16A^>&,N2A)WD [X4*WB7\D\?' M.OO[[S^GZOB6\\G91?E5'_5IOB]1(FY VN^#R/O^C__\C[_/K@V3F'M)RH/? M!C 2/)%1>"45@.G?@L>?>8(Y$O;ZXNFPWW M])^M?]]GS4:[>^J^ M^<>"DI0']T:.A6)?Q#W[%HWYPY/5#G7L,A4LB8QRC?@$AI*Y+AOP\'N<3A)O MRCRN!&K$]42@#B53]G7$XS%?&M-GOMU\Q,O/9 +]\TQ['/;:!^O'/ 26.PZZ MF2K4YK%,#!2@^Y,T]D;84<"*5* JH+R1GP+PAG$T9BJ=3 (I8L7@(@97AK>( M*_SI?L03 X30"U(?OI8A^\KCA'W\Z+"/ #?61_$]U"#0N3X[#T/07_9-3*)8 M8_TJBL?,;1S_[PECYQJLL$@@_> 5W@<8SMTU\[&((?\Q]RG([9 MGRD/$YTO6I]\A5^\&7B@P]*#7]"^THV-Q9A+G6$ND$.1=R&_P]&/$#^PSW@- M= ND '#URZV"JV)H$+8N )NM:"6; C05$R'*ZU)X6,$:^II$X"&MQNO0R9Q]B=O?]5,DSA/F<_DU(6@=#^9L"!>O*1YLDH][(@BR M:WYYTWBC/X,-X>6?GT^$8Q[?RM TDJ=)E']A[!K]S;WTD]'9Z>E)MW':ZG5^ MRHTCL%\"/E'B+/_CW:+-,FM]>:6NL'LZ*X^.K+_69QK6=W]ZVK!::?J9^W=\ M>W>KKW_9$8\-;'UXG2MJQ1C6G^X-_@91X)OG?,WGHXL9F2Z3(SGM+W7:UR_4 ML7VM>]P-6Z)^Z[KW_GD)92U4[-B%"F937F>RZXHG)*J- '<[P*RLJ#9XBK+N M.Y?0=[(6H:.-K)3DC9*\+=W6<]S3S:=YVY?M\K2;M-EH-O;'8-HY]:Z=BN/5 MRX_;I177:=G3DX-FCT,Q]9KV%F/)U+.0^L>F$/>%B,B^.03[QMK&-.(;LF_( MOB'[QM"*O4R.9-^0?5,H%EDW9-VLK2TW\(O@PT3$9..0C;-6N>U^TVT^1QID MZ1QVZM.;*.'!XQO[R-:IZ7F6!TYO>A[BAS.+56?1[2K*O617E$]P7(I!<@GW!9%*XV>=S6A==*[> MGW?[S?W]\W[O;:-C; M\7YJ9<=[IU_K'>_U;GVM.E_3'<+5ML1)/K2)?W9;<3IP)LC\F" I'"FOZ&LO0DQ,>9"?T\>QM^Z33^ G/V^JSQ]H<52*4 M4(9XIBH\4Y,8P^; M\TDH=69"L+Y4GK8;,46+5"K512.]2&%"EE DUI91B:,/M^@M9KI;W]FCPK>$ M-D+;*]#6=QH=>Z?6"6T4?GI0A%_ 0O!X'$\EYG4K(E"!Y ,9R&2J,T&"@18^ MOOY,3B!M/7^1Y]-L.&[+7AKO??=\"%P$KF=LLNLXW=/-GXG>%W =?%CA-YW[ MV7]JLQFY,>3&/*U,K7$?;"PKL<%GS]7*B;02$ME=O(W ;W0, &^TAV+D(GQ]/ MF#]&3H[/CK>74Z(72O12DPT>E.F%&)(8DAARCQC2[3B]%N7"HOC>(^R8Y2[2 MB1VKS90DJQJ6,*R&K$BO2*_J5!NSYF&;#W^F* @P5S- JDFD>+!KV < M3]3'T M2E!O>!4V482K\WR8BUC41U,N*&WRX:G4Z+?>TUVSV.^?-]^?=JW[[ M_*I[\>'THG?>N]IX<0/;,?JYT7OF0_3'I6H(E_).J$0F(%DT.).18%^%+WD2 M2X^=*R56F)TO:?WC";.V*<-GKW,\UK@26O](08[#J=7V_A:R*S&(4QY/F=LT MR8$=/4@7X$'P< H?HENA#QC?RV3$9(*U(P9*PA#&N+^XF/S.[[@O O9UQ.,Q M]T2JN4VQH]^OS]\Z#.!WXK#\FEP!5/[#U?4%PPIU?*)OA.\_?;I@1_]/5H>L MV7BW>$7QD_L.'H]9U+*'_W[-_ANT#Y">/7WN,?E/"[?2==Q)'H"&\5MANJR*OKGN._:_/![(D ?9=^U^\QW[ M\,V!MPTYM IZ=!6('Q+>.$M*;:[2H^?)R7^+'YF0>^WR,;9)+,/O,$O,;EE4 M2P_F4B[U2$30R@2Z-$@5@$FI54V]'T$SV#V(@8U$ -=.40-/9J_48LT@P+@' M3C6.-^J@+ D6A-HUHKL48%]*?!3V)6\-.MCP9CX36E*.3C>"JWL*LK:1*\L>;TC8H MFB.LQ2( )7Y!5,)V]>[@\];R$BO_6 M["YG!G_13#@0MS+4V@"R^Y\TF!KTHT1%Z&??_^8E$0P_)B1O.%D**?PI8[1; M&'\0@U@A8HL]=KK-Y9,%+WG4.Q@>/3YY<['G/,Q0VG3MM=GM.+8&RA ?-'Q! ML^)HRH/$OH:YG9_L*!CH ,8/P;86*L<9U,J?%(M DG$T:Q81DIC9C_L!CDA%/\%FA M,+9 SLG&(M&W@TX53\_$PF\$XO.]HI/1&B6Z'M(S!> MHHF>%F8^! V&_<'0]YT#)O0L5"+5 DGH:2$P9A;U*NLYLX8_(O?! 'Z28PD4 MB)0-WTDU8H'Y1B_9(0XC$Y.:>S#0IR]8"$_"N2]S=/-'EN?4^9_FG$N\E#.D M^6!Z'-V'\,K"D9\N&.-F1LEY?M[=A0;/]-$OZ>/#;N_3&EQNZ*3D(FDS7YNG M( \S+R8CG-*L,M!FE>A%,+!6S9(]U*2'JT:ZC;5BRO-![4V5&DRBR7.BVT]% M]^:&NCM70/3E:S^@N-W7+_Y 3Y\5R-\VG2_0SKT, K3X[R104TX5FAQ-["BS M[(=1/$Z#S'),$W#@_T)N6TU4&-8 B@3K%M6X;!LF>30AXR;]=J3,0*"3*H,H M80,9";CU#MP2W-*@DM3'V .T )@.HP6KFH0M!H('_Q@X)AFIEVPUF5_$> WY M=(E\B'R(?);OFQ$,X#X6$! 3AIL>-8@6R D7#Q8LKL55*^2A <]V(' V@7<"_>". M 7C?W*(1OKSLEJG4V1(4)A"2(2[GX6@_&1L\J8]HK _NMI<:9MLO?@5< M\S 1HGIMWQ,M.0C-EM/HQ+,?E50UV.P@,9#_F= MV:937'O"?B^:M>(!C[2K:(@_OQU)VZO9/H?!;&DZLYI7;,IY]@:F8H?28MMF MC3 [G!;W-IF]=:N:(/5>8D%;@FA+T"UM"=(*]OPM0=W#W!($5,5P7D'8."4R M>SF=XJ:?V=WW41I@;, 3:*(56WS ^1^G8W@( "!@*^7\R! MS!V?LZ>M'*(3 MQGZ%5\_Q[=SZCOB!,0>PZV>34WE*F.^UG@ZR^:QT VJ!A[_HPZMZ\CR'/K6[ M#7C].0.O)S7$=,\5.B$8<<%5]VSC+\^=E(#'MZ@GD=&JD =3)0L%GD0)@ U] MID3J74YXF):CRQ(I)74 @"OPI-($SY8Q7R@OE@/! MD*;L*?CG?T%O /$3_#L*#>H+!Q3@E=59QPT6I;&:*7NB)8:1-G\6K2MVK&G- M*ID_['Q%9?:7].M:3!(QVP>/;FVK8=PH*\\W*"I*Q*(2B$(E9L)$)-@9\H[3 M[RS7+'S1D!^*R[%M[^X<_&[P;( PR;NKM'3N;X:)\ _:]%,V!A M[LV>-)MIS#FIN2GYD9D\V[&V>+O-2:II:646NY1;*OF,95J[P]E*I_K(;)%] MF;EF&F1MUFKM>M:J?YARZSU ,W?(96RTH[#7LY#S:K^B,,=G/V=>DC[_E]VK M3_/-^+?P#X9#5#R]\PPYUXO& XE;:(%Q$6=8<0=:RP.K:E"W0;?9WO6>1K.>QKDL8';Y#5YB'$_=K=)5Q:X$:#5XP'D(SLW. M)"\%'8K3RGF4-2E\6G,$]?K"@3E4XF,C?2YT^=:R!#"X>SBH7$@.XG: >1$2_GN7*B[79MJ/2@>M58:H2491] =RL]/0=Q:%'-/]Y7!S0 M7K%B,V>XGI:%.Q%_6WN[(2) M ,.'T;UVAS"D?8M)JT)CG91^75K7FG5W?E5KQ.]R3PWT +JNS6@EO#3.OZ^> M) :@3!&,:NZ8^F#\SZW:+&C/>FN ,$'-Z]'LQ$(Y=T;AI@\00DY)EKF+!;-B M@ DAOH?1?2#\6Y'MFL,7*1.*A_NG!GU*B.]%1XH,&]DX#L';0]\0ID>"9\L9(Y8L6"@9^I4J;+7!PW,9L_YP+K4^VW %\VW.R,U*)5K MAH2KO,0@+FMQ#A\$563"^RML\,*Z5K-S&MQ'1C:A[7G'KMCTDRUUY:N1ES!# M:%"W,E33R6"KSA.NU65#O()7M8-=]FIRG4M##I1O3BNBM:#,7[KFA#8E50+_ M&>?&+9C ZG'3:T5BKU=F[2IG /O 8USS5E]%?(VQL>>D]NJT/EQ>=4_[W6:K MU>E=7IY?]?JM7J?3N>BUFKV+]L93>RU:%>(*M1Z]'1./1:+U>."EQM>"N1P:*37)%1?#EX@N(TPD;YCX M<^FR2(O; M2QTI5DI+L]A3'XX+O>'V_I\P@N?,&T5HM8.^@%.6!&)) M66?[JV;K13/5U7D)N!HY!1ICO:G:Q";GEF"2^^B$P8O-^5OS(CD\-N]"G1V+ M9!1IU8W%$)-D/1M&:1B@(5D".8;KR_ ^,>LBV:N,-ZB>?+)QH?,>FFC6(O1, M,$NWVSQ08%*%>1'(W#M G.*&XX6<.K,WOES3*ZW6J^R)+5B:!;D+O6\\'XX9 M31DZC";9$N.WZ]_G(@@Z(=)SJ#9F2*#:2]&45YHCTL*]26+!P6R<9F\W.OD: M'V,'TCW72XZAIW/B99H^T%:(SLSQX/2YF#O10-9(:,6\KAVT*%4<_56]!)?,1?86(YCXN?RB,(K'/)C+H^S.G2RR=IAKH>7Y<2WH9U:E M#U,0\HD29_D?2\'9U>>_9B>->BL+WH1K]3O5]1' M6!TLNQG%0K#/$>8=8A]"W.9>[*YBK89#2D=*9UWIOH!E;$'G7E:@
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š?>.AS\W#NFM,W8+5V]'( M$[8"7B]?(P'B"V6HMQP1[8P+(^!&)J(:A+1W>?57-UI[N:34$*O>]/]*^J.+ MB"\+)XY[SN)E$I Q1C&@"FZ6W#0$#M8_&]^9_] ; YJ"->P((8*UH9A)"AV3 MG@.-Q'8NA!8VN/6O,^>A+\4WP:G7*.@#Z7=#_R^NCJ?4J5(]@-Y(4;)[730C]4G3F=O1ZWS2)GAGILSJ3JJ:C'FLFQ" " P6 MNPVSJ0#_K[MKV6T;!H+W?@T?R]>E )_7!D6!'@G7$!H'26RH29K^?47)--"B MDE-)E.5'F?C-XV.2XB!%A#02I8)FGDLD #&5\2)!N_#ZX8IZ>522C MV1!=0X;Z8S WS_7VMH%U'-^&XT4G.8!B7%HF!"AKC- 9&VCJ_VBV%7/GK"&3 MS87GDL=DTS4_Z?J@Y*/%.Q ^5]O]]^Z6 MMW@,K@26_>K(M*5:,F2U3Y):,^$A6>)H[C4:WS6SF"UH*0:O#/KS9.\Y(&TX M[[\>=O6QP]/733JZ[9_.QW&!(M9-T5!A>>Z1@S M1_@H'/$J4(2D!" !<.JLTB%'-<(35MBN7F>_ +X7V;[15?*V"V(]:/@YYE/N)TPNR]FREN+1?+!=A!YM^)-#SN(%GCS=<9:_M[KXW*C84LL2T-:44++^7-_$VUF.]KVU_V^]L___CC;[_]]J=OG[;K/U7;SS^"-(4_'O_J MV4_8[UZU'WME?_0J Z]@]J=ON^4?$N/A9E?;=C#2?OS;D\__!NM/9Y32'^O? M'C^Z6YW[H'EL]N/__.G-A]K/5ZO-;C_?+,H__/M_2Y*&CFVU+M^7UXG]]Z_O M7S^+COYH/_'CIOQL^7Y7;E?5\L-^OMV_F7\JUP9&_;0OV_+Z_"/6V^V#)UB& MJ&4HRRU#__3"@_??;\M_^\-N=7.[-O3\. !_#\#[IV!CH:M)^+D/R"Y6'S\P M,-Z/INN681$_?61@S,V+IC;+&._OX\<&QAX6/?!;SVG[J MC?GJ\$'[] [YK8T?1/7DP>6W?;E9ELM:-!\\.EDM_^T/YJO9W>[5Y_G\=O:^ M- ^;;U;_J(>3'?NTVV_GB_V,% 6&$'""L:9%"LW_JPS!@O""*XGQK'[L8<4X<8Z1)]W%1B7+NW7Y]IK?[5:;0[46WV M)APT(9_Y:K>!.\DOMT/,=^K)-ZZ:< M4VQ5/Z4=L4&C*'2@%NA0]+';>!HCP.A>5Y?M66XCS&Z[/T&F#(3]]Y_*_9=J M^7KSM=SM[=S!TY^6Y<_SFY)]6^UF)-4,8IT7&58JRZ09_;(#'"6X@BY#2G00 MD<>0>Y17B<5DHCN#RG$@B-\"W]-G2<:+7Y[K%.#^7KC#"/ MU@275>+QW*Q&?K7=M?8Y<[*ZF:\V,YX*P0I&.>8@I1H9*ZVXJP)EU%5-!YH9 M72\;7!Z*.93'ES5Q1 J'JMY+[ 73O6Y.GE&V0$1>7KM".5(%?\G<]&?^=;F> M?;@M%ZOY>O_]W9?Y]F;^4WGSJ=S.'SL M'+\%E32HW&1F"%W=\C(24YYY\R.2DE\:2(ZB/(2MY6&1LLYR+LW: S 1V7LD MRM8[*[DTI3"M!?=Y?\\(;0!R+BNP(1RH@KTH;H*Z+%>S-^7G^5J9?'W_O0X9 MLQR*+*4,""8*J-*<,]!:P!G7+DK:Y[F1);2&DS1XO-+;7AQURV=L>OQTTX>9 M,X'8KHW$=N7B3Y^KKS\:[YI S'SQ. 8[X_D9+1C"SV5%8!#R:OC;X=[MFX7:Y[T>&KG#MR^T5V;FS\S+/3T:*7[=W)6/ M$%W\U.5G^G IX:XIG MA5,7'V1@G!1I=0A@YWV2)'_2W-.DJ'SU2I1.J!J0*OESYI\L1>5N4+KDQ:%7 MPO38YQ=2IMX432=IZN_"F;1I(!^N^UID^6G_>K/;;^M7J [5!"$Y8)!F("6* MV.EV(1M#)"6$2)\M*CT>'UEF+:+D'I)7)C6$M&ZA'8DO/YGUI"K*7HRGA'1L MJQC WC1V2 QQH KV)@U1D).IO/BE"[*U^_$MERN]NSS MMBRMO4.\I"&!2B$(F<*%$B)E^%[M.&+.^6)O"[&UY_6[I &6')%YI#_]B7/( M&4?AS%-KSM#5)VWLSYM'WC@*?_T2QWX\NJ6.S[G]7.XXF*8))(_#?:A"OCA^ MP5]C2\\7JW4[TR\5XX7".#=9*4:$=(1S ]B;1B WQ($JV)LT1$':985>'(X147Q=:%3 M4WKQX982FO2SVJXV[ZK=KMS92AV-Y?EF^:%3*85O!Y?4\Z)-X#__ MY<5^KX0U?#/X9+(7;8Z>*6[X9G',?WW)>C8QCL;Z%#+F>,Y5H[RY?A'RZ\VB MNBD_SK^QN_V7RIH]GHX"/-,P95"#W&3S*1J/0;:_JS&"66?IZCCH@Z +'3B*M#.%(%?^E"Z-(AK&>< MLWI_?Z9R =(<*ID>I9#@?+@R.1JZH#;U2NJ'L3I$GR(0&DZA+I+O=_'DK5*> M]$Y9IWQ=<5*J7ORX:Y7IVYOY^GWYM=SGBKB%/F9)4R M(LD00BGAFF@$";;[@HD-^0J:IEX5Y7K:B"Q9]["2&E=B@?7*_7J3Z"948_#G M)U"]J(M35>T\-QUJ-)3-::C08"\>5S$+PLH U3D$:IG,B9*9BI5<&[3)5PO7 M3VM#BVT]9#TPW*)/7ITQ;H$F--+F'.JZ. M.YF#$>TFBF,R[*>$CY!=)0W7%ML?KY(&WM@G]CNYZI"\4"Q/0^>">?/D&']( MEEP5[=VV6I3E-GQ_F]MJ UYN]>1%7G]8EV^W*_6Z&<@5M26[* 29YCC(F M8&LX*X17_AW 7.1@CWW^O*WO$TP6\]V7Y/8 V(K9Z@@UF==8Z^WIV]).PYJX MO8X,-^;5]-2Z$$W@)G"VXYII>"\]R?@\P:1".*WHO,]:A>P'IGH;T MA72HBO9J^A=4JK:O3\X=Z-5FOEF8#MT(+]MN#8YR.2-04:HPPDHK@GD*L_Q0 M?9/ S 2;OA66PEB-+(>V_L1U"^TJF=?@DOD!G7_)I4!4NX9WEV#9-]"S&%^M M-J].3C_I>\8;H E[B?%H59J<".R,_D(WPC3$,()?9PH[Q6#.Z5CON_GW)KFN MMATX9@ C6M!4"%OA+M58%NQHF>'IP9#<5UMRI>BF;/,+!EV"!,#D=#7S\X&JHOR+#'4=P+,-WO_&T(QMT.W+I1 M2[SSS>_;N]N]XOO8CU?W1RF,-Y>Z]6Z7#8_>K/Z MM5Q__UCQ4I:;E1G#E)0" 0&DS@L-&!,$M=4*(4?*ZU!(#/NQE_F/D)-%#? 8 M;)LL^-KB/OP\6=?(DWV5?"K-&&3!>R[TQV@=QX7^"S>,YT+_?9N(0YNP8YO4 MD \_3]ZJT$P3Q2" $A&>P13E&+R8[NG><%IE& MQX[D6S7&.^VY1?MXT[,)YU;[\LWJ:_D$S<>Y^7*6:L@UR"BCVMA%.C) M2#+M=WK$W:Q@LBB$2#&3"!-);!%4#@J:,8A@)K+((56+M!FM+=97-=@SG?N7 M&K#O$9. #> FI1?BWD]' ](>9\>X,XE=V\C#M\0T]#.&8X\WG,?BSN5"^O=V MQK2Y[+X0&950:9R!C'$A9):V?9()[GSW_/T3*844"H8SH_%8XI064F6PH(5! M2S&-75VP!N)U4->3D&Z1BL>%G_XXT1#LBOBCQV?$HA\CE[_XO0?F:L@[X-E[ M#R=4N"9IGIH7,]7V%2T*(O#A=<6HX$Y73CQ^IBY0KI3.H,HR3%)..#!9&",, M
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end XML 69 R16.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Intangible Assets
9 Months Ended

Sep. 30, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets
Goodwill and Intangible Assets
The Company’s amortizable and unamortizable intangible assets at September 30, 2019 and December 31, 2018 are as follows:

September 30, 2019

December 31, 2018
Goodwill and Intangible Assets:

Gross
Value

Accumulated
Amortization

Net Carrying
Amount

Gross
Value

Accumulated
Amortization

Impairment

Net Carrying
Amount

Amortizable intangible assets:

Acquired developed technology - Noctiva

$
—

$
—

$
—

$
73,111

$
(7,024
)

$
(66,087
)

$
—

Acquired developed technology - Vazculep

12,061

(11,042
)

1,019

12,061

(10,432
)

—

1,629

Total amortizable intangible assets

$
12,061

$
(11,042
)

$
1,019

$
85,172

$
(17,456
)

$
(66,087
)

$
1,629

Unamortizable intangible assets:

Goodwill

$
18,491

$
—

$
18,491

$
18,491

$
—

$
—

$
18,491

Total unamortizable intangible assets

$
18,491

$
—

$
18,491

$
18,491

$
—

$
—

$
18,491

The Company recorded amortization expense related to amortizable intangible assets of $205 and $1,620 for the three months ended September 30, 2019 and 2018, respectively and $610 and $4,996 for the nine months ended September 30, 2019 and 2018, respectively.
During the fourth quarter 2018, certain conditions came to light, largely the lack of a meaningful increase in Noctiva prescriptions despite the substantial investment of resources, which indicated that the carrying value of the asset, may not be fully recoverable. As such, the Company performed an impairment test based on a comparison of the pretax discounted cash flows expected to be generated by the asset, which is a Level 3 fair value estimate, to the recorded value of the asset and concluded that the associated cash flows did not support any of the carrying value of the intangible asset and the Company recorded a full impairment charge of $66,087 at December 31, 2018 related to the acquired developed technology associated with Noctiva. The February 6, 2019 Chapter 11 bankruptcy filing of Specialty Pharma, the subsidiary which markets, sells and distributes Noctiva, confirmed management’s conclusion on the impairment.
Amortizable intangible assets are amortized over their estimated useful lives, which generally range from three to fifteen years. Estimated amortization of intangible assets for the next five years is as follows:
Estimated Annual Amortization Expense:

Amount

2019

$
815

2020

814

2021

—

2022

—

2023

—

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for goodwill and intangible assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-URI http://asc.fasb.org/topic&trid=2144416
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 70 R39.htm IDEA: XBRL DOCUMENT v3.19.3

Net Loss Per Share (Tables)
9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Schedule of Earnings Per Share Reconciliation
A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands is as follows:

Three Months Ended September 30,

Nine Months Ended September 30,
Net Loss Per Share:

2019

2018

2019

2018

Net loss

$
(8,864
)

$
(15,771
)

$
(30,487
)

$
(31,445
)

Weighted average shares:

Basic shares

37,436

36,904

37,382

37,410

Effect of dilutive securities—employee and director equity awards outstanding and 2023 Notes

—

—

—

—

Diluted shares

37,436

36,904

37,382

37,410

Net loss per share - basic

$
(0.24
)

$
(0.43
)

$
(0.82
)

$
(0.84
)
Net loss per share - diluted

$
(0.24
)

$
(0.43
)

$
(0.82
)

$
(0.84
)

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 71 R35.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Debt (Tables)
9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Schedule of Debt
Long-term debt is summarized as follows:

September 30, 2019

December 31, 2018
Principal amount of 4.50% exchangeable senior notes due 2023

$
143,750

$
143,750

Less: debt discount and issuance costs, net

(23,618
)

(28,059
)
Net carrying amount of liability component

120,132

115,691

Other debt

35

149

     Subtotal

120,167

115,840

Less: current maturities

(35
)

(106
)
     Long-term debt

$
120,132

$
115,734

Equity component:

Equity component of exchangeable notes, net of issuance costs

$
(26,699
)

$
(26,699
)

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644
+ Details

Name: us-gaap_ScheduleOfDebtInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 72 R6.htm IDEA: XBRL DOCUMENT v3.19.3

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Sep. 30, 2019

Dec. 31, 2018

Statement of Financial Position [Abstract]

Preferred shares, nominal value (in usd per share) $ 0.01 $ 0.01

Preferred shares, shares authorized (in shares) 50,000,000 50,000,000

Preferred shares, shares issued (in shares) 0 0

Preferred shares, shares outstanding (in shares) 0 0

Ordinary shares, nominal value (in usd per share) $ 0.01 $ 0.01

Ordinary shares, shares authorized (in shares) 500,000,000 500,000,000

Ordinary shares, shares issued (in shares) 42,857,000 42,720,000

Ordinary shares, shares outstanding (in shares) 37,450,000 37,313,000

Treasury stock, shares held (in shares) 5,407,000 5,407,000

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29,30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655
+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 73 R2.htm IDEA: XBRL DOCUMENT v3.19.3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Revenues:

Total revenues $ 14,229 $ 19,826 $ 48,220 $ 82,349

Operating expenses:

Cost of products 2,823 3,120 9,711 13,224

Research and development expenses 7,539 11,402 25,160 33,243

Selling, general and administrative expenses 5,316 24,829 22,520 77,159

Intangible asset amortization 205 1,620 610 4,996

Changes in fair value of related party contingent consideration 627 (7,115) 2,384 (17,036)

Restructuring costs 1,866 65 4,600 268

Total operating expenses 18,376 33,921 64,985 111,854

Operating loss (4,147) (14,095) (16,765) (29,505)

Investment and other income, net 781 208 2,548 845

Interest expense (3,125) (3,000) (9,293) (7,577)

Loss on deconsolidation of subsidiary 0 0 (2,840) 0

Other (expense) income - changes in fair value of related party payable (139) 425 (496) 1,432

Loss before income taxes (6,630) (16,462) (26,846) (34,805)

Income tax provision (benefit) 2,234 (691) 3,641 (3,360)

Net loss $ (8,864) $ (15,771) $ (30,487) $ (31,445)

Net income (loss) per share - basic (in dollars per share) $ (0.24) $ (0.43) $ (0.82) $ (0.84)

Net income (loss) per share - diluted (in dollars per share) $ (0.24) $ (0.43) $ (0.82) $ (0.84)

Weighted average number of shares outstanding - basic (in shares) 37,436 36,904 37,382 37,410

Weighted average number of shares outstanding - diluted (in shares) 37,436 36,904 37,382 37,410

Product sales

Revenues:

Total revenues $ 14,229 $ 19,826 $ 48,220 $ 82,103

License revenue

Revenues:

Total revenues $ 0 $ 0 $ 0 $ 246

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460
+ Details

Name: us-gaap_BusinessCombinationAcquisitionRelatedCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfGoodsAndServicesSold

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684
+ Details

Name: us-gaap_DeconsolidationGainOrLossAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 6
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7(a),(b))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.8)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_InvestmentIncomeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (expense) related to nonoperating activities, classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.9)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_RestructuringCharges

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_ProductMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_ProductOrServiceAxis=us-gaap_LicenseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R31.htm IDEA: XBRL DOCUMENT v3.19.3

Inventories (Tables)
9 Months Ended

Sep. 30, 2019

Inventory Disclosure [Abstract]

Schedule of Inventory
The principal categories of inventories, net reserves of $1,212 and $4,757 at September 30, 2019 and December 31, 2018, respectively, are comprised of the following:
Inventory:

September 30, 2019

December 31, 2018

Finished goods

$
1,883

$
4,270

Raw materials

377

500

Total

$
2,260

$
4,770

X

- References
No definition available.
+ Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(c))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766
+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 75 R59.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Related Party Payable Long-Term Related Party Payable - Payable Balance (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2019

Sep. 30, 2018

Related Party Payable Rollforward:

Related party payable, beginning balance $ 24,247 $ 28,840 $ 98,925

Payment of related party payable (3,307) (10,014) (19,261)

Fair value adjustments 2,880 (18,468)

Expiration of warrants (2,167)

Disposition of the pediatric assets (20,337)

Related party payable, ending balance $ 21,706 $ 21,706 $ 38,692

X

- Definition
Business Combination, Changes in Related Party Payable [Roll Forward]
+ References
No definition available.
+ Details

Name: avdl_BusinessCombinationChangesinRelatedPartyPayableRollForward

Namespace Prefix: avdl_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount, measured at acquisition-date fair value, of all liabilities assumed that arise from contingencies and were recognized by the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(1)
-URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472
+ Details

Name: us-gaap_BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230
+ Details

Name: us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.
+ References
No definition available.
+ Details

Name: us-gaap_LiabilitiesFairValueAdjustment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585
+ Details

Name: us-gaap_PaymentsForRepurchaseOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquireBusinessesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 76 R51.htm IDEA: XBRL DOCUMENT v3.19.3

Goodwill and Intangible Assets - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible asset amortization $ 205 $ 1,620 $ 610 $ 4,996

Finite-Lived Intangible Assets [Line Items]

Fixed asset impairment $ 66,087

Noctiva | Developed technology

Finite-Lived Intangible Assets [Line Items]

Fixed asset impairment $ 66,087

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275
+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsFinitelived

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_TitleOfIndividualAxis=avdl_NoctivaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 77 R55.htm IDEA: XBRL DOCUMENT v3.19.3

Leases - Maturities of operating lease liabilities (Details)
$ in Thousands

Sep. 30, 2019

USD ($)

Leases [Abstract]

Remaining three months of 2019 $ 1,117

2020 879

2021 670

2022 678

2023 690

Thereafter 941

Total lease payments 4,975

Less: interest 513

Operating lease liabilities $ 4,462

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980
+ Details

Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from operating lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_OperatingLeaseLiability

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 78 R76.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies - Narrative (Details)
$ in Millions

Jan. 27, 2019

USD ($)

Specialty Pharma

Loss Contingencies [Line Items]

Loss contingency, damages sought, value $ 1.7

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The value (monetary amount) of the award the plaintiff seeks in the legal matter.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349
+ Details

Name: us-gaap_LossContingencyDamagesSoughtValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: dei_LegalEntityAxis=avdl_SpecialtyPharmaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R72.htm IDEA: XBRL DOCUMENT v3.19.3

Net Loss Per Share - Narrative (Details) - shares
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Earnings Per Share [Abstract]

Antidilutive securities excluded from computation of earnings per share, amount (in shares) 19,544 18,742 20,512 16,647

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 80 R13.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurement
9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurement
Fair Value Measurement
The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.

ASC 820, “Fair Value Measurements and Disclosures,” defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques:

•
Income approach, which is based on the present value of a future stream of net cash flows.
•
Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.
As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:
•
Level 1 - Quoted prices for identical assets or liabilities in active markets.
•
Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means.
•
Level 3 - Unobservable inputs that reflect estimates and assumptions.
The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:

As of September 30, 2019

As of December 31, 2018
Fair Value Measurements:

Level 1

Level 2

Level 3

Level 1

Level 2

Level 3

Marketable securities (see Note 6)

Equity securities

$
4,176

$
—

$
—

$
9,145

$
—

$
—

Money market and mutual funds

44,091

—

—

52,996

—

—

Corporate bonds

—

4,258

—

—

6,339

—

Government securities - U.S.

—

5,344

—

—

12,701

—

Other fixed-income securities

—

1,718

—

—

9,409

—

Total assets

$
48,267

$
11,320

$
—

$
62,141

$
28,449

$
—

Related party payable (see Note 10)

$
—

$
—

$
21,706

$
—

$
—

$
28,840

Total liabilities

$
—

$
—

$
21,706

$
—

$
—

$
28,840

A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the periods ended September 30, 2019 and December 31, 2018, respectively, there were no transfers in and out of Level 1, 2, or 3. During the three month periods ended September 30, 2019 and 2018, respectively, we did not recognize any other-than-temporary impairment loss.
Some of the Company’s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.

Debt

We estimate the fair value of our $143,750 aggregate principal amount of 4.50% exchangeable senior notes due 2023 (the “2023 Notes”), a Level 2 input, based on interest rates that would be currently available to the Company for issuance of similar types of debt instruments with similar terms and remaining maturities or recent trading prices obtained from brokers. The estimated fair value of the 2023 Notes at September 30, 2019 is $76,425 compared to a book value of $120,132.

Additionally, the Company’s other debt is reflected in the balance sheet at carrying value. The fair value of these loans is impracticable to estimate as these represent non-interest bearing grants from the French government and are repayable only if the research project is technically or commercially successful.

See Note 11: Long-Term Debt for additional information regarding our debt obligations.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-URI http://asc.fasb.org/topic&trid=2155941
+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 81 R17.htm IDEA: XBRL DOCUMENT v3.19.3

Leases
9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Leases
Leases

In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. On January 1, 2019, the Company adopted the ASU using the modified retrospective transition approach and elected the transition option to recognize the adjustment in the period of adoption rather than in the earliest period presented. As of January 1, 2019, adoption of the new guidance resulted in the initial recognition of operating lease right-of-use assets of $5,046 and operating lease liabilities of $5,131. At September 30, 2019, the balances of the operating lease right-of-use asset and total operating lease liability were $4,385 and $4,462, respectively, of which $1,596 of the operating lease liability is current.

The Company leases certain facilities for office and manufacturing purposes, comprising approximately 99% of the total lease population. All leased facilities are classified as operating leases with remaining lease terms between one and seven years. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. For all of the Company’s leases, lease and non-lease components are accounted for as a single lease component, as all non-lease components are immaterial to break out separately.

The components of lease costs, which are included in selling, general and administrative expenses in the unaudited condensed consolidated statements of loss for the three and nine months ended September 30 were as follows:
Lease cost:

Three months ended September 30, 2019

Nine months ended September 30, 2019

Operating lease costs ⁽¹⁾

$
411

$
1,150

Sublease income ⁽²⁾

82

187

Total lease cost

$
329

$
963

⁽¹⁾Variable lease costs were immaterial for the three and nine months ended September 30, 2019.
⁽²⁾ Represents sublease income received for the vacated office facility in Charlotte, North Carolina, which was acquired with the FSC acquisition in February 2016. The lease and sublease agreements terminate in December 2020. The Company also vacated portions of its office facility in St. Louis, Missouri during May 2019 and August 2019 and started receiving sublease income starting in May 2019 and August 2019 from two different tenants. The lease agreement ends in April 2025 and the sublease agreement that started in May 2019 ends in May 2020, with a one year renewal and the sublease agreement that started in August 2019 ends in July 2020, and can continue thereafter on a month-to-month basis.

During the three and nine months ended September 30, 2019, the Company reduced its operating lease liabilities by $411 and $1,115 for cash paid. In addition, during the nine months ended September 30, 2019, new operating leases commenced resulting in the recognition of operating lease right-of-use assets and liabilities of $1,000 and $0, respectively, as the entire lease payment was paid on March 31, 2019. There were no new leases during the three months ended September 30, 2019. As of September 30, 2019, the Company is aware of one additional embedded lease that has not yet commenced and will not commence until the time of FDA approval of the product (if approved). Once FDA approval is given and the start date is determined, annual production suite fees of approximately $3,000 to $4,000 would commence and at that time an operating lease right-of-use asset and corresponding operating lease liability will be recorded.

In connection with the 2019 French Restructuring plan discussed in Note 15: Restructuring Costs, during the three months ended September 30, 2019, the Company came to an agreement with the landlord of the leased office space in France, to exit the lease by December 31, 2019 with an early termination payment of approximately $820. The Company accounted for this change in the lease term as a modification of the original lease. As a result of this modification, the right-of-use asset and liability related to the French office lease that was remeasured, and the asset was subsequently tested for impairment as the fair value was less than the book value. Since the fair value was determined to be less than the book value, the Company recorded an impairment to the right of use asset of $826, which was recorded as a restructuring cost in the unaudited condensed consolidated statements of loss.

As of September 30, 2019, our operating leases have a weighted-average remaining lease term of 4.3 years and a weighted-average discount rate of 5.3%. Nearly all of Avadel’s lease contracts do not provide a readily determinable implicit rate. For these contracts, Avadel’s estimated incremental borrowing rate is based on information available at the inception of the lease.

Maturities of the Company’s operating lease liabilities were as follows:
Maturities:

Operating Leases

Remaining three months of 2019

$
1,117

2020

879

2021

670

2022

678

2023

690

Thereafter

941

Total lease payments

4,975

Less: interest

513

Present value of lease liabilities

$
4,462

Under the prior lease guidance, minimum rental commitments for non-cancelable leases as of December 31, 2018 were:
Lease Commitment:

Operating Leases

2019

$
1,191

2020

1,208

2021

1,008

2022

767

2023

695

Thereafter

967

Total minimum lease payments

$
5,836

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=77888251
+ Details

Name: us-gaap_LesseeOperatingLeasesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 82 R7.htm IDEA: XBRL DOCUMENT v3.19.3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY Statement - USD ($)
shares in Thousands, $ in Thousands

Total

Ordinary shares

Additional paid-in capital

Accumulated deficit

Accumulated other comprehensive (loss) income

Treasury shares

Beginning balance (in shares) at Dec. 31, 2017 41,463 2,117

Beginning balance at Dec. 31, 2017 $ 85,580 $ 414 $ 393,478 $ (262,685) $ (23,266) $ (22,361)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (12,236) (12,236)

Other comprehensive income (loss) (404) (404)

Stock-based compensation expense 2,134 2,134

Exercise of warrants (in shares) 603

Exercise of warrants 2,911 $ 6 2,905

Expiration of warrants 2,167 2,167

Equity component of 2023 Notes 26,699 26,699

Share repurchases (in shares) 2,307

Share repurchases (20,212) $ (20,212)

Ending balance (in shares) at Mar. 31, 2018 42,066 4,424

Ending balance at Mar. 31, 2018 86,639 $ 420 427,383 (274,921) (23,670) $ (42,573)

Beginning balance (in shares) at Dec. 31, 2017 41,463 2,117

Beginning balance at Dec. 31, 2017 85,580 $ 414 393,478 (262,685) (23,266) $ (22,361)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (31,445)

Ending balance (in shares) at Sep. 30, 2018 42,419 5,407

Ending balance at Sep. 30, 2018 65,742 $ 424 433,097 (294,130) (23,651) $ (49,998)

Beginning balance (in shares) at Mar. 31, 2018 42,066 4,424

Beginning balance at Mar. 31, 2018 86,639 $ 420 427,383 (274,921) (23,670) $ (42,573)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (3,438) (3,438)

Other comprehensive income (loss) 11 11

Stock-based compensation expense 2,224 2,224

Share repurchases (in shares) 983

Share repurchases (7,425) $ (7,425)

Exercise of stock options (in shares) 82

Exercise of stock options 535 $ 1 534

Ending balance (in shares) at Jun. 30, 2018 42,148 5,407

Ending balance at Jun. 30, 2018 78,546 $ 421 430,141 (278,359) (23,659) $ (49,998)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (15,771)

Other comprehensive income (loss) 8 8

Vesting of restricted shares (in shares) 247

Vesting of restricted shares 0 $ 3 (3)

Employee share purchase plan share issuance (in shares) 24

Employee share purchase plan share issuance 127 127

Stock-based compensation expense 2,832 2,832

Ending balance (in shares) at Sep. 30, 2018 42,419 5,407

Ending balance at Sep. 30, 2018 65,742 $ 424 433,097 (294,130) (23,651) $ (49,998)

Beginning balance (in shares) at Dec. 31, 2018 42,720 5,407

Beginning balance at Dec. 31, 2018 2,780 $ 427 433,756 (357,989) (23,416) $ (49,998)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (13,018) (13,018)

Other comprehensive income (loss) 213 213

Vesting of restricted shares (in shares) 1

Vesting of restricted shares 0

Employee share purchase plan share issuance (in shares) 42

Employee share purchase plan share issuance 92 92

Stock-based compensation expense 351 351

Ending balance (in shares) at Mar. 31, 2019 42,763 5,407

Ending balance at Mar. 31, 2019 (9,582) $ 427 434,199 (371,007) (23,203) $ (49,998)

Beginning balance (in shares) at Dec. 31, 2018 42,720 5,407

Beginning balance at Dec. 31, 2018 2,780 $ 427 433,756 (357,989) (23,416) $ (49,998)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (30,487)

Ending balance (in shares) at Sep. 30, 2019 42,857 5,407

Ending balance at Sep. 30, 2019 (26,963) $ 428 434,055 (388,476) (22,972) $ (49,998)

Beginning balance (in shares) at Mar. 31, 2019 42,763 5,407

Beginning balance at Mar. 31, 2019 (9,582) $ 427 434,199 (371,007) (23,203) $ (49,998)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (8,605) (8,605)

Other comprehensive income (loss) 355 355

Stock-based compensation expense 55 55

Ending balance (in shares) at Jun. 30, 2019 42,763 5,407

Ending balance at Jun. 30, 2019 (17,777) $ 427 434,254 (379,612) (22,848) $ (49,998)

Increase (Decrease) in Stockholders' Equity [Roll Forward]

Net loss (8,864)

Other comprehensive income (loss) (124) (124)

Vesting of restricted shares (in shares) 82

Vesting of restricted shares 0 $ 1 (1)

Employee share purchase plan share issuance (in shares) 12

Employee share purchase plan share issuance 31 31

Stock-based compensation expense (229) (229)

Ending balance (in shares) at Sep. 30, 2019 42,857 5,407

Ending balance at Sep. 30, 2019 $ (26,963) $ 428 $ 434,055 $ (388,476) $ (22,972) $ (49,998)

X

- Definition
Stock Issued During Period, Shares, Expiration Of Warrants
+ References
No definition available.
+ Details

Name: avdl_StockIssuedDuringPeriodSharesExpirationOfWarrants

Namespace Prefix: avdl_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Stock Issued During Period, Value, Expiration Of Warrants
+ References
No definition available.
+ Details

Name: avdl_StockIssuedDuringPeriodValueExpirationOfWarrants

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 25
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of other increase (decrease) in additional paid in capital (APIC).
+ References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109196918&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=79507207&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 25
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=109244457&loc=d3e16649-113920
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesOther

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=109197908&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of shares of stock issued attributable to transactions classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of stock issued as a result of the exercise of stock options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Number of shares that have been repurchased during the period and are being held in treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_TreasuryStockSharesAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_TreasuryStockValueAcquiredCostMethod

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 83 R34.htm IDEA: XBRL DOCUMENT v3.19.3

Long-Term Related Party Payable (Tables)
9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Schedule of Related Party Transactions
Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2019 and December 31, 2018:

Activity during the Nine Months Ended
September 30, 2019

Changes in Fair Value of Related Party Payable

Long-Term Related Party Payable:
Balance,
December 31, 2018

Payments to
Related Parties

Operating Expense

Other
Expense

Balance, September 30, 2019

Acquisition-related contingent consideration:

Earn-out payments - Éclat Pharmaceuticals (a)
$
25,615

$
(8,640
)

$
2,384

$
—

$
19,359

Financing-related:

Royalty agreement - Deerfield (b)
2,184

(930
)

—

330

1,584

Royalty agreement - Broadfin (c)
1,041

(444
)

—

166

763

Total related party payable
28,840

$
(10,014
)

$
2,384

$
496

21,706

Less: current portion
(9,439
)

(7,588
)
Total long-term related party payable
$
19,401

$
14,118

Long-term related party payable and related activity are reported at fair value and consist of the following at September 30, 2019 and June 30, 2019:

Activity during the Three Months Ended
September 30, 2019

Changes in Fair Value of Related Party Payable

Long-Term Related Party Payable:
Balance,
June 30, 2019

Payments to
Related Parties

Operating Expense

Other
Expense

Balance, September 30, 2019

Acquisition-related contingent consideration:

Earn-out payments - Éclat Pharmaceuticals (a)
$
21,582

$
(2,850
)

$
627

$
—

$
19,359

Financing-related:

Royalty agreement - Deerfield (b)
1,799

(309
)

—

94

1,584

Royalty agreement - Broadfin (c)
866

(148
)

—

45

763

Total related party payable
24,247

$
(3,307
)

$
627

$
139

21,706

Less: current portion
(8,264
)

(7,588
)
Total long-term related party payable
$
15,983

$
14,118

(a) In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s former CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.
(b)
As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products.
(c)
As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.
The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the nine-month periods ended September 30, 2019 and 2018, respectively:
Related Party Payable Rollforward:

Balance

Balance, December 31, 2017

$
98,925

Payments of related party payable

(19,261
)
Fair value adjustments ⁽¹⁾

(18,468
)
Expiration of warrants

(2,167
)
Disposition of the pediatric assets

(20,337
)
Balance, September 30, 2018

$
38,692

Balance, December 31, 2018

$
28,840

Payments of related party payable

(10,014
)
Fair value adjustments ⁽¹⁾

2,880

Balance, September 30, 2019

$
21,706

⁽¹⁾Fair value adjustments are reported as changes in fair value of related party contingent consideration and other expense - changes in fair value of related party payable in the unaudited condensed consolidated statements of loss.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 84 R30.htm IDEA: XBRL DOCUMENT v3.19.3

Marketable Securities (Tables)
9 Months Ended

Sep. 30, 2019

Investments, Debt and Equity Securities [Abstract]

Schedule of Available-for-sale and Equity Securities
The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of September 30, 2019 and December 31, 2018, respectively:

September 30, 2019
Marketable Securities:

Adjusted Cost

Unrealized Gains

Unrealized Losses

Fair Value

Equity securities

$
4,200

$
—

$
(24
)

$
4,176

Money market and mutual funds

43,306

785

—

44,091

Corporate bonds

4,190

69

(1
)

4,258

Government securities - U.S.

5,217

129

(2
)

5,344

Other fixed-income securities

1,693

26

(1
)

1,718

Total

$
58,606

$
1,009

$
(28
)

$
59,587

December 31, 2018
Marketable Securities:

Adjusted Cost

Unrealized Gains

Unrealized Losses

Fair Value

Equity securities

$
10,101

$
—

$
(956
)

$
9,145

Money market and mutual funds

52,733

316

(53
)

52,996

Corporate bonds

6,411

7

(79
)

6,339

Government securities - U.S.

12,714

66

(79
)

12,701

Other fixed-income securities

9,400

22

(13
)

9,409

Total

$
91,359

$
411

$
(1,180
)

$
90,590

Schedule of Contractual Maturity Dates
The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of September 30, 2019:

Maturities
Marketable Debt Securities:

Less than 1 Year

1-5 Years

5-10 Years

Greater than 10 Years

Total

Corporate bonds

$
556

$
3,360

$
342

$
—

$
4,258

Government securities - U.S.

—

4,600

—

744

5,344

Other fixed-income securities

49

1,669

—

—

1,718

Total

$
605

$
9,629

$
342

$
744

$
11,320

X

- Definition
Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).
+ References
No definition available.
+ Details

Name: us-gaap_TradingSecuritiesAndCertainTradingAssetsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 85 R3.htm IDEA: XBRL DOCUMENT v3.19.3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Other Comprehensive Income (Loss), Tax [Abstract]

Net loss $ (8,864) $ (15,771) $ (30,487) $ (31,445)

Other comprehensive (loss) income, net of tax:

Foreign currency translation gain (loss) (210) (60) (309) (293)

Net other comprehensive income (loss), net of ($5), ($18), ($46) and ($88) tax, respectively 86 68 753 (92)

Total other comprehensive income (loss), net of tax (124) 8 444 (385)

Total comprehensive loss $ (8,988) $ (15,763) $ (30,043) $ (31,830)

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e557-108580

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580
+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax of other comprehensive income (loss) attributable to parent entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(3)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossTaxAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 86 R38.htm IDEA: XBRL DOCUMENT v3.19.3

Restructuring Costs (Tables)
9 Months Ended

Sep. 30, 2019

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs
The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2019 and 2018:
2017 French Restructuring Obligation:

2019

2018

Balance of restructuring accrual at January 1,

$
879

$
1,000

Charges for employee severance, benefits and other

(168
)

268

Payments

(663
)

(668
)
Foreign currency impact

(10
)

(19
)
Balance of restructuring accrual at September 30,

$
38

$
581

The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2019:
2019 Corporate Restructuring Obligation:

2019

Balance of restructuring accrual at January 1,

$
—

Charges for employee severance, benefits and other costs

2,966

Payments

(2,113
)
Balance of restructuring accrual at September 30,

$
853

The following table sets forth activities for the Company’s cost reduction plan obligations for the three and nine months ended September 30, 2019:
2019 French Restructuring Obligation:

2019

Balance of restructuring accrual at January 1,

$
—

Charges for employee severance, benefits and other costs

2,774

Payments

(1,837
)
Foreign currency impact

(42
)
Balance of restructuring accrual at September 30,

$
895

X

- References
No definition available.
+ Details

Name: us-gaap_RestructuringAndRelatedActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747
+ Details

Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 87 R29.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurement (Tables)
9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying unaudited condensed consolidated balance sheets:

As of September 30, 2019

As of December 31, 2018
Fair Value Measurements:

Level 1

Level 2

Level 3

Level 1

Level 2

Level 3

Marketable securities (see Note 6)

Equity securities

$
4,176

$
—

$
—

$
9,145

$
—

$
—

Money market and mutual funds

44,091

—

—

52,996

—

—

Corporate bonds

—

4,258

—

—

6,339

—

Government securities - U.S.

—

5,344

—

—

12,701

—

Other fixed-income securities

—

1,718

—

—

9,409

—

Total assets

$
48,267

$
11,320

$
—

$
62,141

$
28,449

$
—

Related party payable (see Note 10)

$
—

$
—

$
21,706

$
—

$
—

$
28,840

Total liabilities

$
—

$
—

$
21,706

$
—

$
—

$
28,840

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258
+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 88 R21.htm IDEA: XBRL DOCUMENT v3.19.3

Other Assets and Liabilities
9 Months Ended

Sep. 30, 2019

Other Liabilities Disclosure [Abstract]

Other Assets and Liabilities
Other Assets and Liabilities
Various other assets and liabilities are summarized as follows:
Prepaid Expenses and Other Current Assets:

September 30, 2019

December 31, 2018

Valued-added tax recoverable

$
807

$
1,378

Prepaid and other expenses

2,757

2,145

Guarantee from Armistice (see Note 14)

560

534

Income tax receivable

594

921

Research and development tax credit receivable

270

283

Short-term deposit

—

3,350

Other

175

225

Total

$
5,163

$
8,836

Other Non-Current Assets:

September 30, 2019

December 31, 2018

Deferred tax assets, net

$
21,636

$
23,029

Long-term deposits

1,477

1,477

Guarantee from Armistice (see Note 14)

5,271

5,697

Right of use assets at contract manufacturing organizations

6,494

5,894

Other

49

49

Total

$
34,927

$
36,146

Accrued Expenses

September 30, 2019

December 31, 2018

Accrued compensation

$
2,322

$
3,971

Accrued social charges

482

1,009

Accrued restructuring (see Note 15)

1,737

879

Customer allowances

6,244

6,541

Accrued contract research organization charges

3,389

1,000

Accrued contract manufacturing organization costs

1,284

2,028

Accrued contract sales organization and marketing costs

—

3,469

Other

1,559

2,798

Total

$
17,017

$
21,695

Other Non-Current Liabilities:

September 30, 2019

December 31, 2018

Provision for retirement indemnity

$
—

$
1,024

Customer allowances

923

1,352

Unrecognized tax benefits

7,717

5,315

Guarantee to Deerfield (see Note 14)

5,289

5,717

Other

43

594

Total

$
13,972

$
14,002

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other liabilities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20,24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 89 R25.htm IDEA: XBRL DOCUMENT v3.19.3

Comprehensive Loss
9 Months Ended

Sep. 30, 2019

Stockholders' Equity Note [Abstract]

Comprehensive Loss
Comprehensive Loss
The following table shows the components of accumulated other comprehensive loss for the three and nine months ended September 30, 2019 and 2018, respectively, net of tax effects:

Three Months Ended September 30,

Nine Months Ended September 30,
Accumulated Other Comprehensive Loss:

2019

2018

2019

2018

Foreign currency translation adjustment:

Beginning balance

$
(23,720
)

$
(23,435
)

$
(23,621
)

$
(23,202
)
Net other comprehensive loss

(210
)

(60
)

(309
)

(293
)
Balance at September 30,

$
(23,930
)

$
(23,495
)

$
(23,930
)

$
(23,495
)

Unrealized gain (loss) on marketable debt securities, net

Beginning balance

$
872

$
(224
)

$
205

$
(64
)
Net other comprehensive income (loss), net of ($5), ($18), ($46) and ($88) tax, respectively

86

68

753

(92
)
Balance at September 30,

$
958

$
(156
)

$
958

$
(156
)
Accumulated other comprehensive loss at September 30,

$
(22,972
)

$
(23,651
)

$
(22,972
)

$
(23,651
)

The effect on the Company’s unaudited condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.

X

- Definition
The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-URI http://asc.fasb.org/topic&trid=2134417
+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 90 R44.htm IDEA: XBRL DOCUMENT v3.19.3

Revenue Recognition - Narrative (Details)

Sep. 30, 2019

USD ($)

Revenue from Contract with Customer [Abstract]

Deferred contract costs $ 0

X

- Definition
Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 340
-SubTopic 40
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054
+ Details

Name: us-gaap_CapitalizedContractCostNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_RevenueFromContractWithCustomerAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 91 R40.htm IDEA: XBRL DOCUMENT v3.19.3

Comprehensive Income (Loss) (Tables)
9 Months Ended

Sep. 30, 2019

Stockholders' Equity Note [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)
The following table shows the components of accumulated other comprehensive loss for the three and nine months ended September 30, 2019 and 2018, respectively, net of tax effects:

Three Months Ended September 30,

Nine Months Ended September 30,
Accumulated Other Comprehensive Loss:

2019

2018

2019

2018

Foreign currency translation adjustment:

Beginning balance

$
(23,720
)

$
(23,435
)

$
(23,621
)

$
(23,202
)
Net other comprehensive loss

(210
)

(60
)

(309
)

(293
)
Balance at September 30,

$
(23,930
)

$
(23,495
)

$
(23,930
)

$
(23,495
)

Unrealized gain (loss) on marketable debt securities, net

Beginning balance

$
872

$
(224
)

$
205

$
(64
)
Net other comprehensive income (loss), net of ($5), ($18), ($46) and ($88) tax, respectively

86

68

753

(92
)
Balance at September 30,

$
958

$
(156
)

$
958

$
(156
)
Accumulated other comprehensive loss at September 30,

$
(22,972
)

$
(23,651
)

$
(22,972
)

$
(23,651
)

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14A
-URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580
+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 92 R48.htm IDEA: XBRL DOCUMENT v3.19.3

Marketable Securities Marketable Securities - Schedule of Maturities (Details) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Debt Securities, Available-for-sale [Line Items]

Fair Value $ 59,587 $ 90,590

Corporate bonds

Debt Securities, Available-for-sale [Line Items]

Less than 1 Year 556

1-5 Years 3,360

5-10 Years 342

Greater than 10 Years 0

Fair Value 4,258 6,339

Government securities - U.S.

Debt Securities, Available-for-sale [Line Items]

Less than 1 Year 0

1-5 Years 4,600

5-10 Years 0

Greater than 10 Years 744

Fair Value 5,344 12,701

Other fixed-income securities

Debt Securities, Available-for-sale [Line Items]

Less than 1 Year 49

1-5 Years 1,669

5-10 Years 0

Greater than 10 Years 0

Fair Value 1,718 $ 9,409

Debt Securities, Excluding Money Market Funds, Available For Sale

Debt Securities, Available-for-sale [Line Items]

Less than 1 Year 605

1-5 Years 9,629

5-10 Years 342

Greater than 10 Years 744

Fair Value $ 11,320

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security, measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27198-111563

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (aa)
-URI http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563
+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_FixedIncomeSecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FinancialInstrumentAxis=avdl_DebtSecuritiesExcludingMoneyMarketFundsAvailableForSaleMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 93 R63.htm IDEA: XBRL DOCUMENT v3.19.3

Income Taxes - Reconciliation of Tax Rate (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Effective Income Tax Rate Reconciliation, Percent [Abstract]

Statutory tax rate 12.50% 12.50% 12.50% 12.50%

International tax rates differential (4.30%) 7.00% 4.10% 6.90%

Change in valuation allowance (31.10%) (18.30%) (27.00%) (14.90%)

Change in fair value of nondeductible contingent consideration 4.10% 8.70% (0.10%) 9.90%

Nondeductible stock-based compensation 0.00% (3.50%) (0.20%) (2.60%)

Unrecognized tax benefits (8.80%) (3.50%) (3.30%) (3.10%)

State and local income taxes, net of federal (0.20%) 0.10% (0.20%) 0.20%

Nondeductible interest expense (4.50%) 0.00% (2.60%) 0.00%

Other (1.30%) 1.20% 3.10% 0.80%

Effective income tax rate (33.60%) 4.20% (13.70%) 9.70%

Effective Income Tax Rate Reconciliation, Amount [Abstract]

Income tax benefit - at statutory tax rate $ (829) $ (2,058) $ (3,355) $ (4,351)

International tax rates differential 283 (1,153) (1,108) (2,394)

Change in valuation allowance 2,059 3,007 7,242 5,188

Change in fair value of nondeductible contingent consideration (270) (1,431) 33 (3,436)

Nondeductible stock-based compensation 1 578 50 914

Unrecognized tax benefits 581 578 873 1,086

State and local income taxes, net of federal 14 (13) 41 (70)

Nondeductible interest expense 299 0 709 0

Other 96 (199) (844) (297)

Income tax provision (benefit) - at effective income tax rate $ 2,234 $ (691) $ 3,641 $ (3,360)

X

- Definition
Effective income tax rate reconciliation deferred charge from IP transfer.
+ References
No definition available.
+ Details

Name: avdl_EffectiveIncomeTaxRateReconciliationDeferredChargeFromIpTransfer

Namespace Prefix: avdl_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Amount
+ References
No definition available.
+ Details

Name: avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Percent
+ References
No definition available.
+ Details

Name: avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpensePercent

Namespace Prefix: avdl_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible deferred charges from IP transfer costs.
+ References
No definition available.
+ Details

Name: avdl_IncomeTaxReconciliationNondeductibleExpenseDeferredChargeFromIpTransfer

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of domestic federal statutory tax rate applicable to pretax income (loss).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.
+ References
No definition available.
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I)
-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=84176650&loc=d3e32123-109318
+ Details

Name: us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(1))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationOtherReconcilingItems

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319
+ Details

Name: us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 94 R67.htm IDEA: XBRL DOCUMENT v3.19.3

Other Assets and Liabilities - Other Non-Current Liabilities (Details) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Other Non-Current Liabilities:

Provision for retirement indemnity $ 0 $ 1,024

Customer allowances 923 1,352

Unrecognized tax benefits 7,717 5,315

Guarantee to Deerfield 5,289 5,717

Other 43 594

Total $ 13,972 $ 14,002

X

- Definition
The non current portion of provision for retirement indemnity as of the balance sheet date.
+ References
No definition available.
+ Details

Name: avdl_ProvisionForRetirementIndemnityNoncurrent

Namespace Prefix: avdl_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Noncurrent regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CustomerRefundLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03.15)
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.15)
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 25
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=82913062&loc=d3e11019-110243

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 25
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=82913062&loc=d3e11049-110243
+ Details

Name: us-gaap_GuarantyLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.24)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of long-term debt classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16))
-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details

Name: us-gaap_OtherLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319
+ Details

Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2019	Nov. 08, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	AVADEL PHARMACEUTICALS PLC
Entity Central Index Key	0001012477
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Smaller Reporting Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		37,450,300

Subsidiary Bankruptcy and Deconsolidation	9 Months Ended
Subsidiary Bankruptcy and Deconsolidation	Sep. 30, 2019
Reorganizations [Abstract]
Subsidiary Bankruptcy and Deconsolidation	Subsidiary Bankruptcy and Deconsolidation Bankruptcy Filing and Deconsolidation As a result of Specialty Pharma’s bankruptcy filing on February 6, 2019, Avadel has ceded authority for managing the business to the Bankruptcy Court, and Avadel management cannot carry on Specialty Pharma’s activities in the ordinary course of business without Bankruptcy Court approval. Avadel manages the day-to-day operations of Specialty Pharma, but does not have discretion to make significant capital or operating budgetary changes or decisions and purchase or sell significant assets, as Specialty Pharma’s material decisions are subject to review by the Bankruptcy Court. For these reasons, we have concluded that Avadel has lost control of Specialty Pharma, and no longer has significant influence over Specialty Pharma during the pendency of the bankruptcy. Therefore, we deconsolidated Specialty Pharma effective with the filing of the Chapter 11 bankruptcy in February 2019. In order to deconsolidate Specialty Pharma, the carrying values of the assets and certain liabilities of Specialty Pharma were removed from our unaudited condensed consolidated balance sheet as of February 5, 2019, and we recorded our investment in Specialty Pharma at its estimated fair value of $0. As the estimated fair value of our investment in Specialty Pharma was lower than its net book value immediately prior to the deconsolidation, we recorded a non-cash charge of approximately $2,840 for the nine months ended September 30, 2019 associated with the deconsolidation of Specialty Pharma. Subsequent to the deconsolidation of Specialty Pharma, we are accounting for our investment in Specialty Pharma using the cost method of accounting because Avadel does not exercise significant influence over the operations of Specialty Pharma due to the Chapter 11 filing. On April 26, 2019, Specialty Pharma sold its intangible assets and remaining inventory to an unaffiliated third party in exchange for aggregate cash proceeds of approximately $250, pursuant to an order approving such sale which was issued by the Bankruptcy Court on April 15, 2019. As a result of such sale, Specialty Pharma has completed its divestment of the assets of the Noctiva business. On July 2, 2019, Specialty Pharma was made aware of a $50,695 claim made by the Internal Revenue Service (IRS) as part of the bankruptcy claims process against Specialty Pharma. On October 2, 2019 the IRS amended the original claim filed in July, reducing the claim to $9,302. Specialty Pharma files its U.S. federal tax return as a member of the Company’s consolidated U.S. tax group. As such, the IRS claim was filed against Specialty Pharma in the bankruptcy proceedings due to IRS tax law requirements for joint and several liability of all members in a consolidated U.S. tax group. Both Specialty Pharma and the Company disagree with the merits of the amended IRS claim and intend to defend their positions vigorously. DIP Financing – Related Party Relationship In connection with the bankruptcy filing, Specialty Pharma entered into a Debtor in Possession Credit and Security Agreement with Avadel US Holdings (“DIP Credit Agreement”) dated as of February 8, 2019, in an aggregate amount of up to $2,700, of which the funds are to be used by Specialty Pharma solely to fund operations through February 6, 2020. As of September 30, 2019, the Company had funded $407 under the DIP Credit Agreement. As the Company has assessed that it is unlikely that Specialty Pharma will pay back the loan to Avadel, the $407 has been recorded as part of the loss on deconsolidation of subsidiary within the unaudited condensed consolidated statements of loss. At September 30, 2019 the fair value of the remaining commitment under the DIP Credit Agreement is not material.

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income tax provision (benefit)	$ 2,234	$ (691)	$ 3,641	$ (3,360)

Other Assets and Liabilities - Other Non-Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Other Non-Current Assets:
Deferred tax assets, net	$ 21,636	$ 23,029
Long-term deposits	1,477	1,477
Guarantee from Armistice	5,271	5,697
Right of use assets at contract manufacturing organizations	6,494	5,894
Other	49	49
Total	$ 34,927	$ 36,146

Restructuring Costs - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
Restructuring Costs - Narrative (Details) - USD ($)	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 1,866,000	$ 65,000	$ 4,600,000	$ 268,000
Fixed asset impairment						$ 66,087,000
2019 French Restructuring Obligation
Restructuring Cost and Reserve [Line Items]
Restructuring costs	1,259		3,198,000
Fixed asset impairment			598,000
Operating lease, impairment loss			826,000
Restructuring reserve	895,000		895,000			0
2019 French Restructuring Obligation \| Scenario, Forecast
Restructuring Cost and Reserve [Line Items]
Severance costs					$ 3,500,000
2019 French Restructuring Obligation \| Accrued Liabilities
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	884,000		884,000			11,000
2019 Corporate Restructuring Obligations
Restructuring Cost and Reserve [Line Items]
Restructuring costs	607,000		1,570,000
Restructuring reserve	853,000		853,000			0
Share-based compensation forfeitures related to the employees affected by the global reduction in workforce			1,396,000
2019 Corporate Restructuring Obligations \| Scenario, Forecast
Restructuring Cost and Reserve [Line Items]
Severance costs					$ 3,000,000
Lyon France Workforce Reduction
Restructuring Cost and Reserve [Line Items]
Restructuring costs			168,000	268,000
Charges for employee severance, benefits and other			(168,000)	268,000
Restructuring reserve	$ 38,000	$ 581,000	38,000	$ 581,000		$ 879,000	$ 1,000,000
Retirement Indemnity Obligation \| 2019 French Restructuring Obligation
Restructuring Cost and Reserve [Line Items]
Restructuring costs			1,000,000
Employee Severance \| 2019 French Restructuring Obligation
Restructuring Cost and Reserve [Line Items]
Charges for employee severance, benefits and other			$ 2,774,000
Employee Severance \| Corporate Workforce Reduction
Restructuring Cost and Reserve [Line Items]
Expected number of positions eliminated (as a percent)	50.00%		50.00%
Employee Severance \| 2019 Corporate Restructuring Obligations
Restructuring Cost and Reserve [Line Items]
Restructuring costs			$ 2,966,000
Employee Severance \| Lyon France Workforce Reduction
Restructuring Cost and Reserve [Line Items]
Expected number of positions eliminated (as a percent)								50.00%

Divestiture of the Pediatric Assets - Narrative (Details) - USD ($) $ in Thousands		1 Months Ended
	Feb. 12, 2018	Jan. 31, 2021	Oct. 10, 2019	Sep. 30, 2019	Dec. 31, 2018
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Guaranty liabilities				$ 5,289	$ 5,717
2016 MIPA \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Debt instrument, periodic payment, interest	$ 263
Noncash or part noncash acquisition, debt assumed	2,625
Research and development reimbursement, in excess of	1,000
Guaranty liabilities	6,643			5,851
Guaranty assets	$ 6,620			$ 5,831
FSC \| 2016 MIPA \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Percentage of royalty payable on net sales	15.00%
Royalty payable on net sales, maximum	$ 10,300
Scenario, Forecast \| 2016 MIPA \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Repayments of assumed debt		$ 15,263
Subsequent Event \| Cerecor \| Discontinued Operations, Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Guaranty assets			$ 15,000
Escrow deposit			$ 15,000

Long-Term Debt Schedule of Debt (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Net carrying amount of liability component	$ 120,167	$ 115,840
Other debt	43	594
Less: current maturities	(35)	(106)
Long-term debt, less current portion	120,132	115,734
Senior Notes
Debt Instrument [Line Items]
Long-term debt	143,750	143,750
Less: debt discount and issuance costs, net	(23,618)	(28,059)
Net carrying amount of liability component	120,132	115,691
Equity component of exchangeable notes, net of issuance costs	$ (26,699)	$ (26,699)
Debt instrument, interest rate, stated percentage	4.50%	4.50%
Loans Payable
Debt Instrument [Line Items]
Other debt	$ 35	$ 149

Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Prepaid Expenses and Other Current Assets:
Valued-added tax recoverable	$ 807	$ 1,378
Prepaid and other expenses	2,757	2,145
Guarantee from Armistice	560	534
Income tax receivable	594	921
Research and development tax credit receivable	270	283
Short-term deposit	0	3,350
Other	175	225
Total	$ 5,163	$ 8,836

Marketable Securities - Summary of Marketable Securities (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Adjusted Cost	$ 58,606	$ 91,359
Unrealized Gains	1,009	411
Unrealized Losses	(28)	(1,180)
Fair Value	59,587	90,590
Equity securities
Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]
Adjusted Cost	4,200	10,101
Unrealized Gains	0	0
Unrealized Losses	(24)	(956)
Fair Value	4,176	9,145
Money market and mutual funds
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Adjusted Cost	43,306	52,733
Unrealized Gains	785	316
Unrealized Losses	0	(53)
Fair Value	44,091	52,996
Corporate bonds
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Adjusted Cost	4,190	6,411
Unrealized Gains	69	7
Unrealized Losses	(1)	(79)
Fair Value	4,258	6,339
Government securities - U.S.
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Adjusted Cost	5,217	12,714
Unrealized Gains	129	66
Unrealized Losses	(2)	(79)
Fair Value	5,344	12,701
Other fixed-income securities
Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]
Adjusted Cost	1,693	9,400
Unrealized Gains	26	22
Unrealized Losses	(1)	(13)
Fair Value	$ 1,718	$ 9,409

Subsidiary Bankruptcy and Deconsolidation (Details) - USD ($)		3 Months Ended		9 Months Ended
	Apr. 26, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Oct. 02, 2019	Jul. 02, 2019	Feb. 08, 2019
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary		$ 0	$ 0	$ (2,840,000)	$ 0
DIP Credit Agreement \| Debtor in Possession Credit and Security Facility
Business Acquisition, Contingent Consideration [Line Items]
Gain (loss) on deconsolidation of subsidiary		(407,000)
Payments for debtor in possession financing		407,000
Speciality Pharama
Business Acquisition, Contingent Consideration [Line Items]
Aggregate cash proceeds of intangible assets and remaining inventory	$ 250,000
Speciality Pharama \| Internal Revenue Service (IRS)
Business Acquisition, Contingent Consideration [Line Items]
Bankruptcy claims, amount of filed claims likely to be denied							$ 50,695,000
Speciality Pharama \| Internal Revenue Service (IRS) \| Subsequent Event
Business Acquisition, Contingent Consideration [Line Items]
Bankruptcy claims, amount of filed claims likely to be denied						$ 9,302,000
Speciality Pharama \| DIP Credit Agreement \| Debtor in Possession Credit and Security Facility
Business Acquisition, Contingent Consideration [Line Items]
DIP financing, amount arranged								$ 2,700,000
Specialty Pharma
Business Acquisition, Contingent Consideration [Line Items]
Equity method investments, fair value		$ 0		$ 0

Revenue by Product - Summary of Revenue (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) segment	Sep. 30, 2018 USD ($)
Segment Reporting [Abstract]
Number of operating segments (in segments) \| segment			1
Segment Reporting Information [Line Items]
Total revenues	$ 14,229	$ 19,826	$ 48,220	$ 82,349
Bloxiverz
Segment Reporting Information [Line Items]
Total revenues	1,466	3,656	6,392	16,691
Vazculep
Segment Reporting Information [Line Items]
Total revenues	8,786	8,759	27,669	33,097
Akovaz
Segment Reporting Information [Line Items]
Total revenues	4,208	5,991	13,946	28,083
Other
Segment Reporting Information [Line Items]
Total revenues	(231)	1,420	213	4,232
Product sales
Segment Reporting Information [Line Items]
Total revenues	14,229	19,826	48,220	82,103
License revenue
Segment Reporting Information [Line Items]
Total revenues	$ 0	$ 0	$ 0	$ 246

Net Loss Per Share - Reconciliation of Basic and Diluted Calculation (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Net loss	$ (8,864)	$ (8,605)	$ (13,018)	$ (15,771)	$ (3,438)	$ (12,236)	$ (30,487)	$ (31,445)
Weighted average shares:
Basic shares (in shares)	37,436			36,904			37,382	37,410
Effect of dilutive securities—options and warrants outstanding (in shares)	0			0			0	0
Diluted shares (in shares)	37,436			36,904			37,382	37,410
Net income (loss) per share - basic (in dollars per share)	$ (0.24)			$ (0.43)			$ (0.82)	$ (0.84)
Net income (loss) per share - diluted (in dollars per share)	$ (0.24)			$ (0.43)			$ (0.82)	$ (0.84)

Goodwill and Intangible Assets - Estimated Future Amortization (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	5 years
Estimated Annual Amortization Expense:
2019	$ 815
2020	814
2021	0
2022	0
2023	$ 0
Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life (in years)	15 years

Leases - Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Thousands	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 1,191
2020	1,208
2021	1,008
2022	767
2023	695
Thereafter	967
Total minimum lease payments	$ 5,836

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net loss	$ (30,487)	$ (31,445)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,690	5,625
Loss on disposal of property and equipment	478	0
Amortization of premiums on marketable securities	(275)	2,889
Remeasurement of related party acquisition-related contingent consideration	2,384	(17,036)
Remeasurement of related party financing-related contingent consideration	496	(1,432)
Amortization of debt discount and debt issuance costs	4,424	3,402
Change in deferred tax and income tax deferred charge	1,333	(4,675)
Stock-based compensation expense	177	7,190
Loss on deconsolidation of subsidiary	1,750	0
Other adjustments	(392)	117
Net changes in assets and liabilities
Accounts receivable	2,026	5,059
Inventories	2,465	(548)
Prepaid expenses and other current assets	(1,859)	2,194
Research and development tax credit receivable	(749)	(1,350)
Accounts payable & other current liabilities	259	4,312
Accrued expenses	(2,379)	(11,660)
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value	(8,640)	(16,254)
Royalty payments for related party payable in excess of original fair value	(1,374)	(2,362)
Other assets and liabilities	(1,399)	(2,216)
Net cash used in operating activities	(30,072)	(58,190)
Cash flows from investing activities:
Purchases of property and equipment	(29)	(167)
Proceeds from the disposal of property and equipment	154	0
Purchase of intangible asset	0	(20,000)
Proceeds from sales of marketable securities	57,242	308,015
Purchases of marketable securities	(23,814)	(341,036)
Net cash provided by (used in) investing activities	33,553	(53,188)
Cash flows from financing activities:
Earn-out payments for related party contingent consideration	0	(645)
Proceeds from debt issuance	0	143,750
Payments for debt issuance costs	0	(6,190)
Share repurchases	0	(27,637)
Proceeds from issuance of ordinary shares and warrants	123	3,488
Other financing activities, net	(109)	(31)
Net cash provided by financing activities	14	112,735
Effect of foreign currency exchange rate changes on cash and cash equivalents	47	(84)
Net change in cash and cash equivalents	3,542	1,273
Cash and cash equivalents at January 1,	9,325	16,564
Cash and cash equivalents at September 30,	12,867	17,837
Supplemental disclosures of cash flow information:
Interest paid	6,469	3,359
Income taxes paid	$ 140	$ 413

Newly Issued Accounting Pronouncements	9 Months Ended
Newly Issued Accounting Pronouncements	Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Newly Issued Accounting Pronouncements	Newly Issued Accounting Standards Recent Accounting Guidance Not Yet Adopted In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework— Changes to the Disclosure Requirement for Fair Value Measurement” which amends certain disclosure requirements over Level 1, Level 2 and Level 3 fair value measurements. The amendments in ASU 2018-13 are effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2018-13. In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic326): Measurement of Credit Losses on Financial Instruments(“ASU 2016-13”).” This standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 will be effective for the Company for fiscal years beginning on or after January 1, 2020, including interim periods within those annual reporting periods and early adoption is permitted. We are currently evaluating the impact of our adoption of ASU 2016-13 on our condensed consolidated financial statements.

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Inventory reserves	$ 1,212	$ 4,757
Increase in inventory reserves	3,545
Inventory:
Finished goods	1,883	4,270
Raw materials	377	500
Total	$ 2,260	$ 4,770

Fair Value Measurement Fair Value Measurement - Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	$ 59,587	$ 90,590
Book value of long-term debt	120,167	115,840
Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt	$ 143,750	$ 143,750
Debt instrument, interest rate, stated percentage	4.50%	4.50%
Book value of long-term debt	$ 120,132	$ 115,691
4.50% Exchangeable Senior Notes Due 2023 \| Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt instrument, interest rate, stated percentage	4.50%
Long-term debt, fair value	$ 76,425
Book value of long-term debt	120,132
Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	4,176	9,145
Money market and mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	44,091	52,996
Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	4,258	6,339
Government securities - U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	5,344	12,701
Other fixed-income securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	1,718	9,409
Fair Value Measurements, Recurring \| Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	48,267	62,141
Fair Value Measurements, Recurring \| Level 1 \| Equity securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity securities	4,176	9,145
Fair Value Measurements, Recurring \| Level 1 \| Money market and mutual funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	44,091	52,996
Fair Value Measurements, Recurring \| Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	11,320	28,449
Fair Value Measurements, Recurring \| Level 2 \| Corporate bonds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	4,258	6,339
Fair Value Measurements, Recurring \| Level 2 \| Government securities - U.S.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	5,344	12,701
Fair Value Measurements, Recurring \| Level 2 \| Other fixed-income securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market and mutual funds	1,718	9,409
Fair Value Measurements, Recurring \| Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Related party payable	21,706	28,840
Total liabilities	$ 21,706	$ 28,840

Other Assets and Liabilities - Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Accrued Expenses
Accrued compensation	$ 2,322	$ 3,971
Accrued social charges	482	1,009
Accrued restructuring (see Note 15)	1,737	879
Customer allowances	6,244	6,541
Accrued contract research organization charges	3,389	1,000
Accrued contract manufacturing organization costs	1,284	2,028
Accrued contract sales organization and marketing costs	0	3,469
Other	1,559	2,798
Total	$ 17,017	$ 21,695

Goodwill and Intangible Assets - Gross Value and Net Carrying Amount (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Sep. 30, 2019
Amortizable intangible assets:
Gross Value	$ 85,172	$ 12,061
Accumulated Amortization	(17,456)	(11,042)
Impairment	(66,087)
Net Carrying Amount	1,629	1,019
Unamortizable intangible assets:
Gross Value	18,491	18,491
Accumulated Amortization	0	0
Net Carrying Amount	18,491	18,491
Developed technology \| Noctiva
Amortizable intangible assets:
Gross Value	73,111	0
Accumulated Amortization	(7,024)	0
Impairment	(66,087)
Net Carrying Amount	0	0
Developed technology \| Vazculep
Amortizable intangible assets:
Gross Value	12,061	12,061
Accumulated Amortization	(10,432)	(11,042)
Impairment	0
Net Carrying Amount	$ 1,629	$ 1,019

Commitments and Contingencies - Purchase Commitments (Details) - Inventories $ in Thousands	Sep. 30, 2019 USD ($)
Long-term Purchase Commitment [Line Items]
2019	$ 7,194
2020	1,320
2021	1,320
2022	1,320
2023	220
Thereafter	0
Total	$ 11,374

Revenue Recognition	9 Months Ended
Revenue Recognition	Sep. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The Company generates revenue primarily from the sale of pharmaceutical products to customers. From time to time the Company also generates revenue from licensing arrangements whereby the Company provides access to certain of its intellectual property. Product Sales and Services Effective January 1, 2018, the Company implemented ASC 606, “Revenue From Contracts With Customers”. The Company sells products primarily through wholesalers and considers these wholesalers to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the Company’s product and the Company’s performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of price adjustments in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated when the product is delivered based on analysis of historical data for the product or comparable products, as well as future expectations for such products. Reserves to Reduce Gross Revenues to Net Revenues Revenues from product sales are recorded at the net selling price, which includes estimated reserves to reduce gross product sales to net product sales resulting from product returns, chargebacks, payment discounts, rebates, and other sales allowances that are offered within contracts between the Company and its customers and end users. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer, except in the case of the estimated reserve for future expired product returns, which are classified as a liability. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates to reduce gross selling price to net selling price to which it expects to be entitled based on the terms of its contracts. The actual selling price ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Product Returns Consistent with industry practice, the Company maintains a returns policy, that generally offers customers a right of return for product that has been purchased from the Company. The Company estimates the amount of product returns and records this estimate as a reduction of revenue in the period the related product revenue is recognized. The Company currently estimates product return liabilities based on analysis of historical data for the product or comparable products, as well as future expectations for such products and other judgments and analysis. Chargebacks, Discounts and Rebates Chargebacks, discounts and rebates represent the estimated obligations resulting from contractual commitments to sell products to its customers or end users at prices lower than the list prices charged to our wholesale customers. Customers charge the Company for the difference between the gross selling price they pay for the product and the ultimate contractual price agreed to between the Company and these end users. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargebacks, discounts and rebates are estimated at the time of sale to the customer. Revenue from licensing arrangements The terms of the Company’s licensing agreements may contain multiple performance obligations, including certain R&D activities. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments. Each of these payments results in license revenues. License of Intellectual Property If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Disaggregation of revenue The Company’s primary source of revenue is from the sale of pharmaceutical products, which are equally affected by the same economic factors as it relates to the nature, amount, timing, and uncertainty of revenue and cash flows. For further detail about the Company’s revenues by product, see Note 18: Company Operations by Product. Contract Balances The Company does not recognize revenue in advance of invoicing its customers and therefore has no related contract assets. A receivable is recognized in the period the Company sells its products and when the Company’s right to consideration is unconditional. There were no material deferred contract costs at September 30, 2019. Transaction Price Allocated to the Remaining Performance Obligation For product sales, the Company generally satisfies its performance obligations within the same period the product is delivered. Product sales recognized in 2019 from performance obligations satisfied (or partially satisfied) in previous periods were immaterial. For certain licenses of intellectual property, specifically those with performance obligations satisfied over time, the Company allocates a portion of the transaction price to that performance obligation and recognizes revenue using an appropriate measure of progress towards development of the product. The Company has elected certain of the practical expedients from the disclosure requirement for remaining performance obligations for specific situations in which an entity need not estimate variable consideration to recognize revenue. Accordingly, the Company applies the practical expedient in ASC 606 to its stand-alone contracts and does not disclose information about variable consideration from remaining performance obligations for which the Company recognizes revenue.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred shares, nominal value (in usd per share)	$ 0.01	$ 0.01
Preferred shares, shares authorized (in shares)	50,000,000	50,000,000
Preferred shares, shares issued (in shares)	0	0
Preferred shares, shares outstanding (in shares)	0	0
Ordinary shares, nominal value (in usd per share)	$ 0.01	$ 0.01
Ordinary shares, shares authorized (in shares)	500,000,000	500,000,000
Ordinary shares, shares issued (in shares)	42,857,000	42,720,000
Ordinary shares, shares outstanding (in shares)	37,450,000	37,313,000
Treasury stock, shares held (in shares)	5,407,000	5,407,000

Leases - Maturities of operating lease liabilities (Details) $ in Thousands	Sep. 30, 2019 USD ($)
Leases [Abstract]
Remaining three months of 2019	$ 1,117
2020	879
2021	670
2022	678
2023	690
Thereafter	941
Total lease payments	4,975
Less: interest	513
Operating lease liabilities	$ 4,462

Commitments and Contingencies - Narrative (Details) $ in Millions	Jan. 27, 2019 USD ($)
Specialty Pharma
Loss Contingencies [Line Items]
Loss contingency, damages sought, value	$ 1.7

Net Loss Per Share - Narrative (Details) - shares	3 Months Ended		9 Months Ended
Net Loss Per Share - Narrative (Details) - shares	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	19,544	18,742	20,512	16,647

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY Statement - USD ($) shares in Thousands, $ in Thousands	Total	Ordinary shares	Additional paid-in capital	Accumulated deficit	Accumulated other comprehensive (loss) income	Treasury shares
Beginning balance (in shares) at Dec. 31, 2017		41,463				2,117
Beginning balance at Dec. 31, 2017	$ 85,580	$ 414	$ 393,478	$ (262,685)	$ (23,266)	$ (22,361)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(12,236)			(12,236)
Other comprehensive income (loss)	(404)				(404)
Stock-based compensation expense	2,134		2,134
Exercise of warrants (in shares)		603
Exercise of warrants	2,911	$ 6	2,905
Expiration of warrants	2,167		2,167
Equity component of 2023 Notes	26,699		26,699
Share repurchases (in shares)						2,307
Share repurchases	(20,212)					$ (20,212)
Ending balance (in shares) at Mar. 31, 2018		42,066				4,424
Ending balance at Mar. 31, 2018	86,639	$ 420	427,383	(274,921)	(23,670)	$ (42,573)
Beginning balance (in shares) at Dec. 31, 2017		41,463				2,117
Beginning balance at Dec. 31, 2017	85,580	$ 414	393,478	(262,685)	(23,266)	$ (22,361)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(31,445)
Ending balance (in shares) at Sep. 30, 2018		42,419				5,407
Ending balance at Sep. 30, 2018	65,742	$ 424	433,097	(294,130)	(23,651)	$ (49,998)
Beginning balance (in shares) at Mar. 31, 2018		42,066				4,424
Beginning balance at Mar. 31, 2018	86,639	$ 420	427,383	(274,921)	(23,670)	$ (42,573)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(3,438)			(3,438)
Other comprehensive income (loss)	11				11
Stock-based compensation expense	2,224		2,224
Share repurchases (in shares)						983
Share repurchases	(7,425)					$ (7,425)
Exercise of stock options (in shares)		82
Exercise of stock options	535	$ 1	534
Ending balance (in shares) at Jun. 30, 2018		42,148				5,407
Ending balance at Jun. 30, 2018	78,546	$ 421	430,141	(278,359)	(23,659)	$ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(15,771)
Other comprehensive income (loss)	8				8
Vesting of restricted shares (in shares)		247
Vesting of restricted shares	0	$ 3	(3)
Employee share purchase plan share issuance (in shares)		24
Employee share purchase plan share issuance	127		127
Stock-based compensation expense	2,832		2,832
Ending balance (in shares) at Sep. 30, 2018		42,419				5,407
Ending balance at Sep. 30, 2018	65,742	$ 424	433,097	(294,130)	(23,651)	$ (49,998)
Beginning balance (in shares) at Dec. 31, 2018		42,720				5,407
Beginning balance at Dec. 31, 2018	2,780	$ 427	433,756	(357,989)	(23,416)	$ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(13,018)			(13,018)
Other comprehensive income (loss)	213				213
Vesting of restricted shares (in shares)		1
Vesting of restricted shares	0
Employee share purchase plan share issuance (in shares)		42
Employee share purchase plan share issuance	92		92
Stock-based compensation expense	351		351
Ending balance (in shares) at Mar. 31, 2019		42,763				5,407
Ending balance at Mar. 31, 2019	(9,582)	$ 427	434,199	(371,007)	(23,203)	$ (49,998)
Beginning balance (in shares) at Dec. 31, 2018		42,720				5,407
Beginning balance at Dec. 31, 2018	2,780	$ 427	433,756	(357,989)	(23,416)	$ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(30,487)
Ending balance (in shares) at Sep. 30, 2019		42,857				5,407
Ending balance at Sep. 30, 2019	(26,963)	$ 428	434,055	(388,476)	(22,972)	$ (49,998)
Beginning balance (in shares) at Mar. 31, 2019		42,763				5,407
Beginning balance at Mar. 31, 2019	(9,582)	$ 427	434,199	(371,007)	(23,203)	$ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,605)			(8,605)
Other comprehensive income (loss)	355				355
Stock-based compensation expense	55		55
Ending balance (in shares) at Jun. 30, 2019		42,763				5,407
Ending balance at Jun. 30, 2019	(17,777)	$ 427	434,254	(379,612)	(22,848)	$ (49,998)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(8,864)
Other comprehensive income (loss)	(124)				(124)
Vesting of restricted shares (in shares)		82
Vesting of restricted shares	0	$ 1	(1)
Employee share purchase plan share issuance (in shares)		12
Employee share purchase plan share issuance	31		31
Stock-based compensation expense	(229)		(229)
Ending balance (in shares) at Sep. 30, 2019		42,857				5,407
Ending balance at Sep. 30, 2019	$ (26,963)	$ 428	$ 434,055	$ (388,476)	$ (22,972)	$ (49,998)

Revenue Recognition - Narrative (Details)	Sep. 30, 2019 USD ($)
Revenue from Contract with Customer [Abstract]
Deferred contract costs	$ 0

Marketable Securities Marketable Securities - Schedule of Maturities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale [Line Items]
Fair Value	$ 59,587	$ 90,590
Corporate bonds
Debt Securities, Available-for-sale [Line Items]
Less than 1 Year	556
1-5 Years	3,360
5-10 Years	342
Greater than 10 Years	0
Fair Value	4,258	6,339
Government securities - U.S.
Debt Securities, Available-for-sale [Line Items]
Less than 1 Year	0
1-5 Years	4,600
5-10 Years	0
Greater than 10 Years	744
Fair Value	5,344	12,701
Other fixed-income securities
Debt Securities, Available-for-sale [Line Items]
Less than 1 Year	49
1-5 Years	1,669
5-10 Years	0
Greater than 10 Years	0
Fair Value	1,718	$ 9,409
Debt Securities, Excluding Money Market Funds, Available For Sale
Debt Securities, Available-for-sale [Line Items]
Less than 1 Year	605
1-5 Years	9,629
5-10 Years	342
Greater than 10 Years	744
Fair Value	$ 11,320

Other Assets and Liabilities - Other Non-Current Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Other Non-Current Liabilities:
Provision for retirement indemnity	$ 0	$ 1,024
Customer allowances	923	1,352
Unrecognized tax benefits	7,717	5,315
Guarantee to Deerfield	5,289	5,717
Other	43	594
Total	$ 13,972	$ 14,002